

US008221768B2

(12) United States Patent

Chang

(54) CHIMERIC FLAVIVIRUS IMMUNOGENS COMPRISING THE JAPANESE ENCEPHALITIS VIRUS (JEV) PRM SIGNAL SEQUENCE

- (75) Inventor: **Gwong-Jen J. Chang**, Fort Collins, CO (US)
- (73) Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Washington, DC (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 12/580,080
- (22) Filed: Oct. 15, 2009

(65) **Prior Publication Data**

US 2010/0040643 A1 Feb. 18, 2010

Related U.S. Application Data

- (60) Division of application No. 10/500,796, filed as application No. PCT/US02/10764 on Apr. 4, 2002, now Pat. No. 7,662,394, which is a continuation-in-part of application No. 09/826,115, filed on Apr. 4, 2001, now Pat. No. 7,227,011, which is a continuation-in-part of application No. 09/701,536, filed as application No. PCT/US99/12298 on Jun. 3, 1999, now Pat. No. 7,417,136.
- (60) Provisional application No. 60/087,908, filed on Jun. 4, 1998.
- (51) Int. Cl.

A61K 39/12	(2006.01)
A61K 39/00	(2006.01)

- (52) U.S. Cl. 424/218.1; 424/192.1; 424/199.1
- (58) **Field of Classification Search** None See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,810,492	Α	3/1989	Fujita et al.
5,021,347	Α	6/1991	Yasui et al.
5,229,293	Α	7/1993	Matsuura et al.
5,494,671	Α	2/1996	Lai et al.
5,514,375	Α	5/1996	Paoletti et al.
6,074,865	Α	6/2000	Kelly et al.
6,136,561	A *	10/2000	Ivy et al 435/69.3
6,165,477	Α	12/2000	Ivy et al.
6,258,788	B1	7/2001	Schmaljohn
6,455,509	B1 *	9/2002	Kochel et al 514/44 R
6,696,281	B1 *	2/2004	Chambers et al 435/235.1

FOREIGN PATENT DOCUMENTS

ЛЪ	53133627	11/1978
JP	63004895	1/1988
JP	63105682	5/1988
ЛЬ	89025725	5/1989
JP	65000611	1/1990

(10) Patent No.: US 8,221,768 B2

(45) **Date of Patent:** Jul. 17, 2012

JΡ	67025408	1/1992
IР	5276941	10/1993
IР	7265093	10/1995
WO	WO 90/01946	3/1990
WO	WO 92/02548	2/1992
WO	WO 92/03545	3/1992
WO	WO 93/06214	4/1993
WO	WO 98/37911	9/1998
WO	WO 99/06068	2/1999
WO	WO 99/63095	12/1999
WO	WO 02/072036	9/2002
WO	WO 02/083903	10/2002

OTHER PUBLICATIONS

Pletnev, A. G., et al., 1992, Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses, Proc. Natl. Acad. Sci. USA 89:10532-10536.*

Yasui, K., et al., 1990, Analysis of Japanese encephalitis (JE) virus genome and implications for recombinant JE vaccine, SE Asian J. Trop. Med. Pub. Health 21(4):663-669.*

Philipotts, R. J., et al., 1996, Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus, Arch. Virol. 141:743-749.*

Chang, G.-J. J, et al., 2003, Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus, Virol. 306:170-180.*

Stocks, C. E., and M. Lobigs, 1998, Signal peptidase cleavage at the flavivirus C-prM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM, J. Virol. 72(3):2141-2149.*

Aberle et al., "A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms," *J Immunology* 163:6756-6761 (1999).

Allison et al., "Synthesis and Secretion of Recombinant Tick-Borne Encephalitis Virus Protein E in Soluble and Particulate Form," *J Virology* 69(9):5816-5820 (Sep. 1995). Alvarez et al., "A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients," *Hum. Gene Ther.* 8:229-242 (Jan. 20, 1997).

Anderson et al., "Isolation of West Nile Virus from Mosquitoes, Crows, and a Cooper's Hawk in Connecticut," *Science* 286(5448):2331-2333 (Dec. 17, 1999).

Arroyo, J., et al., "Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (chimerivax-je)," *Journal of Virology*, The American Society for Microbiology, US, vol. 75, No. 2, Jan. 2001, pp. 934-942, XP002967301.

(Continued)

Primary Examiner - Jeffrey S. Parkin

(74) Attorney, Agent, or Firm - Klarquist Sparkman, LLP

(57) ABSTRACT

The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus or of a chimeric immunogenic flavivirus antigen comprising sequence from more than one flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.

30 Claims, 8 Drawing Sheets

OTHER PUBLICATIONS

Asnis et al., "The West Nile Virus Outbreak of 1999 in New York: The Flushing Hospital Experience," *Clin. Infect. Dis.* 30: 413-418 (2000). Azevedo et al., "Main features of DNA-based immunization vectors," *Braz. J. Med. Biol. Res.* 32(2):147-153 (1999).

Bray et al., "Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins with or without Nonstructural Protein NSI are Protected Against Fatal Dengue Virus Encephalitis," *J. Virol.* 63(6):2853-2856 (Jun. 1989).

Cavener and Ray, "Eukaryotic start and stop translation sites," *Nucleic Acids Research*, 19(12):3185-3192 (1991).

Chang et al., "A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice," *J. Virol.* 74(9):4244-4252 (May 2000).

Chang et al., "Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus," *Virology*, 306:170-180 (2003).

Chang et al., "Flavivirus DNA Vaccines," Annals New York Academy of Sciences, 951:272-285 (2001).

Chang et al., "Recent advancement in flavivirus vaccine development," *Expert Rev. Vaccines*, 3(2):199-220 (2004).

Chen et al., "Construction of Intertypic Chimeric Dengue Viruses Exhibiting Type 3 Antigenicity and Neurovirulence for Mice," *J Virology*, 69(8):5186-5190 (Aug. 1995).

Clarke et al., "Techniques for Hemagglutination and Hemagglutination-Inhibition With Arthropod-Borne Viruses," *Amer. J. Trop. Med. and Hyg.*, 7:561-573 (1958).

Colombage et al., "DNA-Based and Alphavirus-Vectored Immunisation with PrM and E Proteins Elicits Long-Lived and Protective Immunity against the Flavivirus, Murray Valley Encephalitis Virus," *Virology* 250:151-163 (1998).

Davis et al., "West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses in Vitro a Noninfectious Recombinant Antigen That Can be Used in Enzyme-Linked Immunosorbent Assays," *J. Virol.* 75(9):4040-4047, 2001 (published on-line Apr. 4, 2001).

Deubel et al., "Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Type 2 Virus, Jamaica Genotype," Virology 155:365-377 (1986).

Deubel et al., "Nucleotide Sequence and Deduced Amino Acid Sequence of the Nonstructural Proteins of Dengue Type 2 Virus, Jamaica Genotype: Comparative Analysis of the Full-Length Genome," *Virology* 165:234-244 (1988).

Dmitriev et al., "Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tickborne encephalitis virus cDNA protect mice against lethal encephalitis," *J. Biotechnol.* 44:97-103 (1996).

Duarte dos Santos et al., "Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213," *Virus Res.* 35:35-41 (1995).

Falgout et al., "Proper Processing of Dengue Virus Nonstructural Glycoprotein NSI Requires the N-Terminal Hydrophobic Signal Sequence and the Downstream Nonstructural Protein NS2a," *J. Virol.* 63(5):1852-1860 (May 1989).

Falgout et al., "Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NSI Protects Against Lethal Dengue Virus Encephalitis," *J. Virol.* 64(9):4356-4363 (1990).

Fonseca et al., "Recombinant vaccinia viruses co-expressing dengue-1 glycoprotein prM and E induce neutralizing antibodies in mice," Vaccine 12(3):279-285 (1994).

Garmendia et al., "Recovery and Identification of West Nile Virus from a Hawk in Winter," *J. Clin. Microbiol.* 38(8):3110-3111 (Aug. 2000).

Gruenberg et al., "Partial Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains," *J. Gen. Virol.*, 69:1391-1398 (1988).

Guirakhoo et al., "Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates," *J. Virol.*, 74(12):5477-5485 (2000). Hahn et al., "Nucleotide Sequence of Dengue 2 RNA and Comparison of the Encoded Proteins with Those of Other Flaviviruses," *Virology* 162:167-180 (1988).

Hashimoto et al., "Molecular Cloning and Complete Nucleotide Sequence of the Genome of Japanese Encephalitis Virus Beijing-1 Strain," *Virus Genes* 1(3):305-317 (1988).

Heinz et al., "Flaviviruses." In *Immunochemistry of Viruses II: The Basis for Serodiagnosis and Vaccines*. (edited by von Regenrnortel and Neurath) Elsevier Science Publishers, Chapter 14, pp. 89-305 (1990).

Henchal et al., "Dengue Virus-Specific and Flavivirus Group Determinants Identified With Monoclonal Antibodies by Indirect Immunofluorescence," *Amer. J. Trop. Med. Hyg.* 31:830-836 (1982). Hennessy et al., "Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study," Lancet 347:1583-1586 (Jun. 8, 1996).

Ho et al., "DNA vaccination induces a long-term antibody response and protective immunity against pseudorabies virus in mice," *Arch Virol*, 143:115-125 (1998).

Hubàlek et al., "West Nile Fever—a Reemerging Mosquito-Borne Viral Disease in Europe," *Emerg. Infect. Dis.*, 5(5):643-650 (1999). Hunt et al., "A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen," *J. Virological Methods*, 97:133-149 (2001).

Hunt and Calisher, "Relationships of Bunyamwera Group Viruses by Neutralization," Amer. J. Trop. Med. Hyg., 28(4):740-749 (1979).

Jacobs et al., "High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model," *J. Virol.*, 66(4):2086-2095 (Apr. 1992).

Jacobs, "A novel recombinant adenovirus vector expressing a flavivirus non-structural protein protects against lethal flavivirus challenge," *Clinical Science*, 85:117-122 (1993).

Jia et al., "Genetic analysis of West Nile New York 1999 encephalitis virus," *Lancet*, 354:1971-1972 (Dec. 4, 1999).

Johnson et al., "Detection of Anti-Arboviral Immunoglobulin G by Using a Monoclonal Antibody-Based Capture Enzyme-Linked Immunosorbent Assay," *J. Clin. Microbiol.*, 38(5):1827-1831 (May 2000).

Kimura-Kuroda and Yasui, "Antigenic Comparison of Envelope Protein E between Japanese Encephalitis Virus and Some Other Flaviviruses Using Monoclonal Antibodies," *J. Gen. Virol.*, 67:2663-2672 (1986).

Kimura-Kuroda and Yasui, "Topographical Analysis of Antigenic Determinants on Envelope Glycoprotein V3 (E) of Japanese Encephalitis Virus, Using Monoclonal Antibodies," *J. Virol.*, 45(1):124-132 (Jan. 1983).

Kitchener et al., "Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in health Australian adults," *Vaccine*, 24:1238-1241 (2006).

Klinman et al., "CpG motifs as immune adjuvants," Vaccine, 17 :19-25 (1999).

Kochel et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," *Vaccine*, 15(5):547-552 (1997).

Köhler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," *Nature*, 256:495-497 (Aug. 7, 1975).

Konishi et al., "A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice," *Vaccine* 18:1133-1139 (2000).

Konishi et al., "Comparison of Protective Immunity Elicited by Recombinant Vaccinia Viruses That Synthesize E or NS1 of Japanese Encephalitis Virus," *Virology*, 185:401-410 (1991).

Konishi et al., "Avipox virus-vectored Japanese encephalitis virus vaccines: use a vaccine candidates in combination with purified subunit immunogens," *Vaccine*, 12(7):633-638 (1994).

Konishi et al., "Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles," *J. Virol.* 75(5):2204-2212 (Mar. 2001).

Konishi et al., "The Anamnestic Neutralizing Antibody Response is Critical for Protection of Mice from Challenge following Vaccination with a Plasmid Encoding the Japanese Encephalitis Virus Premembrane and Envelope Genes," J. Virology 73(7):5527-5534 (Jul. 1999).

Konishi et al., "Induction of Protective Immunity against Japanese Encephalitis in Mice by Immunization with a Plasmid Encoding Japanese Encephalitis Virus Premembrane and Envelope Genes," *J Virology*, 72(6):4925-4930 (Jun. 1998).

Konishi et al., "Mice Immunized with a Subviral Particle Containing the Japanese Encephalitis Virus prM/M and E Proteins Are Protected from Lethal JEV Infection," *Virology*, 188:714-720 (1992).

Kozak, "Circumstances and Mechanisms of Inhibition of Translation by Secondary Structure in Eucaryotic mRNAs," *Mol. Cell. Biol.*, 9(11):5134-5142 (Nov. 1989).

Kozak, "An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs," *Nucleic Acids Research*, 15(20):8125-8148 (1987).

Kozak, "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," *J. Mol. Biol.*, 196:947-950 (1987).

Kozak, "Point Mutations Define a Sequence Flanking the AUG Initiator Codon That Modulates Translation by Eukaryotic Ribosomes," *Cell*, 44:283-292 (Jan. 31, 1986).

Kuno et al., "Phylogeny of the Genus Flavivirus," J. Virol., 72(1):73-83 (Jan. 1998).

Laemmli, "Cleavage of Structural Proteins during the Assembly of the Head of Bateriophage T4," *Nature*, 277:680-685 (Aug. 15, 1970). Lai et al., "Immunization of Monkeys with Baculovirus Recombinant-expressed Dengue Envelope and NSI Glycoproteins Induces Partial Resistance to Challenge with Homotypic Dengue Virus," In *Vaccines 90: Modern Approaches to New Vaccines including Prevention of AIDS*, Cold Spring Harbor Laboratory, Cold Springs Harbor, NY, pp. 119-124 (1990).

Lanciotti et al., Origin of the West Nile Virus Responsible for an Outbreak of Encephalitis in the Northeastern United States, *Science*, 286:2333-2337 (Dec. 17, 1999).

Lin et al., "DNA Immunization with Japanese Encephalitis Virus Nonstructural Protein NS1 Elicits Protective Immunity in Mice," *J. Virol.*, 72(1):191-200 (Jan. 1998).

Mackow et al., "The Nucleotide Sequence of Dengue Type 4 Virus: Analysis of Genes Coding for Nonstructural Proteins," *Virology*, 159:217-228 (1987).

Mandl et al., "Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic Elements in Tick-Borne Versus Mosquito-Borne Flaviviruses," *Virology*, 194:173-184 (1993).

Martin et al., "Standardization of Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assays for Routine Diagnosis of Arboviral Infections," *J. Clin. Microbiol.*, 38(5):1823-1826 (May 2000).

Mason et al., "Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1," *Virology*, 161:262-267 (1987).

Mason et al., "Japanese Encephalitis Virus-Vaccinia Recombinants Produce Particulate Forms of the Structural Membrane Proteins and Induce High Levels of Protection against Lethal JEV Infection," *Virology*, 180:294-305 (1991).

Mir et al., "High-efficiency gene transfer into skeletal muscle mediated by electric pulses," *Proc. Nat. Acad. Sci. USA*, 96:4262-4267 (Apr. 1999).

Monath, "Dengue and Yellow Fever—Challenges for the Development and Use of Vaccines," *N. Engl. J. Med.*, 357(22):2222-2225 (Nov. 2007).

Monath, "Flaviviruses," *Virology* (R.N. Fields, ed.), 763-814 (1990). Nitayaphan et al., "Nucleotide Sequence of the Virulent SA-14 Strain of Japanese Encephalitis Virus and Its Attenuated Vaccine Derivative, SA-14-14-2," *Virology*, 177:541-552 (1990).

Osatomi and Sumiyoshi, "Complete Nucleotide Sequence of Dengue Type 3 Virus Genome RNA," *Virology*, 176:643-647 (1990).

Osatomi et al., "Nucleotide Sequence of Dengue Type 3 Virus Genomic RNA Encoding Viral Structural Proteins," *Virus Genes*, 2(1):99-108 (1988).

Phillpotts et al., "Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus," *Arch. Virol.* 141:743-749 (1996).

Pincus et al., "Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis," *Virology*, 187:290-297 (1992).

Pletnev A.G. et al., "Construction and Characterization of Chimeric Tick-Borne Encephalitis/Dengue Type 4 Viruses," *Proceedings of the National Academy of Sciences of USA, National Academy of Science*, Washington, U.S. vol. 89, No. 21, Nov. 1, 1992, pp. 10532-10536.

Porter et al., "Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG Immune-stimulatory motifs on antibody responses," *Arch. Virol.* 143:997-1003 (1998).

Ramelow et al., "Detection of tick-borne encephalitis virus RNA in ticks (*Ixodes ricinus*) by the polymerase chain reaction," *J. Virol. Meth.*, 45:115-9 (1993).

Raviprakash et al., "Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein," *Vaccine* 18:2426-2434 (2000).

Rice et al., "Nucleotide Sequence of Yellow Fever Virus: Implications for Flavivirus Gene Expression and Evolution," *Science*, 229:726-733 (Aug. 23, 1985).

Roehrig et al., "Identification of Epitopes on the E Glycoprotein of Saint Louis Encephalitis Virus Using Monoclonal Antibodies," *Virology*, 128:118-126 (1983).

Roehrig et al., "Synthetic Peptides Derived from the Deduced Amino Acid Sequence of the E-Glycoprotein of Murray Valley Encephalitis Virus Elicit Antiviral Antibody," *Virology*, 171:49-60 (1989).

Rothman, "Dengue: defining protective versus pathologic immunity," J. Clin. Invest., 113(7):946-951 (Apr. 2004).

Sato et al., "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," *Science*, 273(5273):352-354 (Jul. 19, 1996).

Schalich et al., "Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions," *J. Virol.*, 70:4549-4557 (Jul. 1996).

Schimaljohn et al., "Naked DNA Vaccines Expressing the prM and E Genes of Russian Spring Summer Encephalitis Virus and Central European Encephalitis Virus Protect Mice from Homologous and Heterologous Challenge," *J. Virology* 71(12):9563-9569 (Dec. 1997).

Seeger et al., "The cloned genome of ground squirrel hepatitis virus is infectious in the animal," *Proc Natl Aca Sci U.S.A.*, 81(18):5849-4852 (Sep. 1984).

Sela, *The Choice of Carrier. Synthetic Vaccines* vol. I (edited by Amon) CRC Press Inc, Boca Raton, FL., pp. 83-92 (1987).

Simmons et al., "Short Report: Antibody Responses of Mice Immunized with a Tetravalent Dengue Recombinant Protein Subunit Vaccine," *Am. J. Trop. Med. Hyg.* 65(2):159-161 (2001).

Smithburn et al., "A Neurotropic Virus Isolated From the Blood of a Native of Uganda," *Am. J. Trop. Med. Hyg.*, 20:471-492 (1940).

Stephenson, "Understanding dengue pathogenesis: implications for vaccine design," Bull. *World Health Org.*, 83:308-314 (Abstract only).

Stocks and Lobigs, "Posttranslational signal peptidase cleavage at the flavivirus C-prM junction in vitro," *J. Virol.*, 69(12):8123-8126 (1995).

Sumiyoshi et al., "Complete Nucleotide Sequence of the Japanese Encephalitis Virus Genome RNA," *Virology*, 161:497-510 (1987).

Tardei et al., "Evaluation of Immunoglobulin M (IgM) and IgG Enzyme Immunoassays in Serologic Diagnosis of West Nile Virus Infection," *J. Clin. Microbiol.* 38(6):2232-2239 (Jun. 2000).

Trent et al., "Partial Nucleotide Sequence of St. Louis Encephalitis Virus RNA: Structural Proteins. NS1 ns2a and ns2b," *Virology*, 156:293-304 (1987).

Tsai et al., Japanese Encephalitis Vaccines. In Vaccines (2^{nd} edition) (edited by Plotkin and Mortimer), W.B. Saunders Co., Philadelphia, PA, Chapter 24, pp. 671-713 (1994).

Tsai et al., Japanese Encephalitis Vaccines. In Vaccines (3rd edition) (edited by Plotkin and Orenstein), W.B. Saunders Co., Philadelphia, PA, Chapter 27, pp. 672-710 (1999).

Venugopal et al., "Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins," *Vaccines*, 13(11):1000-1005 (1995).

Wang et al., "Immunization of Mice Against West Nile Virus with Recombinant Envelope Protein," *J. Immunol.* 167:5273-5277 (2001). Wang et al., "Immune Response to Neonatal Genetic Immunization," *Virology*, 228:278-284 (1997).

Wolff et al., "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle," *Hum Mol Genet*, 1(6):363-369 (Sep. 1992).

Yang et al., "A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A," *Nature*, 382:319-324 (Jul. 25, 1996). Yasui et al., "Analysis of Japanese encephalitis (JE) virus genome and implications for recombinant JE vaccine," *Southeast Asian J. Trop. Med. Public Health*, 21(4):663-669 (1990).

Zhang et al., "Immunization of Mice with Dengue Structural Proteins and Nonstructural Protein NSI Expressed by Baculovirus Recombinant Induces Resistance to Dengue Virus Encephalitis," *J. Virol.*, 62(8):3027-3031 (Aug. 1988).

Zhang et al., "Passive Protection of Mice, Goats, and Monkeys Against Japanese Encephalitis With Monoclonal Antibodies," *J. Med. Virol.*, 29:133-138 (1989).

Zhao et al., "Cloning Full-Length Dengue Type 4 Viral DNA Sequences: Analysis of Genes Coding for Structural Proteins," *Virology*, 155:77-88 (1986).

Zhao et al., "Expression of Dengue Virus Structural Proteins and Nonstructural Protein NS₁ by a Recombinant Vaccinia Virus," *J. Virol.*, 61(12):4019-4022 (Dec. 1987).

"Update: Surveillance for West Nile Virus in Overwintering Mosquitoes—New York, 2000," *Morb. Mortal. Wkly. Rep.*, 49(09):178-179 (Mar. 10, 2000).

"Update: West Nile Virus Activity—Northeastern United States, 2000," Morb. Mortal. Wkly. Rep., 49(36):820-822 (Sep. 15, 2000).

Zou & Brown, "Translation of the reovirus M1 gene initiates from the first AUG codon in both infected and transfected cells," *Virus Research* 40:75-89, 1996.

Konishi et al., "Japanese Encephalitis DNA Vaccine Candidates Expressing Premembrane and Envelope Genes Induce Virus-Specific Memory B Cells and Long-Lasting Antibodies in Swine," *Virology*, vol. 268:49-55, 2000.

Purdy et al., "Secretion of Noninfectious Dengue Virus-Like Particles and Identification of Amino Acids in the Stem Region Involved in Intracellular Retention of Envelope Protein," *Virology*, vol. 333:239-250, 2005.

* cited by examiner















.....



25

CHIMERIC FLAVIVIRUS IMMUNOGENS COMPRISING THE JAPANESE ENCEPHALITIS VIRUS (JEV) PRM SIGNAL SEOUENCE

CROSS REFERENCE TO RELATED APPLICATIONS

This is a divisional of U.S. application Ser. No. 10/500,796, filed Jul. 6, 2004, and issued as U.S. Pat. No. 7,662,394; ¹⁰ which is the §371 U.S. national stage of PCT/US02/10764, filed Apr. 4, 2002; which is a continuation-in-part of, and claims the benefit of U.S. application Ser. No. 09/826,115, filed Apr. 4, 2001, and issued as U.S. Pat. No. 7,227,011. U.S. application Ser. No. 09/826,115 is a continuation-in-part of, ¹⁵ and claims the benefit of U.S. application Ser. No. 09/701, 536, filed Jun. 18, 2001, and issued as U.S. Pat. No. 7,417, 136. U.S. application Ser. No. 09/701,536 is the §371 U.S. national stage of PCT/US99/12298, filed Jun. 3, 1999; which claims the benefit of U.S. provisional application No. 60/087, ²⁰ 908, filed June 4, 1998. Each of these applications is hereby incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

This invention relates to novel vaccines, diagnostics and methods of using both in the treatment and prevention of the diseases caused by flaviviruses. In particular, the vaccines are recombinant nucleic acids which contain genes for structural proteins of flaviviruses, such as Japanese encephalitis virus ³⁰ (JEV), West Nile virus (WNV) or related flaviviruses. These vaccines serve as a transcriptional unit for the biosynthesis of the virus protein antigens when administered in vivo. The diagnostics are compositions containing antigens produced from the recombinant nucleic acids that can be used to detect ³⁵ flavivirus infection.

BACKGROUND OF THE INVENTION

Flaviviruses are members of the genus Flavivirus, which is 40 classified within the family Flaviviridae. The flaviviruses are largely pathogenic to humans and other mammals. Flaviviruses that inflict disease upon humans and animals include Alfuy, Apoi, Aroa, Bagaza, Banzi, Batu Cave, Bouboui, Bukalasa bat, Bussuquara, Cacipacore, Carey Island, Cow- 45 bone Ridge, Dakar bat, Dengue (serotypes 1, 2, 3 and 4), Edge Hill, Entebbe bat, Gadgets Gully, Iguape, Ilheus, Israel turkey meningoencephalitis, Japanese encephalitis, Jugra, Jutiapa, Kadam, Karshi, Kedougou, Kokobera, Koutango, Kunjin, Kyasanur Forest disease, Langat, Meaban, Modoc, Montana 50 myotis leukoencephalitis, Murray Valley encephalitis, Naranjal, Negishi, Ntaya, Omsk hemorrhagic fever, Phnom Penh bat, Potiskum, Powassan, Rio Bravo, Rocio, Royal Farm, Russian spring summer encephalitis, Saboya, Sal Vieja, San Perlita, Saumarez Reef, Sepik, Sokuluk, Spondweni, St. 55 Louis encephalitis, Stratford, Tick-borne encephalitis-central European subtype, Tick-borne encephalititis-far eastern subtype, Tembusu, THCAr, Tyuleniy, Uganda S, Usutu, West Nile, Yaounde, Yellow fever, Yokose, Ziki, Cell fusing agent and other related flaviviruses, as listed in Kuno et al. (J. Virol. 60 72: 73-83 (1998)).

The flaviviruses contain the following three structural proteins: prM/M, the premembrane and membrane protein; E, the envelope protein; and C, the capsid protein. (Monath, in *Virology* (Fields, ed.), Raven Press, New York, 1990, pp. 65 763-814; Heinz and Roehrig, in *Immunochemistry of Viruses II: The Basis for Serodiagnosis and Vaccines* (van Regenmor-

tel and Neurath, eds.), Elsevier, Amsterdam, 1990, pp. 289-305). M has a molecular weight (MW) of about 7-8 kilodaltons (kDa) and E has a MW of about 55-60 kDa. M is synthesized as a larger precursor termed prM. The pr portion of prM is removed when prM is processed to form M protein in mature virions. M and E are located in the membrane of the flavivirus particle, and so have long been considered to constitute important immunogenic components of the viruses.

The flaviviruses are RNA viruses comprising single stranded RNA having a length, among the various species, of about 10 kilobases (kb). The C protein, with a MW of 12-14 kDa, complexes with the RNA to form a nucleocapsid complex. Several nonstructural proteins are also encoded by the RNA genome which are termed NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5. The genome is translated within the host cell as a polyprotein, then processed co- or post-translationally into the individual gene products by viral- or host-specific proteases (FIG. 1).

The nucleotide sequences of the genomes of several flaviviruses are known, as summarized in U.S. Pat. No. 5,494, 671. That for JEV is provided by Sumiyoshi et al. (*Virology* 161: 497-510 (1987)) and Hashimoto et al. (*Virus Genes* 1: 305-317 (1988)). The nucleotide sequences of the virulent strain SA-14 of JEV and the attenuated strain SA-14-14-2, used as a vaccine in the People's Republic of China, are compared in the work of Nitayaphan et al. (*Virology* 177: 541-552 (1990)).

Nucleotide sequences encoding the structural proteins of other flavivirus species are also known. In many cases, the sequences for the complete genomes have been reported. The sequences available include dengue serotype 1 virus, dengue serotype 2 virus (Deubel et al., *Virology* 155: 365-377 (1986); Gruenberg et al., *J. Gen. Virol.* 69: 1391-1398 (1988); Hahn et al. *Virology* 162: 167-180 (1988)), dengue serotype 3 virus (Osatomi et al., *Virus Genes* 2: 99-108 (1988)), dengue serotype 4 virus (Mackow et al., *Virology* 159: 217-228 (1987), Zhao et al., *Virology* 155: 77-88 (1986)), West Nile virus (Lanciotti et al., *Science* 286: 2331-2333 (1999)), Powassan virus (Mandl et al., *Virology* 194: 173-184 (1993)) and yellow fever virus (YFV) (Rice et al., *Science* 229: 726-733 (1985)).

Many flaviviruses, including St. Louis encephalitis virus (SLEV), WNV and JEV, are transmitted to humans and other host animals by mosquitoes. They therefore occur over wide-spread areas and their transmission is not easily interrupted or prevented.

West Nile fever is a mosquito-borne flaviviral infection that is transmitted to vertebrates primarily by various species of Culex mosquitoes. Like other members of the Japanese encephalitis (JE) antigenic complex of flaviviruses, including JE, SLE and Murray Valley encephalitis (MVE) viruses, WNV is maintained in a natural cycle between arthropod vectors and birds. The virus was first isolated from a febrile human in the West Nile district of Uganda in 1937 (Smithburn et al., Am. J. Trop. Med. Hyg. 20: 471-492 (1940)). It was soon recognized as one of the most widely distributed flaviviruses, with its geographic range including Africa, the Middle East, Western Asia, Europe and Australia (Hubalek et al., Emerg. Infect. Dis. 5: 643-50 (1999)). Clinically, West Nile fever in humans is a self-limited acute febrile illness accompanied by headache, myalgia, polyarthropathy, rash and lymphadenopathy (Monath and Tsai, in Clinical Virology, (Richman, Whitley and Hayden eds.), Churchill-Livingtone, New York, 1997, pp. 1133-1186). Acute hepatitis or pancreatis has been reported on occasion and cases of WNV infection in elderly patients are sometimes complicated by encephalitis or meningitis (Asnis et al., Clin. Infect. Dis. 30: 413-418 (2000)). Thus, infection by WNV is a serious health concern in many regions of the world.

The geographical spread of the disease, particularly the introduction of WNV into the U.S. in 1999, has greatly increased awareness of the human and animal health concerns of this disease. Between late August and early September 1999, New York City and surrounding areas experienced an outbreak of viral encephalitis, with 62 confirmed cases, resulting in seven deaths. Concurrent with this outbreak, local 10 health officials observed increased mortality among birds (especially crows) and horses. The outbreak was subsequently shown to be caused by WNV, based on monoclonal antibody (Mab) mapping and detection of genomic sequences in human, avian and mosquito specimens (Anderson et al., 15 Science 286: 2331-2333 (1999); Jia et al., Lancet 354: 1971-1972 (1999); Lanciotti et al., Science 286: 2333-2337 (1999)). Virus activity detected during the ensuing winter months indicated that the virus had established itself in North America (Morb. Mortal. Wkly. Rep. 49: 178-179 (2000); 20 flaviviruses is disclosed in PCT publication WO 93/06214. Asnis et al., Clin. Infect. Dis. 30: 413-418 (2000); Garmendia et al., J. Clin. Micro. 38: 3110-3111 (2000)). Surveillance data reported from the northeastern and mid-Atlantic states during the year 2000 confirmed an intensified epizootic/epidemic transmission and a geographic expansion of the virus 25 with documentation of numerous cases of infection in birds, mosquitoes and horses, as well as cases in humans (Morb. Mortal. Wkly. Rep. 49: 820-822 (2000)).

Currently, no human or veterinary vaccine is available to prevent WNV infection and mosquito control is the only 30 practical strategy to combat the spread of the disease.

Japanese encephalitis virus (JEV) infects adults and children and there is a high mortality rate among infants, children and the elderly in areas of tropical and subtropical Asia (Tsai et al., in Vaccines (Plotkin, ed.) W.B. Saunders, Philadelphia, 35 Pa., 1999, pp. 672-710). Among survivors, there are serious neurological consequences, related to the symptoms of encephalitis, that persist after infection. In more developed countries of this region, such as Japan, the Republic of China (Taiwan) and Korea, JEV has been largely controlled by use 40 of a vaccine of inactivated JEV. Nevertheless, it is still prevalent in other countries of the region.

Vaccines available for use against JEV infection include live virus inactivated by such methods as formalin treatment, as well as attenuated virus (Tsai et al., in Vaccines (Plotkin, 45 ed.) W.B. Saunders, Philadelphia, Pa., 1994, pp. 671-713). Whole virus vaccines, although effective, do have certain problems and/or disadvantages. The viruses are cultivated in mouse brain or in cell culture using mammalian cells as the host. Such culture methods are cumbersome and expensive. 50 Furthermore, there is the attendant risk of incorporating antigens from the host cells, i.e., the brain or other host, into the final vaccine product, potentially leading to unintended and undesired allergic responses in the vaccine recipients. There is also the risk of inadvertent infection among workers 55 involved in vaccine production. Finally, there is the risk that the virus may not be fully or completely inactivated or attenuated and thus, the vaccine may actually cause disease.

Dengue fever and dengue hemorrhagic fever (DF/DHF) are caused by dengue virus, which is also a mosquito-borne 60 flavivirus. There are four antigenically related, but distinct, dengue virus serotypes, (DEN-1, DEN-2, DEN-3 and DEN-4), all of which can cause DF/DHF. Symptoms of DF, the mild form of dengue-related disease, include fever, rash, severe headache and joint pain. Mortality among those subjects suf-65 fering from DF is low; however, among those subjects suffering from DHF, mortality can be as high as 5%. From

available evidence, more than 3 million cases of DHF and 58,000 deaths have been attributed to DHF over the past 40 years, making DHF a major emerging disease (Halstead, in Dengue and Dengue Hemorrhagic Fever (Gubler and Kuno, eds.) CAB International, New York, N.Y., (1997) pp 23-44). Nevertheless, despite decades of effort, safe and effective vaccines to protect against dengue virus infection are not yet available.

Yellow fever is prevalent in tropical regions of South America and sub-Saharan Africa and is transmitted by mosquitos. Infection leads to fever, chills, severe headache and other pains, anorexia, nausea and vomiting, with the emergence of jaundice. A live virus vaccine, 17D, grown in infected chicken embryos, is considered safe and effective. Nevertheless, there remains a need for a vaccine that is stable under adverse conditions, such as are commonly encountered in the tropical regions of Africa and the Americas where the vaccine is most needed.

A recombinant flavivirus which is a chimera between two The chimera is a construct fusing non-structural proteins from one "type," or serotype, of dengue virus or a flavivirus, with structural proteins from a different "type," or serotype, of dengue virus or other flavivirus.

Several recombinant subunit and viral vaccines have been devised in recent years. U.S. Pat. No. 4,810,492 describes the production of the E glycoprotein of JEV for use as the antigen in a vaccine. The corresponding DNA is cloned into an expression system in order to express the antigen protein in a suitable host cell such as E. coli, yeast, or a higher organism cell culture. U.S. Pat. No. 5,229,293 discloses recombinant baculovirus harboring the gene for JEV E protein. The virus is used to infect insect cells in culture such that the E protein is produced and recovered for use as a vaccine.

U.S. Pat. No. 5,021,347 discloses a recombinant vaccinia virus genome into which the gene for JEV E protein has been incorporated. The live recombinant vaccinia virus is used as the vaccine to immunize against JEV. Recombinant vaccinia viruses and baculoviruses in which the viruses incorporate a gene for a C-terminal truncation of the E protein of dengue serotype 2, dengue serotype 4 and JEV are disclosed in U.S. Pat. No. 5,494,671. U.S. Pat. No. 5,514,375 discloses various recombinant vaccinia viruses which express portions of the JEV open reading frame extending from prM to NS2B. These pox viruses induced formation of extracellular particles that contain the processed M protein and the E protein. Two recombinant viruses encoding these JEV proteins produced high titers of neutralizing and hemagglutinin-inhibiting antibodies, and protective immunity, in mice. The extent of these effects was greater after two immunization treatments than after only one. Recombinant vaccinia virus containing genes for the prM/M and E proteins of JEV conferred protective immunity when administered to mice (Konishi et al., Virology 180: 401-410 (1991)). HeLa cells infected with recombinant vaccinia virus bearing genes for prM and E from JEV were shown to produce subviral particles (Konishi et al., Virology 188: 714-720 (1992)). Dmitriev et al. reported immunization of mice with a recombinant vaccinia virus encoding structural and certain nonstructural proteins from tick-borne encephalitis virus (J. Biotechnology 44: 97-103 (1996)).

Recombinant virus vectors have also been prepared to serve as virus vaccines for dengue fever. Zhao et al. (J. Virol. 61: 4019-4022 (1987)) prepared recombinant vaccinia virus bearing structural proteins and NS1 from dengue serotype 4 and achieved expression after infecting mammalian cells with the recombinant virus. Similar expression was obtained using recombinant baculovirus to infect target insect cells (Zhang et al., J. Virol. 62: 3027-3031 (1988)). Bray et al. (J. Virol. 63: 2853-2856 (1989)) also reported a recombinant vaccinia dengue vaccine based on the E protein gene that confers protective immunity to mice against dengue encephalitis when challenged. Falgout et al. (J. Virol 63: 1852-1860 (1989)) and 5 Falgout et al. (J. Virol. 64: 4356-4363 (1990)) reported similar results. Zhang et al. (J. Virol 62: 3027-3031 (1988)) showed that recombinant baculovirus encoding dengue E and NS1 proteins likewise protected mice against dengue encephalitis when challenged. Other combinations in which structural and 10 nonstructural genes were incorporated into recombinant virus vaccines failed to produce significant immunity (Bray et al., J. Virol. 63: 2853-2856 (1989)). Also, monkeys failed to develop fully protective immunity to dengue virus challenge when immunized with recombinant baculovirus expressing the E protein (Lai et al. (1990) pp. 119-124 in F. Brown, R. M. Chancock, H. S. Ginsberg and R. Lerner (eds.) Vaccines 90: Modern approaches to new vaccines including prevention of AIDS, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).

Immunization using recombinant DNA preparations has been reported for SLEV and dengue-2 virus, using weanling mice as the model (Phillpotts et al., Arch. Virol. 141: 743-749 (1996); Kochel et al., Vaccine 15: 547-552 (1997)). Plasmid DNA encoding the prM and E genes of SLEV provided partial 25 protection against SLEV challenge with a single or double dose of DNA immunization. In these experiments, control mice exhibited about 25% survival and no protective antibody was detected in the DNA-immunized mice (Phillpotts et al., Arch. Virol. 141: 743-749 (1996)). In mice that received three 30 intradermal injections of recombinant dengue-2 plasmid DNA containing prM, 100% developed anti-dengue-2 neutralizing antibodies and 92% of those receiving the corresponding E gene likewise developed neutralizing antibodies (Kochel et al., Vaccine 15: 547-552 (1997)). Challenge 35 experiments using a two-dose schedule, however, failed to protect mice against lethal dengue-2 virus challenge.

The vaccines developed to date for immunizing against infection by JEV, SLEV, dengue virus and other flaviviruses have a number of disadvantages and problems attending their 40 use. Inactivated vaccine is costly and inconvenient to prepare. In addition, any such vaccine entails the risk of allergic reaction originating from proteins of the host cell used in preparing the virus. Furthermore, such vaccines present considerable risk to the workers employed in their production. 45 Candidate attenuated JEV vaccines are undergoing clinical trials, but as of 1996 have not found wide acceptance outside of the People's Republic of China (Hennessy et al., *Lancet* 347: 1583-1586 (1996)).

Recombinant vaccines based on the use of only certain 50 proteins of flaviviruses, such as JEV, produced by biosynthetic expression in cell culture with subsequent purification or treatment of antigens, do not induce high antibody titers. Also, like the whole virus preparations, these vaccines carry the risk of adverse allergic reaction to antigens from the host 55 or to the vector. Vaccine development against dengue virus and WNV is less advanced and such virus-based or recombinant protein-based vaccines face problems similar to those alluded to above.

There is therefore a need for vaccines or improved vaccines 60 directed against flaviviruses such as yellow fever virus, dengue virus, JEV, SLEV and WNV which are inexpensive to prepare, present little risk to workers involved in their manufacture, carry minimal risk of adverse immunological reactions due to impurities or adventitious immunogenic compo-65 nents and are highly effective in eliciting neutralizing antibodies and protective immunity. There is furthermore a

need for a vaccine against JEV, WNV and related flaviviruses that minimizes the number of immunizing doses required.

Many of the shortcomings of the current art as described in detail for the production of vaccines also apply to the production of antigens and antibodies to be used for the production of immunodiagnostics. Particularly, the concurrent risks and costs involved in the production of antigens from viruses and the failure of most currently available recombinantly expressed antigens to elicit effective immune responses are paralleled in the field of immunodiagnostics by the same risks, high costs and a corresponding lack of sensitivity. Thus, because of the high costs, risk of accidental infection with live virus and the lower than desired levels of sensitivity of the previously available tests, there exists a need for rapid, simple and highly sensitive diagnostic tests for detecting flavivirus infection and/or contamination.

The present invention meets these needs by providing highly immunogenic recombinant antigens for use in diagnostic assays for the detection of antibodies to selected fla-²⁰ viviruses. The present invention further provides for the use of recombinant antigens derived from flaviviruses, flavivirus genes or mimetics thereof in immunodiagnostic assays for the detection of antibodies to flavivirus proteins.

SUMMARY OF THE INVENTION

The present invention provides a nucleic acid molecule which contains a transcriptional unit (TU) for an immunogenic flavivirus antigen. The TU directs a host cell, after being incorporated within the cell, to synthesize the antigen. In an important aspect of the invention, the flavivirus can be yellow fever virus (YFV), dengue serotype 1 virus (DEN-1), dengue serotype 2 virus (DEN-2), dengue serotype 3 virus (DEN-3), dengue serotype 4 virus (DEN-4), St. Louis encephalitis virus (SLEV), Japanese encephalitis virus (JEV), West Nile virus (WNV), Powassan virus or any other flavivirus. In important embodiments of the present invention, the antigen can be the flavivirus prM/M protein, the E protein, or both. In important embodiments of the present invention, the antigen can be a chimeric flavivirus protein. In particular, when the TU includes both the prM/M and E proteins, the host cell secretes subviral particles containing the prM/M and E antigens. In a further important aspect of the invention, the nucleic acid is a DNA molecule. In additional significant embodiments, the nucleic acid TU includes a control sequence disposed appropriately such that it operably controls the expression of the prM/M and E antigens and this control sequence can be the cytomegalovirus immediate early promoter. In an additional embodiment, the nucleotide sequence of the TU is engineered to optimize eukaryotic translation by minimizing large hairpin structures in the 5'-end untranslated region of an mRNA produced by the TU and/or the inclusion of a Kozak consensus sequence at the translational start site of an mRNA produced by the TU. In an additional embodiment, the transcriptional unit also includes a poly-A terminator.

The present invention further provides a host cell comprising a nucleic acid molecule which includes a transcriptional unit for an immunogenic flavivirus antigen that directs the host cell to synthesize the immunogenic antigen. The flavivirus may be YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flavivirus. In important embodiments, the antigen may be the prM/M protein, the E protein, or both the prM/M and the E proteins. In the latter case, the cell secretes subviral particles containing the prM/M and E antigens.

Additionally, the invention provides a composition for vaccinating a subject against a flavivirus containing a nucleic acid molecule that includes a transcriptional unit for an immunogenic flaviviral antigen. The transcriptional unit directs a cell within the body of the subject, after being incorporated therein, to synthesize the immunogenic antigen. The composition further includes a pharmaceutically accept-5 able carrier. In significant embodiments, the flavivirus may be YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flavivirus. Furthermore, the antigen may be the prM/M protein, the E protein, or both the prM/M and the E proteins. In the latter instance, the cell secretes 10 subviral particles comprising the flavivirus prM/M and E antigens. These subviral particles are also referred to as noninfectious recombinant antigen (NRA). In important embodiments, the nucleic acid molecule is a DNA molecule. In further significant embodiments, the transcriptional unit 15 additionally contains a control sequence disposed appropriately such that it operably controls the synthesis of the prM/M and E antigens when the nucleic acid is introduced into the cell of the subject. This control sequence can be the cytomegalovirus immediate early promoter. In a still further embodi- 20 ment, the transcriptional unit can also include a poly-A terminator.

The compositions provided by the present invention for vaccinating a subject against a flavivirus can include a nucleic acid molecule, or molecules, that include transcriptional units 25 for more than one immunogenic flaviviral antigen. The more than one immunogenic flaviviral antigen can be from different flavivirus species, strains or isolates in any combination. In significant embodiments, the flaviviruses included can be two or more, three or more, four or more, five or more, or 30 seven or more flaviviruses. Examples of such flaviviruses include, but are not limited to YFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flaviviruses. Combination vaccines can be formulated to confer immunity to flavivirus disease common to particular geo- 35 graphical regions. In a particular embodiment directed toward tropical and subtropical Asia, DEN-1, DEN-2, DEN-3, DEN-4, WN, and JE viruses can be selected. In a particular embodiment directed to Africa, DEN-1, DEN-2, DEN-3, DEN-4, WN and YF can be selected. In a particular embodi- 40 ment directed to Latin America, DEN-1, DEN-2, DEN-3, DEN-4, Rocio and YF viruses can be selected.

The invention provides still further a method of immunizing a subject against infection by a flavivirus. The method involves administering to the subject an effective amount of a 45 vaccinating composition that contains a nucleic acid molecule which includes a transcriptional unit for an immunogenic flavivirus antigen. The transcriptional unit directs a cell within the body of the subject, after being taken up by the cell, to synthesize the immunogenic antigen. The composition 50 additionally includes a pharmaceutically acceptable carrier. In significant embodiments of the method, the flavivirus may beYFV, DEN-1, DEN-2, DEN-3, DEN-4, SLEV, JEV, WNV, Powassan virus or other flavivirus. In yet other important aspects of the method, the antigen may be the prM/M protein, 55 the E protein, or both the prM/M and the E proteins. When the antigen is both the prM/M and the E proteins, the cell within the body of the subject, after incorporating the nucleic acid within it, secretes subviral particles comprising the flaviviral prM/M and E antigens. Additionally, in significant embodi- 60 ments of the method, the vaccinating composition is administered to the subject in a single dose, via a parenteral route. In yet a further aspect of the method, the nucleic acid is a DNA molecule. In yet additional embodiments of the method, the transcriptional unit further includes a control sequence dis- 65 posed appropriately such that it operably controls the synthesis of the prM/M and E antigens and in a significant aspect of

8

this embodiment, the control sequence is the cytomegalovirus immediate early promoter. Furthermore, the transcriptional unit may include a poly-A terminator.

These aspects and embodiments of the invention are the basis for its distinct attributes and advantages. Being a nucleic acid construct involving only portions of the flavivirus genome rather than the sequence encompassing the complete genome, the nucleic acid TU-containing vaccine is completely nonviable. It therefore poses no danger of infection by the flavivirus to those involved in its manufacture or to subjects receiving the vaccine. The nucleic acid vaccine is easy to prepare and easy to administer and is stable in storage prior to use. Unexpectedly it has been found that the nucleic acid vaccine of the invention is essentially 100% successful in conferring protective immunity in mammals after administering only a single dose. A further unexpected result is that the nucleic acid TU is able to engender immunity to a flavivirus in a female mammal which can be transmitted to its progeny through the milk. Without wishing to be limited by theory, the inventor believes that a possible mechanism for the success of the nucleic acid in conferring protective immunity is that a host cell harboring the nucleic acid, such as the cell of a subject to whom the vaccine is administered, produces subviral particles containing the flaviviral prM/M and E antigens. These particles mimic the immunogenic attributes of native flavivirus virions.

The present invention also provides noninfectious antigenic polypeptides, antigenic polypeptide fragments and NRA comprising the prM/M and/or E proteins of flaviviruses, wherein the transmembrane signal sequence is derived from a first flavivirus and the M and/or E proteins are derived from a second flavivirus. Further, the prM/M protein can comprise amino acid sequences from both the first and the second flaviviruses. Further, the E protein can comprise amino acid sequences from both the first and second flaviviruses. "Chimeric" as used herein means any protein or nucleic acid comprising sequence from more than one flavivirus. As used herein, "non-virulent" means the antigen or vaccine of this invention is incapable of causing disease. More particularly, the recombinant protein antigens are free of contaminating genomic material from flaviviruses that is necessary for flavivirus infection, replication and pathogenesis.

The polypeptides of the present invention can comprise the amino acid sequences defined herein, or that are known in the art, of the prM, M and/or E proteins of selected flaviviruses. The nucleic acids of this invention can comprise nucleotide sequence that encodes the prM, M and/or E proteins of selected flaviviruses.

The antigens of the present invention can be unconjugated, or they can be conjugated to a carrier molecule that facilitates placement of the antigen on a solid phase. A carrier molecule is one to which antigens can be conjugated and which will not react with antibodies in human serum. An example of such a carrier is bovine serum albumin (BSA).

The antigens of the present invention can also be recombinant proteins obtained by expressing nucleic acids encoding the antigen in an expression system capable of producing the antigen.

The amino acid sequences of the present antigens can contain an immunoreactive portion of the prM, M and/or E antigen. These antigens may further be attached to sequences designed to provide for some additional property, such as to remove/add amino acids capable of disulfide bonding to increase the reactivity of an epitope by providing a more rigid secondary structure, to increase its bio-longevity or to alter its cytotoxicity or to prevent infection. In any case, the antigen must possess immunoreactivity and/or immunogenicity.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of flaviviral polyprotein processing. The central horizontal region provides a schematic representation of the viral genome. The lines 5 denote the 5' and 3' non-translated regions and the boxed regions represent the open reading frame for structural (left and top) and non-structural (right and bottom) proteins. Cleavage by host cell signalase occurs simultaneously with translation at the E protein C-terminus, separating structural 10 and non-structural regions. A subtilase-like cellular enzyme, furin, may be responsible for prM cleavage. Potential transmembrane domains of viral polyprotein are indicated by shaded areas.

FIG. 2 is a map of the JEV genome (top) and the DNA 15 sequence of oligonucleotides used in a reverse transcriptasepolymerase chain reaction (RT-PCR) (center) to construct the transcription unit for the expression of prM-E protein coding regions (bottom). Potential transmembrane domains of viral polyprotein are indicated by shaded areas.

FIG. 3 shows a schematic representation of the plasmid vectors, pcDNA3, pCBamp, and pCIBamp, and the relationship between them. These plasmids include the CMV (cytomegalovirus) promoter/enhancer element, BGHp(A) (bovine growth hormone polyadenylation signal and 25 transcription termination sequence), ampicillin resistance gene and ColE1 origin of replication for selection and maintenance in E. coli. The f1 origin of replication for singlestranded rescue in E. coli cells, SV40 origin of replication (SV40 ORI), neomycin resistance coding region and SV40p 30 (A) sequences were deleted from pcDNA3 to generate pCBamp. An intron sequence was inserted in the NcoI-KpnI site of pCBamp to generate plasmid pCIBamp.

FIG. 4 shows SDS-PAGE-immunoblot analyses of the sucrose gradient purified subviral particles from JE-4B 35 COS-1 culture fluid (4B, right lane of each pair). The density gradient purified JE virion from JEV infected C6/36 cell culture was used as a positive control (JEV, left lane of each pair). JE RAF (hyperimmune ascitic fluid); 4G2, anti-E monoclonal antibody; JM01, anti-M monoclonal antibody; 40 NMAF (normal mouse ascitic fluid).

FIG. 5 shows a profile of the E antigen in a rate zonal sucrose gradient analysis prepared from the PEG precipitate of JE-4B cell culture medium with or without Triton X-100 treatment.

FIG. 6 shows signal peptide probability of the pCBJE1-14 (pCBJE) predicted by the SignalP-HMM program (panel A; amino acids 1-39 of SEQ ID NO: 18). The signal peptide probability is improved by altering the c-region sequence at -4 and -2 positions (C-4G and G-2S) (panel B, JE-LSS-M; 50 SEQ ID NO: 62), by shortening the n-region (panel C, JE-SS-ORI; SEQ ID NO: 63), or by a combination of both modifications (panel D, JE-SS-M; SEQ ID NO: 64).

FIG. 7 shows schematic representations of plasmid vectors pCBD2-14-16 (100% DEN-2 E), pCBD2-1J-4-3 (90% 55 DEN-2 E: 10% JEV E), and pCB8D2-2H-2-9-1 (80% DEN-2 E: 20% JEV E). These plasmids include the human cytomegalovirus (CMV) early gene promoter; JE virus signal sequence; DEN-2 virus prM and E gene region (amino terminal 100%, 90%, or 80%, respectively); JE virus E gene 60 region (none, 10% or 20%, respectively); and bovine growth hormone poly A signal (BGH).

FIG. 8 shows a comparison of secreted and membranebound recombinant protein by western blot. (A) Analysis of secreted recombinant antigen following PEG-precipitation 65 and ethanol extraction of culture fluid for DEN-2 plasmids pCB8D2-2J-2-9-1, pCB9D2-1J-4-3, pCBD2-14-16, and

control plasmid pEGFP. Lane 1(V), purified DEN-2 virus stained by Gold Blot (Owl Separation Systems, Portsmouth, N.H.). Reactivity of secreted, recombinant antigen from each plasmid with a, anti-envelope (E) specific Mab 1A6A-8; b, a mixture of MAB 1A6A-8, anti-capsid (C) specific Mab 1A2A-1, anti-serum specific for DEN-2 virus premembrane (prM) protein; and c, normal mouse ascites. (B) Analysis of recombinant plasmid-transformed cell hydrophobic membrane proteins. Lane 1 (V), purified DEN-2 virus stained by Gold Blot; lane 2 (V), reactivity of purified DEN-2 virus with a mixture of Mab 1A6A-8, Mab 1A2A-1, anti-serum specific for DEN-2 virus M protein, and anti-serum for DEN-2 virus prM protein. Reactivity of isolated hydrophobic membrane proteins from each plasmid-transformed cell line with a, Mab 1A6A-8; b, a mixture of Mab 1A6A-8, Mab 1A2A-1, antiserum specific for DEN-2 virus M protein, and anti-serum for DEN-2 virus prM protein; and c, normal mouse ascites.

DETAILED DESCRIPTION OF THE INVENTION

The invention encompasses nucleic acid transcriptional units which encode flaviviral antigenic proteins, such as the prM/M and E protein antigens. The nucleic acids function to express the prM/M and E protein antigens when the nucleic acid is taken up by an appropriate cell, especially when the cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid transcriptional unit (TU). The invention further encompasses cells containing a TU. The invention in addition encompasses a method of immunizing a subject against flaviviral infection by administering to the subject an effective amount of a vaccine containing the nucleic acid TU molecules.

The invention provides an isolated nucleic acid comprising a transcriptional unit encoding a signal sequence of a structural protein of a first flavivirus and an immunogenic flavivirus antigen of a second flavivirus, wherein the transcriptional unit directs the synthesis of the antigen. The invention further encompasses the use of the nucleic acid transcriptional unit (TU) to generate flaviviral antigens and the flaviviral antigens produced by the nucleic acid TU. The flaviviral antigens encompassed by the present invention include chimeric flavivirus antigens incorporating amino acid sequence from a first flavivirus and at least one further flavivirus. The invention still further encompasses the use of the flaviviral antigens encoded by the TU of the invention to produce flavivirusspecific antibodies and to detect the presence of flavivirusspecific antibodies.

In one embodiment, the isolated nucleic acid of this invention can comprise a transcriptional unit encoding a Japanese encephalitis virus signal sequence.

In another embodiment, the transcriptional unit of this invention can encode an immunogenic flavivirus antigen which can be from one or more of the following flaviviruses: yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, Japanese encephalitis virus, Powassan virus and West Nile virus

In another embodiment, the transcriptional unit of this invention can encode an immunogenic chimeric flavivirus antigen which can include sequence from more than one of the following flaviviruses: yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, Japanese encephalitis virus, Powassan virus and West Nile virus.

In a particular embodiment, the nucleic acid of this invention can encode a signal sequence of Japanese encephalitis virus and an M protein and an E protein of West Nile virus, SLEV, YFV and/or Powassan virus. The nucleic acid can also encode an immunogenic antigen which can be an M protein of a flavivirus, an E protein of a flavivirus, both an M protein and an E protein of a flavivirus, a portion of an M protein of a flavivirus, a portion of an E protein of a flavivirus and/or both 5 a portion of an M protein of a flavivirus and a portion of an E protein of a flavivirus. In a preferred embodiment, the isolated nucleic acid encodes both the M protein and the E protein of the flavivirus. Further, the nucleic acid of the invention can be DNA and can comprise nucleotide sequence SEQ ID NO:15, 10 SEQ ID NO: 19, SEQ ID NO:21, SEQ ID NO:23 or SEQ ID NO: 42.

In another particular embodiment, the nucleic acid of this invention can encode a signal sequence of Japanese encephalitis virus, an M protein of a second virus and a chimeric E 15 protein formed by from substitution of a portion of the nucleic acid encoding the second virus' E protein with nucleic acid encoding the corresponding portion of the JEV E protein. Alternatively, the portion of sequence corresponding to the deleted portion of the second virus' E protein can be substi- 20 tuted by other sequence selected from a third virus or it can be a non-viral sequence. The second protein can be West Nile virus, SLEV, YFV, Powassan and/or a serotype of Dengue virus. Chimeric E proteins can include those where the carboxy terminal portion can be from one flavivirus and the 25 remainder of the chimeric E protein is from another flavivirus. The carboxy terminal portion can be, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, or 75% of the chimeric E protein. The nucleic acid of the invention can be DNA and can comprise the protein-encoding sequence from nucleotide 30 sequence SEQ ID NO:44 or SEQ ID NO:46. The nucleic acid of the invention can comprise nucleotide sequence SEQ ID NO:44 or SEQ ID NO:46.

The transcriptional unit of this invention can also comprise a control sequence disposed appropriately so that it operably 35 controls the synthesis of the antigen. The control sequence can be, for example, the cytomegalovirus immediate early promoter. The nucleic acid of this invention can also comprise a Kozak consensus sequence located at a translational start site for a polypeptide comprising the antigen encoded by the 40 transcriptional unit. The transcriptional unit of this invention can also comprise a poly-A terminator.

The present invention further provides a cell comprising the nucleic acid of this invention.

Also provided is a composition comprising a pharmaceu- 45 tically acceptable carrier and nucleic acid or cell or antigen of this invention. The present invention additionally provides a method of immunizing a subject against infection by a flavivirus, comprising administering to the subject an effective amount of a composition of this invention. In a particular 50 embodiment, the composition used to immunize a subject directs the synthesis of both the M protein and the E protein of a flavivirus and a cell within the body of the subject, after incorporating the nucleic acid within it, secretes subviral particles comprising the M protein and the E protein. Alter- 55 natively, the composition can comprise an M protein and/or E protein of a flavivirus or subviral particles comprising the M protein and E protein. In the methods of this invention, the immunizing composition can be administered to the subject in a single dose and can be administered via a parenteral route. 60

This invention further provides the antigens produced from the isolated nucleic acids of this invention. As an example, the antigen from the second flavivirus encoded by the nucleotide sequence of TU can be the M protein which can be, for example, from West Nile virus. The antigen can also be protein from dengue virus, St. Louis encephalitis virus, Japanese encephalitis virus, Powassan virus and/or yellow fever virus. In a further embodiment, the antigen comprises a prM/M protein comprising the transmembrane signal sequence from a first flavivirus and further amino acid sequence comprising the remainder of the prM/M protein from a second flavivirus, which can be from SLEV, JEV, YFV, WNV and/or Powassan virus. The transmembrane signal sequence from a first flavivirus can be an improved or modified signal sequence wherein the signal sequence imparts desired characteristics such as a high signal sequence probability. Accomplishing these goals by design or selection can be with the use of machine-learning computer programs including, but not limited to, those using a hidden Markov model.

The antigen encoded by the nucleotide sequence of the TU can be West Nile virus antigen, dengue virus antigen, St. Louis encephalitis virus antigen, Japanese encephalitis virus antigen, Powassan virus antigen and/or yellow fever virus antigen.

The antigen encoded by the nucleotide sequence of the TU can also be the E protein, which can be the E protein from West Nile virus, dengue virus, St. Louis encephalitis virus, Japanese encephalitis virus, Powassan virus and/or yellow fever virus. The antigen encoded can also be a chimeric E protein comprising amino acid sequence selected from more than one flavivirus.

Additionally, the antigen encoded by the nucleotide sequence of the TU can be the M protein and the E protein, which can be from West Nile virus, dengue virus, St. Louis encephalitis virus, Japanese encephalitis virus, Powassan virus and/or yellow fever virus.

As used herein, "M protein" or "pr/M protein" or "prM/M protein" means a flavivirus M protein or flavivirus prM protein. Examples include, but are not limited to, prM proteins comprising amino acid sequence from one or more flavivirus prM proteins, M proteins comprising no additional amino acid sequence and proteins comprising additional amino acid sequences which are processed in vitro or in vivo to generate the mature M protein.

As used herein, "nucleic acid transcriptional unit" or "nucleic acid transcriptional unit molecule" means a nucleic acid encoding one or more specified proteins. The TU has biological activity such that, after having been introduced into a suitable cell, the nucleic acid induces the synthesis of one or more specified gene products encoded by the nucleic acid. The gene product(s) is (are) other biological macromolecules, such as proteins, not chemically related to the TU. The nucleic acid TU induces the cell to employ its cellular components to produce the specific gene product or products encoded by the nucleic acid of the TU. Although any nucleic acid may serve as a TU, in a preferred embodiment, the TU is the DNA of a plasmid or similar vector, wherein the plasmid or vector comprises coding sequences of marker genes or other sequence constructions that facilitate use of the TU for experimentation and biosynthesis.

As used herein, a "control sequence" is a regulatory nucleotide sequence incorporated within a TU which interacts with appropriate cellular components of the cell and leads to enhanced or activated biosynthesis of the gene products encoded by the TU. Thus a suitable control sequence is one with which the components of the cell have the capability to interact, resulting in synthesis of the gene product. When operably disposed in a nucleic acid with respect to a specified coding sequence, a control sequence effectively controls expression of the specified nucleic acid to produce the gene product.

As used herein, a "promoter" is a nucleotide sequence in a TU which serves as a control sequence.

As used herein, a "Kozak sequence" or "Kozak consensus sequence" is a nucleotide sequence at the translational start site which optimizes translation of eukaryotic mRNAs (Kozak, *Mol. Cell. Biology* 9: 5134-5142 (1989)).

As used herein, a "terminator" is an extended nucleotide 5 sequence which acts to induce polyadenylation at the 3' end of a mature mRNA. A terminator sequence is found after, or downstream from, a particular coding sequence.

As used herein, a "cell" is a prokaryotic or eukaryotic cell comprising a TU coding for one or more gene products, or 10 into which such a TU has been introduced. Thus, a cell harbors a foreign or heterologous substance, the TU, which is not naturally or endogenously found in the cell as a component. A suitable cell is one which has the capability for the biosynthesis of the gene products as a consequence of the introduc- 15 tion of the TU. In particular, a suitable cell is one which responds to a control sequence and to a terminator sequence, if any, that may be included within the TU. In important embodiments of the present invention, the cell is a mammalian cell. In particularly important embodiments of this inven- 20 tion, the cell is a naturally occurring cell in the body of a human or nonhuman subject to whom (which) the TU has been administered as a component of a vaccine. Alternatively, in analytical, or diagnostic applications, including preparation of antigen for use as a vaccine or in immunodiagnostic 25 assays, or for demonstrative purposes, the cell may be a human or nonhuman cell cultured in vitro.

As used herein, a "vaccine" or a "composition for vaccinating a subject" specific for a particular pathogen means a preparation, which, when administered to a subject, leads to 30 an immunogenic response in a subject. As used herein, an "immunogenic" response is one that confers upon the subject protective immunity against the pathogen. Without wishing to be bound by theory, it is believed that an immunogenic response may arise from the generation of neutralizing anti-35 bodies (i.e., a humoral immune response) or from cytotoxic cells of the immune system (i.e., a cellular immune response) or both. As used herein, an "immunogenic antigen" is an antigen which induces an immunogenic response when it is introduced into a subject, or when it is synthesized within the 40 cells of a host or a subject. As used herein, an "effective amount" of a vaccine or vaccinating composition is an amount which, when administered to a subject, is sufficient to confer protective immunity upon the subject. Historically, a vaccine has been understood to contain as an active principle 45 one or more specific molecular components or structures which comprise the pathogen, especially its surface. Such structures may include surface components such as proteins, complex carbohydrates, and/or complex lipids which commonly are found in pathogenic organisms.

As used herein, however, it is to be stressed that the terms "vaccine" or "composition for vaccinating a subject" extend the conventional meaning summarized in the preceding paragraph. As used herein, these terms also relate to the TU of the instant invention or to compositions containing the TU. The 55 TU induces the biosynthesis of one or more specified gene products encoded by the TU within the cells of the subject, wherein the gene products are specified antigens of a pathogen. The biosynthetic antigens then serve as an immunogen. As already noted, the TU, and hence the vaccine, may be any 60 nucleic acid that encodes the specified immunogenic antigens. In a preferred embodiment of this invention, the TU of the vaccine is DNA. The TU can include a plasmid or vector incorporating additional genes or particular sequences for the convenience of the skilled worker in the fields of molecular 65 biology, cell biology and viral immunology (See Molecular Cloning: A Laboratory Manual, 2nd Ed., Sambrook, Fritsch

and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989; and *Current Protocols in Molecular Biology*, Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly), which are incorporated herein by reference).

The TU molecules of the instant invention comprise nucleic acids, or derivatives of nucleic acids, having nucleotide sequences that encode specific gene products related to antigens of flaviviruses such as, but not limited to, WNV, JEV, dengue virus, yellow fever virus and SLEV. Although any nucleic acid may serve as a TU, in an important embodiment, the TU is DNA. Alternatively, the nucleic acids may be RNA molecules. They may also be any one of several derivatives of DNA or RNA having a backbone of phosphodiester bonds that have been chemically modified to increase the stability of the TU as a pharmaceutical agent. Modifications so envisioned include, but are not limited to, phosphorothioate derivatives or phosphonate derivatives. These and other examples of derivatives are well known to persons skilled in the field of nucleic acid chemistry.

The genome of JEV has been characterized and sequenced (FIGS. 1 and 2). The M structural protein is expressed as a portion of the polyprotein which includes a pre-M sequence (pr). This pr sequence, immediately amino terminal to the M protein sequence, prevents conformational problems in the processing of the polyprotein. In particular, the presence of the pr sequence is important in preventing misfolding of the E protein. Thus, the presence of prM allows for assembly of JEV particles. Once the virion or particle is formed, the pr sequence can be cleaved from the prM protein to yield mature virus particles containing M proteins, although cleavage of the prM protein to yield M protein is not necessary to produce infectious particles. The prM sequences from many different, related flaviviruses are cleaved to but a low extent, but the flaviviruses themselves are nonetheless, infectious. Examples of such related flaviviruses with similar genomic structures and functions include, but are not limited to WNV, YFV, dengue virus and SLEV.

In one embodiment, the TU encoding flaviviral M and E proteins in the instant invention is DNA. In accord with the discussion in the preceding paragraph, this DNA comprises a nucleotide sequence which encodes the M protein, comprising the pre-M sequence, and a nucleotide sequence encoding the E protein. In this way, the intended gene products are enabled to form subviral particles within the cell. The pre-M sequence can then be cleaved in a fashion analogous to that which occurs with respect to replete virions.

In order to function effectively in vivo as a vaccine, it is advantageous to include within the TU a control sequence 50 that has the effect of enhancing or promoting the transcription of the nucleotide sequences encoding the antigens. Use of such promoters is well known to those of skill in the fields of molecular biology, cell biology and viral immunology (See Molecular Cloning: A Laboratory Manual, 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989; and Current Protocols in Molecular Biology, Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly)). When the TU is used as a vaccine in a mammalian host, the promoter to be employed is preferably one which operates effectively in mammalian cells. Such a promoter is disposed with respect to the coding sequences from which transcription is to be promoted, at a position at which it may operably promote such transcription. In a significant embodiment of the instant invention, this promoter is the cytomegalovirus early promoter. In addition, in a further preferred embodiment of the invention, the coding sequences are followed, in the TU nucleic acid, by a termi-

nator sequence (Sambrook et al.). Particular embodiments of the invention relate to both prokaryotic and eukaryotic cells. Many promoter sequences are known that are useful in either prokaryotic or eukaryotic cells. (See Sambrook et al.)

The nucleic acids of the invention may further include 5 DNA sequences known to those of skill in the art to act as immunostimulatory elements. Examples of such elements include, but are not limited to, certain CpG motifs in bacterial DNA (Sato et al., Science 273: 352-354 (1996); Klinman et al., Vaccine 17: 19-25 (1998)).

Preparation of the Tu of the Invention is Readily Accomplished by Methods Well known to workers of skill in the field of molecular biology. Procedures involved are set forth, for example, in Molecular Cloning: A Laboratory Manual, 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor 15 Laboratory, Cold Spring Harbor, N.Y., 1989 and Current Protocols in Molecular Biology, Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly). The flaviviral RNA molecule may be isolated from a sample of live virus by methods widely known among virologists familiar with fla- 20 viviruses, for example, and with other groups of viruses as well. Methods used with JEV are summarized in Kuno et al. (J. Virol. 72: 73-83 (1998)). The RNA is used as a template for the synthesis of cDNA using reverse transcriptase. From the cDNA, a fragment containing the pre-M through E coding 25 region (FIG. 2) is obtained by digestion with restriction nucleases known to cleave the cDNA appropriately to provide such fragments. Examples of restriction digestion of JEV are provided in Nitayaphan et al. (1990) and Konishi et al. (1991). Incorporation of promoters, such as the cytomegalovirus pro- 30 moter, sequences to promote efficient translation, such as the Kozak sequence, and of the polyadenylation signal, is likewise well known to skilled practitioners in molecular biology and recombinant DNA engineering (Kozak, Mol. Cell. Biology 9: 5134-5142 (1989); Azevedo et al., Braz. J. Med. Biol. 35 Res. 32: 147-153 (1999)). When a nucleic acid comprising a TU containing the desired coding sequences and control sequences is prepared, it may be obtained in larger quantities by methods that amplify nucleic acids. Such methods are widely known to workers skilled in molecular biology and 40 recombinant DNA engineering. Examples of these methods include incorporation of the nucleic acid into a plasmid for replication by culturing in a cell such as a prokaryotic cell and harvesting the plasmid after completing the culture, as well as amplification of the nucleic acid by methods such as PCR and 45 other amplification protocols, as are well known in the art. These examples are not intended to limit the ways in which the nucleic acid containing the TU may be obtained.

The TU-containing nucleic acid molecules of the instant invention may be introduced into appropriate cells in many 50 ways well known to skilled workers in the fields of molecular biology and viral immunology. By way of example, these include, but are not limited to, incorporation into a plasmid or similar nucleic acid vector which is taken up by the cells, or encapsulation within vesicular lipid structures such as lipo-55 somes, especially liposomes comprising cationic lipids, or adsorption to particles that are incorporated into the cell by endocytosis.

In general, a cell of this invention is a prokaryotic or eukaryotic cell comprising a TU, or into which a TU has been 60 introduced. The TU of the present invention induces the intracellular biosynthesis of the encoded prM/M and E antigens. A suitable cell is one which has the capability for the biosynthesis of the gene products as a consequence of the introduction of the nucleic acid. In particular embodiments of the 65 invention, a suitable cell is one which responds to a control sequence and to a terminator sequence, if any, which may be

included within the TU. In order to respond in this fashion, such a cell contains within it components which interact with a control sequence and with a terminator and act to carry out the respective promoting and terminating functions. When the cell is cultured in vitro, it may be a prokaryote, a singlecell eukaryote or a multicellular eukaryote cell. In particular embodiments of the present invention, the cell is a mammalian cell. In these cases, the synthesized prM/M and E protein gene products are available for use in analytical, or diagnostic applications, including preparation of antigen for use as a vaccine or in immunodiagnostic assays, or for demonstrative purposes.

In some circumstances, such as when the cell is a cultured mammalian cell, the prM/M and E antigens are secreted in the form of subviral particles. These are aggregates of prM/M and E proteins resembling live virus in surface ultrastructural morphology and immunogenic properties. Since the TU of the invention does not include the remainder of the flaviviral genome, however, there is no capsid incorporated, and most importantly, no infectious viral RNA.

In another important embodiment of this invention, the cell is a natural cellular component of the subject to whom the TU has been administered as a vaccine. The TU, when administered to the subject, is taken up by the cells of the subject. The subject's cells have the capability of responding to any promoter sequences, and terminator, if present. In any case, the TU induces the subject's cells to synthesize flaviviral prM/M and E gene products. Without wishing to be constrained by theoretical considerations, it is believed that the subject's cells produce subviral particles in vivo consisting of the prM/M and E antigens, just as has been found to occur with cultured mammalian cells in vitro. Such subviral particles, it is believed, then serve as the in vivo immunogen, stimulating the immune system of the subject to generate immunological responses which confer protective immunity on the subject. Again without wishing to be limited by theory, the resulting protective immunity may arise via either humoral or cellular immunity, i.e., via either an MHC class II- or class I-restricted mechanism, respectively, or by both mechanisms.

According to the invention, subjects are immunized against infection by flaviviruses, such as JEV, YFV, dengue virus, SLEV, WNV or other flaviviruses by administering to them an effective amount of a TU comprising nucleic acid which encodes the prM and/or E antigens. The nucleic acid, after being incorporated into the cells of the subject, leads to the synthesis of the flaviviral prM/M and/or E antigens.

In order to administer the TU to the subject, it is incorporated into a composition which comprises a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" means a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an subject along with the immunogenic material (i.e., recombinant flavivirus protein antigens or portions thereof) without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the vaccine in which it is contained. Examples of pharmaceutically acceptable carriers, or components thereof, include water, physiological saline and common physiological buffers (for further examples, see Amon, R. (Ed.) Synthetic Vaccines I: pp. 83-92, CRC Press, Inc., Boca Raton, Fla., 1987).

It is understood by those skilled in the art that the critical value in describing a vaccination dose is the total amount of immunogen needed to elicit a protective response in a host which is subject to infectious disease caused by virulent or wild-type flavivirus infection. The number and volume of doses used can be varied and are determined by the practitioner based on such parameters as, age, weight, gender, species,

type of vaccine to be administered, mode of administration, overall condition of the subject, et cetera, as well as other important factors recognized by those of skill in the art.

The TU may be administered to a subject orally, parenterally (e.g., intravenously), by intramuscular injection, by intra-5 peritoneal injection, transdermally, extracorporeally, intranasally, topically or the like. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation. The exact amount of the TU required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the immunogenicity of the vaccine used, the strain or species of flavivirus against which the subject is being immunized, the mode of administration and the like. Thus, it is not possible to specify an exact amount for every embodiment of the present invention. However, an 15 appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein and what is available in the art.

Parenteral administration of the vaccine of the present invention, if used, is generally characterized by injection. 20 Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system 25 such that a constant dosage is maintained. See, e.g., U.S. Pat. No. 3,610,795, which is incorporated by reference herein.

For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, 30 cellulose, glucose, sucrose, magnesium carbonate, and the like. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, 35 water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the 40 like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences (Martin, E. W. (ed.), 45 latest edition, Mack Publishing Co., Easton, Pa.).

In one embodiment, the TU of this invention can be administered to the subject by the use of electrotransfer mediated in vivo gene delivery, wherein immediately following administration of the TU to the subject, transcutaneous electric pulses 50 are applied to the subject, providing greater efficiency and reproducibility of in vivo nucleic acid transfer to tissue in the subject (Mir et al., Proc. Nat. Acad. Sci USA 96: 4262-4267 (1999)).

In the methods of the present invention which describe the 55 immunization of a subject by administering a vaccine of this invention to a subject, the efficacy of the immunization can be monitored according the clinical protocols well known in the art for monitoring the immune status of a subject.

An effective amount of a vaccinating composition is 60 readily determined by those of skill in the art to be an amount which, when administered to a subject, confers protective immunity upon the subject. In order to undertake such a determination, the skilled artisan can assess the ability to induce flaviviral prM/M- and E-specific antibodies and/or 65 flaviviral prM/M- and E-specific cytotoxic T lymphocytes present in the blood of a subject to whom the vaccine has been

administered. One can also determine the level of protective immunity conferred upon an experimental subject by challenge with live flavivirus corresponding to the antigenic composition used to immunize the experimental subject. Such challenge experiments are well known to those of skill in the art.

In general, in order to immunize a subject against infection by WNV, JEV, YFV, dengue virus, SLEV, or other flaviviruses according to the present invention, and recognizing that the TUs employed in such methods may have differing overall sizes, doses ranging from about 0.1 µg/kg body weight to about 50 µg/kg body weight can be used.

It has unexpectedly been found that a TU of the present invention which is a DNA confers protective immunity at a level of effectiveness approximating 100% after administration of only a single effective dose of the TU by i.m. injection or by electrotransfer. This is in contrast to many immunization methods carried out using conventional vaccines (as described above), which require one or more booster vaccinations and which may not confer protective immunity to an effectiveness near 100%.

It has further been found unexpectedly that protective immunity may be transmitted from a vaccinated female subject to the offspring of the subject. A significant proportion of neonatal mice was shown to be protected against viral challenge after the mothers were vaccinated using the TU DNA of the invention. Without wishing to be limited by theory, it is known that passive immunity may be conferred on neonatal mammals due to the presence in maternal milk of neutralizing antibodies specific for various pathogens. It is possible that the protective immunity against JEV found within the neonates was transmitted to them in this way.

In another embodiment of the invention, the TU encodes a signal sequence of a structural protein of a first flavivirus and an immunogenic flavivirus antigen of a second flavivirus. Thus, in one embodiment, for example, the signal sequence of structural protein of a first flavivirus is replaced by a signal sequence of structural protein of a second flavivirus, which results in proper folding of the nascent polypeptide, proper processing in a host, and/or proper folding of the processed protein.

In another embodiment of the invention, the TU may encode an immunogenic flavivirus antigen wherein the antigen comprises sequence from one or more than one flavivirus. The signal sequence can be an improved signal peptide. Improvement of signal sequences, or selection of more optimal signal sequences, can be accomplished by application of the principles and techniques taught in Example 18 and references cited therein, each of which are incorporated herein by reference for the express teachings in each related to the selection, identification and design of signal sequences with desired properties and functions. Generally, these desired properties and functions will include a high signal sequence probability.

In another embodiment of the invention, more than one TU or a TU encoding an immunogenic flavivirus antigen from more than one flavivirus are included in a single composition. Thus, in one embodiment, for example, a TU can encode a nascent polypeptide or polypeptides that are processed into proteins from more than one flavivirus. Preferably, the processed proteins form subviral particles that elicit an immunological response against the proteins. The subviral particles can be formed from processed proteins derived from the sequence of the same flavivirus, a combination of flaviviruses, or chimeric flavivirus proteins. Combination vaccines, comprising more than one TU or a TU encoding an immunogenic flavivirus antigen from more than one flavivirus can be tailored for use in particular geographical regions by inclusion of proteins from flaviviruses endemic to the region or otherwise likely to be encountered. For example, a vaccine for tropical and subtropical Asia can include TU(s) that encode proteins from the four serotypes of DEN, WN and JE virus vaccines. Similarly useful vaccines for Africa and Latin America could include TU(s) that encode proteins from the four serotypes of DEN, WN and YF viruses and the four serotypes of DEN, Rocio and YF viruses, respectively.

In another embodiment, the TU encodes a signal sequence 10 of a structural protein of a first flavivirus and an immunogenic chimeric flavivirus antigen that includes amino acid sequence from more than one flavivirus. The signal sequence can be a Japanese encephalitis virus signal sequence. The chimeric flavivirus antigen can include sequence from a Japanese 15 encephalitis virus antigen. In certain embodiments, the chimeric antigen is an E protein. The carboxy terminal portion of the E protein can be E protein sequence from the Japanese encephalitis virus. The carboxy terminal portion can be, for example, 5, 10, 15, 20, 25, 30, 40, 50 or 75% of the chimeric 20 immunizing subjects with immunogenic amounts of the pro-E protein. In a preferred embodiment, the TU encodes a signal sequence of a structural protein of Japanese encephalitis virus, a prM protein of a Dengue virus and a chimeric E protein containing sequence from both the Japanese encephalitis virus and the Dengue virus. The chimeric protein can be 25 an E protein wherein the carboxy terminal portion comprises Japanese encephalitis virus sequence. Examples of TUs include nucleic acid sequences shown in SEQ ID NO:44 and SEQ ID NO:46 that can direct the synthesis of flavivirus antigens such as those shown in SEQ ID NO:45 and SEQ ID 30 NO:47.

The present invention further provides immunogenic compositions comprising the polypeptides of this invention in a pharmaceutical acceptable carrier for use as a protein vaccine. Antigens produced from the transcriptional units of the 35 present invention can be used to elicit effective immune responses in a subject. Antigens for this purpose can comprise flavivirus prM protein, flavivirus M protein, flavivirus E protein or any combination thereof, including immunogenic fragments of the proteins. A particularly preferred embodi- 40 ment is the use of the NRA described herein. A further preferred embodiment is a chimeric protein comprising the signal sequence of one flavivirus and the structural protein(s) of one or more different flaviviruses. In a particularly preferred embodiment, the signal sequence of the antigen is the Japa- 45 nese encephalitis virus signal sequence. In other preferred embodiments, the signal sequence is a an improved signal peptide. Improvement of signal sequences, or selection of more optimal signal sequences, can be accomplished by application of the principles and techniques taught in 50 Example 18 and references cited therein each of which are incorporated herein by reference for the express teachings in each related to the selection, identification and design of signal sequences with desired properties and function. Generally, these desired properties and function will include a 55 high signal sequence probability.

In other embodiments, the protein vaccine of this invention further comprises a suitable adjuvant. As used herein, an "adjuvant" is a potentiator or enhancer of the immune response. The term "suitable" is meant to include any sub- 60 stance which can be used in combination with the vaccine immunogen (i.e., flavivirus prM protein, flavivirus M protein, flavivirus E protein, or any combination thereof) to augment the immune response, without producing adverse reactions in the vaccinated subject. Effective amounts of a specific adju- 65 vant may be readily determined so as to optimize the potentiation effect of the adjuvant on the immune response of a

vaccinated subject. In a preferred embodiment, adjuvanting of the vaccines of this invention is a 2-stage process, utilizing first a 2% aluminum hydroxide solution and then a mineral oil. In specific embodiments, suitable adjuvants can be chosen from the following group: mineral, vegetable or fish oil with water emulsions, incomplete Freund's adjuvant, E. coli J5, dextran sulfate, iron oxide, sodium alginate, Bacto-Adjuvant, certain synthetic polymers such as Carbopol (BF Goodrich Company, Cleveland, Ohio), poly-amino acids and copolymers of amino acids, saponin, carrageenan, REGRESSIN (Vetrepharm, Athens, Ga.), AVRIDINE (N,Ndioctadecyl-N',N'-bis(2-hydroxyethyl)-propanediamine), long chain polydispersed β (1,4) linked mannan polymers interspersed with O-acetylated groups (e.g. ACEMANNAN), deproteinized highly purified cell wall extracts derived from non-pathogenic strain of Mycobacterium species (e.g. EQUIMUNE, Vetrepharm Research Inc., Athens Ga.), Mannite monooleate, paraffin oil and muramyl dipeptide.

In another aspect, this invention provides a method for tein vaccine of the invention to elicit an effective immune response in the subject. Immunization can be carried out orally, parenterally, intranasally, intratracheally, intramuscularly, intramammarily, subcutaneously, intravenously and/or intradermally. The vaccine containing the flavivirus prM protein, flavivirus M protein and/or the flavivirus E protein can be administered by injection, by inhalation, by ingestion, or by infusion. A single dose can be given and/or repeated doses of the vaccine preparations, i.e. "boosters," can be administered at periodic time intervals to enhance the initial immune response or after a long period of time since the last dose. The time interval between vaccinations can vary, depending on the age and condition of the subject.

The term "immunogenic amount" means an amount of an immunogen, or a portion thereof, which is sufficient to induce an immune response in a vaccinated subject and which protects the subject against disease caused by wild-type or virulent flavivirus infections upon exposure thereto or which has a therapeutic or commercially beneficial effect that lessens the effect of flavivirus infection on the vaccinated subject.

The invention further provides an antibody produced in response to immunization by the antigen of this invention. The antibodies of the present invention can include polyclonal and monoclonal antibodies which can be intact immunoglobulin molecules, chimeric immunoglobulin molecules, "humanized antibodies," or Fab or F(ab')2 fragments. Such antibodies and antibody fragments can be produced by techniques well known in the art which include those described in Harlow and Lane (Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989) and Kohler et al. (Nature 256:495-97, 1975) and U.S. Pat. Nos. 5,545,806, 5,569,825 and 5,625,126, incorporated herein by reference. The antibodies can be of any isotype IgG, IgA, IgD, IgE and IgM.

The present invention can also include single chain antibodies (ScFv), comprising linked \mathbf{V}_{H} and \mathbf{V}_{L} domains and which retain the conformation and specific binding activity of the native idiotype of the antibody. Such single chain antibodies are well known in the art and can be produced by standard methods. (see, e.g., Alvarez et al., Hum. Gene Ther. 8: 229-242 (1997)).

Antibodies can be produced against the antigens of this invention which are synthesized from nucleic acid sequences encoding immunogenic amino acid sequences of the prM, M and/or E antigens of one or more flaviviruses and the signal sequence of a different flavivirus (e.g., JEV). Immunogenic peptides synthesized from the use of these chimeric constructs can easily be identified by use of methods well known in the art for identifying immunogenic regions in an amino acid sequence and used to produce the antibodies of this invention.

Conditions whereby an antigen/antibody complex can 5 form, as well as assays for the detection of the formation of an antigen/antibody complex and quantitation of the detected protein, are standard in the art. Such assays can include, but are not limited to, Western blotting, immunoprecipitation, immunofluorescence, immunocytochemistry, immunohis- 10 tochemistry, fluorescence activated cell sorting (FACS), fluorescence in situ hybridization (FISH), immunomagnetic assays, ELISA, ELISPOT (Coligan et al., eds. 1995. *Current Protocols in Immunology. Wiley, New York.*), agglutination assays, flocculation assays, cell panning, etc., as are well 15 known to the artisan.

As used herein, the term "bind" means the well characterized binding of antibody to antigen as well as other nonrandom association with an antigen. "Specifically bind" as used herein describes an antibody or other ligand that does not 20 cross react substantially with any antigen other than the one specified, which in this case, is an antigen of this invention.

The antibody or ligand of this invention can be bound to a substrate (e.g., beads, tubes, slides, plates, nitrocellulose sheets, etc.) or conjugated with a detectable moiety or both 25 bound and conjugated. The detectable moieties contemplated for the present invention can include, but are not limited to, an immunofluorescent moiety (e.g., fluorescein, rhodamine), a radioactive moiety (e.g., ³²P, ¹²⁵I, ³⁵S), an enzyme moiety (e.g., horseradish peroxidase, alkaline phosphatase), a colloi- 30 dal gold moiety and a biotin moiety. Such conjugation techniques are standard in the art (for example, Harlow and Lane, *Antibodies: A Laboratory Manual.* Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989); Yang et al., *Nature* 382: 319-324 (1996)).

The present invention further provides a method of detecting flavivirus antibody in a sample, comprising contacting the sample with the flavivirus antigen of the present invention, under conditions whereby an antigen/antibody complex can form; and detecting formation of the complex, thereby detect- 40 ing flavivirus antibody in the sample.

The present invention further provides a method of detecting flavivirus antigen in a sample, comprising contacting the sample with an antibody of this invention under conditions whereby an antigen/antibody complex can form; and detect- 45 ing formation of the complex, thereby detecting flavivirus antigen in the sample.

The method of detecting flavivirus antigen in a sample can be performed, for example, by contacting a fluid or tissue sample from a subject with an antibody of this invention and 50 detecting binding of the antibody to the antigen. It is contemplated that the antigen will be on an intact flavivirus virion, will be a flavivirus-encoded protein displayed on the surface of a flavivirus-infected cell expressing the antigen, or will be a fragment of the antigen. A fluid sample of this method can 55 comprise any biological fluid which could contain the antigen or a cell containing the antigen, such as cerebrospinal fluid, blood, bile, plasma, serum, saliva and urine. Other possible examples of body fluids include sputum, mucus and the like.

The method of detecting flavivirus antibody in a sample 60 can be performed, for example, by contacting a fluid or tissue sample from a subject with an antigen of this invention and detecting the binding of the antigen to the antibody. A fluid sample of this method can comprise any biological fluid which could contain the antibody, such as cerebrospinal fluid, 65 blood, bile, plasma, serum, saliva and urine. Other possible examples of body fluids include sputum, mucus and the like.

Enzyme immunoassays such as immunofluorescence assays (IFA), enzyme linked immunosorbent assays (ELISA) and immunoblotting can be readily adapted to accomplish the detection of flavivirus antibodies according to the methods of this invention. An ELISA method effective for the detection of the antibodies can, for example, be as follows: (1) bind the antigen to a substrate; (2) contact the bound antigen with a fluid or tissue sample containing the antibody; (3) contact the above with a secondary antibody bound to a detectable moiety which is reactive with the bound antibody (e.g., horseradish peroxidase enzyme or alkaline phosphatase enzyme); (4) contact the above with the substrate for the enzyme; (5) contact the above with a color reagent; and (6) observe/measure color change or development.

Another immunologic technique that can be useful in the detection of flavivirus antibodies uses monoclonal antibodies (MAbs) for detection of antibodies specifically reactive with flavivirus antigens in a competitive inhibition assay. Briefly, sample is contacted with an antigen of this invention which is bound to a substrate (e.g., an ELISA 96-well plate). Excess sample is thoroughly washed away. A labeled (e.g., enzymelinked, fluorescent, radioactive, etc.) monoclonal antibody is then contacted with any previously formed antigen-antibody complexes and the amount of monoclonal antibody binding is measured. The amount of inhibition of monoclonal antibody binding is measured relative to a control (no antibody), allowing for detection and measurement of antibody in the sample. The degree of monoclonal antibody inhibition can be a very specific assay for detecting a particular flavivirus variety or strain, when based on monoclonal antibody binding specificity for a particular variety or strain of flavivirus. MAbs can also be used for direct detection of flavivirus antigens in cells by, for example, immunofluorescence assay (IFA) according to standard methods.

As a further example, a micro-agglutination test can be used to detect the presence of flavivirus antibodies in a sample. Briefly, latex beads, red blood cells or other agglutinable particles are coated with the antigen of this invention and mixed with a sample, such that antibodies in the sample that are specifically reactive with the antigen crosslink with the antigen, causing agglutination. The agglutinated antigenantibody complexes form a precipitate, visible with the naked eye or measurable by spectrophotometer. In a modification of the above test, antibodies of this invention can be bound to the agglutinable particles and antigen in the sample thereby detected.

The present invention further provides a method of diagnosing a flavivirus infection in a subject, comprising contacting a sample from the subject with the antigen of this invention under conditions whereby an antigen/antibody complex can form; and detecting antigen/antibody complex formation, thereby diagnosing a flavivirus infection in a subject.

The present invention further provides a method of diagnosing a flavivirus infection in a subject, comprising contacting a sample from the subject with the antibody of this invention under conditions whereby an antigen/antibody complex can form; and detecting antigen/antibody complex formation, thereby diagnosing a flavivirus infection in a subject.

In the diagnostic methods taught herein, the antigen of this invention can be bound to a substrate and contacted with a fluid sample such as blood, serum, urine or saliva. This sample can be taken directly from the patient or in a partially purified form. In this manner, antibodies specific for the antigen (the primary antibody) will specifically react with the bound antigen. Thereafter, a secondary antibody bound to, or labeled with, a detectable moiety can be added to enhance the detection of the primary antibody. Generally, the secondary antibody or other ligand, which is reactive, either specifically with a different epitope of the antigen or nonspecifically with the ligand or reacted antibody, will be selected for its ability to react with multiple sites on the primary antibody. Thus, for example, several molecules of the secondary antibody can ⁵ react with each primary antibody, making the primary antibody more detectable.

The detectable moiety allows for visual detection of a precipitate or a color change, visual detection by microscopy, or automated detection by spectrometry, radiometric mea-¹⁰ surement or the like. Examples of detectable moieties include fluorescein and rhodamine (for fluorescence microscopy), horseradish peroxidase (for either light or electron microscopy and biochemical detection), biotin-streptavidin (for light or electron microscopy) and alkaline phosphatase (for ¹⁵ biochemical detection by color change).

Particular embodiments of the present invention are set forth in the examples which follow. These examples are not intended to limit the scope of the invention as disclosed in this specification.

EXAMPLES

General methods utilizing molecular biology and recombinant DNA techniques related to preparing and expressing ²⁵ the nucleic acid TU molecules of the invention are set forth in, for example, *Current Protocols in Molecular Biology*, Ausubel et al., John Wiley and Sons, New York 1987 (updated quarterly), and *Molecular Cloning: A Laboratory Manual* 2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Har- ³⁰ bor Laboratory, Cold Spring Harbor, N.Y., 1989.

Example 1

Preparation of Recombinant Plasmids Containing the Transcriptional Unit Encoding JEV prM and E Antigens

Genomic RNA was extracted from 150 µL of JEV strain SA 14 virus seed grown from mouse brain using a QIA ampTM 40Viral RNA Kit (Qiagen, Santa Clarita, Calif.). RNA, adsorbed on a silica membrane, was eluted in 80 µL of nuclease-free water, and used as a template for the amplification of JEV prM and E gene coding sequences. Primer sequences were obtained from the work of Nitayaphan et al. (Virology 177: 45 541-552 (1990)). A single cDNA fragment containing the genomic nucleotide region 389-2478 was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR). Restriction sites KpnI and XbaI, the consensus Kozak ribosomal binding sequence, and the translation initiation site 50 were engineered at the 5' terminus of the cDNA by amplimer 14DV389 (nucleotide sequence, SEQ ID NO: 1; amino acid sequence, SEQ ID NO:2). An in-frame translation termination codon, followed by a NotI restriction site, was introduced at the 3' terminus of the cDNA by amplimer c14DV2453 55 (SEQ ID NO:3) (FIG. 2). One-tube RT-PCR was performed using a Titan RT-PCR Kit (Boehringer Mannheim, Indianapolis, Ind.). 10 μ L of viral RNA was mixed with 1 μ L each of 14DV389 (50 µM) and c14DV2453 (50 µM) and 18 µL of nuclease-free water and the mixture was heated at 85° C. for 60 5 min and then cooled to 4° C. 75 μL of reaction mix [20 μL $5 \times$ buffer, 2 µL of dNTP mixture (10 mM each), 5 µL of dithiothreitol (0.1 mM), 0.5 µL of RNasinTM (40 U/µL, Boehringer Mannheim), 2 µL of polymerase mixture, and 45.5 µL of nuclease-free water] was added and RT-PCR performed as 65 follows: 1 cycle (50° C. for 30 min, 94° C. for 3 min, 50° C. for 30 s, 68° C. for 2.5 min), 9 cycles (94° C. for 30 s, 50° C.

for 30 s, 68° C. for 2.5 min), 20 cycles (94° C. for 30 s, 50° C. for 30 s, 68° C. for 2.5 min in the first cycle, with an increment of 5 s per cycle thereafter), and a final extension at 68° C. for 15 min. The RT-PCR product was purified by a QIAquickTM PCR Purification Kit (Qiagen) and eluted with 50 μ L of 1 mM Tris-HCl, pH 7.5.

All vector constructions and analyses were carried out by using standard techniques (Sambrook et al., 1989). RT-PCR amplified cDNA, digested with KpnI and NotI nucleases, was inserted into the KpnI-NotI site of eukaryotic expression plasmid vector (pcDNA3, Invitrogen, Carlsbad, Calif.). Electroporation-competent Escherichia coli XL1-Blue cells (Stratagene, La Jolla, Calif.) were transformed by electroporation (Gene PulserTM, Bio-Rad, Hercules, Calif.) and plated onto LB agar plates containing 100 µg/mL carbenicillin (Sigma Chemical Co., St. Louis, Mo.). Clones were picked and inoculated into 3 mL LB broth containing 100 µg/mL carbenicillin. Plasmid DNA was extracted from a 14 h culture using a QIAprep[™] Spin Miniprep Kit (Qiagen). Automated DNA sequencing was performed as recommended (Applied Biosystems/Perkin Elmer, Foster City, Calif.). Both strands of the cDNA were sequenced and shown to be identical to the sequence for the original SA14 strain (Nitayaphan et al., 1990).

The fragment of plasmid pcDNA3 (Invitrogen, Carlsbad, Calif.) from nucleotide (nt) 1289 to nt 3455, containing fl ori, SV40 ori, the neomycin resistance gene, and SV40 poly(A) elements was deleted by PvuII digestion and then ligated to generate the pCBamp plasmid. The vector pCIBamp, containing a chimeric intron insertion at the NcoI/KpnI site of the pCBamp was constructed by excising the intron sequence from pCI (Promega, Madison, Wis.) by digestion with NcoI and KpnI. The resulting 566-bp fragment was cloned into pCBamp by digesting with NcoI-KpnI to replace its 289-bp fragment. FIG. **3** presents the relationships between the plasmids pCDA3, pCBamp, and pCIBamp.

Plasmids containing the transcriptional unit encoding JEV prM and E proteins were prepared from these plasmids. The cDNA fragment containing the JEV prM and E coding regions in the recombinant plasmid pCDJE2-7 (nucleotide sequence, SEQ ID NO: 10; amino acid sequence, SEQ ID NO: 11), derived from the pcDNA3 vector, was excised by digestion with NotI and KpnI or XbaI and cloned into the KpnI-NotI site of pCBamp, pCIBamp, pCEP4 (Invitrogen, Carlsbad, Calif.), or pREP4 (Invitrogen, Carlsbad, Calif.), or into the SpeI-NotI site of pRc/RSV (Invitrogen, Carlsbad, Calif.) expression vector to create pCBJE1-14 (nucleotide sequence, SEQ ID NO: 17; amino acid sequence, SEQ ID NO:18), pCIBJES14, pCEJE, pREFE, and pRCJE, respectively. Both strands of the cDNA from clones of each plasmid were sequenced and recombinant clones with the correct nucleotide sequence were identified. Plasmid DNA for use in the in vitro transformation of mammalian cells or mouse immunization experiments was purified by anion exchange chromatography using an EndoFree™ Plasmid Maxi Kit (Qiagen).

Example 2

Evaluation of JEV prM and E Proteins Expressed by Various Recombinant Plasmids Using an Indirect Immunofluorescent Antibody Assay

The expression of JEV specific gene products by the various recombinant expression plasmids was evaluated in transiently transfected cell lines of COS-1, COS-7 and SV-T2 (ATCC, Rockville Md.; 1650-CRL, 1651-CRL, and 163.1CCL, respectively) by indirect immunofluorescent antibody assay (IFA). The SV-T2 cell line was excluded from further testing since a preliminary result showed only 1-2% of transformed SV-T2 cells were JEV antigen positive. For transformation, cells were grown to 75% confluence in 150 cm² culture flasks, trypsinized, and resuspended at 4° C. in phosphate buffered saline (PBS) to a final cell count 5×10^6 per mL. 10 µg of plasmid DNA was electroporated into 300 µL of cell suspension using a BioRad Gene Pulse[™] (Bio-Rad) set at 150 V, 960 μ F and 100 Ω resistance. Five minutes after elec-10troporation, cells were diluted with 25 mL fresh medium and seeded into a 75 cm² flask. 48 h after transformation the medium was removed from the cells, and the cells were trypsinized and resuspended in 5 mL PBS with 3% normal goat serum. 10 µL aliquots were spotted onto slides, air dried and fixed with acetone at -20° C. for 20 min. IFA was per-15 formed with acetone-fixed plasmid-transformed cells using fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin G (Sigma Chemical Co.) and JEV HIAF.

To determine the influence of various promoter and poly (A) elements on the JEV prM and E protein expression, ²⁰ larly with the 4B clone or JEV-infected COS-1 cells (Table 2). COS-1 and COS-7 cell lines were transiently transformed by an equal amount of pCDJE2-7 (SEQ ID NO: 10), pCEJE, pREJE, or pRCJE plasmid DNA. JEV antigens were expressed in both cell lines transformed by all four recombinant plasmids, thus confirming that the CMV or RSV (rous 25 sarcoma virus) promoter and BGH or SV40 poly(A) elements were functionally active. However, the percentage of transformed cells and the level of JEV antigens expressed, as determined by the number of IFA positive cells and IFA intensity, respectively, differed greatly among the various 30 plasmids (Table 1). A significantly high percentage of COS-1 cells transformed by pCDJE2-7 (SEQ ID NO: 10), pCBJE1-14 (SEQ ID NO: 17) and pCIBJES14 expressed the JEV antigens, and the level of the expressed proteins was compatible with JEV-infected cells. Cells transfected with pCEJE, 35 pREJE, or pRCJE vectors, on the other hand, had a low percentage of antigen-expressing cells, as well as a low intensity of fluorescence, indicating weak expression of the antigens.

In order to ascertain whether the enhanced expression of 40 JEV proteins by pCDJE2-7 (SEQ ID NO: 10) was influenced by the SV40-encoded eukaryotic origin of replication, the plasmid pCBJE1-14 (SEQ ID NO: 17) was constructed so that a 2166-bp fragment, containing f1 ori, SV40 ori, the neomycin resistance gene and SV40 poly(a) elements from 45 pCDJE2-7, was deleted. A chimeric intron was then inserted into pCBJE1-14 to generate pCIBJES14. The pCIBJES14 plasmid was used to determine if the expression of JEV proteins could be enhanced by the intron sequence. Following transformation, cells harboring both pCBJE1-14 and 50 pCIBJES14 vectors expressed a level of JEV antigens similar to that observed with pCDJE2-7 (Table 1). This result indicates that expression of JEV prM and E antigens by recombinant vectors is influenced only by the transcriptional regulatory elements. Neither the eukaryotic origin of replication 55 nor the intron sequence enhanced JEV antigen expression in the cells used. Vectors containing the CMV promoter and BGH poly(A) (FIG. 3) were selected for further analysis.

Example 3

Selection of an In Vitro Transformed Stable Cell Line Constitutively Expressing JEV Specific Gene Products

COS-1 cells were transformed with 10 µg of pCDJE2-7 DNA by electroporation as described in the previous

65

example. After a 24 hr incubation in non-selective culture medium, cells were treated with neomycin (0.5 mg/mL, Sigma Chemical Co.). Neomycin-resistant colonies, which became visible after 2-3 weeks, were cloned by limited dilution in neomycin-containing medium. Expression of vectorencoded JEV gene products was initially screened by IFA using JEV HIAF. One JEV-IFA positive clone (JE-4B) and one negative clone (JE-SA) were selected for further analysis and maintained in medium containing 200 µg/nL neomycin.

Authenticity of the JEV E protein expressed by the JE-4B clone was demonstrated by epitope mapping by WFA using a panel of JEV E-specific murine monoclonal antibodies (Mab) (Kimura-Kuroda et al., J. Virol. 45: 124-132 (1983); Kimura-Kuroda et al., J. Gen. Virol. 67: 2663-2672 (1986); Zhang et al., J. Med. Virol. 29: 133-138 (1989); and Roehrig et al., Virol. 128: 118-126 (1983)). JEV HIAF and normal mouse serum were used as positive and negative antibody controls, respectively. Four JEV-specific, six flavivirus-subgroup specific, and two flavivirus-group reactive Mabs reacted simi-

Example 4

Antigenic Properties and Immunological Detection of Subviral Particles Secreted by the JE-4B COS-1 Cell Line

a. Preparation of subviral particles. JE-4B COS-1 cells were grown and maintained in medium containing 200 µg/mL of neomycin. The cultured medium was routinely harvested and stored at 4° C., and replenished twice weekly, and the cells were split 1:5 every 7-10 days. Culture medium was clarified by centrifugation at 10,000 rpm for 30 min in a Sorvall F16/250 rotor at 4° C., and centrifuged further for 4 hr at 39,000 rpm in a Sorvall TH641 rotor at 4° C. through a 5% sucrose cushion (w/w, prepared with 10 mM Tris HCl, pH 7.5, 100 mM NaCl (TN buffer)). The pellet containing subviral particles was resuspended in TN buffer and stored at 4° C. Alternatively, 7% or 10% PEG-8000 (w/v) was added to the clarified culture medium. The mixture was stirred at 4° C. for at least 2 hr, and the precipitated particles were collected by centrifugation at 10,000 rpm for 30 min. The precipitate was resuspended in TN buffer and stored at 4° C. The subviral particles were purified from both pelleted and PEG-precipitated preparations by rate zonal centrifugation in a 5-25% continuous sucrose gradient in TN at 38,000 rpm at 4° C. for 90 min. 1-mL fractions were collected from the top of the gradient, tested by antigen capture ELISA (see below), and the positive fractions loaded onto a 25-50% sucrose gradient in TN. This was centrifuged overnight in an equilibrium density centrifugation at 35,000 rpm at 4° C. 0.9-mL fractions from the equilibrium gradients were collected from the bottom. They were tested by antigen-capture ELISA and assessed for hemagglutination (HA) activity at pH 6.6. An aliquot of 100 µL of each fraction was weighed precisely to determine its density. The ELISA-positive fractions were pooled and pelleted at 39,000 rpm at 4° C. for 3-4 hr and the pellet resuspended in TN buffer. Antigen-capture ELISA and HA titers were determined on the pelleted samples. JEV-60 infected COS-1 cell supernatant was also subjected to similar purification protocols as detailed above and used as a positive control for the gradient analysis. JE virions were also purified from infected C6/36 cells 5-6 days postinfection by sedimentation in a glycerol/tartrate equilibrium gradient.

b. Western blots of subviral particles. Gradient-purified samples of the subviral particles were mixed with electrophoresis sample buffer and run on 10 or 12.5% sodium dodecyl sulfate-containing polyacrylamide gels (SDS-PAGE) as described by Laemmli (*Nature* 277: 680-685 (1970)). Proteins were transferred to a nitrocellulose membrane and immunochemically detected with polyclonal JEV HIAF, flavivirus cross-reactive anti-E Mab 4G2 (Henchal et al., *Amer.* 5 *J. Trop. Med. Hyg.* 31: 830-836 (1982)), or mouse anti-prM peptide hyperimmune serum (JM10). FIG. 4 shows a comparison of the M and E proteins produced by JEV infected C6/36 and JE-4B COS-1 cells. Some nonspecific reactivity to E protein was observed in the normal mouse ascitic fluid and ¹⁰ JM01 anti-peptide serum. Proteins identical in size to M and E were secreted in the subviral particles and could be detected by E-specific Mab 4G2 and prM-specific JM01 antiserum, respectively.

c. Density gradient detection of JEV subviral particles in ¹⁵ culture medium. For ELISA, antigen-capture antibody (4G2) was diluted in 0.1 M sodium carbonate buffer, pH 9.6, and used to coat 96-well microtiter plates (Immulon II, Dynatech. Chantilly, Va.) by overnight incubation at 4° C. After blocking with 3% normal goat serum in PBS, two-fold serially-diluted ²⁰ samples were added to the 4G2-coated plate and incubated 1.5 hours at 37° C. Captured antigen was detected by horseradish peroxidase-conjugated 6B6C-1 Mag, and incubated for 1 hour at 37° C. The enzyme activity on the solid phase was then detected with TMB (3,3',5,5'-tetramethylbenzi- ²⁵ dine)-ELISA (Life Technologies, Grand Island, N.Y.).

Approximately 500 mL of cell culture medium from $15 \times 150 \text{ cm}^2$ flasks of JE-4B cells was collected four days after cells were seeded. PEG-precipitated subviral particles were resuspended in 2 mL of TN buffer, pH 7.5; a 0.7 mL 30 aliquot of this resuspended pellet was loaded onto a 5-25% sucrose gradient. Triton X-100, which disrupts subviral particles, was added to another 0.7 mL aliquot to a final concentration of 0.1% and this was loaded onto a 5-25% sucrose gradient prepared in TN buffer containing 0.1% Triton 35 X-100. A definite opaque band was observed approximately 2.5 cm from the top of the gradient containing Triton X-100, but not in the gradient without detergent. Fractions (1 mL) were collected from top to bottom for each gradient (FIG. 5). Each collected fraction was analyzed by antigen capture 40 ELISA. Antigen was detected in fractions 4-6, indicating relatively rapid sedimentation characteristic of subviral particles. Treatment of the PEG precipitate from JE-4B culture medium with Triton X-100 shifted the position of ELISAreactive material to the top of the gradient. Thus treatment 45 with Triton X-100 produces only slow-sedimenting molecules. A similar finding was reported by Konishi et al. (Virol. 188: 714-720 (1992)). These results show that rapidly sedimenting subviral particles containing prM/M and E could be disrupted by detergent treatment.

Hemagglutination (HA) activity was determined in the pH range from 6.1 to 7.0 by the method of Clarke and Casals (*Amer. J. Trop. Med. Hyg.* 7: 561-573 (1958)). The subviral particle secreted by JE-4B cells and the virion particle produced by JEV infected COS-1 cells had a similar HA profile ⁵⁵ with the optimum pH determined to be 6.6.

Example 5

Comparison of the Immune Response in Mice Vaccinated with pCDJE2-7 Nucleic Acid Vaccine of the Invention and Commercial JEV Vaccine

60

Groups of five 3-week-old female, ICR outbred mice were injected intramuscularly in the left and right quadriceps with $_{65}$ 100 µg of pCDJE2-7 plasmid in 100 µL of dH₂O or were given doses of JE-VAX (manufactured by the Research Foun-

dation for Microbial Disease of Osaka University and distributed by Connaught Laboratories, Swiftwater, Pa.) subcutaneously that are one-fifth the dose given to humans. The plasmid pcDNA3/CAT (Invitrogen), which encodes and expresses an unrelated protein, was used as the negative vaccination control. Except for one group of pCDJE2-7-vaccinated mice, all animals were boosted 3 weeks later with an additional dose of plasmid or JE-VAX. Mice were bled from the retroorbital sinus at 3, 6, 9, 23, 40 and 60 weeks after inoculation. JEV antibody titers were determined by enzyme-linked immunosorbent assay (ELISA) against purified JEV or by plaque reduction neutralization tests (PRNT) (Roehrig et al., *Virol.* 171: 49-60 (1989); and Hunt and Calisher, *Amer. J. Trop. Med. Hyg.* 28: 740-749 (1979)).

The pCDJE2-7 nucleic acid vaccine and JE-VAX provided 100% seroconversion within three weeks after the first vaccination in all three groups of mice (Table 3). The JEV ELISA and PRNT antibody titers reached the highest level at week 6 and week 9, respectively, after immunization. Mice receiving 1 dose of DNA vaccine had similar antibody responses as those receiving 2 doses. Comparable ELISA antibody titers were maintained in DNA-vaccinated groups up to 60 weeks, after which the experiment was terminated. However, only one of four mice in the JE-VAX group was JEV antibody positive at 60 weeks post-inoculation. The pcDNA3/CAT control group did not have any measurable JEV antibody. These results demonstrate that a single dose of JEV-specific nucleic acid vaccine is more effective in maintaining JEV antibody in mice than the commercial, FDA-approved JE-VAX vaccine.

Example 6

Comparison of Various Nucleic Acid Vaccine Constructs of the Invention and Commercial JEV Vaccine for Effectiveness of Vaccination at Different Ages

A similar level of JEV protein was expressed by COS-1 cells transformed by either pCDJE2-7, pCBJE1-14, or pCIBJES14. JEV antibody induction by these nucleic acid constructs was compared to JE-VAX commercial vaccine at two different ages at vaccination. Three-day (mixed sex) or 3-week-old (female) ICR outbred mice, 10 per group, were vaccinated intramuscularly with 50 or 100 µg of plasmid DNA, or subcutaneously with doses of JE-VAX that are one-tenth or one-fifth the dose given to humans. Serum specimens were collected at 3 and 7 weeks after immunization and tested at a 1:1600 dilution by ELISA using purified JEV as an antigen. Results are shown in Table 4.

Plasmid pCBJE1-14 provided the highest extent of seroconversion, i.e., antibody titer greater than 1:1600, achieving 80-100% at both ages of vaccination. Administration of pCDJE2-7 or pCIBJES14 provided moderate seroconversion by 7 weeks when 3-day old mice were vaccinated (60% for each), but weaker seroconversion (40% and 10%, respectively) when measured 3 weeks after vaccination. When these plasmids were administered at the age of 3 weeks, however, seroconversions of 90% or 100% were attained at both 3 weeks and 7 weeks after vaccination. In contrast, the commercial vaccine, JE-VAX, conferred no seroconversion when administered at 3 days of age, and 100% when given at 3 weeks of age. Thus the nucleic acid TU's for JEV prM and E provided an extent of seroconversion better than a very high

dose of the commercial vaccine, and unexpectedly high seroconversion in both young and more mature animals.

Example 7

Protective Immunity Conferred by the Nucleic Acid Vaccine of the Invention

Three-day old vaccinated groups from Example 6 were challenged 7 weeks after vaccination by intraperitoneal injection of 50,000 pfu/100 µL of the mouse-adapted JEV strain SA14 and observed for 3 weeks. 100% protection was achieved in groups that received various nucleic acid TUcontaining vaccine constructs for up to 21 days (Table 5). In contrast, 60% of the JE-VAX-vaccinated mice, as well as 70% of the pcDNA3/CAT-vaccinated negative controls, did not survive virus challenge by 21 days. These results indicate that the nucleic acid TU's of the invention confer unexpectedly effective protection on vaccinated mice. This suggests the possibility of employing the nucleic acid vaccine of the invention as an early childhood vaccine for humans. In con- 20 trast, JE-VAX, the inactivated human vaccine currently used, does not appear to be effective in young animals.

Example 8

Passive Protection of Neonatal Mice Correlated with the Maternal Antibody Titer

Female ICR mice at the age of 3 weeks were vaccinated with either one dose or two doses spaced two days apart of pCDJE2-7 plasmid DNA, at 100 µg/100 µL, or with two doses of JE-VAX that were one-fifth the dose given to humans. The negative control group received two doses of $100 \,\mu\text{g}/100 \,\mu\text{L}$ of pcDNA-3/CAT plasmid. Passive protection by maternal antibody was evaluated in pups resulting from matings of experimental females with non-immunized male mice that 35 occurred nine weeks following the first vaccination or 6 weeks following the second vaccination. Pups were challenged between 3-15 days after birth by intraperitoneal administration of 5,000 pfu/100 µL of mouse-adapted SA14 virus and observed daily for 3 weeks (Table 6). The survival $_{40}$ rates correlated with the maternal neutralizing antibody titers. 100% of pups nursed by mothers with a PRNT of 1:80 survived viral infection, whereas none of the pups from the control mother survived (Table 6). Partial protection of 45% and 75% was observed in older pups that were nursed by 45 mothers with a PRNT titer of 1:20 and 1:40, respectively. The survival rates also correlated with the length of time that pups were nursed by the immune mother. As just indicated, 13-15 day old pups had high survival rates. None of the 3-4 day old pups, however, survived virus challenge when the mother had 50 a PRNT titer of 1:20 or 1:40. Thus maternal antibody provides partial to complete protective immunity to the offspring. In addition, JEV antibody was detected by ELISA in the sera of 97% (29/30) of the post-challenge pups.

Mice were inoculated intramuscularly with 1 or 2, 100 µg 55 doses of plasmid DNA, or subcutaneously with two, 1/5 human doses of JE-VAX vaccine. Sera were collected 9 weeks post-vaccination for PRNT testing prior to mating with non-immune male.

Example 9

Preparation of Recombinant Plasmids Containing the Transcriptional Unit Encoding WNV prM and E Antigens

Genomic RNA was extracted from 150 µL of Vero cell culture medium infected with NY 99-6480 strain, an strain

65

isolated from the outbreak in New York 1999, using the QIAamp[™] Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 µl of nuclease-free water, and used as a template for the amplification of WNV prM and E gene coding sequences. Primer sequences were obtained from the work of Lanciotti et al. (Science 286: 2333-2337 (1999)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR). Restriction sites BsmBI and KasI were engineered at the 5' terminus of the cDNA by using amplimer WN466 (nucleotide sequence, SEQ ID NO: 12). An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3' terminus of the cDNA by using amplimer cWN2444 (SEQ ID NO: 13). The RT-PCR product was purified by a QIAquick[™] PCR Purification Kit (Qiagen).

The double-stranded amplicon produced by use of the two amplimers above (SEQ ID NO: 12 and SEQ ID NO: 13) was digested with KasI and NotI enzymes to generate a 998 bp (nt-1470 to 2468) fragment of DNA was inserted into the KasI and NotI sites of a pCBJESS vector to form an intermediate plasmid, pCBINT. The pCBJESS was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engi-²⁵ neered JE signal sequence element (Chang et al., J. Virol. 74: 4244-4252 (2000)). The JE signal sequence element comprises the JE signal sequence (SEQ ID NO: 14).

The cDNA amplicon was subsequently digested with BsmBI and Kas I enzymes and the remaining 1003 bp fragment (nt-466 to 1470) was inserted in to the KasI site of pCBINT to form pCBWN (nucleic acid sequence, SEQ ID NO: 15; amino acid sequence, SEQ ID NO: 16). Automated DNA sequencing using an ABI prism 377 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) was used to confirm that the recombinant plasmid had a correct prM and E sequence as defined by Lanciotti et al. (Science 286: 2333-2337 (1999)).

Plasmid DNA for use in the in vitro transformation of mammalian cells or mouse immunization experiments was purified by anion exchange chromatography as described in Example 1.

Example 10

Immunochemical Characterization and Evaluation of WNV prM and E Proteins Expressed by pCBWN

WNV specific gene products encoded by the pCBWN plasmid were expressed in COS-1 cells. Cells were electroporated and transformed with pCBWN plasmid according to Chang et al. (J. Virol. 74: 4244-4252 (2000)). Electroporated cells were seeded onto 75 cm² culture flasks or a 12-well tissue culture dish containing one sterile coverslip/well. All flasks and 12-well plates were kept at 37° C., 5% CO₂ incubator. Forty hours following electroporation, coverslips containing adherent cells were removed from the wells, washed briefly with PBS, fixed with acetone for 2 minutes at room temperature, and allowed to air dry.

Protein expression was detected using indirect immunof-60 luorescence antibody assay (IFA), as described in Example 2. Flavivirus E-protein specific monoclonal antibody (Mab) 4G2, WNV mouse hyperimmune ascitic fluid (RAF) and normal mouse serum (NMS) at 1:200 dilution in PBS were used as the primary antibody to detect protein expression (Henchal et al., Am. J. Trop. Med. Hyg. 31: 830-836 (1982)).

Tissue culture medium was harvested 40 and 80 hours following electroporation. Antigen-capture (Ag-capture) ELISA was used to detect secreted WN virus antigen in the culture medium of transiently transformed COS-1 cells. The Mab 4G2 and horseradish peroxidase-conjugated Mab 6B6C-1 were used to capture the WN virus antigens and detect captured antigen, respectively (Chang et al., *J. Virol.* 5 74: 4244-4452 (2000); Henchal et al., *Am. J. Trop. Med. Hyg.* 31: 830-836 (1983); Roehrig et al., *Virology* 128: 118-126 (1983)).

WN virus antigen in the medium was concentrated by precipitation with 10% polyethylene glycol (PEG)-8000. The 10 precipitant was resuspended in TNE buffer (50 mM Tris, 100 mM NaCl, 10 mM EDTA, pH 7.5), clarified by centrifugation, and stored at 4° C. Alternatively, the precipitant was resuspended in a lyophilization buffer (0.1 M TRIZMA and 0.4% bovine serum albumin in borate saline buffer, pH 9.0), 15 lyophilized and stored at 4° C. Lyophilized preparations were used as antigen for the evaluation in MAC- and indirect IgG ELISAs.

WN virus-specific protein was detected by IFA on the transiently transformed COS-1 cells. E, prM and M proteins 20 expressed in these cells were secreted into the culture medium. WN virus antigen concentrated by PEG precipitation was extracted with 7.0% ethanol to remove residual PEG (Aizawa et al., Appl. Enviro. Micro. 39: 54-57 (1980)). Ethanol extracted antigens and gradient-purified WN virions were 25 analyzed on a NuPAGE, 4-12% gradient Bis-Tris Gel in a Excel Plus Electrophoresis Apparatus (Invitrogen Corp., Carlsbad, Calif.) and followed by electroblotting onto nitrocellulose membranes using a Excel Plus Blot Unit (Invitrogen Corp.). WN virus-specific proteins produced by the tran- 30 siently transformed COS-1 cells were detected by WN virus specific mouse HIAF or flavivirus E protein reactive Mab 4G2 in a Western blot analysis, using NMS as a negative serum control. The proteins displayed similar reactivity and identical molecular weights to the corresponding gradient 35 purified virion E, prM and M protein derived from WN virus infected suckling mouse brain (SMB).

In analysis of the NRA as an antigen for diagnostic ELISA, one vial of lyophilized NRA, representing antigen harvested from 40 ml of tissue culture fluid, was reconstituted in 1.0 ml 40 of distilled water and compared with the reconstituted WN virus infected suckling mouse brain (SMB) antigen provided as lyophilized as β -propiolactone-inactivated sucrose-acetone extracts (Clarke et al., *Am. J. Trop. Med. Hyg.* 7: 561-573 (1958)). All recombinant proteins, prM, M and E, had a 45 similar reactivity to that of the gradient-purified virion E, prM and M proteins.

Coded human specimens were tested concurrently with antigens in the same test at the developmental stage. The MAC- and IgG ELISA protocols employed were identical to 50 the published methods (Johnson et al., J. Clin. Microbiol. 38: 1827-1831 (2000); Martin et al., J. Clin. Microbiol. 38: 1823-1826. (2000)). Human serum specimens were obtained from the serum bank in our facility, which consists of specimens sent to the DVBID for WN virus confirmation testing during 55 the 1999 outbreak In these tests, a screening MAC- and IgG ELISA were performed on a 1:400 specimen dilution. Specimens yielding positive/negative (P/N) OD ratios between 2 and 3 were considered suspect positives. Suspect serum specimens were subject to confirmation as positives by both 60 ELISA end-point titration and plaque-reduction neutralization test (PRNT). All specimens yielding P/N OD ratios greater than 3.0 were considered positives without further confirmatory testing.

An Ag-capture ELISA employing flavivirus-group reac- 65 tive, anti-E Mab, 4G2 and 6B6C-1, was used to detect NRA secreted into culture fluid of pCBWN transformed COS-1

cells. The antigen could be detected in the medium one day following transformation; and the maximum ELISA titer (1:32-1:64) in the culture fluid without further concentration was observed between day two and day four. NRA was concentrated by PEG precipitation, resuspended in a lyophilization buffer, and lyophilized for preservation. For diagnostic test development, one vial of lyophilized NRA was reconstituted with 1.0 ml distilled water and titrated in the MAC- or indirect IgG ELISA using WN virus positive and negative reference human sera (Johnson et al., J. Clin. Microbiol. 38: 1827-1831 (2000); Martin et al., J. Clin. Microbiol. 38: 1823-1826 (2000)). Dilutions 1:320 and 1:160 of the NRA were found to be the optimal concentrations for use in MAC- and IgG ELISA, respectively. These dilutions resulted in a P/N OD₄₅₀ ratio of 4.19 and 4.54, respectively, for MAC- and IgG test. The WN virus SMB antigens produced by NY-6480 and Eg101 strains were used at 1:320 and 1:640 dilution for MAC-ELISA, and 1:120 and 1:320 for IgG ELISA, respectively. The negative control antigens, PEG precipitates of the culture medium of normal COS-1 cells and normal SMB antigen, were used at the same dilutions as for the respective NRA and SMB antigen. Human serum specimens, diluted at 1:400, were tested concurrently in triplicate with virus-specific and negative control antigens. For the positive test result to be valid, the OD_{450} for the test serum reacted with viral antigen (P) had to be at least two-fold greater than the corresponding optical density value of the same serum reacted with negative control antigen (N).

The reactivity of NRA and NY-06480, Eg101 and SLE virus SMBs were compared by the MAC- and IgG ELISAs using 21 coded human serum specimens. Of the 21 specimens, 19 had similar results on all three antigens (8 negatives and 11 suspect positives or positives). Eighteen specimens were also tested separately using SLE SMB antigen. Only three of 13 Eg-101-SMB positive specimens were positive in the SLE MAC-ELISA (Table 1). None of WN antigen negative specimens was positive by SLE MAC-ELISA. This result confirmed a previous observation that anti-WN virus IgM did not cross-react significantly with other flaviviruses (Tardei et al., J. Clin. Microbiol. 38: 2232-2239 (1940)) and was specific to diagnose acute WN virus infection regardless of whether NRA or SMB antigen was used in the test. All of the specimens were also tested concurrently by indirect IgG ELISA. Ten of 21 specimens were positive using any of the three antigens.

The two discrepant serum specimens (7 and 9) both from the same patient, collected on day-4 and 44 after onset of disease, respectively, were IgM-negative with NRA and SMB NY antigen and IgM-positive using Eg-101 SMB antigen in the initial test. To investigate these two discordant specimens further, six sequentially collected specimens from this patient were retested by end-point MAC- and IgG ELISAs. A greater than 32-fold serial increase shown in the MAC-ELISA titer between day-3 and day-15 could be demonstrated with all antigens used. Cerebrospinal fluid collected on day-9 after onset of disease also confirmed that this patient indeed was infected by WN shortly prior to taking the sample. The cerebrospinal fluid had IgM P/N reading of 13.71 and 2.04 against Eg-101- and SLE-SMB antigens, respectively. Day-31 and day-44 specimens were negative (<1:400) by using NY-SMB antigen but positive by using NRA and Eg101-SMB. Compatible IgG titers were observed with all three antigens used in the test.

Example 11

Evaluation of the Immune Response in Animals Vaccinated with pCBWN

Groups of ten, three-wk-old female ICR mice were used in the study. Mice were injected intramuscularly (i.m.) with a single dose of pCBWN or a green fluorescent protein expressing plasmid (pEGFP) DNA (Clonetech, San Francisco, Calif.). The pCBWN plasmid DNA was purified from XL-1 blue cells with EndoFree Plasmid Giga Kits (Qiagen) and resuspended in PBS, pH 7.5, at a concentration of $1.0 \,\mu\text{g/}\mu\text{l}$. Mice that received 100 µg of pEGFP were used as unvaccinated controls. Mice were injected with the pCBWN plasmid at a dose of 100, 10, 1.0, or 0.1 μ g in a volume of 100 μ l. Groups that received 10, 1.0, or 0.1 µg of pCBWN were vaccinated by the electrotransfer mediated in vivo gene delivery protocol using the EMC-830 square wave electroporator (Genetronics Inc. San Diego, Calif.). The electrotransfer protocol was based on the method of Mir et al., (Proc. Natl. Acad. Sci. USA 96: 4262-4267. (1999)). Immediately following 15 DNA injection, transcutaneous electric pulses were applied by two stainless steel plate electrodes, placed 4.5-5.5 mm apart, at each side of the leg. Electrical contact with the leg skin was ensured by completely wetting the leg with PBS. Two sets of four pulses of 40 volts/mm of 25 msec duration 20 with a 200 msec interval between pulses were applied. The polarity of the electrode was reversed between the set of pulses to enhance electrotransfer efficiency.

Mice were bled every 3 wks following injection. The WN virus specific antibody response was evaluated by Ag-capture²⁵ ELISA and plaque reduction neutralization test (PRNT). Individual sera were tested by IgG-ELISA, and pooled sera from 10 mice of each group were assayed by PRNT. All the mice vaccinated with pCBWN had IgG ELISA titers ranging from 1:640 to 1:1280 three wks after vaccination. The pooled³⁰ sera collected at three and six wks had a Nt antibody titer of 1:80. None of the serum specimens from pEGFP control mice displayed any ELISA or Nt titer to WN virus.

To determine if the single i.m. vaccination of pCBWN could protect mice from WN virus infection, mice were challenged with NY-6480 virus either by intraperitoneal injection or by exposure to the bite of virus-infected *Culex* mosquitoes. Half of the mouse groups were challenged intraperitoneally (ip) at 6 wks post vaccination with 1,000 LD₅₀ (1,025 PFU/ 40 100 μ l) of NY99-6480 virus. The remaining mice were each exposed to the bites of three *Culex tritaeniorhynchus* mosquitoes that has been infected with NY99-6480 virus 7 days prior to the challenge experiment. Mosquitoes were allowed to feed on mice until they were fully engorged. Mice were 45 observed twice daily for three wks after challenge.

It was evident that the presence of Nt antibodies correlated with protective immunity, since all mice immunized with WN virus DNA remained healthy after virus challenge while all control mice developed symptoms of CNS infection 4-6 days 50 following virus challenge and died on an average of 6.9 and 7.4 days after intraperitoneal or infective mosquito challenge, respectively. In the vaccinated group, the pooled sera collected three wks after virus challenge (9-wk post immunization) had Nt antibody titers of 1:640 or 1:320. Pooled vacci-55 nated mouse sera reacted only with E protein in the Western blot analysis.

Groups of ten mice were immunized with 10.0 to 0.1 μ g of pCBWN per animal by use of electrotransfer. All groups that received pCBWN were completely protected from virus challenge. At 6 wks after immunization all groups of electrotransfer mice had Nt titer less than four-fold different than animals receiving 100 μ g of pCBWN by conventional i.m. injection without electrotransfer. Both these results evidencing effective immunization suggest that the electrotransfer protocol 65 enhances the immunogenicity and protective efficacy of the DNA vaccine of the invention (when carried out as described

in (Mir et al., Proc. Natl. Acad. Sci. USA. 96: 4262-4267. (1999))).

Mixed-bred mares and geldings of various ages used in this study were shown to be WN virus and SLE virus antibodynegative by ELISA and PRNT. Four horses were injected i.m. with a single dose (1,000 μ g/1,000 μ l in PBS, pH 7.5) of pCBWN plasmid. Serum specimens were collected every other day for 38 days prior to virus challenge, and the WN virus specific antibody response was evaluated by MAC- or IgG ELISA and PRNT.

Two days prior to virus challenge, 12 horses (4 vaccinated and 8 control) were relocated into a bio-safety level (BSL)-3 containment building at the Colorado State University. The eight unvaccinated control horses were the subset of a study that was designed to investigate WN virus induced pathogenesis in horses and the potential of horses to serve as amplifying hosts. Horses were each challenged by the bite of 14 or 15 Aedes albopictus mosquitoes that had been infected by NY99-6425 or BC787 virus 12 days prior to horse challenge. Mosquitoes were allowed to feed on horses for a period of 10 min. Horses were examined for signs of disease twice daily. Body temperature was recorded, and serum specimens collected twice daily from days 0 (day of infection) to 10, then once daily through day 14. Pulse and respiration were recorded daily after challenge. The collected serum samples were tested by plaque titration for detection of viremia, and by MAC- or IgG ELISA and PRNT for antibody response.

No systemic or local reaction was observed in any vaccinated horse. Individual horse sera were tested by PRNT. Vaccinated horses developed Nt antibody greater than or equal to 1:5 between days 14 and 31. End point titers for vaccinated horses, #5, #6, #7, and #8, on day-37 (two days prior to mosquito challenge) were 1:40, 1:5, 1:20, and 1:20, respectively. Horses vaccinated with the pCBWN plasmid remained healthy after virus challenge. None of them developed a detectible viremia or fever from days 1 to 14. All unvaccinated control horses became infected with WN virus after exposure to infected mosquito bites. Seven of the eight unvaccinated horses developed viremia that appeared during the first 6 days after virus challenge. Viremic horses developed Nt antibody between day-7 and day-9 after virus challenge. The only horse from the entire study to display clinical signs of disease was horse #11, which became febrile and showed neurologic signs beginning 8 days after infection. This horse progressed to severe clinical disease within 24 hours and was euthanized on day 9. Four representing horses, #9, 10, 14 and 15, presenting viremia for 0, 2, 4, or 6 days, were selected and used as examples in this example. Virus titers ranged from $10^{1.0}$ PFU/ml of serum (in horse #10), the lowest level detectable in our assay, to $10^{2.4}$ /ml (in horse #9). Horse #14 did not develop a detectible viremia during the test period. However, this horse was infected by the virus, as evidenced by Nt antibody detected after day 12.

Anamnestic Nt antibody response was not observed in vaccinated horses as evidenced by the gradual increase in Nt titer during the experiment. Pre-existing Nt antibody in the vaccinated horse prior to mosquito challenge could suppress initial virus infection and replication. Without virus replication, the challenge virus antigen provided by infected mosquitoes may not contain a sufficient antigen mass to stimulate anamnestic immune response in the vaccinated horse. All vaccinated horses were euthanized at 14 days after virus challenge. Gross pathological and histopathological lesions indicative of WN viral infection were not observed.

Example 12

Preparation of Recombinant Plasmids Containing Coding Sequences for Yellow Fever Virus (YFV) or St. Louis Encephalitis Virus (SLEV) prM and E Proteins

A strategy similar to constructing the pCDJE2-7 recombinant plasmid was used to prepare YFV and SLEV recombinant plasmids. Genomic RNA was extracted from 150 µL of 10 YFV strain TRI-788379 or SLE strain 78V-6507 virus seeds using Q1Aamp[™] Viral RNA Kit (Qiagen, Santa Clarita, Calif.). The viral RNA was used as a template for amplification of YFV or SLEV prM and E gene coding regions. Primers YFDV389 (nucleotide sequence, SEQ ID NO:4; amino acid 15 sequence, SEQ ID NO:5), cYFDV2452 (SEQ ID NO:6), SLEDV410 (nucleotide sequence, SEQ ID NO:7; amino acid sequence, SEQ ID NO:8) and cSLEDV2449 (SEQ ID NO:9) were used to generate the corresponding recombinant nucleic acids as described above for the preparation of the JEV and 20 WNV recombinant plasmids. RT-PCR amplified cDNA, digested with KpnI and NotI enzymes, was inserted into the KpnI-NotI site of a eukaryotic expression plasmid vector, pcDNA3 (Invitrogen). Both strands of the cDNA were sequenced and verified for identity to sequences from YFV 25 strain TRI-788379 or SLEV strain 78V-6507. Recombinant plasmids pCDYF2 and pCDSLE4-3, which contained the nucleotide sequences of the prM and E coding regions for YFV or SLEV, respectively, were purified using an EndoFree[™] Plasmid Maxi Kit (Qiagen), and used for in vitro trans- 30 formation or mouse immunization.

YFV or SLEV specific antigens were expressed in COS-1 cells transformed by pCDYF2 or pCDSLE4-3, respectively. The level of expressed proteins was similar to a YFV- or SLEV-infected COS-1 cell control. As in the JEV model, ³⁵ COS-1 cell lines transformed by vectors bearing genes for the viral antigens were obtained which constitutively express YFV or SLEV antigenic proteins. Epitope mapping by IFA using a panel of YFV or SLEV E-specific Mabs indicated that the authentic E protein was expressed by the pCDYF2- or ⁴⁰ pCDSLE4-3-transformed COS-1 cells. A preliminary study indicated that 100% of three week-old female, ICR mice seroconverted after intramuscular inoculation with a single dose of 100 μ g/100 μ L of pCDSLE4-3 plasmid in deionized water. ⁴⁵

Example 13

Preparation of Recombinant Plasmids Containing Coding Sequences for St. Louis Encephalitis Virus prM and E Antigens with JEV Signal Sequence

Genomic RNA was extracted from 150 μ L of Vero cell culture medium infected with MSI-7 strain of St. Louis encephalitis virus using the QIAampTM Viral RNA Kit 55 (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 μ l of nuclease-free water, and used as a template for the amplification of St. Louis encephalitis virus prM and E gene coding sequences. Primer sequences were obtained from the work of Trent et al. (*Virology* 156: 293-304 60 (1987)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR). Restriction site AfeI was engineered at the 5' terminus of the cDNA by using amplimer SLE463 (SEQ ID NO:30). An in-frame translation termina-65 tion codon, followed by a NotI restriction site was introduced at the 3' terminus of the cDNA by using amplimer CSLE2447

(SEQ ID NO:31). The RT-PCR product was purified by a QIAquick[™] PCR Purification Kit (Qiagen).

The double-stranded amplicon, produced by use of the two amplimers above (SEQ ID NO:30 and SEQ ID NO:31), was digested with AfeI and NotI enzymes to generate a 2004 fragment of DNA (463 to 2466 nt), and inserted into the AfeI and NotI sites of a pCBJESS-M vector to form pCBSLE (nucleotide sequence, SEQ ID NO:21; amino acid sequence, SEQ ID NO:22). The pCBJESS-M was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engineered, modified JE signal sequence element (SEQ ID NO:27). The JE signal sequence element comprises the modified JE signal sequence at -4 (Cys to Gly) and -2 (Gly to Ser) position in the original pCBJESS plasmid.

Automated DNA sequencing using an ABI prism 377 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) was used to confirm that the recombinant plasmid had a correct prM and E sequence as defined by Trent et al. (*Virology* 156: 293-304 (1987)).

Example 14

Preparation of Recombinant Plasmids Containing Coding Sequences for Yellow Fever Virus (YFV) prM and E Proteins with JEV Signal Sequence

Genomic RNA was extracted from 150 µL of Vero cell culture medium infected with 17D-213 strain of yellow fever virus using the QIAampTM Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in $80 \,\mu$ l of nuclease-free water, and used as a template for the amplification of yellow fever virus prM and E gene coding sequences. Primer sequences were obtained from the work of dos Santos et al. (Virus Research 35: 35-41 (1995)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR). Restriction site AfeI was engineered at the 5' terminus of the cDNA by using amplimer YF482 (SEQ ID NO:28). An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3' terminus of the cDNA by using amplimer cYF2433 (SEQ ID NO:29). The RT-PCR product was purified by a QIAquick[™] PCR Purification Kit (Qiagen)

The double-stranded amplicon, produced by use of the two amplimers above (SEQ ID NO:28 and SEQ ID NO:29), was digested with AfeI and NotI enzymes to generate a 1971 ⁴⁵ fragment of DNA (482 to 2452 nt), and inserted into the AfeI and NotI sites of a pCBJESS-M vector to form pCBYF (nucleotide sequence, SEQ ID NO:23; amino acid sequence, SEQ ID NO:24). The pCBJESS-M was derived from the pCBamp plasmid, that contained the cytomegalovirus early ⁵⁰ gene promoter and translational control element and an engineered JE signal sequence element (SEQ ID NO:27). The JE signal sequence element comprises the modified JE signal sequence at -4 (Cys to Gly) and -2 (Gly to Ser) position of JESS in the pCBJESS plasmid.

Automated DNA sequencing using an ABI prism 377 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) was used to confirm that the recombinant plasmid had a correct prM and E sequence as defined by dos Santos et al. (*Virus Research* 35: 35-41 (1995)).

Example 15

Preparation of Recombinant Plasmids Containing Coding Sequences for Powassan Virus prM and E Antigens with JEV Signal Sequence

Genomic RNA was extracted from 150 μ L of Vero cell culture medium infected with LB strain of Powassan virus

using the QIAamp™ Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was eluted and suspended in 80 µl of nuclease-free water, and used as a template for the amplification of Powassan virus prM and E gene coding sequences. Primer sequences were obtained from the work of Mandl et 5 al. (Virology 194: 173-184 (1993)). A cDNA fragment containing the genomic nucleotide region was amplified by the reverse transcriptase-polymerase chain reaction (RT-PCR). Restriction site AfeI was engineered at the 5' terminus of the 10 cDNA by using amplimer POW454 (SEQ ID NO:25). An in-frame translation termination codon, followed by a NotI restriction site was introduced at the 3' terminus of the cDNA by using amplimer cPOW2417 (SEQ ID NO:26). The RT-PCR product was purified by a QIAquickTM PCR Purification 15 Kit (Qiagen).

The double-stranded amplicon, produced by use of the two amplimers above (SEQ ID NO:25 and SEQ ID NO:26), was digested with AfeI and NotI enzymes to generate a 1983 bp fragment of DNA (454 to 2436 nt), and inserted into the AfeI 20 and NotI sites of a pCBJESS-M vector to form pCBPOW (nucleotide sequence, SEQ ID NO: 19; amino acid sequence, SEQ ID NO:20). The pCBJESS-M was derived from the pCBamp plasmid, that contained the cytomegalovirus early gene promoter and translational control element and an engi-25 indicated in Example 8. neered JE signal sequence element (SEQ ID NO:27). The JE signal sequence element comprises the modified JE signal sequence at -4 (Cys to Gly) and -2 (Gly to Ser) position of JESS in the pCBJESS plasmid.

Automated DNA sequencing using an ABI prism 377 30 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) was used to confirm that the recombinant plasmid had a correct prM and E sequence as defined by Mandl et al. (Virology 194:173-184, (1993)).

Example 16

Preparation of Plasmids Containing Coding Sequences for Dengue Serotype 2 Structural Proteins

Procedures such as those carried out for other flaviviruses (see Examples 1, 9 and 12-15) are to be followed to prepare vectors including nucleic acid TU's for dengue serotype 2 antigens. According to the examples, the amplimers used for 45 construction of the vectors may be chosen to engineer the normal dengue virus signal sequence or they may be chosen so as to engineer a signal sequence from another flavivirus, such as a modified Japanese encephalitis virus signal sequence.

A plasmid containing the dengue serotype 2 gene region from prM to E is to be constructed. The dengue serotype 2 prM and E genes (Deubel et al., Virology 155:365-377 (1986); Gruenberg et al., J. Gen. Virol. 69: 1301-1398 (1988); Hahn et al., Virology 162:167-180 (1988)) are to be ligated into a 55 plasmid such as pcDNA3, and then excised and cloned into vectors such as pCBamp, pCEP4, pREP4, or pRc/RSV (supplied by Invitrogen, Carlsbad, Calif.) to enable expression. If necessary, a dengue serotype 2 virus-specific sequence encoded in a cDNA sequence may be amplified using a pro- 60 cedure such as the polymerase chain reaction (PCR). Alternatively, if the viral RNA is the source of the gene region, a DNA sequence may be amplified by a RT-PCR procedure. A DNA fragment including an initiation codon at the 5' end, and a termination codon at the 3' end is to be cloned into an 65 expression vector at an appropriate restriction nuclease-specific site, in such a way that the cytomegalovirus (CMV)

38

immediate early (1E) promoter, an initiation codon, and a terminator, are operably linked to the dengue serotype 2 virus sequence.

Example 17

Vaccination of Mice Using a Dengue Serotype 2 **DNA Vaccine**

The dengue serotype 2 nucleic TU vaccine encoding the gene region from prM to E prepared in Example 16 is to be suspended in a suitable pharmaceutical carrier, such as water for injection or buffered physiological saline, and injected intramuscularly into groups of weanling mice. Control groups receive a comparable plasmid preparation lacking the dengue serotype 2 specific genes. The generation of dengue serotype 2-specific antibodies, and/or of dengue serotype 2-specific immune system cytotoxic cells, is to be assessed at fixed intervals thereafter, for example at weekly intervals. At about two to four months after administration of the nucleic acid TU vaccine, mice are to be challenged with dengue serotype 2 virus. Levels of viremia are to be assessed at appropriate intervals thereafter, such as every second day. Passive protection by maternal antibody is to be assessed as

Example 18

Design and Construction of Improved Signal Peptides

Signal peptides can determine the translocation and orientation of inserted protein, hence, the topology of prM and E proteins. The most common feature of signal peptides of 35 eukaryotes consists of an 8 to 12 stretch of hydrophobic amino acids called the h-region (von Heijne, "Signal sequences. The limits of variation" J. Mol. Biol. 184: 99-105 (1985)). The region between the initiator Met and the h-region, which is known as the n-region, usually has one to five amino acids, and normally carries positively charged amino acids. Between the h-region and the cleavage site is the c-region, which consists of three to seven polar but mostly uncharged amino acid residues. During viral polyprotein synthesis, modulation of the signalase cleavage site from a cryptic to cleavable conformation at the junction of C and prM proteins depends on prior removal of the C protein by the viral protease complex, NS2B/NS3 (Lobigs, "Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3," Proc. Natl. Acad. Sci. USA. 90: 6218-6222 (1993)). Thus, it is critical to consider the effectiveness of the viral signal sequence when prM and E proteins are to be expressed alone by an expression plasmid.

Signal peptide differences in various plasmid constructs can account, at least in part, for the difference in protein translocation, cleavage site presentation and correct topology, thus, prM and E secretion and VLP formation. The modulation or optimization of these attributes can be improved by selection or use of signal sequences with properties that impart the desired characteristics. This can be accomplished by use of machine-learning computer programs using, for example, a hidden Markov model (HMM) trained on eukaryotes (see Henrik Nielsen et al., "Prediction of signal peptides and signal anchors by a hidden Markov model," In Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology (ISMB 6), AAAI Press, Menlo Park, Calif., pp. 122-130 (1998); Nielsen et al., "Machine learning approaches to the prediction of signal peptides and other protein sorting signals," Protein Engineering 12: 3-9 (1999); Nielsen et al., "A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites," Int. J. Neural Sys. 8: 581- 5 599 (1997); "From sequence to sorting: Prediction of signal peptides," Henrik Nielsen, Ph.D. thesis. Defended at Department of Biochemistry, Stockholm University, Sweden (May 25, 1999); each of which is incorporated herein by reference, particularly for the teaching related to the optimization of 10 signal sequences using computer-enabled algorithms).

An example of the type of program used is that found at http://www.cbs.dtu.dk/services/SignalP-2.0/as of Apr. 3, 2002. The HMM described in the referred to and incorporated references was applied to calculate the signal peptide prob- 15 ability of the prM signal peptide sequences in different plasmid constructs (Table 7). SignalP-HMM searches correctly predicted the signal peptidase cleavage sites in all constructs. However, considerable differences in cleavage probability (ranging between 0.164 and 1.000) and in signal peptide 20 probability (ranging between 0.165 to 1.00) were observed (Table 7). This is not surprising, as the cleavage site and signal peptide probability are known to also be influenced by the positively charged amino acids in the n-region, the length of the hydrophobic amino acid in the h-region and amino acid 25 composition in the c-region in the constructs (Chang et al., "Flavivirus DNA vaccines: current status and potential," Annals of NY Acad. Sci. 951: 272-285 (2001); Sakaguchi et al., "Functions of Signal and Signal-Anchor Sequences are Determined by the Balance Between the Hydrophobic Segment and the N-Terminal Charge," Proc. Natl. Acad. Sci. USA 89: 16-19 (1992)).

Three JE virus plasmid constructs, each derived from different strain of JE virus, showed different vaccine potentials (Lin et al., "DNA immunization with Japanese encephalitis 35 virus nonstructural protein NS1 elicits protective immunity in mice," J. Virol. 72: 191-200 (1998); Konishi et al., "Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes," J. Virol. 72: 40 4925-4930 (1998); Chang et al., "A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice," J. Virol. 74: 4244-4252 (2000)). The signal peptide sequences in these constructs are different in the length of n-region which 45 nogenic than pCBJE1-14 in mice. may or may not contain charged amino acids (Table 7). The n-region containing positively charged amino acids forms a short loop in the cytoplasmic side that causes the h-region (transmembrane helix) to be inserted in a tail orientation, exposing the signalase cleavage site. In our study, secreted 50 VLPs containing prM/M and E proteins could be purified from culture medium of the pCDJE2-7 transformed cell line, JE4B, or pCBJE1-14 transiently transformed COS-1 cells. The gradient-purified VLPs and virions have identical immunological and biochemical properties. Processing efficiency 55 from prM to mature M protein, the hallmark of flavivirus morphogenesis, is also similar between VLPs and virion particles. Thus, prM and E proteins expressed by pCDJE2-7 and pCBJE1-14 can be expressed as type II transmembrane proteins in the orientation similar to that of virion prM and E_{60} (Chang et al., "A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice," J. Virol. 74: 4244-4252 (2000)). In contrast, the prM protein of pcDNA3JEME could be expressed as a type II membrane protein with its trans- 65 membrane h-region inserted in a head orientation because of the absence of positively charged amino acids in its n-region

40

(Konishi et al., "Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes," J. Virol. 72: 4925-4930 (1998)). Efficient protein synthesis in combination with the expressed protein having the correct topology, particularly of the expressed prM and E, can enhance VLP formation and secretion, and thus promote the immunogenicity of the DNA vaccine (Chang et al., "A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice," J. Virol. 74: 4244-4252 (2000)).

The use of computer-based computations, as described above, has been applied to optimize the design of expression plasmid. In particular, the predictive power of the SignalP-HMM program was applied to design the WN virus expression plasmid (Table 2) (Davis et al., "West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays," J. Virol. 75: 4040-4047 (2001)). The pCBWN plasmid consists of a short version of JE virus signal peptide followed by WN virus prM-E gene sequence. Vaccine potential of this construct was amply demonstrated, as a single i.m. injection of pCBWN DNA not only induced a protective immunity but also prevented WN virus infection in mice and horses.

As discussed earlier, and as demonstrated in Examples 13-15, virus-encoded signal sequence from the same virus as the antigen-coding regions is not necessarily the optimal signal peptide available. Further, non-modified signal sequence is not necessarily optimal. For example, the signal peptide encoded in the pCBJE1-14 plasmid can be improved, as measured by the signal sequence probability by shortening n-region, by altering c-region sequence, or by the combination of both modifications (FIG. 6). By way of illustration, a shortened version of JE virus signal peptide has been used for the expression of WN virus prM and E genes as described herein and in papers incorporated herein by reference for the teaching (Davis et al., "West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays," J. Virol. 75: 4040-4047 (2001)). Dose titration studies by single i.m. inoculation indicated that the pCBWN was at least 2-4 fold more immu-

Example 19

Multivalent Vaccines

Multivalent and/or combination vaccines designed to immunize against multiple flaviviruses can also be produced. In preparation of a multivalent vaccine, monovalent vaccine components are prepared that include elements related to pathogens of interest, such as YF, different serotypes of DEN, JE, WN, SLE and TBE (RSSE and CEE) viruses or any other combination of flaviviruses. Design and production of DNA constructs as described in the other examples and in the specification are carried out as described. Combinations of appropriate vaccines can be made to provide multivalent or combination vaccines protective against multiple pathogens. Preliminary data from our group has demonstrated that i.m. injection of the combined pCBJE1-14 and pCBWN DNA vaccines induced JE virus- and WN virus-specific Nt antibodies in mice (Table 8). Each monovalent component, even if constructed using identical transcriptional and translational regulators, should preferably be tested in an analogous model

system to ensure its vaccine potential. A combination vaccine cocktail can then be formulated. These vaccine cocktails can be tailored specifically for particular geographic regions. For example, a vaccine cocktail for tropical and subtropical Asia should include four serotypes of DEN, WN and JE virus 5 vaccines. Similarly useful vaccine cocktails for Africa and Latin America should include four serotypes of DEN, WN and YF virus vaccines and four serotypes of DEN, Rocio and YF virus vaccines, respectively.

Example 20

Preparation and Testing of Recombinant Dengue Virus Type 2 Vaccines

a. Summary of example. A series of plasmids that encode the premembrane (prM) and envelope (E) proteins of the dengue virus type 2 (DEN-2) were constructed. These plasmids included an authentic DEN-2 prM-E construct (pCBD2-14-6) (SEQ ID NO:42) encoding the protein described by 20 SEQ ID NO:43, a 90% DEN-2 E-10% Japanese encephalitis (JE) virus E chimeric construct (pCB9D2-1J-4-3) (SEQ ID NO:44) that encodes the protein described by SEQ ID NO:45 and an 80% DEN-2 E-20% JE E chimeric construct (pCB8D2-2J-2-9-1) (SEQ ID NO:46) that encodes the pro- 25 tein described by SEQ ID NO:47. Monoclonal antibody (MAb) reactivity indicated that all three plasmids expressed E protein epitopes that reacted with a panel of domain 1, 2 and 3 antibodies. However, only the pCB8D2-2J-2-9-1 construct (SEQ ID NO:46) secreted high levels of prM, M (matured 30 prM) and E into the media of the plasmid-transformed COS-1 cells. The major portion of the prM and E protein expressed by COS-1 cells transformed with pCBD2-14-6 plasmid (SEQ ID NO:42) and by COS-1 cells transformed with pCB9D2-4-3 plasmid (SEQ ID NO:44) remained membrane-bound. 35 CO₂ in Dulbecco's modified Eagle minimal essential Replacement of 20% of the sequence encoding the E protein of DEN-2 E with sequence encoding the corresponding JE E protein sequence had no effect on MAbs reactivity.

In testing, groups of mice received two intramuscular immunization of selected plasmids at 0 and 3-wks, and the 40 immune response was evaluated by determining specific neutralizing and ELISA antibody. The plasmid expressing secreted prM and E, which can form subviral-particles (SVPs), was superior to other constructs in stimulating an antibody response. Ninety percent neutralization titers rang- 45 ing from 1:40 to >1:1000 were observed from the 7 of 9 serum specimens of pCB8D2-2J-2-9-1 immunized mice.

b. Importance of DEN-2 virus and vaccines. Dengue (DEN) fever is an acute infection that occurs in subtropical and tropical areas. It is one of the most important flaviviral 50 diseases of humans. As noted earlier, there are four distinct DEN serotypes (DEN-1, DEN-2, DEN-3 and DEN-4) of dengue virus. Infection with any of these is usually either asymptomatic or only causes a self-limited febrile illness known as dengue fever (DF). However, in a small percentage of cases, 55 dengue virus infection results in a much more serious disease, life-threatening dengue hemorrhage fever or dengue shock syndrome (DHF/DSS). Thus, while there are approximately 100 million cases of the relatively mild DF world-wide annually which are of limited concern, there are also an estimated 60 500,000 hospitalized DHF/DSS cases reported annually. To protect against this disease, a safe and effective DEN vaccine effective against all four serotypes is required for administration to children and non-immune adults in the DEN endemic and epidemic regions. 65

Safe vaccines must minimize the potential risk of serious infection by virulent viruses. Such virulent viruses can arise

by gene reversion or recombination of some types of vaccines derived from attenuated vaccine viruses. Such occurrences did arise in the poliovirus eradication campaign (Guillot et al., "Natural Genetic Exchanges between Vaccine and Wild Poliovirus Strains in Humans," J. Virol. 74: 8434-8443 (2000); Liu et al., "Molecular Evolution of a Type 1 Wild-Vaccine Poliovirus Recombinant during Widespread Circulation in China," J. Virol. 74: 11153-11161 (2000)). Further, genomic sequencing of an American strain of yellow fever 10 virus, TRINID79A, demonstrates that there is extensive similarity between this strain and the attenuated yellow fever vaccine virus, FNV (Chang et al., "Nucleotide sequence variation of the envelope protein gene identifies two distinct genotypes of yellow fever virus," J. Virol. 69: 5773-5780 (1995); Pisano et al., "Complete nucleotide sequence and phylogeny of an American strain of yellow fever virus, TRINID79A," Arch. Virol. 144: 1837-1843 (1999)). While not conclusive in and of itself, the similarity strongly suggests that TRINID 79A is derived from the FNV vaccine virus.

The use of DNA-based vaccines is a novel and promising immunization approach for the development of flavivirus vaccines (as described herein, in Chang et al., "Flavivirus DNA vaccines: current status and potential," Ann. NY Acad. Sci. 951: 272-285 (2001), and in references cited therein). In this example, a number of DEN-2 vaccines were produced and the immune response in mice after i.m. immunization of DEN-2 constructs were correlated with the efficiency of prM/M and E secretion. One construct that led to the secretion of significant amounts of prM/M and E antigens was shown to be capable of stimulating high titers of neutralizing antibodies in plasmid-vaccinated mice.

c. Materials and Methods.

i. Cell culture and virus strains. COS-1 cells (ATCC, Manassas, Va.; 1650-CRL) were grown at 37° C. with 5% medium (DMEM, GIBCO, Grand Island, N.Y.) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Hyclone Laboratories, Inc., Logan, Utah), 1 mM sodium pyruvate, 1 mM non-essential amino acids, 30 ml/liter 7.5% NaHCO₃, 100 units/ml of penicillin, and 100 µg/ml of streptomycin. Vero and C6/36 cells were grown under the same conditions used for COS-1 cells. DEN-2 virus, strain-16681, was used for cDNA cloning, IgG ELISA and the plaque reduction neutralization test (PRNT). Virus was propagated in the C6/36 cell culture. Virus used for immunological or biochemical studies was purified by precipitation with 7% polvethylene glycol (PEG-8000; Fisher Scientific, Fair Lawn, N.J.) followed by ultracentrifugation on 30% glycerol-45% potassium-tartrate gradients (Obijeski et al., "Segmented genome and nucleocapsid of La Crosse virus," J. Virol. 20:664-675 (1976)).

ii. Plasmid construction. Genomic RNA was extracted from 150 µl of C6/36 cell culture medium infected with DEN-2 16681 strain using the QIAamp[™] Viral RNA Kit (Qiagen, Santa Clarita, Calif.). Extracted RNA was resuspended in 80 µl of diethyl pyrocarbonate-treated water (DEPC, Sigma, ST. Louis, Mo.) and then used as a template in reverse transcriptase-PCR(RT-PCR) amplification of DEN-2 virus prM and E genes. Primer sequences (Table 9) were designed based on published sequences (Gadkari et al., "Critical evaluation of Kyasanur Forest disease virus neutralizing antibodies found in bats (a preliminary report)," Indian J. Med. Res. 64: 64-67 (1976); Kinney et al., "Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53," Virology 230: 300-308 (1997)). The recognition and cleavage site for restriction enzyme KasI was incorporated at the 5' terminus of

the cDNA amplicon. An in-frame termination codon, followed by a NotI restriction site, was introduced at the 3'terminus of the cDNA amplicon. The DEN-2 virus cDNA amplicon was digested with KasI and NotI enzymes, and was then inserted into the KasI and NotI sites of a pCBJESS vector 5 to form the 100% DEN-2 E plasmid, pCBD2-14-6 (SEQ ID NO:42).

To construct the 90% and 80% DEN-2 E plasmids, the 100% DEN-2 plasmid, pCBD2-14-6 (SEQ ID NO:42), and the JE plasmid, pCBJE1-14 (SEQ ID NO:17), were used as 10 the PCR templates to amplify DEN-2 and JE DNA sequence, respectively. Sets of primers used in amplification reactions to obtain the DEN-2 and JE gene fragments are listed in Table 9. T7 and SP6 priming sites are found in the pCBamp plasmid, derived from original pCDNA-3 plasmid (Invitrogen, 15 Carlsbad, Calif.), and can be utilized as desired or as required. PCR amplified DNA fragments for the 90% DEN-2-10% JE E protein gene were digested with BxtXI restriction endonuclease, ligated using T4 DNA ligase, digested with KasI and NotI enzyme, and inserted into the KasI and NotI sites of the 20 pCBJESS vector to obtain the plasmid, pCB9D2-1J-4-3 (SEQ ID NO:44). PCR amplified DNA fragments for the 80% DEN-2-20% JE E gene were digested with BsmBI, ligated with T4 DNA ligase, digested with KasI and NotI enzyme, and inserted into the KasI and NotI sites of the pCBJESS 25 vector to obtain the plasmid, pCB8D2-2J-2-9-1 (SEQ ID NO:46). Schematic representations of the three plasmid constructs are shown in FIG. 7. The 90% DEN-2-10% JE E and the 80% DEN-2-20% JE E protein junction regions, respectively, are shown in Table 9.

Automated DNA sequencing was performed on an ABI Prism 377 Sequencer (Applied Biosystems/Perkin Elmer, Foster City, Calif.) according to the manufacture's recommended procedures. Recombinant plasmids with the correct prM and E sequences were identified using sequence analy- 35 sis.

iii. Transient expression of DEN-2 recombinant antigen in COS-1 cells by electroporation. COS-1 cells were electroporated separately with each DEN-2 plasmid or green fluorescent protein expression plasmid control (pEGFP, Clonetech, 40 San Francisco, Calif.) using the protocol described elsewhere in the examples and in Chang et al., ("A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice," *J. Virol.* 74: 4244-4252 (2000)). Electroporated cells were 45 seeded onto 75 cm² culture flasks, and kept at 37° C. and 5% CO₂. Six hours following electroporation the growth media were replaced with a maintenance media containing 2% fetal bovine serum. Tissue culture medium and cells were harvested separately 48 hours following electroporation for anti- 50 gen characterization.

iv. Epitope mapping using DEN-2 E-specific monoclonal antibodies. Forty-eight hours following electroporation, adherent cells were trypsinized, resuspended in PBS containing 5% goat serum, spotted on a 12 well spot-slide and air 55 dried. Cells adhered to the spot-slide were fixed with acetone for 10 minutes at -20° C. and allowed to air dry. E-protein specific monoclonal antibodies (MAb) were used to detect protein expression by the indirect immunofluorescence antibody assay (IFA), as described previously (Table 10; Chang et 60 al., "A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice," *J. Virol.* 74: 4244-4252 (2000)).

v. Characterization of the recombinant DEN-2 virus antigen. Tissue culture medium was harvested 48 hours following 65 electroporation. Antigen-capture (Ag-capture) ELISA was used to detect secreted DEN-2 virus antigen in the culture

medium of transiently transformed COS-1 cells. The MAb 4G2 and horseradish peroxidase-conjugated MAb 6B6C-1 were used to capture the DEN virus antigens and detect captured antigen, respectively (Chang et al., "A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice," *J. Virol.* 74: 4244-4252 (2000); Hunt et al., "A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen," *J. Virol. Methods.* 97: 133-149 (2001)).

Forty-eight hours following electroporation, transformed cells for each plasmid were trypsinized and resuspended in PBS as aliquots containing 5×10^6 cells. These cell samples were processed for membrane protein extraction using the Mem-PER mammalian membrane protein extraction reagent kit (Pierce, Rockford, III.) following the manufacturer's suggested protocol. Both hydrophobic and hydrophilic proteins are isolated. This procedure was developed for enrichment of integral membrane protein found in the hydrophobic phase. Both hydrophobic and hydrophilic fractions were analyzed by Ag-capture ELISA for DEN-2 recombinant antigen.

Recombinant antigen in the medium was concentrated by precipitation with 10% polyethylene glycol (PEG)-8000. The precipitant was resuspended in TNE buffer (50 mM Tris, 100 mM NaCl, 10 mM EDTA, pH 7.5) to 1/100% of the original volume, clarified by centrifugation, and stored at 4° C. Recombinant antigen concentrated by PEG precipitation and resuspended in TNE buffer was extracted with 4.0% ethanol to remove residual PEG (Hunt et al., "A recombinant particulate antigen of Japanese encephalitis virus produced in stablytransformed cells is an effective noninfectious antigen and subunit immunogen," J. Virol. Methods. 97: 133-149 (2001)). Ethanol-extracted antigens, hydrophobic membrane proteins from the transformed cells and gradient-purified DEN-2 virions were analyzed on a NuPAGE, 4-12% Bis-Tris gradient gel in an Excel Plus Electrophoresis Apparatus™ (Invitrogen Corp., Carlsbad, Calif.), followed by electroblotting onto nitrocellulose membranes using a Excel Plus Blot Unit (Invitrogen Corp.). DEN-2 virus-specific protein was detected by western blot using DEN-2 virus specific MAbs 1A6A-8 (E specific) and 1A2A-1 (capsid specific), as well as rabbit antiserum specific for DEN-2 prM and mouse serum specific for a peptide composed of amino acid 1-34 of the DEN-2 M protein, and normal mouse ascitic fluid was used as negative control (Murray et al., "Processing of the dengue virus type 2 proteins prM and C-prM," J. Gen. Virol. 74 (Pt 2): 175-182 (1993); Roehrig et al., "Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica," Virology 246: 317-328 (1998)).

vi. Mouse vaccination. Groups of ten, three-wk-old female ICR out-bred mice were used in the study. Mice were i.m. injected with pCBD2-14-6, pCB9D2-1J-4-3, pCB8D2-2J-29-1 or pEGFP on week-0 and week-3 at a dose of 100 μ g in a volume of 100 μ l per mouse. The plasmid DNA was purified from XL-1 blue cells with EndoFree Plasmid Giga KitsTM (Qiagen) and resuspended in PBS, pH 7.5, at a concentration of 1.0 μ g/ μ l. Mice that received 100 μ g of pEGFP were used as plasmid-vaccinated controls. Mice were bled every 3 wks following injection, and the DEN-2 virus specific antibody response was evaluated by use of indirect ELISA and PRNT.

vii. Serological tests. Pre- and post-vaccination serum specimens were tested for antibody binding ability to purified DEN-2 virion by ELISA, for neutralizing (Nt) antibody by PRNT, and for antibodies that recognize purified DEN-2 virus proteins by Western blotting. PRNT was performed with Vero cells, as previously described (Chang et al., "A

single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice," *J. Virol.* 74: 4244-4252 (2000)), using DEN-2 (strain-16681) and JE (strain-Nakayama) virus. Endpoints were determined at a 90% plaque-reduction level (Hunt et al., 5 "A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen," *J. Virol. Methods.* 97: 133-149 (2001)).

d. Results.

i. Transient expression of DEN-2 virus recombinant antigen. Expression of the prM and E genes of DEN-2 virus or a chimeric E gene from a combination of DEN-2 and JE virus sequences (80% DEN-20% JE or 90% DEN-10% JE) was accomplished by separate transformations of each of the three 15 recombinant DEN-2 DNA plasmids into COS-1 cells. The basic plasmid design was based on results from previous studies with JE virus and WN virus recombinant plasmids in which plasmid-transformed cells expressed, and secreted authentic viral proteins into the cell culture fluid (Chang et al., 20 "A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice," J. Virol. 74: 4244-4252 (2000); Davis et al., "West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro 25 a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays," J. Virol. 75: 4040-4047 (2001)). Transient expression of DEN-2 recombinant proteins was initially assessed by Ag-capture ELISA of cell culture supernatants and by IFA of acetone-fixed, trans- 30 formed COS-1 cells (Chang et al., "A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice," J. Virol. 74: 4244-4252 (2000)). The point of optimum antigen expression was determined to be 48 hours following elec- 35 troporation.

ii. Epitope mapping of the E protein expressed by transiently-transformed COS-1 cells. The DEN-2 protein expressed by each of the recombinant plasmids was evaluated by IFA using a panel of murine MAbs with known reactivity 40 to DEN-2 virus (Table 10; Henchal et al., "Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies," Am. J. Trop. Med. Hyg. 34: 162-169 (1985); Roehrig et al., "Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, 45 Jamaica," Virology 246: 317-328 (1998)). The MAb panel included antibodies reactive with each of the three antigenic domains of the E protein of flaviviruses as well as prM and C proteins. (Mandl et al., "Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne 50 encephalitis virus as a model," J. Virol. 63: 564-571 (1989); Rey et al., "The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution," Nature 375: 291-298 (1995)). The MAbs specific for flavivirus antigenic Domains 2 and 3 showed nearly identical qualitative reactivity with 55 DEN-2 virus and each of the three plasmid-expressed proteins. One of the Domain 1-specific MAbs, 1B4C-2, also showed a similar reactivity pattern with all expressed proteins. However, two of the Domain 1-specific MAbs, 2B3A-1 and 9A4D-1, were much less reactive with E protein 60 expressed by plasmids pCBD2-14-6 and pCB9D2-1J-4-3 as shown by endpoint titration (values in parentheses, Table 10). Comparison of the endpoint titers revealed the apparent poor expression of epitopes C3 and C4 in constructs containing 100% DEN-2 E and 90% DEN-2 E-10% JE E. MAb 2H2, 65 specific for prM, had the same reactivity with antigen expressed by all three plasmids. Anti-C MAb 1A2A-1 reacted

46

well with DEN-2 virus and had low level, non-specific reactivity with the plasmid-expressed viral proteins, which included prM and E, but not C.

iii. Comparison of secreted protein and membrane-bound protein produced by each of the three DEN-2 recombinant plasmids. Similar amounts of cell culture fluid were harvested from COS-1 cells 48 hours post-transformation for each recombinant DEN-2 plasmid. Secreted recombinant antigen found in the culture fluid was concentrated 100-fold by PEG precipitation, followed by ethanol extraction to remove PEG which interfered with subsequent analysis by polyacrylamide gel electrophoresis. The relative amount of secreted antigen expressed by each plasmid was determined by Ag-capture ELISA analysis of both PEG-precipitated and ethanol-extracted cell culture fluid preparations (Table 11). Secreted antigen was detected only from cells transfected with pCB8D2-2J-2-9-1 (SEQ ID NO:34), which contained 80% DEN-2 E and 20% JE E genes. The recombinant plasmids containing either 100% DEN-2 E or 90% DEN-2 E-10% JE E genes produced no ELISA-detectable antigen in the culture fluid, despite efforts to concentrate expressed protein.

Western blot analysis was also used to evaluate the production of secreted antigen by each of the DEN-2 recombinant plasmids. For comparison purposes, equivalent volumes of PEG-precipitated, ethanol-extracted cell culture supernatant were run on NuPAGE gradient gels, electroblotted to nitrocellulose, and analyzed using MAbs or polyclonal antisera capable of reacting with all DEN-2 structural proteins (FIG. 8A). Western blot analysis showed greater sensitivity in detecting recombinant antigen than Ag-capture ELISA since DEN-2-specific proteins were detected in the culture fluid from two of the plasmids, pCB8D2-2J-2-9-1 and pCB9D2-1J-4-3 (SEQ ID NOS:46 and 44, respectively). Plasmid pCB8D2-2J-2-9-1 (SEQ ID NO:46) expressed the greatest amount of secreted antigen which was shown to be composed of E, prM, and M proteins. Relatively less secreted antigen was produced by pCB9D2-1J-4-3 (SEQ ID NO:44) and barely detectable levels were found for the pCBD2-14-6 (SEQ ID NO:42) preparation, which appeared to contain relatively less expressed E protein, especially if the nonspecific reactivity of the E-specific MAb, 1A6A-8, on the control pEGFP was taken into consideration (FIG. 8A, lanes a, b for 14-6 and GFP).

Since E, prM, and M are membrane-associated proteins throughout their intracellular synthesis, any assessment of the expression of these proteins by the three recombinant DEN-2 plasmids should include an evaluation of cell membrane preparations from plasmid-transformed cells. The Mem-PER Mammalian Membrane Protein Extraction Reagent kit (Pierce) was used to isolate the integral membrane proteins from equivalent numbers of cells transformed by each of the recombinant plasmids. Hydrophobic proteins were separated from hydrophilic proteins by phase partitioning. Preliminary analysis by Ag-capture ELISA indicated that the hydrophilic protein fraction was non-reactive; however, the hydrophobic protein fractions from COS-1 cells transformed with each of the recombinant DEN-2 plasmids had similar titers in ELISA tests (Table 11). These results indicated that recombinant antigen encoded by all three plasmids was expressed following transformation, but that the recombinant antigens expressed were not all secreted at the same level.

Confirmation of the Ag-capture results for the hydrophobic protein fractions was accomplished by western blot (FIG. 8B). Equivalent volumes of hydrophobic protein fractions from each of the plasmid-transformed cells were diluted according to the manufacturer's recommendations for SDSpolyacrylamide gel electrophoresis in order to reduce band and lane distortion. Immunoblotting with E-, prM-, C-, and M-specific MAbs or polyclonal antisera demonstrated that all three recombinant DEN-2 plasmids induced the production of similar amounts of recombinant antigen composed of E and prM. No M protein was detected, either because it was not 5 processed from prM or because the levels were too low to be detected. Despite efforts to reduce band distortion, high levels of detergent in the hydrophobic protein samples apparently caused E and prM to run in a slightly aberrant manner (slower migration) compared to samples without such high concen-10 trations of detergents (compare E and prM migration in FIGS. **8**A and **8**B).

iv. Comparison of the immune response in mice vaccinated with three different DEN-2 recombinant DNA plasmids. Three-week old ICR mice were immunized by i.m. injection 15 with 100 µg of pCB8D2-2J-2-9-1 (SEQ ID NO:46), pCB9D2-1J-4-3 (SEQ ID NO:44), pCBD2-14-6 (SEQ ID NO:42), or pEGFP on weeks 0 and 3. Mice were bled 3, 6, and 9 weeks after the primary immunization. Individual and pooled sera were tested by indirect ELISA, using screening 20 dilutions of 1:100 and 1:400 at 3 and 6 weeks post-vaccination and endpoint titrations at 9 weeks post-vaccination. Nine-week sera were also tested by PRNT with both DEN-2 and JE viruses. The ELISA results showed that after one immunization (3-week sera), all mice given pCB8D2-2J-2- 25 9-1 had seroconverted, whereas only 50% of pCB9D2-1J-4-3 and 20% of pCBD2-14-6-vaccinated mice reacted with DEN-2 virus (Table 12). By 9 weeks post-vaccination, all mice vaccinated with either pCB8D2-2J-2-9-1 or pCBD2-1J-4-3 demonstrated anti-DEN-2 ELISA reactivity; however, 30 the geometric mean titers differed significantly (titers of 1:20, 000 versus 1:708, respectively). Only 40% of pCBD2-14-6immunized mice had anti-DEN-2 ELISA titers greater than 1:100. A western blot of pooled 9-week sera from pCB8D2-2J-2-9-1-immunized mice on purified DEN-2 virus showed 35 that the immunodominant response was to the E glycoprotein. Slight reactivity reactivity to prM and M were also detected.

More significantly, in terms of evaluating the vaccine potential of the three DEN-2 plasmids, the induction of virusneutralizing antibody in 7 of 9 mice immunized with 40 pCB8D2-2J-2-9-1 (SEQ ID NO:46) was observed based on a 90% plaque-reduction endpoint (Table 10). However, if a 50% neutralization endpoint is used, then all 9 of 9 sera have PRNT titers of ³ 1:40. Ninety percent neutralization titers ranged from 1:40 to >1:1000 for the 7 sera with neutralizing 45 activity. None of the mice immunized with pCB9D2-1J-4-3 produced neutralizing antibody, and only 1 of 10 sera from pCBD2-14-6-vaccinated mice neutralized virus, but at a titer of only 1:8.

Since two of the recombinant plasmids, namely pCB9D2-1J-4-3 (SEQ ID NO:44) and pCB8D2-2J-2-9-1 (SEQ ID NO:46) contained JE virus E-gene sequences, all sera were also evaluated for the presence of JE virus neutralizing activity. However, no such activity was detected at the 90% neutralization endpoint for mice in any of the immunization groups. Not surprisingly, mice immunized with the control plasmid pEGFP exhibited no reactivity to either DEN-2 or JE viruses.

e. Discussion. The same steps used earlier for the JE and WN vaccines was initially used to construct a recombinant ⁶⁰ DEN-2 plasmid, pCBD2-14-6 (SEQ ID NO:42), consisting of the authentic DEN-2 prM and E gene region. Antigenic mapping of DEN-2 proteins expressed by COS-1 cells transformed by this plasmid, using a panel of MAb by IFA, indicated the prM and E protein had a compatible fluorescent ⁶⁵ intensity and a similar MAb reactivity as virus infected cells (Table 10). However, these COS-1 cells transformed by the 48

plasmid encoding an authentic DEN-2 prM and E region failed to secrete detectable DEN-2 antigen into the culture fluid (as measured by antigen-capture ELISA). In addition, vaccination using the plasmid encoding an authentic DEN-2 prM and E region failed to stimulate anti-DEN-2 virus neutralizing antibody in i.m. immunized-mice (Table 13). Interestingly, transformation of cells by pCBD2-14-6 resulted in a punctuated-globular fluorescent staining that suggested that the C-terminus of the E protein of DEN-2 may contribute to that protein's membrane retention signal. This IFA staining pattern was not observed in either the JE or WN constructtransformed cells (Chang et al., "A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice," J. Virol. 74: 4244-4252 (2000); Davis et al., "West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays," J. Virol. 75: 4040-4047 (2001)). Therefore, in light of the observation made in accordance with the teachings of the present application, two additional plasmids, pCB9D2-1J-4-3 (SEQ ID NO:44) and pCB8D2-2J-2-9-1 (SEQ ID NO:46), in which appropriate manipulation of the DNA sequence was made for 10% or 20% of C-terminal E of DEN-2 to be replaced with the corresponding region of JE virus E protein, respectively. Relative effectiveness of the different constructs in stimulating detectable anti-DEN-2 ELISA antibody in vaccinated mice is shown in Table 13.

These results are consistent with the model that interactions between prM and E can influence the processes of particle assembly and secretion. Support for this model can be found in a study of tick-borne encephalitis virus that putatively suggests that interactions between prM and the ectodomain of E are involved in prM-mediated intracellular transport of prM-E, thus, secretion of virus-like particle (Allison et al., "Mapping of functional elements in the stemanchor region of tick-borne encephalitis virus envelope protein E," J. Virol. 73: 5605-5612 (1999)).

In the present example, replacing a C-terminal portion of DEN-2 E protein with JE E protein, corresponding to TBE $H1^{pred}$ to TM2, resulted in DEN-2 prM protein and chimeric E protein secretion. However, in contrast, replacement of TM1 and TM2, in TBE, caused only a minor improvement in antigen secretion. The major portion of the prM and E protein expressed by either COS-1 transformed pCBD2-14-6 and pCB9D2-4-3 plasmid remained membrane-bound (Table 13). These results indicated that an unidentified membrane retention sequence is located in the C-terminal stem region of DEN-2 E protein. Substitution of this C-terminal stem region with sequence from the JE virus removes or renders ineffective this retention sequence.

It has been asserted by others that the prM protein is essential for maintaining proper conformation and secretion of E protein during prM-E maturation (Aberle et al., "A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms," *J. Immunol.* 163: 6756-6761 (1999), Allison et al., "Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form," *J. Virol.* 69:5816-5820 (1995)). Further, it has also been demonstrated that the ectodomain of the E protein interacts with prM. This interaction has been estimated to involve amino acid sequence within amino acid residues 200-327 of E in the Murray Valley encephalitis virus (Guirakhoo et al., "The Murray Valley encephalitis virus prM protein confers acid
35

resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein," Virology 191: 921-931 (1992)).

Proper prM and E interactions and retained integrity of the E protein's structure are likely maintained in the protein expressed by all three DEN-2 constructs, at least insofar as they are required for immunoreactivity. Furthermore, the replacement of the C-terminus 20% E in the pCB8D2-2J-2-9-1 resulted in a protein that maintained 395 amino acids of authentic DEN-2 E. Any such modification is expected to have minimal influence on E and prM-E interactions and their influence on the antigenic nature of the chimeric E protein. As replacing the C-terminus region of DEN-2 E with JE stemanchor sequence had no effect on MAbs reactivity (Table 10), retention of the DEN-2 sequence so replaced can only be optional in attaining a DEN-2 specific immunological response.

Previously, it has been shown that a plasmid construct encoding a secreted subviral particle of tick-borne encepha-20 litis virus prM and E protein was superior, in terms of the extent and functionality of the antibody response and in terms of response to virus challenge, to other constructs that encoded C-terminally truncated soluble E-dimer that was secreted, full-length E that was not secreted, or a truncated E that was not efficiently secreted (Aberle et al., "A DNA immunization model study with constructs expressing the tickborne encephalitis virus envelope protein E in different physical forms," J. Immunol. 163: 6756-6761 (1999)). However, here we have demonstrated that the vaccine potency of DEN-2 DNA is correlated with the secretion of prM/M and E (Table 13). The morphology and physical character of secreted prM and E were not demonstrated in this study. However, the prM and E, secreted by the pCB8D2-2J-2-9-1 construct, does likely form a viral-like particle. It is believed that the presentation of multiple protective antigens on the particle surface improves vaccine potency of this construct.

Previous attempts for the development of DEN-2 virus DNA vaccine has resulted in varying degrees of success (Kochel et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," ⁴⁰ Vaccine 15: 547-552 (1997); Konishi et al., "A DNA vaccine expressing dengue type 2 virus premembrane and envelope

50

genes induces neutralizing antibody and memory B cells in mice," Vaccine 18: 1133-1139 (2000)). To improve the level of effectiveness, differing strategies have been adopted. For example, coimmunization of the immuno-stimulatory CpG motif containing pUC19 plasmid, plasmid expressing murine GM-CSF in the vaccine regimen, or replacing C-terminus 43 amino acid of E with lysosome-associated membrane retention sequence improved the antibody response to the DEN-2 vaccine has been used (Porter et al., "Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses," Arch. Virol. 143: 997-1003 (1998); Raviprakash et al., "Synergistic Neutralizing Antibody Response to a Dengue Virus Type 2 DNA Vaccine by Incorporation of Lysosome-Associated Membrane Protein Sequences and Use of Plasmid Expressing GM-CSF," Virology 290: 74-82 (2001)). Unmethylated CpG motifs directly activates macrophages, natural killer cells and lymphocytes to secrete cytokines and chemokines, and supports the development of immune responses mediated by Th1 cytokines (Manders et al., "Immunology of DNA vaccines: CpG motifs and antigen presentation," Inflamm. Res. 49: 199-205 (2000)). However, inclusion of the CpG might bias the host's cytokine profile and thereby contribute to the both the development of Th-1-mediated organ-specific autoimmune disorders and interfere with immune homeostasis (Smith et al., "The regulation of DNA vaccines," Curr. Opin. Biotech. 12: 299-303 (2001)). There is also evidence in mice that excess levels of cytokine, although increasing the response of certain T-helper cells, can decrease or shutdown the response of other actors in the immune response, leading to generalized immunosuppression or chronic inflammation (Robertson et al., "Assuring the quality, safety, and efficacy of DNA vaccines," Mol. Biotechnol. 17: 143-149 (2001)). Correspondingly, the safety and efficacy of flavivirus DNA immunization could be benefited by manipulation of an expression plasmid to enhance transcription and translation and targeting prM and E proteins for secretion that promote correct polyprotein processing and assembly (Chang et al., "Flavivirus DNA vaccines: current status and potential," Ann. NY Acad. Sci. 951: 272-285 (2001)). Future improvements could be focused on enhancing DNA uptake by antigen presenting cells or by muscle cells (Rodriguez et al., "Enhancing DNA immunization," Virology 268: 233-238 (2000)).

TABLE 1

Trans	sient express	sion of JE i Vector	prM and E p n two transfe	oroteins l erred cel	y various recomb l lines. 	inant plasr IFA in percen anti positiv	nids tensity/ tage of gen- e cells*
	Promotor	Intron	Poly (A)	ORI	Plasmid	COS-1	COS-7
pCDNA3 pCBamp pC1Bamp pCEP4 pREP4 pRe/RSV pCDNA3	CMV CMV CMV CMV RSV RSV CMV	No No Yes No No No	BGH BGH SV40 SV40 BGH BGH	SV40 No No OriP OriP SV40 SV40	pCDJE2-7 pCBJE1-14 pC1BJES14 pCEJE pREJE pRCJE pCDNA3/CAT	3+/40 3+/45 3+/39 2+/4 1+/3 1+/3	3+/35 nd nd 2+/3 1+/2 1+/3

*Various cell lines were transformed with pCDNA3/CAT (negative control), pCDJE2-7, pCBJE1-14, pCIBJES14, pCEJEm pREJE, or pRCJE, Cells ere trypsinized 48 hours later and tested by an indirect immunofluorescent antibody assay (IEA) with JE vints-specific HIAF. Data are presented as the intensity (scale of 1+ to 4+) and the percentage of IFA positive cells. The pCDNA3/CAT transformed cells were used as the negative control

TABLE 2

Characterization of proteins expressed by a pCDJE2-7 stably transformed clone (JE-4B) of COS-1 cells with JE virus-reactive antibodies.

	Biolc Activity	gical of Mab	Immunofluc intensity o	orescent f cells	
Mab or antiserum	Specificity	Biological Function	JEV infected	4B	
Mab:					_ 1
MC3	JEV Specific		2+	2+	
2F2	JEV Specific	HI, N	4+	4+	
112	JEV Specific		4+	4+	
503	JEV Specific	Ν	4+	3+	1
109	Subgroup	HI	2+	1+	
N.04	Subgroup	HI, N	3+	4+	
201	Subgroup		1+	1+	
203	Subgroup		4+	3+	
204	Subgroup		2+	2+	
301	Subgroup	HI	2+	2+	2
504	Flavivirus		4+	4+	2
6B6C-1	Flavivirus		2+	2+	
3B4C-4	VEE		—		
H1AF:	_				
Anti-JEV			4+	3+	
Anti-WEE			_	_	2
PBS			—		

TABLE 5

Protection from JEV challenge in 8 week old mice following vaccination at 3 days old with various JEV vaccines. Days post-challenge

	Pre-challenge JEV		surv	ival rate	(%)	
Vaccine	seroconversion	6	7	8	9	21
JE-VAX	0	100	100	60	40	40
pCDNA3/CAT	0	100	80	30	30	30
pCDJE2-7	60	100	100	100	100	100
pC1BJES14	60	100	100	100	100	100
pCBJE1-14	100	100	100	100	100	100

TABLE 6

Evaluation of the ability of maternal antibody from JEV-nucleic acid-
vaccinated female mice to protect their pups from fatal JEV encephalitis.
IFV challenged pupe

		JEVC	nanciigeu pups	
Vaccinated	mother	Challenge age		
Vaccine	PRNT _{90%}	(days)	No. survival ¹	ELISA ²
1 x pCDJE2-7	40	4	0/11	
2 x pCDJE2-7	80	4	12/12	12/12
2 x JE-VAX	20	3	0/16	

TABLE 3

Persiste	nce of the	immune re	esponse in	mice imn	unized w	ith pCDJE2-7 or .	JE-VEX	vaccine	e.
			ELIS/	A Titer (lo	g ₁₀)		PF	2NT 00%	Titer
	3 wks	6 wks	9 wks	23 wks	40 wks	60 wks*	3 wks	6 wks	9 wks
1x pCDJE2-7	2.6-3.2	3.8-5.0	3.8-4.4	>3.2	>3.2	2.4, 2.4, 3.8, 4.4	<20	20	40-160
2x pCDJE2-7	2.6-3.8	4.4	3.8-4.4	>3.2	>3.2	2.6, 3.8, 3.8	<20	20-40	40-160
2x JE-VAX	2.6-3.8	4.4-5.0	3.8-5.6	>3.2	>3.2	<2, <2, <2, 4.4	<20	20-40	20-160
2x pCDNA3/CAT	<2	<2	<2	ND	ND	<2	<20	<20	<20

Mice were inoculated with 1 or 2, 100 $\mu g/dose plasmid DNA$, or $^{1/3}$ human dose of JE-VAX vaccine. Sera were collected for testing prior to the second immunization. *Individual serum titers.

45

TABLE 6-continued

Evaluation of the ability of maternal antibody from JEV-nucleic acidvaccinated female mice to protect their pups from fatal JEV encephalitis.

JEV challenged pups

The age-o	dependent perce vaccination w	nt seropositive	rate in mice fo	llowing	50
	3-da	y old	3-we	ek old	55
	3 weeks PV	7 weeks PV	3 weeks PV	7 weeks PV	
JE-VAX	0	0	100	100	60
pCDNA3/CAT	0	0	0	0	
pCDJE2-7	40	60	90	90	
pC1BJES14	10	60	80	100	
pCBJE1-14	80	100	100	100	65

TABLE 4

Vaccinated m	other	Challenge age		
Vaccine	PRNT _{90%}	(days)	No. survival ¹	ELISA ²
2 x pCDNA-3/CAT	<10	5	0/14	
1 x pCDJE2-7	20	15	5/11	5/5
2 x pCDJE2-7	40	14	8/12	7/8
2 x JE-VAX	80	13	5/5	5/5
2 x pCDNA-3/CAT	<10	14	0/14	

Mice were inoculated intramuscularly with 1 or 2, 100 μg dose of plasmid DNA, or subcutaneously with two, $1\!\!/_{5}$ human dose of JE-VAX vaccine. Sera were collected 9 weeks post-vaccination for PRNT testing prior to mating with non-immune male.

¹No Survivors/total for each litter.

 2Number of JEV ELISA-antibody-positive animals (titer $\geqq1:400)/No.$ of survivors; sera were collected for testing 12 weeks after challenge.

TABLE 7

	Characteristic of the signal peptides and thei among flavivirus DNA vaccine co	r vacci nstruct	ne of pote s	entials	
			Signal pep probabili	tide .ty ^a	Immunization
Plasmid	Signal peptide sequence preceding prM protein	SP	AP	Csite	protocol/protection
pSLE1	?L <u>D</u> TIN <u>RR</u> PS <u>KKR</u> GGT <u>R</u> SLLGLAALIGLASS/ LQLLSTYQG (SEQ ID NO:32)	0.702	0.292	0.352	im \times 2/Partial
рЈМЕ	MWLASLAVVIACAGA/M <u>K</u> LSNFQG <u>K</u> (SEQ ID NO: 33)	0.998	0.000	0.778	im × 2/Partial
PCJEME	MN E GSIMWLASLAVVIACAGA/M <u>K</u> LSNFQG <u>K</u> (SEQ ID NO: 34)	0.985	0.012	0.785	im × 2/100%
pCBJE1-14	MG <u>RKQNKR</u> GGN <u>E</u> GSIMWLASLAVVTACAGA/ M <u>K</u> LSNFQG <u>K</u> (SEQ ID NO: 35)	0.791	0.199	0.623	im × 1/100%
pcDNA3prM-E	MS <u>KKR</u> GGS <u>E</u> TSVLMVIFMLIGFAAA/L <u>K</u> LSNFQG <u>K</u> (SEQ ID NO: 36)	0.721	0.277	0.622	im × 4/Partial gg × 2-4/100%
pCBWN	MG <u>KR</u> SAGSIMWLASLAVVIACAGA/VTLSNFQG <u>K</u> (SEQ ID NO: 37)	0.976	0.024	0.526	im × 1/100%
p1012D2ME	MNVL <u>R</u> GF <u>RKE</u> IGRMLNILN <u>RRRR</u> TAGMIIMLIPTVMA/ F <u>H</u> LTT <u>R</u> NG <u>E</u> (SEQ ID NO: 38)	0.165	0.778	0.164	id $\times 2/None$
SV-PE	MVGLQ <u>KR</u> G <u>KRR</u> SATDWMSWLLVITLLGMTLA/ ATV <u>RKER</u> GD (SEQ ID NO: 39)	0.943	0.056	0.899	im or gg x 2/100%
pWRG7077- RSSE	MGWLLVVVLLGVTLA/ATV RKER GD (SEQ ID NO: 40)	1.000	0.000	0.912	gg × 2/100%
pWRG7077- CEE	MSWLLVITLLGMTIA/ATV <u>RKER</u> GD (SEQ ID NO: 41)	0.999	0.000	0.821	gg x 2/100%

"The SignalP HMM program was applied to calculate signal peptide (SP), anchor peptide (AP) and signalase cleavage site (C site) probabilities. Single amino acid codes were used, and charged amino acids were highlighted by underline-bold letters. The signalase cleavage site separating SP and prM is indicated by "/". DNA vaccines were inoculated by intramuscluar (im), intradermal (id), or gene gun (gg) method.

TABLE 8

Neutralizing antibo	dy (Nt) respons combined WN	ses in mice imm and JE virus D	uunized with di NA vaccines.	fferent doses o	f the
		pCBWN + j	oCBJE1-14		pCB
Dose per plasmid (µg)	100 + 100	40 + 40	20 + 20	10 + 10	Control 100
Percentage of mice with Nt:					
WN virus/JE virus: Range of PRNT ₉₀ titer:	100/100	100/70	70/0	60/0	0/0
WN virus: JE virus:	1:320-1:80 1:40-1:10	1:80-1:20 1:10-<1:10	1:80-<1:10 <1:10	1:20-<1:10 <1:10	<1:10 <1:10

Groups of ten, three-week-old female ICR out-bred mice were i.m. injected with a single dose of Combined plasmid DNAs as indicated. The serum specimens collected 12-week after immunization were assayed by the plaque-reduction neutralization test (PRNT). The end-point titters against JE and WN virus were calculated based on the 90% percent plaque reduction using JE virus (strain SA-14) and West Nile virus (strain NY-6480), respectively.

TABLE 9

Oligon plasmids,	ucleo and t	tides used he junction	to constr region o	uct DEN-2 y f chimeric	virus prM-E e DEN-2 and JE	xpres E in	ssic ndic	on atec	1.
			100% DEN	-2 prM-E:					
D2KasI-438ª	5'	tgtgca <u>GGC</u>	<u>GCC</u> TTCCAT	TTAACCACAC	GTAACG	(SEQ	ID	NO :	48)
CD2NotI-2402	5'	tcga <u>GCGGC</u>	<u>CGC</u> TCAAC	TAATTAGGCCI	IGCACCATGACTC	(SEQ	ID	NO :	49)

TABLE 9-continued

Oligonucleotides used to construct DEN-2 virus prM-E expression plasmids, and the junction region of chimeric DEN-2 and JE E indicated.

	90% DEN-2E & 10% JE E:			
Τ7	5' CTTATCGAAATTAATACGACTCACTATAGG	(SEQ	ID NO:	50)
CD2BstXI-2244	5' ATAGATTGCT <u>CC4</u> AA <u>C</u> ACT <u>TGG</u> TGG	(SEQ	ID NO:	51)
JE-2281	5' ACTCCATAGGAAAAGCCGTTCACC	(SEQ	ID NO:	52)
CSP6	5' GCGAGCTCTAGCATTTAGGTGACACTATAG	(SEQ	ID NO:	53)
90-10 Junction:	DEN-2 🖛 🚚 JE Leu His Gln Val Phe Gly Gly Ala Phe Arg Thr	(SEQ	ID NO:	55)
	CTC CAC CAA GTG TTT GGT GGT GCC TTC AGA ACA	(SEQ	ID NO:	54)
	80% DEN-2E & 20% JE E:			
 T7	80% DEN-2E & 20% JE E: 5' CTTATCGAAATTAATACGACTCACTATAGG	(SEQ	ID NO:	56)
T7 CD2BsmBI-2097	80% DEN-2E & 20% JE E: 5' CTTATCGAAATTAATACGACTCACTATAGG 5' GAATT <u>CGTCTC</u> ACTTCCTTTCTTAAACCAGTTGAGCTTC	(SEQ (SEQ	ID NO: ID NO:	56) 57)
T7 CD2BsmBI-2097 JEBsmBI-2175	80% DEN-2E & 20% JE E: 5' CTTATCGAAATTAATACGACTCACTATAGG 5' GAATT <u>CGTCTC</u> ACTTCCTTTCTTAAACCAGTTGAGCTTC 5' GGAATT <u>CGTCTC</u> GGAAGCACGCTGGGCAAGG	(SEQ (SEQ (SEQ	ID NO: ID NO: ID NO:	56) 57) 58)
T7 CD2BsmBI-2097 JEBsmBI-2175 CSP6	80% DEN-2E & 20% JE E: 5' CTTATCGAAATTAATACGACTCACTATAGG 5' GGAATT <u>CGTCTC</u> ACTTCCTTTCTTAAACCAGTTGAGCTTC 5' GGAATT <u>CGTCTC</u> GGAAGCACGCTGGGCAAGG 5' GCGAGCTCTAGCATTTAGGTGACACTATAG 3'	(SEQ (SEQ (SEQ (SEQ	ID NO: ID NO: ID NO: ID NO:	56) 57) 58) 59)
T7 CD2BsmBI-2097 JEBsmBI-2175 CSP6 80-20 Junction:	80% DEN-2E & 20% JE E: 5' CTTATCGAAATTAATACGACTCACTATAGG 5' GGAATT <u>CGTCTC</u> ACTTCCTTTCTTAAACCAGTTGAGCTTC 5' GGGAATT <u>CGTCTC</u> GGAAGCACGCTGGGCAAGG 5' GCGAGCTCTAGCATTTAGGTGACACTATAG 3' DEN-2 JE Asn Trp Lys Lys Gly Ser Thr Leu Gly Lys Ala	(SEQ (SEQ (SEQ (SEQ	ID NO: ID NO: ID NO: ID NO: ID NO:	56) 57) 58) 59) 61)

"Restriction enzyme sites encoded in oligonucleotides were highlighted by the bold, italic and underline.

TA	BL	Æ	1	0

	Characterization of DEN-2 E glycoprotein epitopes expressed by the recombinant DEN-2 plasmids as determined by the indirect fluorescent antibody assay (IFA).												
			Controls	8 ^a	-								
	Antibody		DEN-2	Normal	Plasmid construct ^a								
MAb (Epitope) ^b	b (Epitope) ^b Antigenic Domain ^c PRNT ^d		infected cells	cells	pCBD2-14-6	pCB9D2-1J-4-3	pCB8D2-2J-2-9-1						
4G2 (A1)	2	+/-	4+	_	4+	4+	4+						
4E5 (A2)	2	Yes	3+	_	3-4+	3-4+	2-3+						
1B7 (A5)	2	Yes	3-4+	_	4+	4+	2-3+						
1B4C-2 (C1)	1	No	3-4+ (8000)		2-3+(4000)	2-3+(4000)	2-3+(8000)						
2B3A-1 (C3)	1	No	3-4+ (≧3200)	_	3+(100)	2+(100)	2-3+ (≧3200)						
9A4D-1 (C4)	1	No	3-4+	_	2-3+ (400)	1-3+ (400)	3+ (≧12800)						
3H5 (B2)	3	Yes	4+		4+	4+	4+						
10A4D-2 (B3)	3	Yes	2-3+		3-4+	3-4+	2-3+						
1A1D-2 (B4)	3	Yes	4+	_	3-4+	4+	3-4+						
9D12-6		Yes	2-4+		2-3+	2-3+	3-4+						
2H2	prM	No	4+		4+	3-4+	3-4+						
1A2A-1	Capsid	No	2-3+	_	1+	2+	1-2+						

^aIFA substrates were acetone-fixed COS-1 cells, either infected with DEN-2 16681, uninfected controls, or transformed with a DEN-2 recombinant plasmid. ^aIFA substrates were acetone-fixed COS-1 cells, either infected with DEN-2 16681, uninfected controls, or transformed with a DEN-2 recombinant plasmid. ^bMonoclonal antibodies were used at a predetermined optimum dilution based on reactivity with DEN-2 16681 virus. For some MAbs, endpoint titers, shown in parentheses, are reported and for others, only qualitative values are reported based on a scale from 1+ to 4+, with 3-4+ considered positive, 2+ equivocal, and 1+ negative. ^cAntigenic domains based on the E-glycoprotein of TBE virus (Mandl et al., "Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model," *J. Virol.* 63: 564-571 (1989); Rey et al., "The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution," *Nature* 375: 291-298 (1995)). ^ePlaque-reduction neutralization activity at a 1:100 dilution of ascitic fluid, using a 90% plaque-reduction endpoint, except for 4G2 and 9D12-6, for which a 50% neutralization endpoint is reported (Henchal et al., "Epitopic analysis of antigenic determinants on the surface of dengue-2 virons using monoclonal antibodies," *Am. J. Trop. Med. Hyg.* 34: 162-169 (1985); Roehrig et al., "Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica," *Virology* 246: 317-328 (1998)).

FABLE 11

.

Detectio	n of secreted and membrane-bound	l DEN-2 recombinant
	protein by antigen-capture E	LISA.
		Endpoint
Dia and di	Commute terms	ET TO A CA

Plasmid	Sample type	ELISA titer
pCBD2-14-6	PEG-precipitated culture fluid ^a	<1:10
pCBD2-14-6	PEG-precipitated, ethanol- extracted culture fluid ^b	<1:20
pCBD2-14-6	Hydrophobic membrane protein preparation ^c	1:160
pCB9D2-1J-4-3	PEG-precipitated culture fluid ^a	<1:10
pCB9D2-1J-4-3	PEG-precipitated, ethanol- extracted culture fluid ^b	<1:20
pCB9D2-1J-4-3	Hydrophobic membrane protein preparation ^c	1:80
pCB8D2-2J-2-9-1	PEG-precipitated culture fluid ^a	1:640
pCB8D2-2J-2-9-1	PEG-precipitated, ethanol- extracted culture fluid ^b	1:80

TABLE	11-co	ntinu	ed

5	Plasmid	Sample type	Endpoint ELISA titer
	pCB8D2-2J-2-9-1	Hydrophobic membrane protein preparation ^c	1:80
	pEGFP	PEG-precipitated culture fluid ^a	<1:10
0	pEGFP	PEG-precipitated, ethanol- extracted culture fluid ^b	<1:10
	pEGFP	Hydrophobic membrane protein preparation ^c	<1:10

Culture supernatant from plasmid-transformed cells was precipitated with 10% polyethyl-ene glycol (PEG) and resuspended in 1/10% forginal volume.
 ⁶PEG-precipitated culture supernatant was extracted with 4% ethanol to remove PEG and the pellet was resuspended in 1/3 of the volume extracted.
 ^cHydrophobic membrane fractions were prepared as described in Materials and Methods.

TABLE 12

	Immunog	genicity	of three	e DEN-	2 recom	binant plasmids	in ICR mice.		
			EL	ISA on	DEN-2	PRNT on	PRNT on JE		
		Scre wks,	en 3 p.v. ^c	Scre wks,	een 6 p.v. ^c	Endpoint titer	DEN-2 virus ^a Endpoint titer	virus" Endpoint titer	
Plasmid DNA b	d DNA ^b Mouse # $1:10$		1:400	1:100	1:400	9 wks, p.v.	9 wks, p.v.	9 wks, p.v.	
pCB8D2-2J-2-9-1	Pool, 1, 2, 4-10	ND^d	ND	+	+	64,000	ND	ND	
	1	+	+	+	+	64,000	>1000	<2	
	2	+	+	+	+	32,000	>1000	<2	
	4	+	+	+	+	16,000	200	<2	
	5	+	+	+	+	4,000	<10	<2	
	6	+	+	+	+	16,000	200	<2	
	7	+	-	+	+	64,000	100	<2	
	8	+	-	+	+	8,000	40	<2	
	9	+	+	+	+	6,400	<2	<4	
	10	+	+	+	+	64,000	>1000	<2	
pCB9D2-1J-	Pool, 1-10	ND	ND	+	+	1,000	ND	$<2^{e}$	
4-3	1	-	-	+	-	400	<10	ND	
	2	+	-	+	+	200	<10	ND	
	3	+	+	+	+	4,000	<2	≦4	
	4	+	-	+	-	200	<10	ND	
	5	-	-	+	+	400	<10	ND	
	6	+	+	+	+	4,000	<2	2	
	7	_	+/-	_	_	100	<10	ND	
	8	_	_	_	-	200	<10	ND	
	9	+	_	+	_	4.000	<2	<2	
	10	_	_	+	+	4 000	<2	<2	
nCBD2-	Pool 1-10	ND	ND	_		200	< V	< 28	
14-6	1 1001, 1 10	-	-	<u>.</u>	_	400	<10	ND	
14-0	2360		-	-	-	<100	ND	ND	
	2, 5, 0-9	-	-	-	-	1 000	~2		
	4	+	+	+	+	1,000	~2	~2	
	5	-	-	+	-	2,000	8	~2	
DOD	10	+	-	-	-	<100	ND	ND	
PEGFP	Pool, 1-10	-	ND	-	ND	<100	<2	<2	

^aPRNT, plaque-reduction neutralization test, 90% neutralization endpoint.

 bMice were immunized intramuscularly with 100 μg plasmid DNA on weeks 0 and 3.

^cELISA screens used sera diluted 1:100 and 1:400.

^dND, not done.

"Pool, 1, 2, 4, 5, 7, 8.

^fPool, 2, 3, 6-10.

^gPool, 1-3, 6-10.

Summary of the characteristics of three DEN-2 recombinant plasmids.														
		Ag- ELI	capture SA titer	ELISA tit DEN-	ter on 2 ^b	DEN-2								
	IFA ^a	Secreted	Hydrophobic membrane	No.	Pooled sera	PRNT ^e No. sera								
Plasmid	+/- Globular/Diffuse	antigen	protein prep	sera ≧1:100	titer	≧1:10								
pCB8D2- 2J-2-9-1	+ Diffuse	1:640	1:80	9/9	1:64000	7/9 ^d								
pCB9D2- 1J-4-3	+ Globular	<1:10	1:80	10/10	1:1000	0/10								
pCBD2- 14-6	+ Globular	<1:10	1:160	3/10	1:200	0/10								

TABLE 13

"Indirect fluorescent antibody assay (IFA) staining characteristics, + or -, and diffuse or globular pattern.

Induct notech antoday assay (IrA) standing characteristics, \neq of \neg , and dimites of globular partern. Anti-DEN-2 ELISA titer of sera from mice immunized with the recombinant plasmids. Sera were collected 9 weeks post-vaccination (weeks 0 and 3). Number of mice with titer of \ge 1:100/total number of mice is shown, including the endpoint ELISA titer of the pooled serum sample. Number of mice with paque-reduction neutralization titers (PRNT, 90% reduction) \ge 1:10/total number of mice. Sera were collected 9 weeks post-vaccination. 20 CHt = 7 mice with neutralizing antibody, 3 mice had PRNT titers of >1:1000, 3 had titers of \ge 1:100 < 1:1000, and one had a titer of 1:40.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 64 <210> SEQ ID NO 1 <211> LENGTH: 48 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(48) <223> OTHER INFORMATION: Amplimer 14DV389 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (25)..(48) <400> SEQUENCE: 1 cttggtacct ctagagccgc cgcc atg ggc aga aag caa aac aaa aga 48 Met Gly Arg Lys Gln Asn Lys Arg 1 5 <210> SEQ ID NO 2 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct <400> SEQUENCE: 2 Met Gly Arg Lys Gln Asn Lys Arg 1 5 <210> SEQ ID NO 3 <211> LENGTH: 50 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(50) <223> OTHER INFORMATION: Amplimer c14DV2453

<400> SEQUENCE: 3 ttttcttttg cggccgctca aacttaagca tgcacattgg tcgctaagaa 50 <210> SEQ ID NO 4 <211> LENGTH: 48 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(48) <223> OTHER INFORMATION: Amplimer YFDV389 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (25)..(48) <400> SEQUENCE: 4 cttggtacct ctagagccgc cgcc atg cgt tcc cat gat gtt ctg act 48 Met Arg Ser His Asp Val Leu Thr 5 1 <210> SEQ ID NO 5 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct <400> SEQUENCE: 5 Met Arg Ser His Asp Val Leu Thr 1 5 <210> SEQ ID NO 6 <211> LENGTH: 41 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(41) <223> OTHER INFORMATION: Amplimer cYFDV2452 <400> SEQUENCE: 6 ttttcttttg cggccgctca cgccccaact cctagagaaa c 41 <210> SEQ ID NO 7 <211> LENGTH: 51 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <221> NAME/NEL: miss_reasons <222> LOCATION: (1)...(51) <223> OTHER INFORMATION: Amplimer SLEDV410 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (25)..(51) <400> SEOUENCE: 7 cttggtacct ctagagccgc cgcc atg tct aaa aaa aga gga ggg acc aga 51 Met Ser Lys Lys Arg Gly Gly Thr Arg 1 5

-continued

<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct <400> SEQUENCE: 8 Met Ser Lys Lys Arg Gly Gly Thr Arg 1 <210> SEQ ID NO 9 <211> LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(38) <223> OTHER INFORMATION: Amplimer cSLEDV2449 <400> SEOUENCE: 9 38 ttttcttttg cggccgctta ggcttgcacg ctggttgc <210> SEO ID NO 10 <211> LENGTH: 7500 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(7500) <223> OTHER INFORMATION: pCDJE 2-7 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (916)..(3009) <400> SEQUENCE: 10 gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180 ttagggttag gegttttgeg etgettegeg atgtaeggge eagatataeg egttgaeatt 240 gattattgac tagttattaa tagtaatcaa ttacgggggtc attagttcat agcccatata 300 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420 attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480 atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540 atgeccagta catgacetta tgggaettte etaettggea gtacatetae gtattagtea 600 tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660 actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720 aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780 gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840 ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gcttggtacc 900 gagetegeeg eegee atg gge aga aag caa aac aaa aga gga gga aat gaa 951 Met Gly Arg Lys Gln Asn Lys Arg Gly Gly Asn Glu 1 5 10

ggc Gly	tca Ser	atc Ile 15	atg Met	tgg Trp	ctc Leu	gcg Ala	agc Ser 20	ttg Leu	gca Ala	gtt Val	gtc Val	ata Ile 25	gct Ala	tgt Cys	gcg Ala	999	
gga Gly	gcc Ala 30	atg Met	aag Lys	ttg Leu	tcg Ser	aat Asn 35	ttc Phe	cag Gln	999 999	aag Lys	ctt Leu 40	ttg Leu	atg Met	acc Thr	atc Ile	1047	
aac Asn 45	aac Asn	acg Thr	gac Asp	att Ile	gca Ala 50	gac Asp	gtt Val	atc Ile	gtg Val	att Ile 55	ccc Pro	acc Thr	tca Ser	aaa Lys	gga Gly 60	1095	
gag Glu	aac Asn	aga Arg	tgc Cys	tgg Trp 65	gtc Val	cgg Arg	gca Ala	atc Ile	gac Asp 70	gtc Val	ggc Gly	tac Tyr	atg Met	tgt Cys 75	gag Glu	1143	
gac Asp	act Thr	atc Ile	acg Thr 80	tac Tyr	gaa Glu	tgt Cys	cct Pro	aag Lys 85	ctt Leu	acc Thr	atg Met	ggc Gly	aat Asn 90	gat Asp	cca Pro	1191	
gag Glu	gat Asp	gtg Val 95	gat Asp	tgc Cys	tgg Trp	tgt Cys	gac Asp 100	aac Asn	caa Gln	gaa Glu	gtc Val	tac Tyr 105	gtc Val	caa Gln	tat Tyr	1239	
gga Gly	cgg Arg 110	tgc Cys	acg Thr	cgg Arg	acc Thr	agg Arg 115	cat His	tcc Ser	aag Lys	cga Arg	agc Ser 120	agg Arg	aga Arg	tcc Ser	gtg Val	1287	
tcg Ser 125	gtc Val	caa Gln	aca Thr	cat His	999 Gly 130	gag Glu	agt Ser	tca Ser	cta Leu	gtg Val 135	aat Asn	aaa Lys	aaa Lys	gag Glu	gct Ala 140	1335	
tgg Trp	ctg Leu	gat Asp	tca Ser	acg Thr 145	aaa Lys	gcc Ala	aca Thr	cga Arg	tat Tyr 150	ctc Leu	atg Met	aaa Lys	act Thr	gag Glu 155	aac Asn	1383	
tgg Trp	atc Ile	ata Ile	agg Arg 160	aat Asn	cct Pro	ggc Gly	tat Tyr	gct Ala 165	ttc Phe	ctg Leu	gcg Ala	gcg Ala	gta Val 170	ctt Leu	ggc Gly	1431	
tgg Trp	atg Met	ctt Leu 175	ggc Gly	agt Ser	aac Asn	aac Asn	ggt Gly 180	caa Gln	cgc Arg	gtg Val	gta Val	ttt Phe 185	acc Thr	atc Ile	ctc Leu	1479	
ctg Leu	ctg Leu 190	ttg Leu	gtc Val	gct Ala	ccg Pro	gct Ala 195	tac Tyr	agt Ser	ttt Phe	aat Asn	tgt Cys 200	ctg Leu	gga Gly	atg Met	ggc Gly	1527	
aat Asn 205	cgt Arg	gac Asp	ttc Phe	ata Ile	gaa Glu 210	gga Gly	gcc Ala	agt Ser	gga Gly	gcc Ala 215	act Thr	tgg Trp	gtg Val	gac Asp	ttg Leu 220	1575	
gtg Val	ctg Leu	gaa Glu	gga Gly	gat Asp 225	agc Ser	tgc Cys	ttg Leu	aca Thr	atc Ile 230	atg Met	gca Ala	aac Asn	gac Asp	aaa Lys 235	cca Pro	1623	
aca Thr	ttg Leu	gac Asp	gtc Val 240	cgc Arg	atg Met	att Ile	aac Asn	atc Ile 245	gaa Glu	gct Ala	agc Ser	caa Gln	ctt Leu 250	gct Ala	gag Glu	1671	
gtc Val	aga Arg	agt Ser 255	tac Tyr	tgc Cys	tat Tyr	cat His	gct Ala 260	tca Ser	gtc Val	act Thr	gac Asp	atc Ile 265	tcg Ser	acg Thr	gtg Val	1719	
gct Ala	cgg Arg 270	tgc Cys	ccc Pro	acg Thr	act Thr	gga Gly 275	gaa Glu	gcc Ala	cac His	aac Asn	gag Glu 280	aag Lys	cga Arg	gct Ala	gat Asp	1767	
agt Ser 285	agc Ser	tat Tyr	gtg Val	tgc Cys	aaa Lys 290	caa Gln	ggc Gly	ttc Phe	act Thr	gac Asp 295	cgt Arg	д1у 999	tgg Trp	ggc Gly	aac Asn 300	1815	
gga Gly	tgt Cys	gga Gly	ctt Leu	ttc Phe 305	д1À ааа	aag Lys	gga Gly	agc Ser	att Ile 310	gac Asp	aca Thr	tgt Cys	gca Ala	aaa Lys 315	ttc Phe	1863	
tcc Ser	tgc Cys	acc Thr	agt Ser 320	aaa Lys	gcg Ala	att Ile	ggg Gly	aga Arg 325	aca Thr	atc Ile	cag Gln	cca Pro	gaa Glu 330	aac Asn	atc Ile	1911	

aaa Lys	tac Tyr	gaa Glu 335	gtt Val	ggc Gly	att Ile	ttt Phe	gtg Val 340	cat His	gga Gly	acc Thr	acc Thr	act Thr 345	tcg Ser	gaa Glu	aac Asn	1959	
cat His	999 Gly 350	aat Asn	tat Tyr	tca Ser	gcg Ala	caa Gln 355	gtt Val	999 Gly	gcg Ala	tcc Ser	cag Gln 360	gcg Ala	gca Ala	aag Lys	ttt Phe	2007	
aca Thr 365	gta Val	aca Thr	ccc Pro	aat Asn	gct Ala 370	cct Pro	tcg Ser	ata Ile	acc Thr	ctc Leu 375	aaa Lys	ctt Leu	ggt Gly	gac Asp	tac Tyr 380	2055	
gga Gly	gaa Glu	gtc Val	aca Thr	ctg Leu 385	gac Asp	tgt Cys	gag Glu	cca Pro	agg Arg 390	agt Ser	gga Gly	ctg Leu	aac Asn	act Thr 395	gaa Glu	2103	
gcg Ala	ttt Phe	tac Tyr	gtc Val 400	atg Met	acc Thr	gtg Val	д1У ддд	tca Ser 405	aag Lys	tca Ser	ttt Phe	ctg Leu	gtc Val 410	cat His	agg Arg	2151	
gag Glu	tgg Trp	ttt Phe 415	cat His	gac Asp	ctc Leu	gct Ala	ctc Leu 420	ccc Pro	tgg Trp	acg Thr	tcc Ser	cct Pro 425	tcg Ser	agc Ser	aca Thr	2199	
gcg Ala	tgg Trp 430	aga Arg	aac Asn	aga Arg	gaa Glu	ctc Leu 435	ctc Leu	atg Met	gaa Glu	ttt Phe	gaa Glu 440	gag Glu	gcg Ala	cac His	gcc Ala	2247	
aca Thr 445	aaa Lys	cag Gln	tcc Ser	gtt Val	gtt Val 450	gct Ala	ctt Leu	999 999	tca Ser	cag Gln 455	gaa Glu	gga Gly	ggc Gly	ctc Leu	cat His 460	2295	
cag Gln	gcg Ala	ttg Leu	gca Ala	gga Gly 465	gcc Ala	atc Ile	gtg Val	gtg Val	gag Glu 470	tac Tyr	tca Ser	agc Ser	tca Ser	gtg Val 475	aag Lys	2343	
tta Leu	aca Thr	tca Ser	ggc Gly 480	cac His	ctg Leu	aaa Lys	tgt Cys	agg Arg 485	ctg Leu	aaa Lys	atg Met	gac Asp	aaa Lys 490	ctg Leu	gct Ala	2391	
ctg Leu	aaa Lys	ggc Gly 495	aca Thr	acc Thr	tat Tyr	ggc Gly	atg Met 500	tgt Cys	aca Thr	gaa Glu	aaa Lys	ttc Phe 505	tcg Ser	ttc Phe	gcg Ala	2439	
aaa Lys	aat Asn 510	ccg Pro	gcg Ala	gac Asp	act Thr	ggt Gly 515	cac His	gga Gly	aca Thr	gtt Val	gtc Val 520	att Ile	gaa Glu	ctc Leu	tcc Ser	2487	
tac Tyr 525	tct Ser	gga gga	agt Ser	gat Asp	ggc Gly 530	ccc Pro	tgc Cys	aaa Lys	att Ile	ccg Pro 535	att Ile	gct Ala	tcc Ser	gtt Val	gcg Ala 540	2535	
agc Ser	ctc Leu	aat Asn	gac Asp	atg Met 545	acc Thr	ccc Pro	gtt Val	gga gga	cgg Arg 550	ctg Leu	gtg Val	aca Thr	gtg Val	aac Asn 555	ccc Pro	2583	
ttc Phe	gtc Val	gcg Ala	act Thr 560	tcc Ser	agt Ser	gcc Ala	agc Ser	tca Ser 565	aag Lys	gtg Val	ctg Leu	gtc Val	gag Glu 570	atg Met	gaa Glu	2631	
ccc Pro	ccc Pro	ttc Phe 575	gga Gly	gac Asp	tcc Ser	tac Tyr	atc Ile 580	gta Val	gtt Val	gga Gly	agg Arg	gga Gly 585	gac Asp	aag Lys	cag Gln	2679	
atc Ile	aac Asn 590	cac His	cat His	tgg Trp	cac His	aaa Lys 595	gct Ala	gga Gly	agc Ser	acg Thr	ctg Leu 600	ggc Gly	aag Lys	gcc Ala	ttt Phe	2727	
tca Ser 605	aca Thr	act Thr	ttg Leu	aag Lys	gga Gly 610	gct Ala	caa Gln	aga Arg	ctg Leu	gca Ala 615	gcg Ala	ttg Leu	ggc Gly	gac Asp	aca Thr 620	2775	
gcc Ala	tgg Trp	gac Asp	ttt Phe	ggc Gly 625	tct Ser	att Ile	gga Gly	ggg ggg	gtc Val 630	ttc Phe	aac Asn	tcc Ser	ata Ile	gga Gly 635	aaa Lys	2823	
gcc Ala	gtt Val	cac His	caa Gln 640	gtg Val	ttt Phe	ggt Gly	ggt Gly	gcc Ala 645	ttc Phe	aga Arg	aca Thr	ctc Leu	ttt Phe 650	999 Gly	gga Gly	2871	

atg tct tgg atc aca caa ggg cta atg ggt gcc cta ctg ctc tgg atg Met Ser Trp Ile Thr Gln Gly Leu Met Gly Ala Leu Leu Leu Trp Met 655 660 665	2919
ggc gtc aac gca cga gac cga tca att gct ttg gcc ttc tta gcc aca Gly Val Asn Ala Arg Asp Arg Ser Ile Ala Leu Ala Phe Leu Ala Thr 670 675 680	2967
ggg ggt gtg ctc gtg ttc tta gcg acc aat gtg cat gct taa Gly Gly Val Leu Val Phe Leu Ala Thr Asn Val His Ala 685 690 695	3009
ttagtttgag cggccgctcg agcatgcatc tagagggccc tattctatag tgtcacctaa	3069
atgetagage tegetgatea geetegaetg tgeettetag ttgeeageea tetgttgttt	3129
gcccctcccc cgtgccttcc ttgaccctgg aaggtgccac tcccactgtc ctttcctaat	3189
aaaatgagga aattgcatcg cattgtctga gtaggtgtca ttctattctg gggggtgggg	3249
tggggcagga cagcaagggg gaggattggg aagacaatag caggcatgct ggggatgcgg	3309
tgggctctat ggcttctgag gcggaaagaa ccagctgggg ctctaggggg tatccccacg	3369
cgccctgtag cggcgcatta agcgcggcgg gtgtggtggt tacgcgcagc gtgaccgcta	3429
cacttgccag cgccctagcg cccgctcctt tcgctttctt cccttccttt ctcgccacgt	3489
tcgccggctt tccccgtcaa gctctaaatc ggggcatccc tttagggttc cgatttagtg	3549
ctttacggca cctcgacccc aaaaaacttg attagggtga tggttcacgt agtgggccat	3609
cgccctgata gacggttttt cgccctttga cgttggagtc cacgttcttt aatagtggac	3669
tettgtteea aaetggaaca acaeteaace etateteggt etattetttt gatttataag	3729
ggattttggg gatttcggcc tattggttaa aaaatgagct gatttaacaa aaatttaacg	3789
cgaattaatt ctgtggaatg tgtgtcagtt agggtgtgga aagtccccag gctccccagg	3849
caggcagaag tatgcaaagc atgcatctca attagtcagc aaccaggtgt ggaaagtccc	3909
caggeteeec ageaggeaga agtatgeaaa geatgeatet eaattagtea geaaceatag	3969
tecegeeest aasteegees atceegees taasteegee cagtteegee catteteege	4029
cccatggetg actaatttt tttatttatg cagaggeega ggeegeetet geetetgage	4089
tatteeagaa gtagtgagga ggettttttg gaggeetagg ettttgeaaa aageteeegg	4149
gagettgtat atceatttte ggatetgate aagagaeagg atgaggateg tttegeatga	4209
ttgaacaaga tggattgcac gcaggttctc cggccgcttg ggtggagagg ctattcggct	4269
atgactgggc acaacagaca atcggctgct ctgatgccgc cgtgttccgg ctgtcagcgc	4329
aggggcgccc ggttcttttt gtcaagaccg acctgtccgg tgccctgaat gaactgcagg	4389
acgaggcage geggetateg tggetggeea egaegggegt teettgegea getgtgeteg	4449
acgttgtcac tgaagcgggga agggactggc tgctattggg cgaagtgccg gggcaggatc	4509
teetgteate teacettget eetgeegaga aagtateeat eatggetgat geaatgegge	4569
ggetgeatae gettgateeg getaeetgee cattegaeea ceaagegaaa categeateg	4629
agegageaeg taeteggatg gaageeggte ttgtegatea ggatgatetg gaegaagage	4689
atcaggggct cgcgccagcc gaactgttcg ccaggctcaa ggcgcgcatg cccgacggcg	4749
aggatetegt egtgaceeat ggegatgeet gettgeegaa tateatggtg gaaaatggee	4809
gcttttctgg attcatcgac tgtggccggc tgggtgtggc ggaccgctat caggacatag	4869
cgttggctac ccgtgatatt gctgaagagc ttggcggcga atgggctgac cgcttcctcg	4929
tgetttaegg tategeeget eeegattege agegeatege ettetatege ettettgaeg	4989
agttettetg agegggaete tggggttega aatgaeegae caagegaege ecaaeetgee	5049

continued

-continued	
	5109
ccgggacgcc ggctggatga teetecageg eggggatete atgetggagt tettegeeea	5169
ccccaacttg tttattgcag cttataatgg ttacaaataa agcaatagca tcacaaattt	5229
cacaaataaa gcattttttt cactgcattc tagttgtggt ttgtccaaac tcatcaatgt	5289
atcttatcat gtctgtatac cgtcgacctc tagctagagc ttggcgtaat catggtcata	5349
gctgtttcct gtgtgaaatt gttatccgct cacaattcca cacaacatac gagccggaag	5409
cataaagtgt aaagcctggg gtgcctaatg agtgagctaa ctcacattaa ttgcgttgcg	5469
ctcactgccc gctttccagt cgggaaacct gtcgtgccag ctgcattaat gaatcggcca	5529
acgegegggg agaggeggtt tgegtattgg gegetettee getteetege teaetgaete	5589
gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg cggtaatacg	5649
gttatccaca gaatcagggg ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa	5709
ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc cataggctcc gccccctga	5769
cgagcatcac aaaaatcgac gctcaagtca gaggtggcga aacccgacag gactataaag	5829
ataccaggeg ttteeceetg gaageteeet egtgegetet eetgtteega eeetgeeget	5889
taccggatac ctgtccgcct ttctcccttc gggaagcgtg gcgctttctc aatgctcacg	5949
ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc	6009
ccccgttcag cccgaccgct gcgccttatc cggtaactat cgtcttgagt ccaacccggt	6069
aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca gagcgaggta	6129
tgtaggcggt gctacagagt tcttgaagtg gtggcctaac tacggctaca ctagaaggac	6189
agtatttggt atctgcgctc tgctgaagcc agttaccttc ggaaaaagag ttggtagctc	6249
ttgatccggc aaacaaacca ccgctggtag cggtggtttt tttgtttgca agcagcagat	6309
tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc	6369
tcagtggaac gaaaactcac gttaagggat tttggtcatg agattatcaa aaaggatctt	6429
cacctagatc cttttaaatt aaaaatgaag ttttaaatca atctaaagta tatatgagta	6489
aacttggtct gacagttacc aatgcttaat cagtgaggca cctatctcag cgatctgtct	6549
atttcgttca tccatagttg cctgactccc cgtcgtgtag ataactacga tacgggaggg	6609
cttaccatct ggccccagtg ctgcaatgat accgcgagac ccacgctcac cggctccaga	6669
tttatcagca ataaaccagc cagccggaag ggccgagcgc agaagtggtc ctgcaacttt	6729
atccgcctcc atccagtcta ttaattgttg ccgggaagct agagtaagta gttcgccagt	6789
taatagtttg cgcaacgttg ttgccattgc tacaggcatc gtggtgtcac gctcgtcgtt	6849
tggtatggct tcattcagct ccggttccca acgatcaagg cgagttacat gatcccccat	6909
gttgtgcaaa aaagcggtta gctccttcgg tcctccgatc gttgtcagaa gtaagttggc	6969
cgcagtgtta tcactcatgg ttatggcagc actgcataat tctcttactg tcatgccatc	7029
cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag tcattctgag aatagtgtat	7089
geggegaeeg agttgetett geeeggegte aataegggat aataeegege cacatageag	7149
aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg cgaaaactct caaggatctt	7209
accgctgttg agatccagtt cgatgtaacc cactcgtgca cccaactgat cttcagcatc	7269
ttttactttc accagcgttt ctgggtgagc aaaaacagga aggcaaaatg ccgcaaaaaa	7329
gggaataagg gcgacacgga aatgttgaat actcatactc ttcctttttc aatattattg	7389
aagcatttat cagggttatt gtctcatgag cggatacata tttgaatgta tttagaaaaa	7449

taaa	acaaa	ata ç	ggggt	tcc	ge g	caca	tttco	c ccé	gaaaa	agtg	cca	cctga	acg 1	t		7500			
<210 <211 <211 <211 <211 <220 <221	0 > 51 L > L1 2 > T 3 > 01 0 > F1 3 > 0	EQ II ENGTH TPE : RGANI EATUH THER	D NO H: 69 PRT ISM: RE: INFO	11 97 Art: DRMA	ific: FION	ial : : Syn	Seque	ence tic (Const	truct	z.								
< 400	D> SI	EQUEI	ICE :	11															
Met 1	Gly	Arg	Гла	Gln 5	Asn	Гла	Arg	Gly	Gly 10	Asn	Glu	Gly	Ser	Ile 15	Met				
Trp	Leu	Ala	Ser 20	Leu	Ala	Val	Val	Ile 25	Ala	Cys	Ala	Gly	Ala 30	Met	Lys				
Leu	Ser	Asn 35	Phe	Gln	Gly	Гла	Leu 40	Leu	Met	Thr	Ile	Asn 45	Asn	Thr	Asp				
Ile	Ala 50	Asp	Val	Ile	Val	Ile 55	Pro	Thr	Ser	Lys	Gly 60	Glu	Asn	Arg	Суз				
Trp 65	Val	Arg	Ala	Ile	Asp 70	Val	Gly	Tyr	Met	Суя 75	Glu	Asp	Thr	Ile	Thr 80				
Tyr	Glu	Сув	Pro	Lys 85	Leu	Thr	Met	Gly	Asn 90	Asp	Pro	Glu	Asp	Val 95	Asp				
Суз	Trp	Cys	Asp 100	Asn	Gln	Glu	Val	Tyr 105	Val	Gln	Tyr	Gly	Arg 110	Cys	Thr				
Arg	Thr	Arg 115	His	Ser	LÀa	Arg	Ser 120	Arg	Arg	Ser	Val	Ser 125	Val	Gln	Thr				
His	Gly 130	Glu	Ser	Ser	Leu	Val 135	Asn	Lys	Lys	Glu	Ala 140	Trp	Leu	Asp	Ser				
Thr 145	Lys	Ala	Thr	Arg	Tyr 150	Leu	Met	Lys	Thr	Glu 155	Asn	Trp	Ile	Ile	Arg 160				
Asn	Pro	Gly	Tyr	Ala 165	Phe	Leu	Ala	Ala	Val 170	Leu	Gly	Trp	Met	Leu 175	Gly				
Ser	Asn	Asn	Gly 180	Gln	Arg	Val	Val	Phe 185	Thr	Ile	Leu	Leu	Leu 190	Leu	Val				
Ala	Pro	Ala 195	Tyr	Ser	Phe	Asn	Cys 200	Leu	Gly	Met	Gly	Asn 205	Arg	Asp	Phe				
Ile	Glu 210	Gly	Ala	Ser	Gly	Ala 215	Thr	Trp	Val	Asp	Leu 220	Val	Leu	Glu	Gly				
Asp 225	Ser	Суз	Leu	Thr	Ile 230	Met	Ala	Asn	Asp	Lys 235	Pro	Thr	Leu	Asp	Val 240				
Arg	Met	Ile	Asn	Ile 245	Glu	Ala	Ser	Gln	Leu 250	Ala	Glu	Val	Arg	Ser 255	Tyr				
Суз	Tyr	His	Ala 260	Ser	Val	Thr	Asp	Ile 265	Ser	Thr	Val	Ala	Arg 270	Сүз	Pro				
Thr	Thr	Gly 275	Glu	Ala	His	Asn	Glu 280	Lys	Arg	Ala	Asp	Ser 285	Ser	Tyr	Val				
СЛа	Lys 290	Gln	Gly	Phe	Thr	Asp 295	Arg	Gly	Trp	Gly	Asn 300	Gly	Cys	Gly	Leu				
Phe 305	Gly	Lys	Gly	Ser	Ile 310	Asp	Thr	Сув	Ala	Lys 315	Phe	Ser	Сүз	Thr	Ser 320				
ГЛа	Ala	Ile	Gly	Arg 325	Thr	Ile	Gln	Pro	Glu 330	Asn	Ile	Lys	Tyr	Glu 335	Val				
Gly	Ile	Phe	Val 340	His	Gly	Thr	Thr	Thr 345	Ser	Glu	Asn	His	Gly 350	Asn	Tyr				
Ser	Ala	Gln 355	Val	Gly	Ala	Ser	Gln 360	Ala	Ala	Lys	Phe	Thr 365	Val	Thr	Pro				

Asn	Ala 370	Pro	Ser	Ile	Thr	Leu 375	Гла	Leu	Gly	Asp	Tyr 380	Gly	Glu	Val	Thr
Leu 385	Asp	Суз	Glu	Pro	Arg 390	Ser	Gly	Leu	Asn	Thr 395	Glu	Ala	Phe	Tyr	Val 400
Met	Thr	Val	Gly	Ser 405	Lys	Ser	Phe	Leu	Val 410	His	Arg	Glu	Trp	Phe 415	His
Asp	Leu	Ala	Leu 420	Pro	Trp	Thr	Ser	Pro 425	Ser	Ser	Thr	Ala	Trp 430	Arg	Asn
Arg	Glu	Leu 435	Leu	Met	Glu	Phe	Glu 440	Glu	Ala	His	Ala	Thr 445	Lys	Gln	Ser
Val	Val 450	Ala	Leu	Gly	Ser	Gln 455	Glu	Gly	Gly	Leu	His 460	Gln	Ala	Leu	Ala
Gly 465	Ala	Ile	Val	Val	Glu 470	Tyr	Ser	Ser	Ser	Val 475	Lys	Leu	Thr	Ser	Gly 480
His	Leu	Lys	Суз	Arg 485	Leu	Lys	Met	Asp	Lys 490	Leu	Ala	Leu	Lys	Gly 495	Thr
Thr	Tyr	Gly	Met 500	Сүз	Thr	Glu	Lys	Phe 505	Ser	Phe	Ala	Lys	Asn 510	Pro	Ala
Asp	Thr	Gly 515	His	Gly	Thr	Val	Val 520	Ile	Glu	Leu	Ser	Tyr 525	Ser	Gly	Ser
Asp	Gly 530	Pro	Суз	Lys	Ile	Pro 535	Ile	Ala	Ser	Val	Ala 540	Ser	Leu	Asn	Asp
Met 545	Thr	Pro	Val	Gly	Arg 550	Leu	Val	Thr	Val	Asn 555	Pro	Phe	Val	Ala	Thr 560
Ser	Ser	Ala	Ser	Ser 565	Lys	Val	Leu	Val	Glu 570	Met	Glu	Pro	Pro	Phe 575	Gly
Asp	Ser	Tyr	Ile 580	Val	Val	Gly	Arg	Gly 585	Asp	Lys	Gln	Ile	Asn 590	His	His
Trp	His	Lys 595	Ala	Gly	Ser	Thr	Leu 600	Gly	Lys	Ala	Phe	Ser 605	Thr	Thr	Leu
Lys	Gly 610	Ala	Gln	Arg	Leu	Ala 615	Ala	Leu	Gly	Asp	Thr 620	Ala	Trp	Asp	Phe
Gly 625	Ser	Ile	Gly	Gly	Val 630	Phe	Asn	Ser	Ile	Gly 635	Lys	Ala	Val	His	Gln 640
Val	Phe	Gly	Gly	Ala 645	Phe	Arg	Thr	Leu	Phe 650	Gly	Gly	Met	Ser	Trp 655	Ile
Thr	Gln	Gly	Leu 660	Met	Gly	Ala	Leu	Leu 665	Leu	Trp	Met	Gly	Val 670	Asn	Ala
Arg	Asp	Arg 675	Ser	Ile	Ala	Leu	Ala 680	Phe	Leu	Ala	Thr	Gly 685	Gly	Val	Leu
Val	Phe 690	Leu	Ala	Thr	Asn	Val 695	His	Ala							
<210 <211 <212 <213 <220 <223 <220 <221 <222 <223	0 > SI 1 > LI 2 > T 3 > OI 3 > O 3 > O 5 3 > O 5 1 > N 2 > LO 3 > O	EQ II ENGTI YPE: RGAN: EATUI THER YNTH EATUI AME/J DCAT: THER	D NO H: 40 DNA ISM: RE: INFC RE: KEY: ION: INFC	12 Art: DRMA cons miso (1) DRMA	ific: FION struc c_fea (4) FION	ial : : De: ct ature 5) : WN	Seque scrip 466	ence	n of	art:	ific:	ial :	seque	ence;	: note =

cttggtaccc gtctcggcgc cgtgaccctc tcgaacttcc agggca

<210> SEQ ID NO 13 <211> LENGTH: 43 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(43) <223> OTHER INFORMATION: CWN2444 <400> SEQUENCE: 13 43 agaggcactt gcacgtgcgg acttccgccg gcgaaaaaga aaa <210> SEQ ID NO 14 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: MISC_FEATURE <223> OTHER INFORMATION: JE Signal <400> SEOUENCE: 14 Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 10 1 5 15 Val Val Ile Ala Cys Ala Gly Ala 20 <210> SEQ ID NO 15 <211> LENGTH: 5308 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(5308) <223> OTHER INFORMATION: pCBWN <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (911) .. (2986) <400> SEQUENCE: 15 gacggategg gagateteee gateeeetat ggtgeactet eagtacaate tgetetgatg 60 cogcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180 ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240 gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420 attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt 480 atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540 atgeccagta catgacetta tgggaettte etaettggea gtacatetae gtattagtea 600 tegetattac catggtgatg eggtttttgg cagtacatea atgggegtgg atageggttt 660 gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt gttttggcac 720

-continued

_																				
ca	aaa	tcaa		ggad	ettt	cc a	aaat	gtcg	t aa	caac	tccg	ccc	catt	gac	gcaa	atgggc	780			
gg	gtag	gcgt	g t	acgo	gtgg	ga g	gtct	atat	a ag	caga	gctc	tct	ggct	aac	taga	gaaccc	840			
ac	ctgc	ttac	t g	ggctt	cate	ga a	atta	atac	g ac	tcac	tata	aaa	agac	сса	agct	tggtac	900			
cç	lccd	ccgc	ca N	itg g let (ggc a 31y 1	aag Lys	agg Arg	tcc Ser 5	gcc Ala	ggc Gly	tca Ser	atc Ile i	atg Met 10	tgg Trp	ctc Leu	gcg Ala	949			
aç Se	gc ti er Lo 1!	tg g eu A 5	ıca la	gtt Val	gtc Val	ata Ile	a gct 20	tgt Cys	gca Ala	ggc Gly	gcc Ala	gtg Val 25	acc Thr	ctc Leu	tcg Ser	aac Asn	997			
tt Pł 30	ic ca ne Gi)	ag g ln G	gc ly	aag Lys	gtg Val	atg Met 35	g atg : Met	acg Thr	gta Val	aat Asn	gct Ala 40	act Thr	gac Asp	gtc Val	aca Thr	gat Asp 45	1045			
gt Va	c at al I	tc a le 1	lcg 'hr	att Ile	cca Pro 50	aca Thr	a gct Ala	gct Ala	gga Gly	aag Lys 55	aac Asn	cta Leu	tgc Cys	att Ile	gtc Val 60	aga Arg	1093			
go Al	ca at La Me	tg g et A	lat Sp	gtg Val 65	gga Gly	tac Tyr	: atg : Met	tgc Cys	gat Asp 70	gat Asp	act Thr	atc Ile	act Thr	tat Tyr 75	gaa Glu	tgc Cys	1141			
cc Pi	ca gi co Va	tg c al I 8	tg eu 0	tcg Ser	gct Ala	ggt Gly	: aat ⁄ Asn	gat Asp 85	cca Pro	gaa Glu	gac Asp	atc Ile	gac Asp 90	tgt Cys	tgg Trp	tgc Cys	1189			
ac Tł	a a nr Ly 9!	ag t ys S 5	ca er	gca Ala	gtc Val	tac Tyr	gtc Val 100	agg Arg	tat Tyr	gga Gly	aga Arg	tgc Cys 105	acc Thr	aag Lys	aca Thr	cgc Arg	1237			
ca Hi 11	ac to Ls So LO	ca a er A	ıga Arg	cgc Arg	agt Ser	cgg Arg 115	g agg g Arg 5	tca Ser	ctg Leu	aca Thr	gtg Val 120	cag Gln	aca Thr	cac His	gga Gly	gaa Glu 125	1285			
aç Se	gc a er Tl	ct c hr I	ta eu	gcg Ala	aac Asn 130	aag Lys	g aag g Lys	g1À 833	gct Ala	tgg Trp 135	atg Met	gac Asp	agc Ser	acc Thr	aag Lys 140	gcc Ala	1333			
ac Tł	a ag nr A:	gg t rg 1	at Yr	ttg Leu 145	gta Val	ааа Lуз	aca Thr	gaa Glu	tca Ser 150	tgg Trp	atc Ile	ttg Leu	agg Arg	aac Asn 155	cct Pro	gga Gly	1381			
ta Ty	at ge vr Al	cc c la I 1	tg eu .60	gtg Val	gca Ala	gcc Ala	gtc Val	att Ile 165	ggt Gly	tgg Trp	atg Met	ctt Leu	999 Gly 170	agc Ser	aac Asn	acc Thr	1429			
at Me	et G 1	ag a ln A 75	ıga Irg	gtt Val	gtg Val	ttt Ph∈	: gtc 9 Val 180	gtg Val	cta Leu	ttg Leu	ctt Leu	ttg Leu 185	gtg Val	gcc Ala	cca Pro	gct Ala	1477			
ta T <u>y</u> 19	ac ag 7r Se 90	gc t er F	tc he	aac Asn	tgc Cys	ctt Leu 195	: gga 1 Gly 5	. atg Met	agc Ser	aac Asn	aga Arg 200	gac Asp	ttc Phe	ttg Leu	gaa Glu	gga Gly 205	1525			
gt Va	g to al So	ct g er G	ıga ly	gca Ala	aca Thr 210	tgg Trp	g gtg Val	gat Asp	ttg Leu	gtt Val 215	ctc Leu	gaa Glu	ggc Gly	gac Asp	agc Ser 220	tgc Cys	1573			
gt Va	g a al Tl	ct a hr I	tc le	atg Met 225	tct Ser	aag Lys	g gac g Asp	aag Lys	cct Pro 230	acc Thr	atc Ile	gat Asp	gtg Val	aag Lys 235	atg Met	atg Met	1621			
aa As	at a sn Me	tg g et G 2	ag lu 40	gcg Ala	gcc Ala	aac Asr	ctg Leu	gca Ala 245	gag Glu	gtc Val	cgc Arg	agt Ser	tat Tyr 250	tgc Cys	tat Tyr	ttg Leu	1669			
go Al	t a la Ti 2!	cc g hr V 55	ntc Mal	agc Ser	gat Asp	cto Leu	tcc Ser 260	acc Thr	aaa Lys	gct Ala	gcg Ala	tgc Cys 265	ccg Pro	acc Thr	atg Met	gga Gly	1717			
ga G] 27	aa go lu Ai 70	ct c la F	ac Iis	aat Asn	gac Asp	aaa Lys 275	a cgt 3 Arg 5	gct Ala	gac Asp	cca Pro	gct Ala 280	ttt Phe	gtg Val	tgc Cys	aga Arg	caa Gln 285	1765			
gg G]	ga gi Ly Va	tg g al V	ıtg 'al	gac Asp	agg Arg	ggc Gly	tgg 7 Trp	ggc Gly	aac Asn	ggc Gly	tgc Cys	gga Gly	cta Leu	ttt Phe	ggc Gly	aaa Lys	1813			

				290					295					300			
gga Gly	agc Ser	att Ile	gac Asp 305	aca Thr	tgc Cys	gcc Ala	aaa Lys	ttt Phe 310	gcc Ala	tgc Cys	tct Ser	acc Thr	aag Lys 315	gca Ala	ata Ile	1861	
gga Gly	aga Arg	acc Thr 320	atc Ile	ttg Leu	aaa Lys	gag Glu	aat Asn 325	atc Ile	aag Lys	tac Tyr	gaa Glu	gtg Val 330	gcc Ala	att Ile	ttt Phe	1909	
gtc Val	cat His 335	gga Gly	cca Pro	act Thr	act Thr	gtg Val 340	gag Glu	tcg Ser	cac His	gga Gly	aac Asn 345	tac Tyr	tcc Ser	aca Thr	cag Gln	1957	
gtt Val 350	gga Gly	gcc Ala	act Thr	cag Gln	gca Ala 355	999 G1y	aga Arg	ttc Phe	agc Ser	atc Ile 360	act Thr	cct Pro	gcg Ala	gcg Ala	cct Pro 365	2005	
tca Ser	tac Tyr	aca Thr	cta Leu	aag Lys 370	ctt Leu	gga Gly	gaa Glu	tat Tyr	gga Gly 375	gag Glu	gtg Val	aca Thr	gtg Val	gac Asp 380	tgt Cys	2053	
gaa Glu	cca Pro	cgg Arg	tca Ser 385	999 999	att Ile	gac Asp	acc Thr	aat Asn 390	gca Ala	tac Tyr	tac Tyr	gtg Val	atg Met 395	act Thr	gtt Val	2101	
gga Gly	aca Thr	aag Lys 400	acg Thr	ttc Phe	ttg Leu	gtc Val	cat His 405	cgt Arg	gag Glu	tgg Trp	ttc Phe	atg Met 410	gac Asp	ctc Leu	aac Asn	2149	
ctc Leu	cct Pro 415	tgg Trp	agc Ser	agt Ser	gct Ala	gga Gly 420	agt Ser	act Thr	gtg Val	tgg Trp	agg Arg 425	aac Asn	aga Arg	gag Glu	acg Thr	2197	
tta Leu 430	atg Met	gag Glu	ttt Phe	gag Glu	gaa Glu 435	cca Pro	cac His	gcc Ala	acg Thr	aag Lys 440	cag Gln	tct Ser	gtg Val	ata Ile	gca Ala 445	2245	
ttg Leu	ggc Gly	tca Ser	caa Gln	gag Glu 450	gga Gly	gct Ala	ctg Leu	cat His	caa Gln 455	gct Ala	ttg Leu	gct Ala	gga Gly	gcc Ala 460	att Ile	2293	
cct Pro	gtg Val	gaa Glu	ttt Phe 465	tca Ser	agc Ser	aac Asn	act Thr	gtc Val 470	aag Lys	ttg Leu	acg Thr	tcg Ser	ggt Gly 475	cat His	ttg Leu	2341	
aag Lys	tgt Cys	aga Arg 480	gtg Val	aag Lys	atg Met	gaa Glu	aaa Lys 485	ttg Leu	cag Gln	ttg Leu	aag Lys	gga Gly 490	aca Thr	acc Thr	tat Tyr	2389	
ggc Gly	gtc Val 495	tgt Cys	tca Ser	aag Lys	gct Ala	ttc Phe 500	aag Lys	ttt Phe	ctt Leu	с1 ^у ааа	act Thr 505	ccc Pro	gcg Ala	gac Asp	aca Thr	2437	
ggt Gly 510	cac His	ggc Gly	act Thr	gtg Val	gtg Val 515	ttg Leu	gaa Glu	ttg Leu	cag Gln	tac Tyr 520	act Thr	ggc Gly	acg Thr	gat Asp	gga Gly 525	2485	
cct Pro	tgc Cys	aaa Lys	gtt Val	cct Pro 530	atc Ile	tcg Ser	tca Ser	gtg Val	gct Ala 535	tca Ser	ttg Leu	aac Asn	gac Asp	cta Leu 540	acg Thr	2533	
cca Pro	gtg Val	ggc Gly	aga Arg 545	ttg Leu	gtc Val	act Thr	gtc Val	aac Asn 550	cct Pro	ttt Phe	gtt Val	tca Ser	gtg Val 555	gcc Ala	acg Thr	2581	
gcc Ala	aac Asn	gct Ala 560	aag Lys	gtc Val	ctg Leu	att Ile	gaa Glu 565	ttg Leu	gaa Glu	cca Pro	ccc Pro	ttt Phe 570	gga Gly	gac Asp	tca Ser	2629	
tac Tyr	ata Ile 575	gtg Val	gtg Val	ggc Gly	aga Arg	gga Gly 580	gaa Glu	caa Gln	cag Gln	atc Ile	aat Asn 585	cac His	cat His	tgg Trp	cac His	2677	
aag	tct	gga	agc	agc	att	ggc	aaa	gcc	ttt	aca	acc	acc	ctc	aaa	gga	2725	

aag tet gga age age age att gge aaa gee ttt aca ace ace etc aaa gga2725Lys Ser Gly Ser Ser lle Gly Lys Ala Phe Thr Thr Thr Leu Lys Gly
595290geg cag aga eta gee get eta gga gae aca get tgg gae ttt gga tea
Ala Gln Arg Leu Ala Ala Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser2773

-continued	
610 615 620	
gtt gga ggg gtg ttc acc tca gtt ggg aag gct gtc cat caa gtg ttc Val Gly Gly Val Phe Thr Ser Val Gly Lys Ala Val His Gln Val Phe 625 630 635	2821
gga gga gca ttc cgc tca ctg ttc gga ggc atg tcc tgg ata acg caa Gly Gly Ala Phe Arg Ser Leu Phe Gly Gly Met Ser Trp Ile Thr Gln	2869
gga ttg ctg ggg gct ctc ctg ttg tgg atg ggc atc aat gct cgt gat Gly Leu Leu Gly Ala Leu Leu Leu Trp Met Gly Ile Asn Ala Arg Asp	2917
655 660 665 agg tcc ata gct ctc acg ttt ctc gca gtt gga gga gtt ctg ctc ttc Arg Ser Ile Ala Leu Thr Phe Leu Ala Val Gly Gly Val Leu Leu Phe	2965
670 675 680 685 ctc tcc gtg aac gtg cac gcc tgaaggcggc cgctcgagca tgcatctaga Leu Ser Val Asn Val His Ala	3016
690	
gggccctatt ctatagtgtc acctaaatgc tagagctcgc tgatcagcct cgactgtgcc	3076
ttctagttgc cagecatetg ttgtttgeec etceeegtg eetteettga eeetggaagg	3136
tgccactccc actgtccttt cctaataaaa tgaggaaatt gcatcgcatt gtctgagtag	3196
gtgtcattct attctggggg gtgggggggg gcaggacagc aaggggggagg attgggaaga	3256
caatagcagg catgctgggg atgcggtggg ctctatggct tctgaggcgg aaagaaccag	3316
ctgcattaat gaatcggcca acgcgcgggg agaggcggtt tgcgtattgg gcgctcttcc	3376
getteetege teactgaete getgegeteg gtegttegge tgeggegage ggtateaget	3436
cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg	3496
tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc	3556
cataggetee geeeceetga egageateae aaaaategae geteaagtea gaggtggega	3616
aaccogacag gactataaag ataccaggog tttoccootg gaageteeet ogtgegetet	3676
cctgttccga ccctgccgct taccggatac ctgtccgcct ttctcccttc gggaagcgtg	3736
gegetttete atageteacg etgtaggtat eteagttegg tgtaggtegt tegeteeaag	3796
ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct gcgccttatc cggtaactat	3856
cgtcttgagt ccaacccggt aagacacgac ttatcgccac tggcagcagc cactggtaac	3916
aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg gtggcctaac	3976
tacggctaca ctagaagaac agtatttggt atctgcgctc tgctgaagcc agttaccttc	4036
ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cggtggtttt	4096
tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc	4156
ttttctacgg ggtctgacgc tcagtggaac gaaaactcac gttaagggat tttggtcatg	4216
agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatca	4276
atctaaagta tatatgagta aacttggtct gacagttacc aatgcttaat cagtgaggca	4336
cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag	4396
ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat accqcqaqac	4456
ccacgeteae eggeteeaga tttateagea ataaaceage eageeggaag ggeegaagege	4516
agaagtggtc ctgcaacttt atccgcctcc atccaqtcta ttaattqttq ccqqqaaqct	4576
aqaqtaaqta qttcqccaqt taataqtttq cqcaacqttq ttqccattqc tacaqqcatc	4636
atgatateac actedteatt tagtataget teatteaget coggiteess acgateaagg	4696
J-JJ-J-sab Jeeegeegee eggeneggee conceanger eeggereeen negattaagg	

cgagttacat gatcccccat gttgtgcaaa aaagcggtta gctccttcgg tcctccgatc 4756

85

continued

gttgtcagaa gtaagttgge egeagtgtta teaeteatag ttatggeage actgeataat 4816 tetettaetg teatgeeate egtaagatge ttttetgtga etggtagta eteaaceaag 4876 teattetgag aatagtgtat geggegaeeg agttgetett geeeggegte aataegggat 4936 aataeegege eacatageag aaetttaaaa gtgeteatea teggaaaaeg tetteeggg 4996 egaaaaetet eaaggatett acegetgtg agateeagtt egatgtaace eactegtgea 5056 eccaaetgat etteageate tttaette aceagegtt etgggtgage aaaaaeagga 5116 aggeaaaatg eegeaaaaa gggaataagg gegaeegga aatgttgaat acteatee 5176 tteetttte aatattattg aageattat eagggttatt gteetatgag eggataeata 5236 tttgaatgta tttagaaaaa taaaeaaata ggggteegg geaeattee eegaaaagtg 5296 eccaeetgae tttagetee 5308 <210> SEQ ID N0 16 <211> LENGTH: 692 <212> TTPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct <400> SEQUENCE: 16 Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 1 5 Val Val Ile Ala Cys Ala Gly Ala Val Thr Leu Ser Asm Phe Gln Gly 20 25 30 Lys Val Met Met Thr Val Asm Ala Thr Asp Val Thr Asp Val Ile Thr 35 11e Pro Thr Ala Ala Gly Lys Asm Leu Cys Ile Val Arg Ala Met Asp 50 50 Val Gly Tyr Met Cys Asm Asm Thr Ile Thr Tyr Glu Cys Pro Val Leu 65 70 75 80 Ser Ala Gly Asm Asm Pro Glu Asm Ile Asm Cys Trp Cys Thr Lys Ser 95 Ala Val Tyr Val Arg Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg 100 105 100 105 100
tctcttactg tcatgccatc cgtaagatge ttttetgtga ctggtgagta ctcaaccaag 4876 tcattetgag aatagtgtat geggegaeeg agttgetett geeeggegte aataegggat 4936 aataecegege cacatageag aaetttaaaa gtgeteatea ttggaaaaeg ttettegggg 4996 egaaaaetet caaggatett acegetgtg agateeagtt egatgtaace cactegtgea 5056 eccaaetgat etteageate ttttaette aceagegttt etgggtgage aaaaaeagga 5116 aggeaaaatg eegeaaaaa gggaataagg gegaeaegga aatgttgaat acteataete 5176 tteetttte aatattatg aageattat eagggttatt gteetatgag eggataeata 5236 tttgaatgta tttagaaaaa taaaeaaata ggggteegg geaeattee cegaaaagg 5296 ecaeetgaeg te 5308 <210 > SEQ ID N0 16 <211 > LENGTH: 692 <212 > TYPE: PTT <223 > OTHER INFORMATION: Synthetic Construct $<400 > SEQUENCE: 16Met Gly Lys Arg Ser Ala Gly Ser ILe Met Trp Leu Ala Ser Leu Ala1 = 510 = 15Val Val ILe Ala Cys Ala Gly Ala Val Thr Leu Ser Asn Phe Gln Gly2025250 = 60Val Gly Tyr Met Cys Asp Asp Thr ILe Thr Asp Val ILe Thr4045ILe Pro Thr Ala Ala Gly Lys Asn Leu Cys ILe Val Arg Ala Met Asp5050Ser Ala Gly Asn Asp Thr ILe Thr Tyr Glu Cys Pro Val Leu65707580Ser Ala Gly Asn Asp Thr ILe Thr Tyr Gly Spr Dva ILeu65Ala Val Tyr Val Arg Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg100105110$
tcattctgag aatagtgtat geggegaeeg agttgetett geeeggegte aataegggat 4936 aataeegege cacatageag aactttaaaa gtgeteate tggaaaaeg ttettegggg 4996 egaaaaetet caaggatett acegetgttg agateeagtt egatgtaaee cactegtgea 5056 eccaaetgat etteageate ttttaette aceagegtt etgggtgage aaaaaeagga 5116 aggeaaaatg eegeaaaaa gggaataagg gegaeaegga aatgttgaat acteataete 5176 tteetttte aatattattg aageatttat eagggttatt gteetagga eggataeata 5236 tttgaatgta tttagaaaaa taaaeaaata ggggteege geaeattee eegaaaagt 5296 eccaeetgaeg te 5308 <210 > SEQ ID NO 16 <211 > LENGTH: 692 <212 > TYPE: PET $<213 > ORGANISM: Artificial Sequence<220 > FEATURE:<220 > FEATURE:<223 > OTHER INFORMATION: Synthetic Construct<400 > SEQUENCE: 16Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala1 5 30Lys Val Met Met Thr Val Asn Ala Thr Asp Val Thr Asp Val Ile Thr\frac{40}{25} \frac{1}{25} \frac{1}{25} \frac{1}{25} \frac{1}{25} \frac{1}{25}Lie Pro Thr Ala Ala Gly Lys Asn Leu Cys Ile Val Arg Ala Met Asp\frac{50}{25} \frac{1}{70} \frac{75}{75} \frac{80}{80}Ser Ala Gly Ann Asp Pro Glu Asp Ile Asp Cys Trp Cys Thr Lys Ser\frac{90}{90}Ala Val Tyr Val Arg Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg\frac{100}{105} \frac{100}{10} \frac{100}{10}$
aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg 4996 cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca 5056 cccaactgat cttcagcatc ttttacttc accagcgtt ctgggtgagc aaaaacagga 5116 aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc 5176 ttccttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata 5236 tttgaatgta tttagaaaaa taaacaaata ggggtccgc gcacattcc ccgaaaagtg 5296 ccacctgacg tc 5308 <210> SEQ ID N0 16 <211> LENGTH: 692 <212> TYPE: PRT <213> ORCANISM: Artificial Sequence <220> FEATURE: <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct <400> SEQUENCE: 16 Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 1 5 10 15 Val Val Ile Ala Cys Ala Gly Ala Val Thr Leu Ser Asn Phe Gln Gly 20 25 30 Lys Val Met Met Thr Val Asn Ala Thr Asp Val Thr Asp Val Ile Thr 40 45 11 Ile Pro Thr Ala Ala Gly Lys Asn Leu Cys Ile Val Arg Ala Met Asp 50 55 60 Val Gly Tyr Met Cys Asp Asp Thr Ile Thr Tyr Glu Cys Pro Val Leu 65 70 75 80 Ser Ala Gly Asn Asp Pro Glu Asp Ile Asp Cys Trp Cys Thr Lys Ser 85 Ala Val Tyr Val Arg Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg 100 105 110
cgaaaactct caaggatctt accgctgttg agatccagt cgatgtaacc cactcgtgca 5056 cccaactgat cttcagcatc ttttactttc accagcgtt ctgggtgagc aaaaacagga 5116 aggcaaaatg ccgcaaaaa gggaataagg gcgacacgga aatgttgat actcatactc 5176 ttcctttttc aatattatg aagcatttat cagggttatt gtctcatgag cggatacata 5236 tttgaatgta tttagaaaaa taaacaaata ggggttccge gcacattcc ccgaaaagtg 5296 ccacctgacg tc 5308 <210> SEQ ID N0 16 <211> LENGTH: 692 <212> TYPE: PRT <212> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct <400> SEQUENCE: 16 Met Gly Lys Arg Ser Ala Gly Ser IIe Met Trp Leu Ala Ser Leu Ala 15 Val Val IIe Ala Cys Ala Gly Ala Val Thr Leu Ser Asn Phe Gln Gly 20 25 20 25 20 $30Lys Val Met Met Thr Val Asn Ala Thr Asp Val Thr Asp Val IIe Thr 4550$ 510 10 10 1055 50 $60Val Gly Tyr Met Cys Asp Asp Thr IIe Thr Tyr Glu Cys Pro Val Leu 6570$ 70 75 80 100
$ \begin{array}{llllllllllllllllllllllllllllllllllll$
aggcaaaatg ccgcaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc 5176 ttccttttc aatatattg aagcattat cagggtatt gtctcatgag cggatacata 5236 tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg 5296 ccacctgacg tc 5308 <210> SEQ ID N0 16 <211> LENGTH: 692 <212> TYPE: PRT <212> OrgANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct <400> SEQUENCE: 16 Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 1 5 Val Val Ile Ala Cys Ala Gly Ala Val Thr Leu Ser Asn Phe Gln Gly 20 25 30 30 Lys Val Met Met Thr Val Asn Ala Thr Asp Val Thr Asp Val Ile Thr 35 Val Gly Tyr Met Cys Asp Asp Thr Ile Thr Tyr Glu Cys Pro Val Leu 65 70 70 75 10 80 Ser Ala Gly Asn Asp Pro Glu Asp Ile Asp Cys Trp Cys Thr Lys Ser 95 Ala Val Tyr Val Arg Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg 100 105 110
ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata5236tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg5296ccacctgacg tc5308<210> SEQ ID NO 16<211> LENGTH: 692<212> ORGANISM: Artificial Sequence<220> FEATURE:<223> OTHER INFORMATION: Synthetic Construct<400> SEQUENCE: 16Met Gly Lys Arg Ser Ala Gly Ala Val Thr Leu Ser Asn Phe Gln Gly 20Val Val Ile Ala Cys Ala Gly Ala Val Thr Leu Ser Asn Phe Gln Gly 20Lys Val Met Met Thr Val Asn Ala Thr Asp Val Thr Asp Val Ile Thr 351e Pro Thr Ala Ala Gly Lys Asn Leu Cys Ile Val Arg Ala Met Asp 50Ser Ala Gly Asn Asp Pro Glu Asp Ile Asp Cys Trp Cys Thr Lys Ser 90Ala Val Tyr Val Arg Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg 100Arg Ser Arg Arg Ser Leu Thr Val Gln Thr His Gly Glu Ser Thr Leu
tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagt5296ccacctgacg tc5308<210> SEQ ID N0 16<211> LENGTH: 692<212> TYPE: PRT<213> ORGANISM: Artificial Sequence<220> FEATURE:<222> OTHER INFORMATION: Synthetic Construct<400> SEQUENCE: 16Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 11Val Val Ile Ala Cys Ala Gly Ala Val Thr Leu Ser Asn Phe Gln Gly 20Lys Val Met Met Thr Val Asn Ala Thr Asp Val Thr Asp Val Ile Thr 35Ile Pro Thr Ala Ala Gly Lys Asn Leu Cys Ile Val Arg Ala Met Asp 50Ser Ala Gly Asn Asp Pro Glu Asp Ile Asp Cys Trp Cys Thr Lys Ser 90Ala Val Tyr Val Arg Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg 100Arg Ser Arg Arg Ser Leu Thr Val Gln Thr His Gly Glu Ser Thr Leu
ccacctgacg tc 5308 <210> SEQ ID N0 16 <211> LENGTH: 692 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <220> THER INFORMATION: Synthetic Construct <400> SEQUENCE: 16 Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 15 Val Val Ile Ala Cys Ala Gly Ala Val Thr Leu Ser Asn Phe Gln Gly 20 Lys Val Met Met Thr Val Asn Ala Thr Asp Val Thr Asp Val Ile Thr 35 Ile Pro Thr Ala Ala Gly Lys Asn Leu Cys Ile Val Arg Ala Met Asp 50 Val Gly Tyr Met Cys Asp Asp Thr Ile Thr Tyr Glu Cys Pro Val Leu 80 Ser Ala Gly Asn Asp Pro Glu Asp Ile Asp Cys Trp Cys Thr Lys Ser 95 Ala Val Tyr Val Arg Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg 100 Arg Ser Arg Arg Ser Leu Thr Val Gln Thr His Gly Glu Ser Thr Leu
<pre><210> SEQ ID NO 16 <211> LENGTH: 692 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct <400> SEQUENCE: 16 Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 1 5 10 15 15 Val Val Ile Ala Cys Ala Gly Ala Val Thr Leu Ser Asn Phe Gln Gly 20 25 25 25 20 20 20 25 Lys Val Met Met Thr Val Asn Ala Thr Asp Val Thr Asp Val Ile Thr 35 11e Pro Thr Ala Ala Gly Lys Asn Leu Cys Ile Val Arg Ala Met Asp 50 Val Gly Tyr Met Cys Asp Asp Thr Ile Thr Tyr Glu Cys Pro Val Leu 65 Ser Ala Gly Asn Asp Pro Glu Asp Ile Asp Cys Trp Cys Thr Lys Ser 90 Ser Ala Gly Asn Asp Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg 100 Arg Ser Arg Arg Ser Leu Thr Val Gln Thr His Gly Glu Ser Thr Leu</pre>
<pre><400> SEQUENCE: 16 Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 1</pre>
MetGlyLysArgSerAlaGlySerIleMetTrpLeuAlaSerLeuAla1ValValIleAlaCysAlaGlyAlaValThrLeuSerAsnPheGlnGlyLysValMetMetThrValAsnAlaThrAspValThrAspValIleThrJleProThrAlaAlaGlyLysAsnLeuCysIleValArgAlaMetAsp50ThrAlaAlaGlyLysAsnLeuCysIleValArgAlaMetAsp50ThrAlaAlaGlyLysAsnLeuCysIleValArgAlaMetAsp61GlyTyrMetCysAspAspThrIleThrTyrGluCysProValLeu65MatGlyAsnAspProGluAspIleAspGysTrpCysThrLysSer61GlyAsnAspProGluAspIleAspGysTrpCysThrLysSer62SerAlaGlyAsnAspProGluAspIleAspSerSerSerSer63SerAsgTyrGlyAsg </td
ValValIleAlaCysAlaGlyAlaValThrLeuSerAsnPheGlnGlyLysValMetMetThrValAsnAlaThrAspValThrAspValIleThrJleProThrAlaAlaGlyLysAsnLeuCysIleValArgAlaMetAspJleProThrAlaAlaGlyLysAsnLeuCysIleValArgArgAspValGlyTyrMetCysAspAspThrIleThrTyrGluCysProValLeu65GlyTyrMetCysAspAspThrIleThrTyrGluCysProValLeu65GlyTyrMetCysAspAspThrIleThrTyrGluCysProValLeu65GlyTyrMetCysAspCysThrTyrCysSerSerSer65AlaGlyAsnAspProGluAspIleAspCysTrrCysThrLysSer65AsiGlyAsiAspProGluAspIleAspCysTrrCysThrLysSer65AsiGlyAsiTyrGlyAs
LysValMetThrValAsnAlaThrAspValThrAspValIleThrIleProThrAlaAlaGlyLysAsnLeuCysIleValArgAlaMetAsp50ThrAlaAlaGlyLysAsnLeuCysIleValArgArgArgAspValGlyTyrMetCysAspAspThrIleThrTyrGluCysProValLeu65GlyTyrMetCysAspAspThrIleThrTyrGluCysProValLeu65GlyTyrMetCysAspAspThrIleThrTyrGlySerSer65AlaGlyAsnAspProGluAspIleAspCysTrpCysThrLysSer65AlaGlyAsnAspProGluAspIleAspCysTrpCysThrLysSer65AlaGlyAsnAspProGluAspIleAspCysTrpCysThrLysSer65AlaGlyAsnAspTyrGlyAspCysThrLysThrLysSerAsp65GlyAsnAspTyrGlyAspCys<
IleProThrAlaAlaGlyLysAsnLeuCysIleValArgAlaArgAlaMetAspValGlyTyrMetCysAspAspThrIleThrTyrGluCysProValLeu65GlyTyrMetCysAspAspThrIleThrTyrGluCysProValLeu80SerAlaGlyAsnAspProGluAspIleAspCysTrpCysThrLysSerAlaValTyrValArgTyrGlyArgCysThrLysThrArgHisSerArgArgSerArgArgArgSerLeuThrValGlnThrHisGlyGluSerThrLeu
Val Gly Tyr MetCysAspAspThrIleThrTyrGluCysProValLeu65707080SerAlaGlyAsnAspProGluAspIleAspCysTrpCysThrLysSerSerAlaGlyAsnAspProGluAspIleAspCysThrLysThrLysSerAlaValTyrValArgTyrGlyArgCysThrLysThrArgHisSerArgArgSerArgArgSerLeuThrValGlnThrHisGlyGluSerThrLeu
Ser Ala Gly Asn Asp Pro Glu Asp Ile Asp Cys Trp Cys Thr Lys Ser 85 Ala Val Tyr Val Arg Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg 100 Arg Ser Arg Arg Ser Leu Thr Val Gln Thr His Gly Glu Ser Thr Leu
Ala Val Tyr Val Arg Tyr Gly Arg Cys Thr Lys Thr Arg His Ser Arg 100 105 110 Arg Ser Arg Arg Ser Leu Thr Val Gln Thr His Gly Glu Ser Thr Leu
Arg Ser Arg Arg Ser Leu Thr Val Gln Thr His Gly Glu Ser Thr Leu
115 120 125
Ala Asn Lys Lys Gly Ala Trp Met Asp Ser Thr Lys Ala Thr Arg Tyr 130 135 140
Leu Val Lys Thr Glu Ser Trp Ile Leu Arg Asn Pro Gly Tyr Ala Leu 145 150 155 160
Val Ala Ala Val Ile Gly Trp Met Leu Gly Ser Asn Thr Met Gln Arg 165 170 175
Val Val Phe Val Val Leu Leu Leu Val Ala Pro Ala Tyr Ser Phe 180 185 190
Asn Cys Leu Gly Met Ser Asn Arg Asp Phe Leu Glu Gly Val Ser Gly 195 200 205
Ala Thr Trp Val Asp Leu Val Leu Glu Gly Asp Ser Cys Val Thr Ile
Met Ser Lys Asp Lys Pro Thr Ile Asp Val Lys Met Met Asn Met Glu
Ala Ala Asn Leu Ala Glu Val Arg Ser Tyr Cys Tyr Leu Ala Thr Val
Ser Asp Leu Ser Thr Lys Ala Ala Cys Pro Thr Met Gly Glu Ala His

Asn	Asp	Lys 275	Arg	Ala	Asp	Pro	Ala 280	Phe	Val	Суз	Arg	Gln 285	Gly	Val	Val
Asp	Arg 290	Gly	Trp	Gly	Asn	Gly 295	Суз	Gly	Leu	Phe	Gly 300	Lys	Gly	Ser	Ile
Asp 305	Thr	Суз	Ala	Lys	Phe 310	Ala	Суз	Ser	Thr	Lys 315	Ala	Ile	Gly	Arg	Thr 320
Ile	Leu	Lys	Glu	Asn 325	Ile	Lys	Tyr	Glu	Val 330	Ala	Ile	Phe	Val	His 335	Gly
Pro	Thr	Thr	Val 340	Glu	Ser	His	Gly	Asn 345	Tyr	Ser	Thr	Gln	Val 350	Gly	Ala
Thr	Gln	Ala 355	Gly	Arg	Phe	Ser	Ile 360	Thr	Pro	Ala	Ala	Pro 365	Ser	Tyr	Thr
Leu	Lys 370	Leu	Gly	Glu	Tyr	Gly 375	Glu	Val	Thr	Val	Asp 380	Суз	Glu	Pro	Arg
Ser 385	Gly	Ile	Asp	Thr	Asn 390	Ala	Tyr	Tyr	Val	Met 395	Thr	Val	Gly	Thr	Lys 400
Thr	Phe	Leu	Val	His 405	Arg	Glu	Trp	Phe	Met 410	Aap	Leu	Asn	Leu	Pro 415	Trp
Ser	Ser	Ala	Gly 420	Ser	Thr	Val	Trp	Arg 425	Asn	Arg	Glu	Thr	Leu 430	Met	Glu
Phe	Glu	Glu 435	Pro	His	Ala	Thr	Lys 440	Gln	Ser	Val	Ile	Ala 445	Leu	Gly	Ser
Gln	Glu 450	Gly	Ala	Leu	His	Gln 455	Ala	Leu	Ala	Gly	Ala 460	Ile	Pro	Val	Glu
Phe 465	Ser	Ser	Asn	Thr	Val 470	Lys	Leu	Thr	Ser	Gly 475	His	Leu	Lys	Суз	Arg 480
Val	Lys	Met	Glu	Lys 485	Leu	Gln	Leu	Lys	Gly 490	Thr	Thr	Tyr	Gly	Val 495	Сув
Ser	Lys	Ala	Phe 500	Lys	Phe	Leu	Gly	Thr 505	Pro	Ala	Asp	Thr	Gly 510	His	Gly
Thr	Val	Val 515	Leu	Glu	Leu	Gln	Tyr 520	Thr	Gly	Thr	Asp	Gly 525	Pro	Суз	Lys
Val	Pro 530	Ile	Ser	Ser	Val	Ala 535	Ser	Leu	Asn	Asp	Leu 540	Thr	Pro	Val	Gly
Arg 545	Leu	Val	Thr	Val	Asn 550	Pro	Phe	Val	Ser	Val 555	Ala	Thr	Ala	Asn	Ala 560
Lys	Val	Leu	Ile	Glu 565	Leu	Glu	Pro	Pro	Phe 570	Gly	Asp	Ser	Tyr	Ile 575	Val
Val	Gly	Arg	Gly 580	Glu	Gln	Gln	Ile	Asn 585	His	His	Trp	His	Lys 590	Ser	Gly
Ser	Ser	Ile 595	Gly	Lys	Ala	Phe	Thr 600	Thr	Thr	Leu	Lys	Gly 605	Ala	Gln	Arg
Leu	Ala 610	Ala	Leu	Gly	Asp	Thr 615	Ala	Trp	Asp	Phe	Gly 620	Ser	Val	Gly	Gly
Val 625	Phe	Thr	Ser	Val	Gly 630	ГÀа	Ala	Val	His	Gln 635	Val	Phe	Gly	Gly	Ala 640
Phe	Arg	Ser	Leu	Phe 645	Gly	Gly	Met	Ser	Trp 650	Ile	Thr	Gln	Gly	Leu 655	Leu
Gly	Ala	Leu	Leu 660	Leu	Trp	Met	Gly	Ile 665	Asn	Ala	Arg	Asp	Arg 670	Ser	Ile

690

<210> SEQ ID NO 17 <211> LENGTH: 5334 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(5334) <223> OTHER INFORMATION: pCBJE 1-14 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (916)..(3006) <400> SEOUENCE: 17 qacqqatcqq qaqatctccc qatcccctat qqtqcactct caqtacaatc tqctctqatq 60 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180 ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240 gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420 attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt 480 atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540 atgeccagta catgacetta tgggaettte etaettggea gtacatetae gtattagtea 600 tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660 actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720 aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780 gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840 ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gcttggtacc 900 tctagagccg ccgcc atg ggc aga aag caa aac aaa aga gga gga aat gaa 951 Met Gly Arg Lys Gln Asn Lys Arg Gly Gly Asn Glu 1 10 gge tea ate atg tgg ete geg age ttg gea gtt gte ata get tgt geg 999 Gly Ser Ile Met Trp Leu Ala Ser Leu Ala Val Val Ile Ala Cys Ala 20 15 25 gga gcc atg aag ttg tcg aat ttc cag ggg aag ctt ttg atg acc atc 1047 Gly Ala Met Lys Leu Ser Asn Phe Gln Gly Lys Leu Leu Met Thr Ile 30 35 40 1095 aac aac acg gac att gca gac gtt atc gtg att ccc acc tca aaa gga Asn Asn Thr Asp Ile Ala Asp Val Ile Val Ile Pro Thr Ser Lys Gly 45 50 55 60 gag aac aga tg
c tgg gtc cgg gca atc gac gtc ggc tac atg tgt gag % f(x) = f(x) + f(x) +1143 Glu Asn Arg Cys Trp Val Arg Ala Ile Asp Val Gly Tyr Met Cys Glu 65 70 gac act atc acg tac gaa tgt cct aag ctt acc atg ggc aat gat cca 1191 Asp Thr Ile Thr Tyr Glu Cys Pro Lys Leu Thr Met Gly Asn Asp Pro 80 85 90 gag gat gtg gat tgc tgg tgt gac aac caa gaa gtc tac gtc caa tat 1239 Glu Asp Val Asp Cys Trp Cys Asp Asn Gln Glu Val Tyr Val Gln Tyr 95 100 105 1287 gga cgg tgc acg cgg acc agg cat tcc aag cga agc agg aga tcc gtg

Gly Arg Cys Thr Arg Thr Arg His Ser Lys Arg Ser Arg Arg Ser Val

-continued

	110					115					120						
tcg Ser 125	gtc Val	caa Gln	aca Thr	cat His	999 Gly 130	gag Glu	agt Ser	tca Ser	cta Leu	gtg Val 135	aat Asn	aaa Lys	aaa Lys	gag Glu	gct Ala 140	1335	
tgg Trp	ctg Leu	gat Asp	tca Ser	acg Thr 145	aaa Lys	gcc Ala	aca Thr	cga Arg	tat Tyr 150	ctc Leu	atg Met	aaa Lys	act Thr	gag Glu 155	aac Asn	1383	
tgg Trp	atc Ile	ata Ile	agg Arg 160	aat Asn	cct Pro	ggc Gly	tat Tyr	gct Ala 165	ttc Phe	ctg Leu	gcg Ala	gcg Ala	gta Val 170	ctt Leu	ggc Gly	1431	
tgg Trp	atg Met	ctt Leu 175	ggc Gly	agt Ser	aac Asn	aac Asn	ggt Gly 180	caa Gln	cgc Arg	gtg Val	gta Val	ttt Phe 185	acc Thr	atc Ile	ctc Leu	1479	
ctg Leu	ctg Leu 190	ttg Leu	gtc Val	gct Ala	ccg Pro	gct Ala 195	tac Tyr	agt Ser	ttt Phe	aat Asn	tgt Cys 200	ctg Leu	gga Gly	atg Met	ggc Gly	1527	
aat Asn 205	cgt Arg	gac Asp	ttc Phe	ata Ile	gaa Glu 210	gga Gly	gcc Ala	agt Ser	gga Gly	gcc Ala 215	act Thr	tgg Trp	gtg Val	gac Asp	ttg Leu 220	1575	
gtg Val	ctg Leu	gaa Glu	gga Gly	gat Asp 225	agc Ser	tgc Cys	ttg Leu	aca Thr	atc Ile 230	atg Met	gca Ala	aac Asn	gac Asp	aaa Lys 235	cca Pro	1623	
aca Thr	ttg Leu	gac Asp	gtc Val 240	cgc Arg	atg Met	att Ile	aac Asn	atc Ile 245	gaa Glu	gct Ala	agc Ser	caa Gln	ctt Leu 250	gct Ala	gag Glu	1671	
gtc Val	aga Arg	agt Ser 255	tac Tyr	tgc Cys	tat Tyr	cat His	gct Ala 260	tca Ser	gtc Val	act Thr	gac Asp	atc Ile 265	tcg Ser	acg Thr	gtg Val	1719	
gct Ala	cgg Arg 270	tgc Cys	ccc Pro	acg Thr	act Thr	gga Gly 275	gaa Glu	gcc Ala	cac His	aac Asn	gag Glu 280	aag Lys	cga Arg	gct Ala	gat Asp	1767	
agt Ser 285	agc Ser	tat Tyr	gtg Val	tgc Cys	aaa Lys 290	caa Gln	ggc Gly	ttc Phe	act Thr	gac Asp 295	cgt Arg	ggg Gly	tgg Trp	ggc Gly	aac Asn 300	1815	
gga Gly	tgt Cys	gga Gly	ctt Leu	ttc Phe 305	999 999	aag Lys	gga Gly	agc Ser	att Ile 310	gac Asp	aca Thr	tgt Cys	gca Ala	aaa Lys 315	ttc Phe	1863	
tcc Ser	tgc Cys	acc Thr	agt Ser 320	aaa Lys	gcg Ala	att Ile	д17 ддд	aga Arg 325	aca Thr	atc Ile	cag Gln	cca Pro	gaa Glu 330	aac Asn	atc Ile	1911	
aaa Lys	tac Tyr	gaa Glu 335	gtt Val	ggc Gly	att Ile	ttt Phe	gtg Val 340	cat His	gga Gly	acc Thr	acc Thr	act Thr 345	tcg Ser	gaa Glu	aac Asn	1959	
cat His	999 Gly 350	aat Asn	tat Tyr	tca Ser	gcg Ala	caa Gln 355	gtt Val	д1À ааа	gcg Ala	tcc Ser	cag Gln 360	gcg Ala	gca Ala	aag Lys	ttt Phe	2007	
aca Thr 365	gta Val	aca Thr	ccc Pro	aat Asn	gct Ala 370	cct Pro	tcg Ser	ata Ile	acc Thr	ctc Leu 375	aaa Lys	ctt Leu	ggt Gly	gac Asp	tac Tyr 380	2055	
gga Gly	gaa Glu	gtc Val	aca Thr	ctg Leu 385	gac Asp	tgt Cys	gag Glu	cca Pro	agg Arg 390	agt Ser	gga Gly	ctg Leu	aac Asn	act Thr 395	gaa Glu	2103	
gcg Ala	ttt Phe	tac Tyr	gtc Val 400	atg Met	acc Thr	gtg Val	GJÀ âââ	tca Ser 405	aag Lys	tca Ser	ttt Phe	ctg Leu	gtc Val 410	cat His	agg Arg	2151	
gag Glu	tgg Trp	ttt Phe 415	cat His	gac Asp	ctc Leu	gct Ala	ctc Leu 420	ccc Pro	tgg Trp	acg Thr	tcc Ser	cct Pro 425	tcg Ser	agc Ser	aca Thr	2199	
gcg Ala	tgg Trp	aga Arg	aac Asn	aga Arg	gaa Glu	ctc Leu	ctc Leu	atg Met	gaa Glu	ttt Phe	gaa Glu	gag Glu	gcg Ala	cac His	gcc Ala	2247	

4	430					435					440					
aca a Thr 1 445	aaa Lys	cag Gln	tcc Ser	gtt Val	gtt Val 450	gct Ala	ctt Leu	ддд ддд	tca Ser	cag Gln 455	gaa Glu	gga Gly	ggc Gly	ctc Leu	cat His 460	2295
cag q Gln 2	gcg Ala	ttg Leu	gca Ala	gga Gly 465	gcc Ala	atc Ile	gtg Val	gtg Val	gag Glu 470	tac Tyr	tca Ser	agc Ser	tca Ser	gtg Val 475	aag Lys	2343
tta a Leu '	aca Thr	tca Ser	ggc Gly 480	cac His	ctg Leu	aaa Lys	tgt Cys	agg Arg 485	ctg Leu	aaa Lys	atg Met	gac Asp	aaa Lys 490	ctg Leu	gct Ala	2391
ctg a Leu l	aaa Lys	ggc Gly 495	aca Thr	acc Thr	tat Tyr	ggc Gly	atg Met 500	tgt Cys	aca Thr	gaa Glu	aaa Lys	ttc Phe 505	tcg Ser	ttc Phe	gcg Ala	2439
aaa a Lys i !	aat Asn 510	ccg Pro	gcg Ala	gac Asp	act Thr	ggt Gly 515	cac His	gga Gly	aca Thr	gtt Val	gtc Val 520	att Ile	gaa Glu	ctc Leu	tcc Ser	2487
tac 1 Tyr 5 525	tct Ser	glà aaa	agt Ser	gat Asp	ggc Gly 530	ccc Pro	tgc Cys	aaa Lys	att Ile	ccg Pro 535	att Ile	gct Ala	tcc Ser	gtt Val	gcg Ala 540	2535
agc (Ser 1	ctc Leu	aat Asn	gac Asp	atg Met 545	acc Thr	ccc Pro	gtt Val	ggg gly	cgg Arg 550	ctg Leu	gtg Val	aca Thr	gtg Val	aac Asn 555	ccc Pro	2583
ttc o Phe V	gtc Val	gcg Ala	act Thr 560	tcc Ser	agt Ser	gcc Ala	agc Ser	tca Ser 565	aag Lys	gtg Val	ctg Leu	gtc Val	gag Glu 570	atg Met	gaa Glu	2631
ccc (Pro l	ccc Pro	ttc Phe 575	gga Gly	gac Asp	tcc Ser	tac Tyr	atc Ile 580	gta Val	gtt Val	gga Gly	agg Arg	gga Gly 585	gac Asp	aag Lys	cag Gln	2679
atc a Ile A	aac Asn 590	cac His	cat His	tgg Trp	cac His	aaa Lys 595	gct Ala	gga Gly	agc Ser	acg Thr	ctg Leu 600	ggc Gly	aag Lys	gcc Ala	ttt Phe	2727
tca a Ser 5 605	aca Thr	act Thr	ttg Leu	aag Lys	gga Gly 610	gct Ala	caa Gln	aga Arg	ctg Leu	gca Ala 615	gcg Ala	ttg Leu	ggc Gly	gac Asp	aca Thr 620	2775
gcc 1 Ala 1	tgg Trp	gac Asp	ttt Phe	ggc Gly 625	tct Ser	att Ile	gga Gly	999 Gly	gtc Val 630	ttc Phe	aac Asn	tcc Ser	ata Ile	gga Gly 635	aaa Lys	2823
gcc q Ala V	gtt Val	cac His	caa Gln 640	gtg Val	ttt Phe	ggt Gly	ggt Gly	gcc Ala 645	ttc Phe	aga Arg	aca Thr	ctc Leu	ttt Phe 650	д1У ддд	gga Gly	2871
atg 1 Met 1	tct Ser	tgg Trp 655	atc Ile	aca Thr	caa Gln	ддд ддд	cta Leu 660	atg Met	ggt Gly	gcc Ala	cta Leu	ctg Leu 665	ctc Leu	tgg Trp	atg Met	2919
ggc g Gly V	gtc Val 670	aac Asn	gca Ala	cga Arg	gac Asp	cga Arg 675	tca Ser	att Ile	gct Ala	ttg Leu	gcc Ala 680	ttc Phe	tta Leu	gcc Ala	aca Thr	2967
999 9 Gly 0 685	ggt Gly	gtg Val	ctc Leu	gtg Val	ttc Phe 690	tta Leu	gcg Ala	acc Thr	aat Asn	gtg Val 695	cat His	gct Ala	taai	tagi	tt	3016
gage	ggco	ege t	ccga	gcat	gc at	tcta	gagg	g cco	ctatt	ccta	tagi	gtc	acc 1	caaat	cgctag	3076
agcto	cgct	:ga t	tcage	cctc	ga ci	tgtg	cctto	c taç	gttgo	ccag	ccat	cctg	ttg 1	ttg	ccctc	3136
cccc	gtgo	ect t	tccti	tgac	cc t	ggaa	ggtg	c ca	ctcco	cact	gtco	cttt	cct a	aataa	aaatga	3196
ggaaa	atto	gca t	tcgca	attg	c t	gagta	aggto	g tca	attct	att	ctg	99999	gtg 🤉	gggt	ggggca	3256
ggaca	agca	ag g	3333	aggat	t g	ggaag	gacaa	a taq	gcago	gcat	gct	3333	atg (cggt	gggete	3316
tatg	gctt	ct ç	gaggo	cgga	aa ga	aacca	agcto	g cat	taat	gaa	tcg	geca	acg (cgcgé	gggaga	3376
ggcg	gttt	ge g	gtati	tggg	cg ct	tctt	ccgct	t t c	ctcgo	ctca	ctga	actc	gct 🤅	geget	cggtc	3436

95

-continued

		00110111404	
gttcggctgc ggcgagcg	gt atcageteae teaaagg	gogg taataoggtt atocacagaa	3496
tcaggggata acgcagga	aa gaacatgtga gcaaaag	ggcc agcaaaaggc caggaaccgt	3556
aaaaaggccg cgttgctg	gc gtttttccat aggctcc	egee cecetgaega geateaeaaa	3616
aatcgacgct caagtcag	ag gtggcgaaac ccgacag	ggac tataaagata ccaggcgttt	3676
ccccctggaa gctccctc	gt gegeteteet gtteega	accc tgccgcttac cggatacctg	3736
teegeettte teeetteg	gg aagcgtggcg ctttctc	ata gctcacgctg taggtatctc	3796
agttcggtgt aggtcgtt	cg ctccaagctg ggctgtg	tgc acgaaccccc cgttcagccc	3856
gaccgctgcg ccttatcc	gg taactatcgt cttgagt	cca acccggtaag acacgactta	3916
tcgccactgg cagcagcc	ac tggtaacagg attagca	agag cgaggtatgt aggcggtgct	3976
acagagttct tgaagtgg	tg gcctaactac ggctaca	acta gaagaacagt atttggtatc	4036
tgcgctctgc tgaagcca	gt taccttcgga aaaagag	yttg gtagctcttg atccggcaaa	4096
caaaccaccg ctggtagc	gg tggtttttt gtttgca	aagc agcagattac gcgcagaaaa	4156
aaaggatctc aagaagat	cc tttgatcttt tctacgg	gggt ctgacgctca gtggaacgaa	4216
aactcacgtt aagggatt	tt ggtcatgaga ttatcaa	aaaa ggatetteae etagateett	4276
ttaaattaaa aatgaagt	tt taaatcaatc taaagta	atat atgagtaaac ttggtctgac	4336
agttaccaat gcttaatc	ag tgaggcacct atctcag	gega tetgtetatt tegtteatee	4396
atagttgcct gactcccc	gt cgtgtagata actacga	atac gggagggett accatctggc	4456
cccagtgctg caatgata	cc gcgagaccca cgctcac	ccgg ctccagattt atcagcaata	4516
aaccagccag ccggaagg	gc cgagcgcaga agtggtc	ctg caactttatc cgcctccatc	4576
cagtctatta attgttgc	cg ggaagctaga gtaagta	agtt cgccagttaa tagtttgcgc	4636
aacgttgttg ccattgct	ac aggcatcgtg gtgtcac	gct cgtcgtttgg tatggcttca	4696
ttcagctccg gttcccaa	cg atcaaggcga gttacat	gat cccccatgtt gtgcaaaaaa	4756
gcggttagct ccttcggt	cc tccgatcgtt gtcagaa	agta agttggccgc agtgttatca	4816
ctcatggtta tggcagca	ct gcataattct cttactg	ytca tgccatccgt aagatgcttt	4876
tctgtgactg gtgagtac	tc aaccaagtca ttctgag	gaat agtgtatgcg gcgaccgagt	4936
tgctcttgcc cggcgtca	at acgggataat accgcgc	cac atagcagaac tttaaaagtg	4996
ctcatcattg gaaaacgt	tc ttcggggcga aaactct	caa ggatcttacc gctgttgaga	5056
tccagttcga tgtaaccc	ac tcgtgcaccc aactgat	ctt cagcatettt taettteace	5116
agcgtttctg ggtgagca	aa aacaggaagg caaaatg	geeg caaaaaaggg aataagggeg	5176
acacggaaat gttgaata	ct catactcttc ctttttc	aat attattgaag catttatcag	5236
ggttattgtc tcatgagc	gg atacatattt gaatgta	attt agaaaaataa acaaataggg	5296
gttccgcgca catttccc	cg aaaagtgcca cctgacg	jt	5334
<210> SEQ ID NO 18 <211> LENGTH: 697 <212> TYPE: PRT <213> ORGANISM: Art <220> FEATURE: <223> OTHER INFORMA	ificial Sequence TION: Synthetic Const	ruct	
<400> SEQUENCE: 18			
Met Gly Arg Lys Gln 1 5	Asn Lys Arg Gly Gly 10	Asn Glu Gly Ser Ile Met 15	
Trp Leu Ala Ser Leu 20	Ala Val Val Ile Ala 25	Cys Ala Gly Ala Met Lys 30	

Leu	Ser	Asn 35	Phe	Gln	Gly	Lys	Leu 40	Leu	Met	Thr	Ile	Asn 45	Asn	Thr	Asp
Ile	Ala 50	Asp	Val	Ile	Val	Ile 55	Pro	Thr	Ser	Lys	Gly 60	Glu	Asn	Arg	Суз
Trp 65	Val	Arg	Ala	Ile	Asp 70	Val	Gly	Tyr	Met	Суз 75	Glu	Asp	Thr	Ile	Thr 80
Tyr	Glu	Суз	Pro	Lys 85	Leu	Thr	Met	Gly	Asn 90	Asp	Pro	Glu	Asp	Val 95	Asp
Сүз	Trp	Суз	Asp 100	Asn	Gln	Glu	Val	Tyr 105	Val	Gln	Tyr	Gly	Arg 110	Cys	Thr
Arg	Thr	Arg 115	His	Ser	Lys	Arg	Ser 120	Arg	Arg	Ser	Val	Ser 125	Val	Gln	Thr
His	Gly 130	Glu	Ser	Ser	Leu	Val 135	Asn	Lys	Lys	Glu	Ala 140	Trp	Leu	Asp	Ser
Thr 145	Lys	Ala	Thr	Arg	Tyr 150	Leu	Met	Lys	Thr	Glu 155	Asn	Trp	Ile	Ile	Arg 160
Asn	Pro	Gly	Tyr	Ala 165	Phe	Leu	Ala	Ala	Val 170	Leu	Gly	Trp	Met	Leu 175	Gly
Ser	Asn	Asn	Gly 180	Gln	Arg	Val	Val	Phe 185	Thr	Ile	Leu	Leu	Leu 190	Leu	Val
Ala	Pro	Ala 195	Tyr	Ser	Phe	Asn	Cys 200	Leu	Gly	Met	Gly	Asn 205	Arg	Asp	Phe
Ile	Glu 210	Gly	Ala	Ser	Gly	Ala 215	Thr	Trp	Val	Aap	Leu 220	Val	Leu	Glu	Gly
Asp 225	Ser	Суа	Leu	Thr	Ile 230	Met	Ala	Asn	Asp	Lys 235	Pro	Thr	Leu	Asp	Val 240
Arg	Met	Ile	Asn	Ile 245	Glu	Ala	Ser	Gln	Leu 250	Ala	Glu	Val	Arg	Ser 255	Tyr
Суз	Tyr	His	Ala 260	Ser	Val	Thr	Asp	Ile 265	Ser	Thr	Val	Ala	Arg 270	Суз	Pro
Thr	Thr	Gly 275	Glu	Ala	His	Asn	Glu 280	Lys	Arg	Ala	Asp	Ser 285	Ser	Tyr	Val
Суз	Lys 290	Gln	Gly	Phe	Thr	Asp 295	Arg	Gly	Trp	Gly	Asn 300	Gly	Cys	Gly	Leu
Phe 305	Gly	Lys	Gly	Ser	Ile 310	Asp	Thr	Суз	Ala	Lys 315	Phe	Ser	Суз	Thr	Ser 320
Lys	Ala	Ile	Gly	Arg 325	Thr	Ile	Gln	Pro	Glu 330	Asn	Ile	Гла	Tyr	Glu 335	Val
Gly	Ile	Phe	Val 340	His	Gly	Thr	Thr	Thr 345	Ser	Glu	Asn	His	Gly 350	Asn	Tyr
Ser	Ala	Gln 355	Val	Gly	Ala	Ser	Gln 360	Ala	Ala	Lya	Phe	Thr 365	Val	Thr	Pro
Asn	Ala 370	Pro	Ser	Ile	Thr	Leu 375	Гла	Leu	Gly	Asp	Tyr 380	Gly	Glu	Val	Thr
Leu 385	Asp	Суз	Glu	Pro	Arg 390	Ser	Gly	Leu	Asn	Thr 395	Glu	Ala	Phe	Tyr	Val 400
Met	Thr	Val	Gly	Ser 405	ГЛа	Ser	Phe	Leu	Val 410	His	Arg	Glu	Trp	Phe 415	His
Asp	Leu	Ala	Leu 420	Pro	Trp	Thr	Ser	Pro 425	Ser	Ser	Thr	Ala	Trp 430	Arg	Asn
Arg	Glu	Leu 435	Leu	Met	Glu	Phe	Glu 440	Glu	Ala	His	Ala	Thr 445	Гла	Gln	Ser
Val	Val 450	Ala	Leu	Gly	Ser	Gln 455	Glu	Gly	Gly	Leu	His 460	Gln	Ala	Leu	Ala

Gly 465	Ala	Ile	Val	Val	Glu 470	Tyr	Ser	Ser	Ser	Val 475	Lys	Leu	Thr	Ser	Gly 480		
His	Leu	Lys	Суз	Arg 485	Leu	Lys	Met	Asp	Lys 490	Leu	Ala	Leu	Гла	Gly 495	Thr		
Thr	Tyr	Gly	Met 500	Сүз	Thr	Glu	Lys	Phe 505	Ser	Phe	Ala	ГЛа	Asn 510	Pro	Ala		
Asp	Thr	Gly 515	His	Gly	Thr	Val	Val 520	Ile	Glu	Leu	Ser	Tyr 525	Ser	Gly	Ser		
Aap	Gly 530	Pro	Сүз	Lys	Ile	Pro 535	Ile	Ala	Ser	Val	Ala 540	Ser	Leu	Asn	Asp		
Met 545	Thr	Pro	Val	Gly	Arg 550	Leu	Val	Thr	Val	Asn 555	Pro	Phe	Val	Ala	Thr 560		
Ser	Ser	Ala	Ser	Ser 565	Lys	Val	Leu	Val	Glu 570	Met	Glu	Pro	Pro	Phe 575	Gly		
Asp	Ser	Tyr	Ile 580	Val	Val	Gly	Arg	Gly 585	Asp	Lys	Gln	Ile	Asn 590	His	His		
Trp	His	Lys 595	Ala	Gly	Ser	Thr	Leu 600	Gly	Lys	Ala	Phe	Ser 605	Thr	Thr	Leu		
Гла	Gly 610	Ala	Gln	Arg	Leu	Ala 615	Ala	Leu	Gly	Asp	Thr 620	Ala	Trp	Asp	Phe		
Gly 625	Ser	Ile	Gly	Gly	Val 630	Phe	Asn	Ser	Ile	Gly 635	Lys	Ala	Val	His	Gln 640		
Val	Phe	Gly	Gly	Ala 645	Phe	Arg	Thr	Leu	Phe 650	Gly	Gly	Met	Ser	Trp 655	Ile		
Thr	Gln	Gly	Leu 660	Met	Gly	Ala	Leu	Leu 665	Leu	Trp	Met	Gly	Val 670	Asn	Ala		
Arg	Asp	Arg 675	Ser	Ile	Ala	Leu	Ala 680	Phe	Leu	Ala	Thr	Gly 685	Gly	Val	Leu		
Val	Phe 690	Leu	Ala	Thr	Asn	Val 695	His	Ala									
<210 <211 <211 <221 <221 <221 <221 <221	D> SI 1> LI 2> T 3> OF 3> O 3> O 3> O 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	EQ II ENGTH (PE: RGAN) EATUH (HER /nthe EATUH AME/I OCAT	D NO H: 52 DNA ISM: RE: INF(Stic RE: (EY: ION:	19 283 Art: DRMA CDS (910	ific: FION: struc	ial : : De: :t (2964	Seque scrij 1)	ence	ı of	art:	ific:	ial :	seque	ence	: note	=	
gace	ggato	çad d	gagai	tete	cc ga	atcco	cctat	t ggt	cga	ctct	cagt	caca	atc 1	tget	tgatg		60
ccg	catag	gtt a	aagco	cagta	at ct	get	ccct	g cti	gtgt	gtt	gga	ggtc	get (gagta	agtgcg		120
cga	gcaaa	aat t	taa	gcta	ca ac	caago	gcaa	g gct	tgad	ccga	caat	tge	atg a	aagaa	atctgc		180
ttaq	gggtt	ag g	gcgti	tttg	cg ct	gcti	cgcę	g ato	gtaco	gggc	caga	atata	acg (cgtt	gacatt		240
gatt	catto	gac t	tagti	tatta	aa ta	agtaa	atcaa	a tta	acggą	ggtc	atta	agtto	cat a	ageco	catata		300
tgga	agtto	ccg d	gtta	acata	aa ct	tace	ggtaa	a atç	ggcco	cgcc	tgg	ctga	ccg (cccaa	acgacc		360
cccç	geeea	att ç	gacgi	tcaat	ca at	gaco	gtato	g tto	cccat	agt	aaco	geca	ata 🤉	ggga	etttcc		420
attę	gacgt	ca a	atgg	gtgga	ac ta	attta	acggt	t aaa	actgo	ccca	ctt	ggca	gta 🤇	catca	aagtgt		480
atca	atatç	gee a	aagta	acgco	cc co	ctatt	gaco	g tca	aatga	acgg	taaa	atgg	ccc (gcct	ggcatt		540
atgo	cccaç	gta d	catga	accti	ta to	ggga	cttt	c cta	actt	ggca	gta	cate	tac 🤉	gtati	agtca		600

										-	con	tin	ued			
tcgctatt	ac c	atgo	gtga	tg c	ggtti	ttgg	c agt	taca	tcaa	tgg	gegt	gga 1	age	ggtttg	660	
actcacgg	igg a	ttto	ccaa	gt c	tcca	ccca	a ttç	gacgi	tcaa	tgg	gagti	ttg	ttt	ggcacc	720	
aaaatcaa	ıcg g	gact	ttc	ca a	aatgi	tcgta	a aca	aacto	ccgc	ccca	attga	acg (caaat	gggcg	780	
gtaggcgt	gt a	cggt	ggg	ag gi	tcta	tataa	a gca	agago	ctct	ctg	gcta	act a	agaga	aaccca	840	
ctgcttac	tg g	ctta	atcga	aa at	ttaa	tacga	a cto	cacta	atag	gga	gacco	caa 🤉	gctt	ggtacc	900	
geegeege	c at Me 1	g gg t G]	gc aa Ly Ly	ag ag ys A:	gg to rg Se 5	cc go er Al	cc go la GI	gc to ly Se	ca at er I	tc at le Me 10	tg tg et T: 0	gg ci rp Li	cc go eu Al	cg agc La Ser	951	
ttg gca Leu Ala 15	gtt Val	gtc Val	ata Ile	gct Ala 20	ggt Gly	aca Thr	agc Ser	gct Ala	acc Thr 25	acc Thr	atc Ile	cac His	cgg Arg	gac Asp 30	999	
agg gaa Arg Glu	gga Gly	tac Tyr	atg Met 35	gtt Val	atg Met	cgg Arg	gcc Ala	agt Ser 40	gga Gly	agg Arg	gac Asp	gct Ala	gca Ala 45	agc Ser	1047	
cag gtc Gln Val	agg Arg	gta Val 50	caa Gln	aac Asn	gga Gly	acg Thr	tgc Cys 55	gtc Val	atc Ile	ctg Leu	gca Ala	aca Thr 60	gac Asp	atg Met	1095	
gga gag Gly Glu	tgg Trp 65	tgt Cys	gaa Glu	gat Asp	tca Ser	atc Ile 70	acc Thr	tac Tyr	tct Ser	tgc Cys	gtc Val 75	acg Thr	att Ile	дас Авр	1143	
cag gag Gln Glu 80	gaa Glu	gaa Glu	ccc Pro	gtt Val	gac Asp 85	gtg Val	gac Asp	tgc Cys	ttc Phe	tgc Cys 90	cga Arg	ggt Gly	gtt Val	gat Asp	1191	
agg gtt Arg Val 95	aag Lys	tta Leu	gag Glu	tat Tyr 100	gga Gly	cgc Arg	tgt Cys	gga Gly	agg Arg 105	caa Gln	gct Ala	gga Gly	tct Ser	agg Arg 110	1239	
ggg aaa Gly Lys	agg Arg	tct Ser	gtg Val 115	gtc Val	att Ile	cca Pro	aca Thr	cat His 120	gca Ala	caa Gln	aaa Lys	gac Asp	atg Met 125	gtc Val	1287	
ggg cga Gly Arg	ggt Gly	cat His 130	gca Ala	tgg Trp	ctt Leu	aaa Lys	ggt Gly 135	gac Asp	aat Asn	att Ile	cga Arg	gat Asp 140	cat His	gtc Val	1335	
acc cga Thr Arg	gtc Val 145	gag Glu	ggc Gly	tgg Trp	atg Met	tgg Trp 150	aag Lys	aac Asn	aag Lys	ctt Leu	cta Leu 155	act Thr	gcc Ala	gcc Ala	1383	
att gtg Ile Val 160	gcc Ala	ttg Leu	gct Ala	tgg Trp	ctc Leu 165	atg Met	gtt Val	gat Asp	agt Ser	tgg Trp 170	atg Met	gcc Ala	aga Arg	gtg Val	1431	
act gtc Thr Val 175	atc Ile	ctc Leu	ttg Leu	gcg Ala 180	ttg Leu	agt Ser	cta Leu	д17 ааа	cca Pro 185	gtg Val	tac Tyr	gcc Ala	acg Thr	agg Arg 190	1479	
tgc acg Cys Thr	cat His	ctt Leu	gag Glu 195	aac Asn	aga Arg	gat Asp	ttt Phe	gtg Val 200	aca Thr	gga Gly	act Thr	caa Gln	999 Gly 205	acc Thr	1527	
acc aga Thr Arg	gtg Val	tcc Ser 210	cta Leu	gtt Val	ttg Leu	gaa Glu	ctt Leu 215	gga Gly	ggc Gly	tgc Cys	gtg Val	acc Thr 220	atc Ile	aca Thr	1575	
gct gag Ala Glu	ggc Gly 225	aag Lys	cca Pro	tcc Ser	att Ile	gat Asp 230	gta Val	tgg Trp	ctc Leu	gaa Glu	gac Asp 235	att Ile	ttt Phe	cag Gln	1623	
gaa agc Glu Ser 240	ccg Pro	gct Ala	gaa Glu	acc Thr	aga Arg 245	gaa Glu	tac Tyr	tgc Cys	ctg Leu	cac His 250	gcc Ala	aaa Lys	ttg Leu	acc Thr	1671	
aac aca Asn Thr 255	aaa Lys	gtg Val	gag Glu	gct Ala 260	cgc Arg	tgt Cys	cca Pro	acc Thr	act Thr 265	gga Gly	ccg Pro	gcg Ala	aca Thr	ctt Leu 270	1719	
ccg gag Pro Glu	gag Glu	cat His	cag Gln	gct Ala	aat Asn	atg Met	gtg Val	tgc Cys	aag Lys	aga Arg	gac Asp	caa Gln	agc Ser	gac Asp	1767	

- 1	Λ	-
		•
	U	

				275					280					285		
cgt Arg	gga Gly	tgg Trp	gga Gly 290	aac Asn	cac His	tgc Cys	glà aaa	ttt Phe 295	ttt Phe	д1У ааа	aag Lys	ggc Gly	agt Ser 300	ata Ile	gtg Val	1815
gct Ala	tgt Cys	gca Ala 305	aag Lys	ttt Phe	gaa Glu	tgc Cys	gag Glu 310	gaa Glu	gca Ala	aaa Lys	aaa Lys	gct Ala 315	gtg Val	ggc Gly	cac His	1863
gtc Val	tat Tyr 320	gac Asp	tcc Ser	aca Thr	aag Lys	atc Ile 325	acg Thr	tat Tyr	gtt Val	gtc Val	aag Lys 330	gtt Val	gag Glu	ccc Pro	cac His	1911
aca Thr 335	д1У ддд	gat Asp	tac Tyr	ttg Leu	gct Ala 340	gca Ala	aat Asn	gag Glu	acc Thr	aat Asn 345	tca Ser	aac Asn	agg Arg	aaa Lys	tca Ser 350	1959
gca Ala	cag Gln	ttt Phe	acg Thr	gtg Val 355	gca Ala	tcc Ser	gag Glu	aaa Lys	gtg Val 360	atc Ile	ctg Leu	cgg Arg	ctc Leu	ggc Gly 365	gac Asp	2007
tat Tyr	gga Gly	gat Asp	gtg Val 370	tcg Ser	ctg Leu	acg Thr	tgt Cys	aaa Lys 375	gtg Val	gca Ala	agt Ser	glà dlà	att Ile 380	gat Asp	gtc Val	2055
gcc Ala	caa Gln	act Thr 385	gtg Val	gtg Val	atg Met	tca Ser	ctc Leu 390	gac Asp	agc Ser	agc Ser	aag Lys	gac Asp 395	cac His	ctg Leu	cct Pro	2103
tct Ser	gca Ala 400	tgg Trp	caa Gln	gtg Val	cac His	cgt Arg 405	gac Asp	tgg Trp	ttt Phe	gag Glu	gac Asp 410	ttg Leu	gcg Ala	ctg Leu	ccc Pro	2151
tgg Trp 415	aaa Lys	cac His	aag Lys	gac Asp	aac Asn 420	caa Gln	gat Asp	tgg Trp	aac Asn	agt Ser 425	gtg Val	gag Glu	aaa Lys	ctt Leu	gtg Val 430	2199
gaa Glu	ttt Phe	gga Gly	cca Pro	cca Pro 435	cat His	gct Ala	gtg Val	aaa Lys	atg Met 440	gat Asp	gtt Val	ttc Phe	aat Asn	ctg Leu 445	G1À ààà	2247
gac Asp	cag Gln	acg Thr	gct Ala 450	gtg Val	ctg Leu	ctc Leu	aaa Lys	tca Ser 455	ctg Leu	gca Ala	gga Gly	gtt Val	ccg Pro 460	ctg Leu	gcc Ala	2295
agt Ser	gtg Val	gag Glu 465	ggc Gly	cag Gln	aaa Lys	tac Tyr	cac His 470	ctg Leu	aaa Lys	agc Ser	ggc Gly	cat His 475	gtt Val	act Thr	tgt Cys	2343
gat Asp	gtg Val 480	gga Gly	ctg Leu	gaa Glu	aag Lys	ctg Leu 485	aaa Lys	ctg Leu	aaa Lys	ggc Gly	aca Thr 490	acc Thr	tac Tyr	tcc Ser	atg Met	2391
tgt Cys 495	gac Asp	aaa Lys	gca Ala	aag Lys	ttc Phe 500	aaa Lys	tgg Trp	aag Lys	aga Arg	gtt Val 505	cct Pro	gtg Val	gac Asp	agc Ser	ggc Gly 510	2439
cat His	gac Asp	aca Thr	gta Val	gtc Val 515	atg Met	gag Glu	gta Val	tca Ser	tac Tyr 520	aca Thr	gga Gly	agc Ser	gac Asp	aag Lys 525	cca Pro	2487
tgt Cys	cgg Arg	atc Ile	ccg Pro 530	gtg Val	cgg Arg	gct Ala	gtg Val	gca Ala 535	cat His	ggt Gly	gtc Val	cca Pro	gcg Ala 540	gtt Val	aat Asn	2535
gta Val	gcc Ala	atg Met 545	ctc Leu	ata Ile	acc Thr	ccc Pro	aat Asn 550	cca Pro	acc Thr	att Ile	gaa Glu	aca Thr 555	aat Asn	ggt Gly	ggc Gly	2583
gga Gly	ttc Phe 560	ata Ile	gaa Glu	atg Met	cag Gln	ctg Leu 565	cca Pro	cca Pro	д1У даа	gat Asp	aac Asn 570	atc Ile	atc Ile	tat Tyr	gtg Val	2631
gga Gly 575	gac Asp	ctt Leu	agc Ser	cag Gln	cag Gln 580	tgg Trp	ttt Phe	cag Gln	aaa Lys	ggc Gly 585	agt Ser	acc Thr	att Ile	ggt Gly	aga Arg 590	2679
atg Met	ttt Phe	gaa Glu	aaa Lys	acc Thr	cgc Arg	agg Arg	gga Gly	ttg Leu	gaa Glu	agg Arg	ctc Leu	tct Ser	gtg Val	gtt Val	gga Gly	2727

-continued

		concinaca	
595	600	605	
gaa cat gca tgg gac t Glu His Ala Trp Asp P 610	tt ggc tca gta ggc ggg he Gly Ser Val Gly Gly 615	gta ctg tct tct gtg Val Leu Ser Ser Val 620	2775
ggg aag gca atc cac a Gly Lys Ala Ile His T 625	cg gtg ctg ggg gga gct hr Val Leu Gly Gly Ala 630	ttc aac acc ctt ttt Phe Asn Thr Leu Phe 635	2823
ggg ggg gtt gga ttc a Gly Gly Val Gly Phe I 640	tc cct aag atg ctg ctg le Pro Lys Met Leu Leu 645	ggg gtt gct ctg gtc Gly Val Ala Leu Val 650	2871
tgg ttg gga cta aat g Trp Leu Gly Leu Asn A 655 6	cc agg aat cca acg atg la Arg Asn Pro Thr Met 60 665	tcc atg acg ttt ctt Ser Met Thr Phe Leu 670	2919
gct gtg ggg gct ttg a Ala Val Gly Ala Leu T 675	ca ctg atg atg aca atg hr Leu Met Met Thr Met 680	gga gtt ggg gca Gly Val Gly Ala 685	2964
tgagcggccg ctcgagcatg	catctagagg gccctattct	atagtgtcac ctaaatgcta	3024
gagetegetg ateageeteg	actgtgcctt ctagttgcca	gccatctgtt gtttgcccct	3084
cccccgtgcc ttccttgacc	ctggaaggtg ccactcccac	tgtcctttcc taataaaatg	3144
aggaaattgc atcgcattgt	ctgagtaggt gtcattctat	tetggggggt ggggtgggge	3204
aggacagcaa ggggggaggat	tgggaagaca atagcaggca	tgctggggat gcggtgggct	3264
ctatggcttc tgaggcggaa	agaacagctg cattaatgaa	tcggccaacg cgcggggaga	3324
ggcggtttgc gtattgggcg	ctcttccgct tcctcgctca	ctgactcgct gcgctcggtc	3384
gttcggctgc ggcgagcggt	atcagctcac tcaaaggcgg	taatacggtt atccacagaa	3444
tcaggggata acgcaggaaa	gaacatgtga gcaaaaggcc	agcaaaaggc caggaaccgt	3504
aaaaaggccg cgttgctggc	gtttttccat aggctccgcc	cccctgacga gcatcacaaa	3564
aatcgacgct caagtcagag	gtggcgaaac ccgacaggac	tataaagata ccaggcgttt	3624
ccccctggaa gctccctcgt	gegeteteet gtteegaeee	tgccgcttac cggatacctg	3684
teegeettte teeetteggg	aagcgtggcg ctttctcaat	gctcacgctg taggtatctc	3744
agttcggtgt aggtcgttcg	ctccaagctg ggctgtgtgc	acgaaccccc cgttcagccc	3804
gaccgctgcg ccttatccgg	taactatcgt cttgagtcca	acccggtaag acacgactta	3864
tcgccactgg cagcagccac	tggtaacagg attagcagag	cgaggtatgt aggcggtgct	3924
acagagttct tgaagtggtg	gcctaactac ggctacacta	gaaggacagt atttggtatc	3984
tgcgctctgc tgaagccagt	taccttcgga aaaagagttg	gtagctcttg atccggcaaa	4044
caaaccaccg ctggtagcgg	tggttttttt gtttgcaagc	agcagattac gcgcagaaaa	4104
aaaggatctc aagaagatcc	tttgatcttt tctacggggt	ctgacgctca gtggaacgaa	4164
aactcacgtt aagggatttt	ggtcatgaga ttatcaaaaa	ggatetteae etagateett	4224
ttaaattaaa aatgaagttt	taaatcaatc taaagtatat	atgagtaaac ttggtctgac	4284
agttaccaat gcttaatcag	tgaggcacct atctcagcga	tctgtctatt tcgttcatcc	4344
atagttgcct gactccccgt	cgtgtagata actacgatac	gggagggctt accatctggc	4404
cccagtgctg caatgatacc	gcgagaccca cgctcaccgg	ctccagattt atcagcaata	4464
aaccagccag ccggaagggc	cgagcgcaga agtggtcctg	caactttatc cgcctccatc	4524
cagtctatta attgttgccg	ggaagctaga gtaagtagtt	cgccagttaa tagtttgcgc	4584
aacgttgttg ccattgctac	aggcatcgtg gtgtcacgct	cgtcgtttgg tatggcttca	4644
ttcagctccg gttcccaacg	atcaaggcga gttacatgat	cccccatgtt gtgcaaaaaa	4704

1	0	7
---	---	---

-continued

										<u></u>		<u>ucu</u>			 	 	
gcggttagct	cett	cggt	cc to	ccgat	tcgtt	gto	cagaa	agta	agti	tggc	cgc a	agtgi	tatca	4764	 		
ctcatggtta	a tggo	agca	ct g	cataa	attct	ctt	cacto	gtca	tgc	catco	cgt a	aaga	gettt	4824			
tctgtgact	g gtga	gtac	tc a	accaa	agtca	a tto	ctga	gaat	agt	gtat	gcg g	gcga	ccgagt	4884			
tgctcttgco	c cggc	gtca	at a	cggga	ataat	acc	cgcgo	ccac	ata	gcaga	aac 1	ttta	aaagtg	4944			
ctcatcatto	g gaaa	acgti	tc ti	tcggg	ggcga	a aaa	actct	caa	ggat	tetta	acc g	gctgi	tgaga	5004			
tccagttcga	a tgta	accc	ac to	cgtgo	cacco	c aad	ctgat	ctt	cag	catc	ttt 1	tacti	tcacc	5064			
agcgtttcto	g ggtg	agca	aa aa	acago	gaago	g caa	aaato	geeg	caa	aaaa	aaa 4	aata	agggcg	5124			
acacggaaat	t gttg	aata	ct ca	atact	tctto	c ctt	ttt	caat	atta	attga	aag (catt	tatcag	5184			
ggttattgto	c tcat	gage	gg at	tacat	tatt	: gaa	atgta	attt	aga	aaaat	taa a	acaa	ataggg	5244			
gtteegegea	a catt	tccc	cg a	aaagt	tgeea	a cct	gace	gtc						5283			
<210> SEQ <211> LENC <212> TYPI <213> ORG; <220> FEA' <223> OTHI	ID NC GTH: 6 E: PRI ANISM: FURE: ER INF	20 85 Art: ORMA	ific: TION	ial Syr	Seque	ence cic (Const	ruci	t								
<400> SEQ	JENCE :	20															
Met Gly Ly 1	ys Arg	Ser 5	Ala	Gly	Ser	Ile	Met 10	Trp	Leu	Ala	Ser	Leu 15	Ala				
Val Val I	le Ala 20	Gly	Thr	Ser	Ala	Thr 25	Thr	Ile	His	Arg	Asp 30	Arg	Glu				
Gly Tyr Me 3!	et Val 5	Met	Arg	Ala	Ser 40	Gly	Arg	Asp	Ala	Ala 45	Ser	Gln	Val				
Arg Val G 50	ln Asn	Gly	Thr	Сув 55	Val	Ile	Leu	Ala	Thr 60	Asp	Met	Gly	Glu				
Trp Cys G 65	lu Asp	Ser	Ile 70	Thr	Tyr	Ser	Суз	Val 75	Thr	Ile	Asp	Gln	Glu 80				
Glu Glu Pı	ro Val	Asp 85	Val	Asp	Суз	Phe	Суз 90	Arg	Gly	Val	Asp	Arg 95	Val				
Lys Leu G	lu Tyr 100	Gly	Arg	Суз	Gly	Arg 105	Gln	Ala	Gly	Ser	Arg 110	Gly	Lys				
Arg Ser Va 1:	al Val 15	Ile	Pro	Thr	His 120	Ala	Gln	ГЛа	Asp	Met 125	Val	Gly	Arg				
Gly His A 130	la Trp	Leu	ГЛа	Gly 135	Asp	Asn	Ile	Arg	Asp 140	His	Val	Thr	Arg				
Val Glu G 145	ly Trp	Met	Trp 150	Lys	Asn	Lys	Leu	Leu 155	Thr	Ala	Ala	Ile	Val 160				
Ala Leu Al	la Trp	Leu 165	Met	Val	Asp	Ser	Trp 170	Met	Ala	Arg	Val	Thr 175	Val				
Ile Leu Le	eu Ala 180	Leu	Ser	Leu	Gly	Pro 185	Val	Tyr	Ala	Thr	Arg 190	Суз	Thr				
His Leu G 19	lu Asn 95	. Arg	Asp	Phe	Val 200	Thr	Gly	Thr	Gln	Gly 205	Thr	Thr	Arg				
Val Ser Le 210	eu Val	Leu	Glu	Leu 215	Gly	Gly	Сув	Val	Thr 220	Ile	Thr	Ala	Glu				
Gly Lys Pı 225	ro Ser	Ile	Asp 230	Val	Trp	Leu	Glu	Asp 235	Ile	Phe	Gln	Glu	Ser 240				
Pro Ala G	lu Thr	Arg 245	Glu	Tyr	Сүз	Leu	His 250	Ala	Lys	Leu	Thr	Asn 255	Thr				
Lys Val G	lu Ala 260	Arg	Суз	Pro	Thr	Thr 265	Gly	Pro	Ala	Thr	Leu 270	Pro	Glu				

Glu	His	Gln 275	Ala	Asn	Met	Val	Cys 280	Lys	Arg	Asp	Gln	Ser 285	Asp	Arg	Gly
Trp	Gly 290	Asn	His	Суз	Gly	Phe 295	Phe	Gly	Lys	Gly	Ser 300	Ile	Val	Ala	Cys
Ala 305	Lys	Phe	Glu	Сүз	Glu 310	Glu	Ala	Lys	Lys	Ala 315	Val	Gly	His	Val	Tyr 320
Asp	Ser	Thr	Lys	Ile 325	Thr	Tyr	Val	Val	Lys 330	Val	Glu	Pro	His	Thr 335	Gly
Asp	Tyr	Leu	Ala 340	Ala	Asn	Glu	Thr	Asn 345	Ser	Asn	Arg	Lys	Ser 350	Ala	Gln
Phe	Thr	Val 355	Ala	Ser	Glu	Lys	Val 360	Ile	Leu	Arg	Leu	Gly 365	Asp	Tyr	Gly
Asp	Val 370	Ser	Leu	Thr	Сүз	Lys 375	Val	Ala	Ser	Gly	Ile 380	Asp	Val	Ala	Gln
Thr 385	Val	Val	Met	Ser	Leu 390	Asp	Ser	Ser	Lys	Asp 395	His	Leu	Pro	Ser	Ala 400
Trp	Gln	Val	His	Arg 405	Asp	Trp	Phe	Glu	Asp 410	Leu	Ala	Leu	Pro	Trp 415	Lys
His	Lys	Asp	Asn 420	Gln	Asp	Trp	Asn	Ser 425	Val	Glu	Lys	Leu	Val 430	Glu	Phe
Gly	Pro	Pro 435	His	Ala	Val	Lys	Met 440	Asp	Val	Phe	Asn	Leu 445	Gly	Asp	Gln
Thr	Ala 450	Val	Leu	Leu	Lys	Ser 455	Leu	Ala	Gly	Val	Pro 460	Leu	Ala	Ser	Val
Glu 465	Gly	Gln	Lys	Tyr	His 470	Leu	Lys	Ser	Gly	His 475	Val	Thr	Сүз	Asp	Val 480
Gly	Leu	Glu	Lys	Leu 485	Lys	Leu	Lys	Gly	Thr 490	Thr	Tyr	Ser	Met	Cys 495	Asp
Lys	Ala	Lys	Phe 500	ГЛа	Trp	Lys	Arg	Val 505	Pro	Val	Asp	Ser	Gly 510	His	Asp
Thr	Val	Val 515	Met	Glu	Val	Ser	Tyr 520	Thr	Gly	Ser	Asp	Lys 525	Pro	Cys	Arg
Ile	Pro 530	Val	Arg	Ala	Val	Ala 535	His	Gly	Val	Pro	Ala 540	Val	Asn	Val	Ala
Met 545	Leu	Ile	Thr	Pro	Asn 550	Pro	Thr	Ile	Glu	Thr 555	Asn	Gly	Gly	Gly	Phe 560
Ile	Glu	Met	Gln	Leu 565	Pro	Pro	Gly	Asp	Asn 570	Ile	Ile	Tyr	Val	Gly 575	Aap
Leu	Ser	Gln	Gln 580	Trp	Phe	Gln	ГЛа	Gly 585	Ser	Thr	Ile	Gly	Arg 590	Met	Phe
Glu	Lys	Thr 595	Arg	Arg	Gly	Leu	Glu 600	Arg	Leu	Ser	Val	Val 605	Gly	Glu	His
Ala	Trp 610	Asp	Phe	Gly	Ser	Val 615	Gly	Gly	Val	Leu	Ser 620	Ser	Val	Gly	Lys
Ala 625	Ile	His	Thr	Val	Leu 630	Gly	Gly	Ala	Phe	Asn 635	Thr	Leu	Phe	Gly	Gly 640
Val	Gly	Phe	Ile	Pro 645	Lys	Met	Leu	Leu	Gly 650	Val	Ala	Leu	Val	Trp 655	Leu
Gly	Leu	Asn	Ala 660	Arg	Asn	Pro	Thr	Met 665	Ser	Met	Thr	Phe	Leu 670	Ala	Val
Gly	Ala	Leu 675	Thr	Leu	Met	Met	Thr 680	Met	Gly	Val	Gly	Ala 685			

<210> SEQ ID NO 21 <211> LENGTH: 5304													
<pre><210> SEQ ID NO 21 <211> LENGTH: 5304 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (910)(2985)</pre>													
<400> SEQUE	NCE: 21												
gacggatcgg	gagatctc	cc gatcc	cctat go	ftcgactct	cagtacaat	c tgctctgatg	60						
ccgcatagtt	aagccagt	at ctgct	ccctg ct	tgtgtgtt	ggaggtege	t gagtagtgcg	120						
cgagcaaaat	ttaagcta	ca acaag	gcaag gc	ttgaccga	caattgcat	g aagaatctgc	180						
ttagggttag	gcgttttg	cg ctgct	tcgcg at	gtacgggc	cagatatac	g cgttgacatt	240						
gattattgac	tagttatt	aa tagta	atcaa tt	acggggtc	attagttca	t agcccatata	300						
tggagttccg	cgttacat	aa cttac	ggtaa at	ggcccgcc	tggctgacc	g cccaacgacc	360						
cccgcccatt	gacgtcaa	ta atgac	gtatg tt	cccatagt	aacgccaat	a gggactttcc	420						
attgacgtca	atgggtgg	ac tattt	acggt a <i>a</i>	actgccca	cttggcagt	a catcaagtgt	480						
atcatatgcc	aagtacgc	cc cctat	tgacg to	aatgacgg	taaatggcc	c gcctggcatt	540						
atgcccagta	catgacct	ta tggga	ctttc ct	acttggca	gtacatcta	c gtattagtca	600						
tcgctattac	catggtga	tg cggtt	ttggc ag	jtacatcaa	tgggcgtgg	a tagcggtttg	660						
actcacgggg	atttccaa	gt ctcca	cccca tt	gacgtcaa	tgggagttt	g ttttggcacc	720						
aaaatcaacg	ggactttc	ca aaatg	togta ac	aactccgc	cccattgac	g caaatgggcg	780						
gtaggcgtgt	acggtggg	ag gtcta	tataa go	agagctct	ctggctaac	t agagaaccca	840						
ctgcttactg	gcttatcg	aa attaa	tacga ct	cactatag	ggagaccca	a gcttggtacc	900						
gccgccgcc a M 1	tg ggc a et Gly L	ag agg t ys Arg S 5	cc gcc g er Ala G	gc tca a Sly Ser I	tc atg tgg le Met Trp 10	ctc gcg agc Leu Ala Ser	951						
ttg gca gtt Leu Ala Val 15	gtc ata Val Ile	gct ggt Ala Gly 20	aca ago Thr Ser	gct ttg Ala Leu 25	cag tta to Gln Leu So	ca acc tat er Thr Tyr 30	999						
cag ggg aaa Gln Gly Lys	gtg tta Val Leu 35	atg tca Met Ser	atc aac Ile Asr	aag act Lys Thr 40	gac gct ca Asp Ala G	aa agc gcc ln Ser Ala 45	1047						
ata aac att Ile Asn Ile	cct agt Pro Ser 50	gcc aac Ala Asn	gga gca Gly Ala 55	ı aac act ı Asn Thr	tgc att gi Cys Ile Va 60	tg agg gct al Arg Ala 0	1095						
cta gat gtg Leu Asp Val 65	ggg gtc Gly Val	atg tgc Met Cys	aaa gat Lys Asr 70	gac atc Asp Ile	aca tac ci Thr Tyr Le 75	tg tgc cca eu Cys Pro	1143						
gtg ctt tca Val Leu Ser 80	gcg gga Ala Gly	aat gat Asn Asp 85	ccc gag Pro Glu	gac att Asp Ile	gac tgt tg Asp Cys T: 90	gg tgt gac rp Cys Asp	1191						
gtc gaa gag Val Glu Glu 95	gtg tgg Val Trp	gtg cac Val His 100	tac ggo Tyr Gly	aga tgc Arg Cys 105	acg cgc at Thr Arg Ma	tg gga cat et Gly His 110	1239						
tcg agg cgt Ser Arg Arg	agc cga Ser Arg 115	cgg tca Arg Ser	atc tct Ile Ser	gtg cag Val Gln 120	cat cat g His His G	ga gat tcc ly Asp Ser 125	1287						
aca ctg gca Thr Leu Ala	aca aag Thr Lys 130	aac acg Asn Thr	cca tgo Pro Trp 135	g ttg gac b Leu Asp	acc gtg aa Thr Val Ly 14	aa acc acc ys Thr Thr 40	1335						

aaa tac ttg aca aaa gta gaa aac tgg gtt ttg cgc aat cct gga tat 1383

Lys	Tyr	Leu 145	Thr	Lys	Val	Glu	Asn 150	Trp	Val	Leu	Arg	Asn 155	Pro	Gly	Tyr	
gcc Ala	cta Leu 160	gtt Val	gcg Ala	ctg Leu	gcg Ala	att Ile 165	gga Gly	tgg Trp	atg Met	ctc Leu	ggt Gly 170	agc Ser	aac Asn	aac Asn	aca Thr	1431
cag Gln 175	aga Arg	gtg Val	gtt Val	ttt Phe	gtg Val 180	atc Ile	atg Met	ctg Leu	atg Met	ctg Leu 185	att Ile	gct Ala	ccg Pro	gca Ala	tac Tyr 190	1479
agc Ser	ttc Phe	aac Asn	tgt Cys	ctg Leu 195	gga Gly	aca Thr	tca Ser	aac Asn	agg Arg 200	gac Asp	ttt Phe	gtc Val	gag Glu	gga Gly 205	gcc Ala	1527
agt Ser	glà dâð	gca Ala	aca Thr 210	tgg Trp	att Ile	gac Asp	ttg Leu	gta Val 215	ctt Leu	gaa Glu	glà aaa	gga Gly	agc Ser 220	tgt Cys	gtc Val	1575
aca Thr	gtg Val	atg Met 225	gca Ala	cca Pro	gag Glu	aaa Lys	cca Pro 230	aca Thr	ctg Leu	gac Asp	ttc Phe	aaa Lys 235	gtg Val	atg Met	aag Lys	1623

atg	gag	gct	acc	gag	tta	gcc	act	gtg	cgt	gag	tat	tgt	tac	gaa	gca	1671
Met	Glu	Ala	Thr	Glu	Leu	Ala	Thr	Val	Arg	Glu	Tyr	Cys	Tyr	Glu	Ala	
	240					245					250					

acc ttg gac acg ctg tca aca gtg gca agg tgc ccc aca aca gga gaa Thr Leu Asp Thr Leu Ser Thr Val Ala Arg Cys Pro Thr Thr Gly Glu 255 260 265 270	ia 171 .u 70	gga gaa Gly Glu 270	aca Thr	aca Thr	ccc Pro	tgc Cys 265	agg Arg	gca Ala	gtg Val	aca Thr	tca Ser 260	ctg Leu	acg Thr	gac Asp	ttg Leu	acc Thr 255
---	--------------------	---------------------------	------------	------------	------------	-------------------	------------	------------	------------	------------	-------------------	------------	------------	------------	------------	-------------------

gct Ala	cac His	aac Asn	acc Thr	aaa Lys 275	agg Arg	agt Ser	gac Asp	cca Pro	aca Thr 280	ttt Phe	gtc Val	tgc Cys	aaa Lys	aga Arg 285	gat Asp	-	L767
att	ata	gac	cac	aaa	taa	aat	aac	aaa	tat	aat	cta	ttt	aaa	aaa	aaa		1815

Val	Val	Asp	Arg 290	Gly	Trp	Gly	Asn	Gly 295	Cys	Gly	Leu	Phe	Gly 300	Lys	Gly		
age	att	gac	aca	tac	act	aaq	ttc	aca	tac	aaa	aac	aad	aca	aca	aaa	186	3

age	acc	gue	aca	cgc	gee	aag	LLL	aca	Lgc	uuu	auc	uug	gea	aca	999	 T O (
Ser	Ile	Asp	Thr	Cys	Ala	Lys	Phe	Thr	Cys	Lys	Asn	Lys	Ala	Thr	Gly	
		305					310					315				

- aag acg atc ttg aga gaa aac atc aag tat gag gtt gca atc ttt gtg Lys Thr Ile Leu Arg Glu Asn Ile Lys Tyr Glu Val Ala Ile Phe Val
- cat ggt tea acg gae tet acg tea cat gge aat tae tet gag cag att His Gly Ser Thr Asp Ser Thr Ser His Gly Asn Tyr Ser Glu Gln Ile gga aaa aac caa gcg gct aga ttc acc ata agc ccg caa gca ccg tcc
- Gly Lys Asn Gln Ala Ala Arg Phe Thr Ile Ser Pro Gln Ala Pro Ser ttt acg gcc aac atg ggc gag tat gga aca gtt acc att gat tgt gaa Phe Thr Ala Asn Met Gly Glu Tyr Gly Thr Val Thr Ile Asp Cys Glu
- gca aga tca gga atc aac acg gag gat tat tat gtt ttc act gtc aag Ala Arg Ser Gly Ile Asn Thr Glu Asp Tyr Tyr Val Phe Thr Val Lys
- gag aag tca tgg cta gtg aac agg gac tgg ttt cac gac ttg aac ctt Glu Lys Ser Trp Leu Val Asn Arg Asp Trp Phe His Asp Leu Asn Leu cca tgg acg agc cct gcc aca act gat tgg cgc aac aga gaa aca ctg
- Pro Trp Thr Ser Pro Ala Thr Thr Asp Trp Arg Asn Arg Glu Thr Leu gtg gaa ttt gag gaa ccg cat gcc acc aag caa act gta gta gcc cta Val Glu Phe Glu Glu Pro His Ala Thr Lys Gln Thr Val Val Ala Leu
- gga tcg caa gaa ggt gcc ctg cac aca gca ttg gct gga gcc att cca Gly Ser Gln Glu Gly Ala Leu His Thr Ala Leu Ala Gly Ala Ile Pro

Ala Thr Val Ser Ser Ser Thr Leu Thr Leu Gln Ser Gly His Leu Lys

tgc Cys	aga Arg 480	gct Ala	aag Lys	ctt Leu	gac Asp	aag Lys 485	gtc Val	aaa Lys	atc Ile	aag Lys	gga Gly 490	acg Thr	aca Thr	tat Tyr	ggc Gly	2391
atg Met 495	tgt Cys	gac Asp	tct Ser	gcc Ala	ttc Phe 500	acc Thr	ttc Phe	agc Ser	aag Lys	aac Asn 505	cca Pro	act Thr	gac Asp	aca Thr	999 Gly 510	2439
cac His	999 Gly	aca Thr	gtg Val	att Ile 515	gtg Val	gaa Glu	ctg Leu	cag Gln	tat Tyr 520	act Thr	gga Gly	agc Ser	aac Asn	gga Gly 525	ccc Pro	2487
tgc Cys	cga Arg	gtt Val	ccc Pro 530	atc Ile	tcc Ser	gtg Val	act Thr	gca Ala 535	aac Asn	ctc Leu	atg Met	gat Asp	ttg Leu 540	aca Thr	ccg Pro	2535
gtt Val	gga Gly	aga Arg 545	ttg Leu	gtc Val	acg Thr	gtc Val	aat Asn 550	ccc Pro	ttt Phe	ata Ile	agc Ser	aca Thr 555	glà aaa	gga Gly	gcg Ala	2583
aac Asn	aac Asn 560	aag Lys	gtc Val	atg Met	atc Ile	gaa Glu 565	gtt Val	gaa Glu	cca Pro	ccc Pro	ttt Phe 570	ggc Gly	gat Asp	tct Ser	tac Tyr	2631
atc Ile 575	gtc Val	gtc Val	gga Gly	aga Arg	ggc Gly 580	acc Thr	acc Thr	cag Gln	att Ile	aac Asn 585	tac Tyr	cac His	tgg Trp	cac His	aaa Lys 590	2679
gag Glu	gga Gly	agc Ser	agc Ser	att Ile 595	д1 <u>у</u> ддд	aag Lys	gct Ala	ttg Leu	gcg Ala 600	acc Thr	aca Thr	tgg Trp	aaa Lys	gga Gly 605	gcc Ala	2727
caa Gln	cgg Arg	cta Leu	gcc Ala 610	gtc Val	tta Leu	glà aaa	gac Asp	aca Thr 615	gcg Ala	tgg Trp	gac Asp	ttt Phe	gga Gly 620	tct Ser	att Ile	2775
gga Gly	gga Gly	gtt Val 625	ttc Phe	aat Asn	tca Ser	att Ile	ggc Gly 630	aaa Lys	gct Ala	gtc Val	cac His	caa Gln 635	gtt Val	ttc Phe	gga Gly	2823
gga Gly	gcg Ala 640	ttc Phe	agg Arg	act Thr	ctg Leu	ttc Phe 645	д1У ддд	gga Gly	atg Met	tcc Ser	tgg Trp 650	atc Ile	aca Thr	cag Gln	glÅ aaa	2871
cta Leu 655	ctt Leu	gga Gly	gct Ala	ctt Leu	ctc Leu 660	ctg Leu	tgg Trp	atg Met	д1У ааа	ttg Leu 665	cag Gln	gcc Ala	cgc Arg	gac Asp	agg Arg 670	2919
agc Ser	atc Ile	tcg Ser	ctg Leu	act Thr 675	cta Leu	ctg Leu	gct Ala	gtc Val	gga Gly 680	gga gga	att Ile	ctc Leu	atc Ile	ttt Phe 685	ctg Leu	2967
gca Ala	acc Thr	agc Ser	gtg Val 690	caa Gln	gcc Ala	tga	gcgg	ccg (tcga	agcat	tg da	atcta	agago	9		3015
gcc	ctatt	cct a	atagi	gtca	ac ct	caaat	geta	a gag	geteç	gctg	atca	agcct	ccg a	actgi	geett	3075
cta	gttgo	cca ç	gccat	cctgi	t gt	ttgo	eccet	c ccc	cccgt	gcc	ttco	cttga	acc d	ctgga	aaggtg	3135
cca	eteed	cac t	tgtco	cttt	cc ta	aataa	aaato	g ago	gaaat	tgc	atco	gcatt	gt (ctga	gtaggt	3195
gtca	attct	tat t	tctg	3333	gt ge	gggt	33334	c ago	gacaç	gcaa	aaaa	ggago	gat 1	ggga	aagaca	3255
ata	gcago	gca t	tgete	33334	at go	cggt	gggct	t cta	atggo	ette	tgaç	ggcgé	gaa a	agaa	cagetg	3315
cat	caato	gaa t	cgg	ccaa	cg cá	acaaá	ggaga	a ggo	ggtt	tgc	gtat	tgg	gcg (ctct	ceget	3375
tcci	cgct	cca d	ctga	ctcg	ct go	cgct	cggt	c gtt	cggo	ctgc	ggcó	gagco	ggt a	atcaç	gctcac	3435
tca	aaggo	egg t	taata	acggt	t at	cca	cagaa	a tca	agggg	gata	acgo	cagga	aaa q	gaaca	atgtga	3495
gcaa	aaago	gee a	agcaa	aaago	ge ea	aggaa	accgt	: aaa	aaago	geeg	cgtt	cgct	ggc (gttti	tccat	3555
aggo	ctcc	gee d	ccct	cgaco	ga go	catca	acaaa	a aat	cgad	gct	caaç	gtcaç	gag 🤉	gtgg	cgaaac	3615
ccga	acago	gac t	tataa	aagat	ta co	caggo	gtt	c ccc	cct	ggaa	gcto	cct	gt g	geget	cctcct	3675

-continued

gttccgaccc	tgccgcttac	cggatacctg	tccgcctttc	tcccttcggg	aagcgtggcg	3735
ctttctcaat	gctcacgctg	taggtatctc	agttcggtgt	aggtcgttcg	ctccaagctg	3795
ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	ccttatccgg	taactatcgt	3855
cttgagtcca	acccggtaag	acacgactta	tcgccactgg	cagcagccac	tggtaacagg	3915
attagcagag	cgaggtatgt	aggcggtgct	acagagttct	tgaagtggtg	gcctaactac	3975
ggctacacta	gaaggacagt	atttggtatc	tgcgctctgc	tgaagccagt	taccttcgga	4035
aaaagagttg	gtagctcttg	atccggcaaa	caaaccaccg	ctggtagcgg	tggtttttt	4095
gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	aagaagatcc	tttgatcttt	4155
tctacggggt	ctgacgctca	gtggaacgaa	aactcacgtt	aagggatttt	ggtcatgaga	4215
ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaa	aatgaagttt	taaatcaatc	4275
taaagtatat	atgagtaaac	ttggtctgac	agttaccaat	gcttaatcag	tgaggcacct	4335
atctcagcga	tctgtctatt	tcgttcatcc	atagttgcct	gactccccgt	cgtgtagata	4395
actacgatac	gggagggctt	accatctggc	cccagtgctg	caatgatacc	gcgagaccca	4455
cgctcaccgg	ctccagattt	atcagcaata	aaccagccag	ccggaagggc	cgagcgcaga	4515
agtggtcctg	caactttatc	cgcctccatc	cagtctatta	attgttgccg	ggaagctaga	4575
gtaagtagtt	cgccagttaa	tagtttgcgc	aacgttgttg	ccattgctac	aggcatcgtg	4635
gtgtcacgct	cgtcgtttgg	tatggcttca	ttcagctccg	gttcccaacg	atcaaggcga	4695
gttacatgat	cccccatgtt	gtgcaaaaaa	gcggttagct	ccttcggtcc	tccgatcgtt	4755
gtcagaagta	agttggccgc	agtgttatca	ctcatggtta	tggcagcact	gcataattct	4815
cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	gtgagtactc	aaccaagtca	4875
ttctgagaat	agtgtatgcg	gcgaccgagt	tgetettgee	cggcgtcaat	acgggataat	4935
accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	gaaaacgttc	ttcggggcga	4995
aaactctcaa	ggatcttacc	gctgttgaga	tccagttcga	tgtaacccac	tcgtgcaccc	5055
aactgatctt	cagcatcttt	tactttcacc	agcgtttctg	ggtgagcaaa	aacaggaagg	5115
caaaatgccg	caaaaaaggg	aataagggcg	acacggaaat	gttgaatact	catactcttc	5175
ctttttcaat	attattgaag	catttatcag	ggttattgtc	tcatgagcgg	atacatattt	5235
gaatgtattt	agaaaaataa	acaaataggg	gttccgcgca	catttccccg	aaaagtgcca	5295
cctgacgtc						5304
<210> SEQ : <211> LENG <212> TYPE <213> ORGAI <220> FEATU <223> OTHEN <400> SEQUI	ID NO 22 IH: 692 : PRT NISM: Artif: JRE: R INFORMATIC ENCE: 22	icial Seque DN: Synthet	nce ic Construct	5		
Met Gly Ly:	s Arg Ser Al	la Gly Ser	Ile Met Trp	Leu Ala Sei	r Leu Ala	
1	5		10		15	
Val Val Ile	e Ala Gly Th 20	nr Ser Ala	Leu Gln Leu 25	Ser Thr Typ 30	r Gln Gly	
Lys Val Let 35	ı Met Ser I	le Asn Lys 40	Thr Asp Ala	Gln Ser Ala 45	a Ile Asn	
Ile Pro Se: 50	r Ala Asn G	ly Ala Asn 55	Thr Cys Ile	Val Arg Ala 60	a Leu Asp	
Val Gly Va	l Met Cys Ly	ya Aap Aap	Ile Thr Tyr	Leu Cys Pro	o Val Leu	

											_	COII	ιm	ueu	
65					70					75					80
Ser	Ala	Gly	Asn	Asp 85	Pro	Glu	Asp	Ile	Asp 90	Сув	Trp	Суз	Asp	Val 95	Glu
Glu	Val	Trp	Val 100	His	Tyr	Gly	Arg	Cys 105	Thr	Arg	Met	Gly	His 110	Ser	Arg
Arg	Ser	Arg 115	Arg	Ser	Ile	Ser	Val 120	Gln	His	His	Gly	Asp 125	Ser	Thr	Leu
Ala	Thr 130	Lys	Asn	Thr	Pro	Trp 135	Leu	Asp	Thr	Val	Lys 140	Thr	Thr	ГЛа	Tyr
Leu 145	Thr	Lys	Val	Glu	Asn 150	Trp	Val	Leu	Arg	Asn 155	Pro	Gly	Tyr	Ala	Leu 160
Val	Ala	Leu	Ala	Ile 165	Gly	Trp	Met	Leu	Gly 170	Ser	Asn	Asn	Thr	Gln 175	Arg
Val	Val	Phe	Val 180	Ile	Met	Leu	Met	Leu 185	Ile	Ala	Pro	Ala	Tyr 190	Ser	Phe
Asn	Суз	Leu 195	Gly	Thr	Ser	Asn	Arg 200	Asp	Phe	Val	Glu	Gly 205	Ala	Ser	Gly
Ala	Thr 210	Trp	Ile	Asp	Leu	Val 215	Leu	Glu	Gly	Gly	Ser 220	Суз	Val	Thr	Val
Met 225	Ala	Pro	Glu	Lys	Pro 230	Thr	Leu	Asp	Phe	Lys 235	Val	Met	Lys	Met	Glu 240
Ala	Thr	Glu	Leu	Ala 245	Thr	Val	Arg	Glu	Tyr 250	Сув	Tyr	Glu	Ala	Thr 255	Leu
Asp	Thr	Leu	Ser 260	Thr	Val	Ala	Arg	Сув 265	Pro	Thr	Thr	Gly	Glu 270	Ala	His
Asn	Thr	Lys 275	Arg	Ser	Asp	Pro	Thr 280	Phe	Val	Сув	Гла	Arg 285	Asp	Val	Val
Asp	Arg 290	Gly	Trp	Gly	Asn	Gly 295	Суз	Gly	Leu	Phe	Gly 300	Гла	Gly	Ser	Ile
Asp 305	Thr	Сув	Ala	Lys	Phe 310	Thr	Суз	Lys	Asn	Lys 315	Ala	Thr	Gly	Lys	Thr 320
Ile	Leu	Arg	Glu	Asn 325	Ile	Lys	Tyr	Glu	Val 330	Ala	Ile	Phe	Val	His 335	Gly
Ser	Thr	Asp	Ser 340	Thr	Ser	His	Gly	Asn 345	Tyr	Ser	Glu	Gln	Ile 350	Gly	Lys
Asn	Gln	Ala 355	Ala	Arg	Phe	Thr	Ile 360	Ser	Pro	Gln	Ala	Pro 365	Ser	Phe	Thr
Ala	Asn 370	Met	Gly	Glu	Tyr	Gly 375	Thr	Val	Thr	Ile	Asp 380	Суз	Glu	Ala	Arg
Ser 385	Gly	Ile	Asn	Thr	Glu 390	Asp	Tyr	Tyr	Val	Phe 395	Thr	Val	Lys	Glu	Lys 400
Ser	Trp	Leu	Val	Asn 405	Arg	Asp	Trp	Phe	His 410	Asp	Leu	Asn	Leu	Pro 415	Trp
Thr	Ser	Pro	Ala 420	Thr	Thr	Asp	Trp	Arg 425	Asn	Arg	Glu	Thr	Leu 430	Val	Glu
Phe	Glu	Glu 435	Pro	His	Ala	Thr	Lys 440	Gln	Thr	Val	Val	Ala 445	Leu	Gly	Ser
Gln	Glu 450	Gly	Ala	Leu	His	Thr 455	Ala	Leu	Ala	Gly	Ala 460	Ile	Pro	Ala	Thr
Val 465	Ser	Ser	Ser	Thr	Leu 470	Thr	Leu	Gln	Ser	Gly 475	His	Leu	Lys	Cys	Arg 480
Ala	Lys	Leu	Asp	Lys 485	Val	Lys	Ile	Lys	Gly 490	Thr	Thr	Tyr	Gly	Met 495	Cys
-continued															

Asp Ser Ala Phe Thr Phe Ser Lys Asn Pro Thr Asp Thr Gly His Gly 500 505 510															
Thr Val Ile Val Glu Leu Gln Tyr Thr Gly Ser Asn Gly Pro Cys Arg 515 520 525															
Val Pro Ile Ser Val Thr Ala Asn Leu Met Asp Leu Thr Pro Val Gly 530 535 540															
Arg Leu Val Thr Val Asn Pro Phe Ile Ser Thr Gly Gly Ala Asn Asn 545 550 555 560															
Lys Val Met Ile Glu Val Glu Pro Pro Phe Gly Asp Ser Tyr Ile Val 565 570 575															
Val Gly Arg Gly Thr Thr Gln Ile Asn Tyr His Trp His Lys Glu Gly 580 585 590															
Ser Ser Ile Gly Lys Ala Leu Ala Thr Thr Trp Lys Gly Ala Gln Arg 595 600 605															
Leu Ala Val Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly 610 615 620															
Val Phe Asn Ser Ile Gly Lys Ala Val His Gln Val Phe Gly Gly Ala 625 630 635 640															
Phe Arg Thr Leu Phe Gly Gly Met Ser Trp Ile Thr Gln Gly Leu Leu 645 650 655															
Gly Ala Leu Leu Trp Met Gly Leu Gln Ala Arg Asp Arg Ser Ile 660 665 670															
Ser Leu Thr Leu Leu Ala Val Gly Gly Ile Leu Ile Phe Leu Ala Thr 675 680 685															
Ser Val Gln Ala															
<pre><210> SEQ ID NO 23 <211> LENGTH: 5271 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <220> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (910)(2952)</pre>															
<400> SEQUENCE: 23															
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60															
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120															
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180															
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240															
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300															
tggagtteeg egttaeataa ettaeggtaa atggeeegee tggetgaeeg eeeaacgaee 360															
cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420															
attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480															
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540															
atgcccagta catgacetta tgggaettte etaettggea gtaeatetae gtattagtea 600															
tegetattae eatggtgatg eggttttgge agtaeateaa tgggegtgga tageggtttg 660															
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720															
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780															
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840															

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gcttggtacc	900
gccgccgcc atg ggc aag agg tcc gcc ggc tca atc atg tgg ctc gcg agcMet Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser1510	951
ttg gca gtt gtc ata gct ggt aca agc gct gtg acc ttg gtg cgg aaa Leu Ala Val Val Ile Ala Gly Thr Ser Ala Val Thr Leu Val Arg Lys 15 20 25 30	999
aac aga tgg ttg ctc cta aat gtg aca tct gag gac ctc ggg aaa aca Asn Arg Trp Leu Leu Leu Asn Val Thr Ser Glu Asp Leu Gly Lys Thr 35 40 45	1047
ttc tct gtg ggc aca ggc aac tgc aca aca aac att ttg gaa gcc aag Phe Ser Val Gly Thr Gly Asn Cys Thr Thr Asn Ile Leu Glu Ala Lys 50 55 60	1095
tac tgg tgc cca gac tca atg gaa tac aac tgt ccc aat ctc agt cca Tyr Trp Cys Pro Asp Ser Met Glu Tyr Asn Cys Pro Asn Leu Ser Pro 65 70 75	1143
aga gag gag cca gat gac att gat tgc tgg tgc tat ggg gtg gaa aac Arg Glu Glu Pro Asp Asp Ile Asp Cys Trp Cys Tyr Gly Val Glu Asn 80 85 90	1191
gtt aga gtc gca tat ggt aag tgt gac tca gca ggc agg tct agg agg Val Arg Val Ala Tyr Gly Lys Cys Asp Ser Ala Gly Arg Ser Arg Arg 95 100 105 110	1239
tca aga agg gcc att gac ttg cct acg cat gaa aac cat ggt ttg aag Ser Arg Arg Ala Ile Asp Leu Pro Thr His Glu Asn His Gly Leu Lys 115 120 125	1287
acc cgg caa gaa aaa tgg atg act gga aga atg ggt gaa agg caa ctc Thr Arg Gln Glu Lys Trp Met Thr Gly Arg Met Gly Glu Arg Gln Leu 130 135 140	1335
caa aag att gag aga tgg ttc gtg agg aac ccc ttt ttt gca gtg acg Gln Lys Ile Glu Arg Trp Phe Val Arg Asn Pro Phe Phe Ala Val Thr 145 150 155	1383
gct ctg acc att gcc tac ctt gtg gga agc aac atg acg caa cga gtc Ala Leu Thr Ile Ala Tyr Leu Val Gly Ser Asn Met Thr Gln Arg Val 160 165 170	1431
gtg att gcc cta ctg gtc ttg gct gtt ggt ccg gcc tac tca gct cac Val Ile Ala Leu Leu Val Leu Ala Val Gly Pro Ala Tyr Ser Ala His 175 180 185 190	1479
tgc att gga att act gac agg gat ttc att gag ggg gtg cat gga gga Cys Ile Gly Ile Thr Asp Arg Asp Phe Ile Glu Gly Val His Gly Gly 195 200 205	1527
act tgg gtt tca gct acc ctg gag caa gac aag tgt gtc act gtt atg Thr Trp Val Ser Ala Thr Leu Glu Gln Asp Lys Cys Val Thr Val Met 210 215 220	1575
gcc cct gac aag cct tca ttg gac atc tca cta gag aca gta gcc att Ala Pro Asp Lys Pro Ser Leu Asp Ile Ser Leu Glu Thr Val Ala Ile 225 230 235	1623
gat aga cct gct gag gtg agg aaa gtg tgt tac aat gca gtt ctc act Asp Arg Pro Ala Glu Val Arg Lys Val Cys Tyr Asn Ala Val Leu Thr 240 245 250	1671
cat gtg aag att aat gac aag tgc ccc agc act gga gag gcc cac cta His Val Lys Ile Asn Asp Lys Cys Pro Ser Thr Gly Glu Ala His Leu 255 260 265 270	1719
gct gaa gag aac gaa ggg gac aat gcg tgc aag cgc act tat tct gat Ala Glu Glu Asn Glu Gly Asp Asn Ala Cys Lys Arg Thr Tyr Ser Asp 275 280 285	1767
aga ggc tgg ggc aat ggc tgt ggc cta ttt ggg aaa ggg agc att gtg Arg Gly Trp Gly Asn Gly Cys Gly Leu Phe Gly Lys Gly Ser Ile Val 290 295 300	1815
gca tgc gcc aaa ttc act tgt gcc aaa tcc atg agt ttg ttt gag gtt	1863

610

-continued

Ala	Cys	Ala 305	Lys	Phe	Thr	Суз	Ala 310	Lys	Ser	Met	Ser	Leu 315	Phe	Glu	Val	
gat Asp	cag Gln 320	acc Thr	aaa Lys	att Ile	cag Gln	tat Tyr 325	gtc Val	atc Ile	aga Arg	gca Ala	caa Gln 330	ttg Leu	cat His	gta Val	gl ^à aaa	1911
gcc Ala 335	aag Lys	cag Gln	gaa Glu	aat Asn	tgg Trp 340	act Thr	acc Thr	gac Asp	att Ile	aag Lys 345	act Thr	ctc Leu	aag Lys	ttt Phe	gat Asp 350	1959
gcc Ala	ctg Leu	tca Ser	ggc Gly	tcc Ser 355	cag Gln	gaa Glu	gtc Val	gag Glu	ttc Phe 360	att Ile	999 G1y	tat Tyr	gga Gly	aaa Lys 365	gct Ala	2007
aca Thr	ctg Leu	gaa Glu	tgc Cys 370	cag Gln	gtg Val	caa Gln	act Thr	gcg Ala 375	gtg Val	gac Asp	ttt Phe	ggt Gly	aac Asn 380	agt Ser	tac Tyr	2055
atc Ile	gct Ala	gag Glu 385	atg Met	gaa Glu	aca Thr	gag Glu	agc Ser 390	tgg Trp	ata Ile	gtg Val	gac Asp	aga Arg 395	cag Gln	tgg Trp	gcc Ala	2103
cag Gln	gac Asp 400	ttg Leu	acc Thr	ctg Leu	cca Pro	tgg Trp 405	cag Gln	agt Ser	gga Gly	agt Ser	ggc Gly 410	д1у д9д	gtg Val	tgg Trp	aga Arg	2151
gag Glu 415	atg Met	cat His	cat His	ctt Leu	gtc Val 420	gaa Glu	ttt Phe	gaa Glu	cct Pro	ccg Pro 425	cat His	gcc Ala	gcc Ala	act Thr	atc Ile 430	2199
aga Arg	gta Val	ctg Leu	gcc Ala	ctg Leu 435	gga Gly	aac Asn	cag Gln	gaa Glu	ggc Gly 440	tcc Ser	ttg Leu	aaa Lys	aca Thr	gct Ala 445	ctt Leu	2247
act Thr	ggc Gly	gca Ala	atg Met 450	agg Arg	gtt Val	aca Thr	aag Lys	gac Asp 455	aca Thr	aat Asn	gac Asp	aac Asn	aac Asn 460	ctt Leu	tac Tyr	2295
aaa Lys	cta Leu	cat His 465	ggt Gly	gga Gly	cat His	gtt Val	tct Ser 470	tgc Cys	aga Arg	gtg Val	aaa Lys	ttg Leu 475	tca Ser	gct Ala	ttg Leu	2343
aca Thr	ctc Leu 480	aag Lys	gga gga	aca Thr	tcc Ser	tac Tyr 485	aaa Lys	ata Ile	tgc Cys	act Thr	gac Asp 490	aaa Lys	atg Met	ttt Phe	ttt Phe	2391
gtc Val 495	aag Lys	aac Asn	cca Pro	act Thr	gac Asp 500	act Thr	ggc Gly	cat His	ggc Gly	act Thr 505	gtt Val	gtg Val	atg Met	cag Gln	gtg Val 510	2439

495	-				500		-		-	505					510	
aaa Lys	gtg Val	tca Ser	aaa Lys	gga Gly 515	gcc Ala	ccc Pro	tgc Cys	agg Arg	att Ile 520	cca Pro	gtg Val	ata Ile	gta Val	gct Ala 525	gat Asp	2487
gat Asp	ctt Leu	aca Thr	gcg Ala 530	gca Ala	atc Ile	aat Asn	aaa Lys	ggc Gly 535	att Ile	ttg Leu	gtt Val	aca Thr	gtt Val 540	aac Asn	ccc Pro	2535

atc gcc tca acc aat gat gat gaa gtg ctg att gag gtg aac cca cct Ile Ala Ser Thr Asn Asp Asp Glu Val Leu Ile Glu Val Asn Pro Pro 2583 545 550 555

ttt gga gac agc tac att atc gtt ggg aga gga gat tca cgt ctc act Phe Gly Asp Ser Tyr Ile Ile Val Gly Arg Gly Asp Ser Arg Leu Thr 2631 560 565 570 tac cag tgg cac aaa gag gga agc tca ata gga aag ttg ttc act cag Tyr Gln Trp His Lys Glu Gly Ser Ser Ile Gly Lys Leu Phe Thr Gln 2679 580 585 575 590

acc atg aaa ggc gtg gaa cgc ctg gcc gtc atg gga gac acc gcc tgg 2727 Thr Met Lys Gly Val Glu Arg Leu Ala Val Met Gly Asp Thr Ala Trp 595 600 605 gat ttc agc tcc gct gga ggg ttc ttc act tcg gtt ggg aaa gga att 2775 Asp Phe Ser Ser Ala Gly Gly Phe Phe Thr Ser Val Gly Lys Gly Ile

620

2823

615

cat acg gtg ttt ggc tct gcc ttt cag ggg cta ttt ggc ggc ttg aac

His Thr Val Phe Gly Ser Ala Phe Gln Gly Leu Phe Gly Gly Leu Asn 625 630 635	
tgg ata aca aag gtc atc atg ggg gcg gta ctt ata tgg gtt ggc atc Trp Ile Thr Lys Val Ile Met Gly Ala Val Leu Ile Trp Val Gly Ile 640 645 650	2871
aac aca aga aac atg aca atg tcc atg agc atg atc ttg gta gga gtg Asn Thr Arg Asn Met Thr Met Ser Met Ser Met Ile Leu Val Gly Val 655 660 665 670	2919
atc atg atg ttt ttg tct cta gga gtt ggg gcg tgagcggccg ctcgagcatg Ile Met Met Phe Leu Ser Leu Gly Val Gly Ala 675 680	2972
catctagagg gccctattct atagtgtcac ctaaatgcta gagctcgctg atcagcctcg	3032
actgtgcett etagttgeea gecatetgtt gtttgeeeet eeeegtgee tteettgaee	3092
ctggaaggtg ccactcccac tgtcctttcc taataaaatg aggaaattgc atcgcattgt	3152
ctgagtaggt gtcattctat tctggggggt ggggtggggc aggacagcaa ggggggaggat	3212
tgggaagaca atagcaggca tgctggggat gcggtgggct ctatggcttc tgaggcggaa	3272
agaacagctg cattaatgaa teggeeaaeg egeggggaga ggeggtttge gtattgggeg	3332
ctcttccgct tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt	3392
atcagctcac tcaaaggcgg taatacggtt atccacagaa tcaggggata acgcaggaaa	3452
gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc	3512
gtttttccat aggeteegee eeeetgaega geateacaaa aategaeget caagteagag	3572
gtggcgaaac ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt	3632
gegeteteet gtteegaeee tgeegettae eggataeetg teegeettte teeetteggg	3692
aagcgtggcg ctttctcaat gctcacgctg taggtatctc agttcggtgt aggtcgttcg	3752
ctccaagetg ggetgtgtge acgaaceeee egtteageee gaeegetgeg eettateegg	3812
taactategt ettgagteea acceggtaag acaegaetta tegeeaetgg eageageeae	3872
tggtaacagg attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg	3932
gcctaactac ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt	3992
taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg	4052
tggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc	4112
tttgatettt tetaeggggt etgaegetea gtggaaegaa aaeteaegtt aagggatttt	4172
ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa	4232
taaatcaatc taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag	4292
tgaggcacct atctcagcga tctgtctatt tcgttcatcc atagttgcct gactccccgt	4352
cgtgtagata actacgatac gggagggctt accatctggc cccagtgctg caatgatacc	4412
gcgagaccca cgctcaccgg ctccagattt atcagcaata aaccagccag ccggaagggc	4472
cgagogcaga agtggtcctg caactttatc cgcctccatc cagtctatta attgttgccg	4532
ggaagctaga gtaagtagtt cgccagttaa tagtttgcgc aacgttgttg ccattgctac	4592
aggeategtg gtgteaeget egtegtttgg tatggettea tteageteeg gtteeeaaeg	4652
atcaaggoga gttacatgat cocccatgtt gtgcaaaaaa goggttagot cottoggtoo	4712
teegategtt gteagaagta agttggeege agtgttatea eteatggtta tggeageaet	4772
gcataattct cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagtactc	4832
aaccaagtca ttotgagaat agtgtatgog gogaoogagt tgotottgoo oggogtoaat	4892

acgggataat accgcgccac atagcagaac tttaaaagtg ctcatcattg gaaaacgttc 4952

1	1	n
1	4	У

ttcggggcga aaactctc	saa ggatettaee getgttgaga	tccagttcga tgtaacccac	5012
tcgtgcaccc aactgatc	tt cagcatettt taettteace	agcgtttctg ggtgagcaaa	5072
aacaggaagg caaaatgc	cg caaaaaaggg aataagggcg	acacggaaat gttgaatact	5132
catactcttc ctttttca	at attattgaag catttatcag	ggttattgtc tcatgagcgg	5192
atacatattt gaatgtat	tt agaaaaataa acaaataggg	gttccgcgca catttccccg	5252
aaaagtgcca cctgacgt	c		5271
<210> SEQ ID NO 24 <211> LENGTH: 681 <212> TYPE: PRT <213> ORGANISM: Art <220> FEATURE: <223> OTHER INFORMA	ificial Sequence ATION: Synthetic Construc	t	
<400> SEQUENCE: 24			
Met Gly Lys Arg Ser 1	Ala Gly Ser Ile Met Trp 10	Leu Ala Ser Leu Ala 15	
Val Val Ile Ala Gly 20	⁷ Thr Ser Ala Val Thr Leu 25	Val Arg Lys Asn Arg 30	
Trp Leu Leu Leu Asn 35	ı Val Thr Ser Glu Asp Leu 40	Gly Lys Thr Phe Ser 45	
Val Gly Thr Gly Asn 50	1 Cys Thr Thr Asn Ile Leu 55	Glu Ala Lys Tyr Trp 60	
Cys Pro Asp Ser Met 65	: Glu Tyr Asn Cys Pro Asn 70 75	Leu Ser Pro Arg Glu 80	
Glu Pro Asp Asp Ile 85	Asp Cys Trp Cys Tyr Gly 90	Val Glu Asn Val Arg 95	
Val Ala Tyr Gly Lys 100	3 Cys Asp Ser Ala Gly Arg 105	Ser Arg Arg Ser Arg 110	
Arg Ala Ile Asp Leu 115	ι Pro Thr His Glu Asn His 120	Gly Leu Lys Thr Arg 125	
Gln Glu Lys Trp Met 130	: Thr Gly Arg Met Gly Glu 135	Arg Gln Leu Gln Lys 140	
Ile Glu Arg Trp Phe 145	Val Arg Asn Pro Phe Phe 150 155	Ala Val Thr Ala Leu 160	
Thr Ile Ala Tyr Leu 165	Val Gly Ser Asn Met Thr	Gln Arg Val Val Ile	
Ala Leu Leu Val Leu	Ala Val Gly Pro Ala Tyr	Ser Ala His Cys Ile	
Gly Ile Thr Asp Arg	Asp Phe Ile Glu Gly Val	His Gly Gly Thr Trp	
Val Ser Ala Thr Leu	200 1 Glu Gln Asp Lys Cys Val	Thr Val Met Ala Pro	
Asp Lys Pro Ser Leu	Asp Ile Ser Leu Glu Thr	Val Ala Ile Asp Arg	
Pro Ala Glu Val Arg	Lys Val Cys Tyr Asn Ala	Val Leu Thr His Val	
Lys Ile Asn Asp Lys	250 8 Cys Pro Ser Thr Gly Glu	∠⊃5 Ala His Leu Ala Glu	
260 Glu Asn Glu Gly Asp	265 > Asn Ala Cys Lys Arg Thr	270 Tyr Ser Asp Arg Gly	
275 Trp Gly Asn Gly Cys	280 3 Gly Leu Phe Gly Lys Gly	285 Ser Ile Val Ala Cys	
290	295	300	

Ala 305	Lys	Phe	Thr	Суз	Ala 310	ГЛЗ	Ser	Met	Ser	Leu 315	Phe	Glu	Val	Asp	Gln 320
Thr	Lys	Ile	Gln	Tyr 325	Val	Ile	Arg	Ala	Gln 330	Leu	His	Val	Gly	Ala 335	Lys
Gln	Glu	Asn	Trp 340	Thr	Thr	Asp	Ile	Lys 345	Thr	Leu	Гла	Phe	Asp 350	Ala	Leu
Ser	Gly	Ser 355	Gln	Glu	Val	Glu	Phe 360	Ile	Gly	Tyr	Gly	Lys 365	Ala	Thr	Leu
Glu	Cys 370	Gln	Val	Gln	Thr	Ala 375	Val	Asp	Phe	Gly	Asn 380	Ser	Tyr	Ile	Ala
Glu	Met	Glu	Thr	Glu	Ser	Trp	Ile	Val	Aab	Arg	Gln	Trp	Ala	Gln	Asp
Leu	Thr	Leu	Pro	Trp	Gln	Ser	Gly	Ser	Gly	Gly	Val	Trp	Arg	Glu	Met
His	His	Leu	Val	Glu	Phe	Glu	Pro	Pro	His	Ala	Ala	Thr	Ile	Arg	Val
Leu	Ala	Leu	420 Gly	Asn	Gln	Glu	Gly	425 Ser	Leu	Lys	Thr	Ala	430 Leu	Thr	Gly
Ala	Met	435 Arg	Val	Thr	Lys	Asp	440 Thr	Asn	Asp	Asn	Asn	445 Leu	Tyr	Lys	Leu
His	450 Glv	Glv	His	Val	Ser	455 Cvs	Ara	Val	Lvs	Leu	460 Ser	Ala	- Leu	- Thr	Leu
465	d1	The	Gen	Term	470	- y 5		The se	ly o	475	Mat	Dhe	Dha		480
гда	стλ	Thr	ser	1yr 485	гда	тте	сув	Inr	Азр 490	гла	Met	Рпе	гле	vai 495	пЛа
Asn	Pro	Thr	Asp 500	Thr	Gly	His	Gly	Thr 505	Val	Val	Met	Gln	Val 510	Lys	Val
Ser	Lys	Gly 515	Ala	Pro	Сүз	Arg	Ile 520	Pro	Val	Ile	Val	Ala 525	Asp	Asp	Leu
Thr	Ala 530	Ala	Ile	Asn	Lys	Gly 535	Ile	Leu	Val	Thr	Val 540	Asn	Pro	Ile	Ala
Ser 545	Thr	Asn	Asp	Asp	Glu 550	Val	Leu	Ile	Glu	Val 555	Asn	Pro	Pro	Phe	Gly 560
Asp	Ser	Tyr	Ile	Ile 565	Val	Gly	Arg	Gly	Asp 570	Ser	Arg	Leu	Thr	Tyr 575	Gln
Trp	His	Lys	Glu 580	Gly	Ser	Ser	Ile	Gly 585	Lys	Leu	Phe	Thr	Gln 590	Thr	Met
ГЛа	Gly	Val 595	Glu	Arg	Leu	Ala	Val	Met	Gly	Asp	Thr	Ala 605	Trp	Asp	Phe
Ser	Ser	Ala	Gly	Gly	Phe	Phe	Thr	Ser	Val	Gly	Lys	Gly	Ile	His	Thr
Val	610 Phe	Gly	Ser	Ala	Phe	615 Gln	Gly	Leu	Phe	Gly	620 Gly	Leu	Asn	Trp	Ile
625 Thr	Lys	Val	Ile	Met	630 Gly	Ala	Val	Leu	Ile	635 Trp	Val	Gly	Ile	Asn	640 Thr
Arc	Δan	Met	Thr	645 Met	Ser	Met	Ser	Met	650 Tle	Len	Val	Glv	Val	655 T1e	Met
лту	A DI	net	660	net	Det	net	Det	665	116	цец	vaı	GTÀ	670	116	net
Met	Phe	Leu 675	Ser	Leu	Gly	Val	GLY 680	Ala							
<21	<210 1> LH)> SH ENGTH	EQ II 1: 35	O NO	25										
<212	2 > T 3 > OF	PE: RGANI	DNA ISM:	Art	ific	ial :	Seque	ence							
<223	3> 0. 3> 0. sv	THER /nthe	INF(etic	ORMA'	TION struk	: De: ct	scrij	ption	n of	art	ific:	ial :	eque	ence;	note

-continued <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(35) <223> OTHER INFORMATION: POW 454 <400> SEQUENCE: 25 35 aaaagaaaaa gcgctaccac catccaccgg gacag <210> SEQ ID NO 26 <211> LENGTH: 41 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature
<222> LOCATION: (1)...(41) <223> OTHER INFORMATION: CPOW 2417 <400> SEOUENCE: 26 actgttaccc tcaaccccgt actcgccggc gaaaaagaaa a 41 <210> SEQ ID NO 27 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <223> OTHER INFORMATION: Modified JE Signal <400> SEQUENCE: 27 Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 1 5 10 15 Val Val Ile Ala Gly Thr Ser Ala 20 <210> SEQ ID NO 28 <211> LENGTH: 36 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(36) <223> OTHER INFORMATION: YF 482 <400> SEQUENCE: 28 aaaagaaaaa gcgctgtgac cttggtgcgg aaaaac 36 <210> SEO ID NO 29 <211> LENGTH: 41 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature $<\!222\!>$ LOCATION: (1)..(41) <223> OTHER INFORMATION: CYF 2433 <400> SEQUENCE: 29 acagagatee teaaceege actegeegge gaaaaagaaa a 41

con	+ i	m	hor
COL		111	1ea

<210> SEQ ID NO 30 <211> LENGTH: 41 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(41) <223> OTHER INFORMATION: SLE 463 <400> SEQUENCE: 30 41 aaaagaaaaa gcgctttgca gttatcaacc tatcagggga a <210> SEQ ID NO 31 <211> LENGTH: 40 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1)..(40) <223> OTHER INFORMATION: CSLE 2477 <400> SEQUENCE: 31 accgttggtc gcacgttcgg actcgccggc gaaaaagaaa 40 <210> SEQ ID NO 32 <211> LENGTH: 39 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 32 Leu Asp Thr Ile Asn Arg Arg Pro Ser Lys Lys Arg Gly Gly Thr Arg 1 5 10 15 Ser Leu Leu Gly Leu Ala Ala Leu Ile Gly Leu Ala Ser Ser Leu Gln 20 25 30 Leu Leu Ser Thr Tyr Gln Gly 35 <210> SEQ ID NO 33 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEOUENCE: 33 Met Trp Leu Ala Ser Leu Ala Val Val Ile Ala Cys Ala Gly Ala Met 1 5 10 15 Lys Leu Ser Asn Phe Gln Gly Lys 20 <210> SEQ ID NO 34 <211> LENGTH: 30 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note =

synthetic construct

<400> SEQUENCE: 34 Met Asn Glu Gly Ser Ile Met Trp Leu Ala Ser Leu Ala Val Val Ile 1 10 15 Ala Cys Ala Gly Ala Met Lys Leu Ser Asn Phe Gln Gly Lys 20 25 <210> SEQ ID NO 35 <211> LENGTH: 39 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 35 Met Gly Arg Lys Gln Asn Lys Arg Gly Gly Asn Glu Gly Ser Ile Met 1 5 10 15 Trp Leu Ala Ser Leu Ala Val Val Ile Ala Cys Ala Gly Ala Met Lys 20 25 30 Leu Ser Asn Phe Gln Gly Lys 35 <210> SEO ID NO 36 <211> LENGTH: 34 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 36 Met Ser Lys Lys Arg Gly Gly Ser Glu Thr Ser Val Leu Met Val Ile 15 5 1 10 Phe Met Leu Ile Gly Phe Ala Ala Ala Leu Lys Leu Ser Asn Phe Gln 20 25 30 Gly Lys <210> SEQ ID NO 37 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 37 Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 5 10 15 1 Val Val Ile Ala Cys Ala Gly Ala Val Thr Leu Ser Asn Phe Gln Gly 25 20 30 Lys <210> SEQ ID NO 38 <211> LENGTH: 46 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 38 Met Asn Val Leu Arg Gly Phe Arg Lys Glu Ile Gly Arg Met Leu Asn 5 10 1 15

140

Ile Leu Asn Arg Arg Arg Arg Thr Ala Gly Met Ile Ile Met Leu Ile 25 20 30 Pro Thr Val Met Ala Phe His Leu Thr Thr Arg Asn Gly Glu 40 35 45 <210> SEQ ID NO 39 <211> LENGTH: 40 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 39 Met Val Gly Leu Gln Lys Arg Gly Lys Arg Arg Ser Ala Thr Asp Trp 10 1 5 15 Met Ser Trp Leu Leu Val Ile Thr Leu Leu Gly Met Thr Leu Ala Ala 2.0 25 30 Thr Val Arg Lys Glu Arg Gly Asp 35 40 <210> SEQ ID NO 40 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 40 Met Gly Trp Leu Leu Val Val Val Leu Leu Gly Val Thr Leu Ala Ala 15 5 10 1 Thr Val Arg Lys Glu Arg Gly Asp 20 <210> SEQ ID NO 41 <211> LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 41 Met Ser Trp Leu Leu Val Ile Thr Leu Leu Gly Met Thr Ile Ala Ala 10 5 15 1 Thr Val Arg Lys Glu Arg Gly Asp 20 <210> SEQ ID NO 42 <211> LENGTH: 5292 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (910) .. (2964) <400> SEOUENCE: 42 gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgctctgatg 60 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

cont inued

			-0	.one mued	
ttagggttag	gcgttttgcg c	tgcttcgcg atgt	tacgggc caga	tatacg cgttgacatt	240
gattattgac	tagttattaa t	agtaatcaa ttac	cggggtc attag	gttcat agcccatata	300
tggagttccg	cgttacataa c	ttacggtaa atgo	geeegee tgge	tgaccg cccaacgacc	360
cccgcccatt	gacgtcaata a	tgacgtatg ttco	ccatagt aacg	ccaata gggactttcc	420
attgacgtca	atgggtggag t	atttacggt aaad	ctgecca cttg	gcagta catcaagtgt	480
atcatatgcc	aagtacgccc c	ctattgacg tcaa	atgacgg taaa	tggccc gcctggcatt	540
atgcccagta	catgacctta t	gggactttc ctac	cttggca gtaca	atctac gtattagtca	600
tcgctattac	catggtgatg c	ggttttggc agta	acatcaa tggg	cgtgga tagcggtttg	660
actcacgggg	atttccaagt c	tecacecca ttga	acgtcaa tggga	agtttg ttttggcacc	720
aaaatcaacg	ggactttcca a	aatgtcgta acaa	acteege eeca	ttgacg caaatgggcg	780
gtaggcgtgt	acggtgggag g	tctatataa gcaq	gagetet etgg	ctaact agagaaccca	840
ctgcttactg	gcttatcgaa a	ttaatacga ctca	actatag ggaga	acccaa gcttggtacc	900
gccgccgcc a M 1	tg ggc aag a let Gly Lys A	gg tee gee gge rg Ser Ala Gly 5	c tca atc atg y Ser Ile Me 10	g tgg ctc gcg agc t Trp Leu Ala Ser	951
ttg gca gtt Leu Ala Val 15	gtc ata gct Val Ile Ala 20	tgt gca ggc g Cys Ala Gly A	gcc ttc cat 1 Ala Phe His 1 25	tta acc aca cgt Leu Thr Thr Arg 30	999
aac gga gaa Asn Gly Glu	cca cac atg Pro His Met 35	atc gtc agc a Ile Val Ser A 4	aga caa gag a Arg Gln Glu 1 40	aaa ggg aaa agt Lys Gly Lys Ser 45	1047
ctt ctg ttt Leu Leu Phe	aaa aca gag Lys Thr Glu 50	gat ggc gtg a Asp Gly Val A 55	aac atg tgt a Asn Met Cys '	acc ctc atg gcc Thr Leu Met Ala 60	1095
atg gac ctt Met Asp Leu 65	ggt gaa ttg Gly Glu Leu	tgt gaa gac a Cys Glu Asp 1 70	aca atc acg f Thr Ile Thr '	tac aag tgt ccc Tyr Lys Cys Pro 75	1143
ctt ctc agg Leu Leu Arg 80	r cag aat gag r Gln Asn Glu	cca gaa gac a Pro Glu Asp 1 85	ata gac tgt 1 Ile Asp Cys ' 90	tgg tgc aac tct Trp Cys Asn Ser	1191
acg tcc acg Thr Ser Thr 95	tgg gta act Trp Val Thr 100	tat ggg acg t Tyr Gly Thr (tgt acc acc a Cys Thr Thr I 105	atg gga gaa cat Met Gly Glu His 110	1239
aga aga gaa Arg Arg Glu	aaa aga tca Lys Arg Ser 115	gtg gca ctc g Val Ala Leu V J	gtt cca cat o Val Pro His V 120	gtg gga atg gga Val Gly Met Gly 125	1287
ctg gag aca Leu Glu Thr	cga act gaa Arg Thr Glu 130	aca tgg atg t Thr Trp Met S 135	tca tca gaa g Ser Ser Glu (ggg gcc tgg aaa Gly Ala Trp Lys 140	1335
cat gtc cag His Val Gln 145	aga att gaa Arg Ile Glu	act tgg atc t Thr Trp Ile I 150	ttg aga cat d Leu Arg His I	cca ggc ttc acc Pro Gly Phe Thr 155	1383
atg atg gca Met Met Ala 160	gca atc ctg Ala Ile Leu	gca tac acc a Ala Tyr Thr I 165	ata gga acg a Ile Gly Thr ' 170	aca cat ttc caa Thr His Phe Gln	1431
aga gcc ctg Arg Ala Leu 175	att ttc atc Ile Phe Ile 180	tta ctg aca g Leu Leu Thr A	gct gtc act o Ala Val Thr 1 185	cct tca atg aca Pro Ser Met Thr 190	1479

atg cgt tgc ata gga atg tca aat aga gac ttt gtg gaa ggg gtt tca Met Arg Cys Ile Gly Met Ser Asn Arg Asp Phe Val Glu Gly Val Ser gga gga agc tgg gtt gac ata gtc tta gaa cat gga agc tgt gtg acg Gly Gly Ser Trp Val Asp Ile Val Leu Glu His Gly Ser Cys Val Thr

acg Thr	atg Met	gca Ala 225	aaa Lys	aac Asn	aaa Lys	cca Pro	aca Thr 230	ttg Leu	gat Asp	ttt Phe	gaa Glu	ctg Leu 235	ata Ile	aaa Lys	aca Thr	1623
gaa Glu	gcc Ala 240	aaa Lys	cag Gln	cct Pro	gcc Ala	acc Thr 245	cta Leu	agg Arg	aag Lys	tac Tyr	tgt Cys 250	ata Ile	gag Glu	gca Ala	aag Lys	1671
cta Leu 255	acc Thr	aac Asn	aca Thr	aca Thr	aca Thr 260	gaa Glu	tct Ser	cgc Arg	tgc Cys	cca Pro 265	aca Thr	caa Gln	д1у 999	gaa Glu	ccc Pro 270	1719
agc Ser	cta Leu	aat Asn	gaa Glu	gag Glu 275	cag Gln	gac Asp	aaa Lys	agg Arg	ttc Phe 280	gtc Val	tgc Cys	aaa Lys	cac His	tcc Ser 285	atg Met	1767
gta Val	gac Asp	aga Arg	gga Gly 290	tgg Trp	gga Gly	aat Asn	gga Gly	tgt Cys 295	gga Gly	cta Leu	ttt Phe	gga Gly	aag Lys 300	gga Gly	ggc Gly	1815
att Ile	gtg Val	acc Thr 305	tgt Cys	gct Ala	atg Met	ttc Phe	aga Arg 310	tgc Cys	aaa Lys	aag Lys	aac Asn	atg Met 315	gaa Glu	gga Gly	aaa Lys	1863
gtt Val	gtg Val 320	caa Gln	cca Pro	gaa Glu	aac Asn	ttg Leu 325	gaa Glu	tac Tyr	acc Thr	att Ile	gtg Val 330	ata Ile	aca Thr	cct Pro	cac His	1911
tca Ser 335	gly aaa	gaa Glu	gag Glu	cat His	gca Ala 340	gtc Val	gga Gly	aat Asn	gac Asp	aca Thr 345	gga Gly	aaa Lys	cat His	ggc Gly	aag Lys 350	1959
gaa Glu	atc Ile	aaa Lys	ata Ile	aca Thr 355	cca Pro	cag Gln	agt Ser	tcc Ser	atc Ile 360	aca Thr	gaa Glu	gca Ala	gaa Glu	ttg Leu 365	aca Thr	2007
ggt Gly	tat Tyr	ggc Gly	act Thr 370	gtc Val	aca Thr	atg Met	gag Glu	tgc Cys 375	tct Ser	cca Pro	aga Arg	acg Thr	ggc Gly 380	ctc Leu	gac Asp	2055
ttc Phe	aat Asn	gag Glu 385	atg Met	gtg Val	ttg Leu	ttg Leu	cag Gln 390	atg Met	gaa Glu	aat Asn	aaa Lys	gct Ala 395	tgg Trp	ctg Leu	gtg Val	2103
cac His	agg Arg 400	caa Gln	tgg Trp	ttc Phe	cta Leu	gac Asp 405	ctg Leu	ccg Pro	tta Leu	cca Pro	tgg Trp 410	ttg Leu	ccc Pro	gga Gly	gcg Ala	2151
gac Asp 415	aca Thr	caa Gln	д1У даа	tca Ser	aat Asn 420	tgg Trp	ata Ile	cag Gln	aaa Lys	gag Glu 425	aca Thr	ttg Leu	gtc Val	act Thr	ttc Phe 430	2199
aaa Lys	aat Asn	ccc Pro	cat His	gcg Ala 435	aag Lys	aaa Lys	cag Gln	gat Asp	gtt Val 440	gtt Val	gtt Val	tta Leu	gga Gly	tcc Ser 445	caa Gln	2247
gaa Glu	gjà djà	gcc Ala	atg Met 450	cac His	aca Thr	gca Ala	ctt Leu	aca Thr 455	д1 ^у ааа	gcc Ala	aca Thr	gaa Glu	atc Ile 460	caa Gln	atg Met	2295
tca Ser	tca Ser	gga Gly 465	aac Asn	tta Leu	ctc Leu	ttc Phe	aca Thr 470	gga Gly	cat His	ctc Leu	aag Lys	tgc Cys 475	agg Arg	ctg Leu	aga Arg	2343
atg Met	gac Asp 480	aag Lys	cta Leu	cag Gln	ctc Leu	aaa Lys 485	gga Gly	atg Met	tca Ser	tac Tyr	tct Ser 490	atg Met	tgc Cys	aca Thr	gga Gly	2391
aag Lys 495	ttt Phe	aaa Lys	gtt Val	gtg Val	aag Lys 500	gaa Glu	ata Ile	gca Ala	gaa Glu	aca Thr 505	caa Gln	cat His	gga Gly	aca Thr	ata Ile 510	2439
gtt Val	atc Ile	aga Arg	gtg Val	caa Gln 515	tat Tyr	gaa Glu	gga gga	gac Asp	ggc Gly 520	tct Ser	cca Pro	tgc Cys	aag Lys	atc Ile 525	cct Pro	2487
ttt Phe	gag Glu	ata Ile	atg Met 530	gat Asp	ttg Leu	gaa Glu	aaa Lys	aga Arg 535	cat His	gtc Val	tta Leu	ggt Gly	cgc Arg 540	ctg Leu	att Ile	2535

-continued	
aca gtc aac cca att gtg aca gaa aaa gat agc cca gtc aac ata gaa Thr Val Asn Pro Ile Val Thr Glu Lys Asp Ser Pro Val Asn Ile Glu 545 550 555	2583
gca gaa cct cca ttc gga gac agc tac atc atc ata gga gta gag ccg Ala Glu Pro Pro Phe Gly Asp Ser Tyr Ile Ile Ile Gly Val Glu Pro 560 565 570	2631
gga caa ctg aag ctc aac tgg ttt aag aaa gga agt tct atc ggc caa Gly Gln Leu Lys Leu Asn Trp Phe Lys Lys Gly Ser Ser Ile Gly Gln 575 580 585 590	2679
atg ttt gag aca aca atg agg ggg gcg aag aga atg gcc att tta ggt Met Phe Glu Thr Thr Met Arg Gly Ala Lys Arg Met Ala Ile Leu Gly 595 600 605	2727
gac aca gcc tgg gat ttt gga tcc ttg gga gga gtg ttt aca tct ata Asp Thr Ala Trp Asp Phe Gly Ser Leu Gly Gly Val Phe Thr Ser Ile 610 615 620	2775
gga aag gct ctc cac caa gtc ttt gga gca atc tat gga gct gcc ttc Gly Lys Ala Leu His Gln Val Phe Gly Ala Ile Tyr Gly Ala Ala Phe 625 630 635	2823
agt ggg gtt tca tgg act atg aaa atc ctc ata gga gtc att atc aca Ser Gly Val Ser Trp Thr Met Lys Ile Leu Ile Gly Val Ile Ile Thr 640 645 650	2871
tgg ata gga atg aat tca cgc agc acc tca ctg tct gtg aca cta gta Trp Ile Gly Met Asn Ser Arg Ser Thr Ser Leu Ser Val Thr Leu Val 655 660 665 670	2919
ttg gtg gga att gtg aca ctg tat ttg gga gtc atg gtg cag gcc Leu Val Gly Ile Val Thr Leu Tyr Leu Gly Val Met Val Gln Ala 675 680 685	2964
taattagttg ageggeeget egageatgea tetagaggge eetattetat agtgteacet	3024
aaaugetaga getegetgat cageetegae tgtgeettet agttgeeage eatetgttgt	3084
ttgecectee ceegtgeett eettgaeeet ggaaggtgee acteeeaetg teettteeta	3144
ataqaacaa gacaacaaa addaagatta gaaagacaat adcaagacata ctagagatag	3204
ggtgggetet atggettetg aggeggaaag aaccagetge attaatgaat eggecaacqe	3324
geggggagag geggtttgeg tattgggege tetteegett eetegeteae tgactegetg	3384
cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta	3444
tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc	3504
aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag	3564
catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac	3624
caggegttte eccetggaag etceetegtg egeteteetg tteegaeeet geegettaee	3684
ggatacetgt eegeetttet eeetteggga agegtggege ttteteatag eteaegetgt	3744
aggtatetea gtteggtgta ggtegttege teeaagetgg getgtgtgea egaaceeee	3804
gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga	3864
cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta	3924
yyuyyuyuu cayayuuuu yaagtggtgg cotaactacg gotacactag aagaacagta	3984 4044
tocggcaaac aaaccaccgc tggtagcggt ggtttttttq tttqcaaqca qcaqattacq	4104
cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag	4164
tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc	4224
tagateettt taaattaaaa atgaagtttt aaateaatet aaagtatata tgagtaaaet	4284

-continued	
tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt	4344
cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggctta	4404
ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc tccagattta	4464
tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc aactttatcc	4524
gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat	4584
agtttgcgca acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc gtcgtttggt	4644
atggetteat teageteegg tteecaaega teaaggegag ttaeatgate ecceatgttg	4704
tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa gttggccgca	4764
gtgttatcac tcatggttat ggcagcactg cataattete ttactgteat gecateegta	4824
agatgetttt etgtgaetgg tgagtaetea accaagteat tetgagaata gtgtatgegg	4884
cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca tagcagaact	4944
ttaaaagtgc tcatcattgg aaaacgttct tcgggggcgaa aactctcaag gatcttaccg	5004
ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc agcatcttt	5064
actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga	5124
ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc	5184
atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa	5244
caaatagggg tteegegeae attteeeega aaagtgeeae etgaegte	5292
<211> LENGTH: 685 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct	
<400> SEQUENCE: 43	
Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 1 5 10 15	
Val Val Ile Ala Cys Ala Gly Ala Phe His Leu Thr Thr Arg Asn Gly	
20 25 30	
35 40 45	
Phe Lys Thr Glu Asp Gly Val Asn Met Cys Thr Leu Met Ala Met Asp 50 55 60	
Leu Gly Glu Leu Cys Glu Asp Thr Ile Thr Tyr Lys Cys Pro Leu Leu	
65 70 75 80	
Arg Gln Asn Glu Pro Glu Asp Ile Asp Cys Trp Cys Asn Ser Thr Ser 85 90 95	
Thr Trp Val Thr Tyr Gly Thr Cys Thr Thr Met Gly Glu His Arg Arg	
Glu Lys Arg Ser Val Ala Leu Val Pro His Val Gly Met Gly Leu Gly	
115 120 125	
Thr Arg Thr Glu Thr Trp Met Ser Ser Glu Gly Ala Trp Lys His Val 130 135 140	
Gln Arq Ile Glu Thr Trp Ile Leu Arq His Pro Gly Phe Thr Met Met	
145 150 155 160	
Ala Ala Ile Leu Ala Tyr Thr Ile Gly Thr Thr His Phe Gln Arg Ala 165 170 175	
Leu Ile Phe Ile Leu Leu Thr Ala Val Thr Pro Ser Met Thr Met Arg 180 185 190	

Суз	Ile	Gly 195	Met	Ser	Asn	Arg	Asp 200	Phe	Val	Glu	Gly	Val 205	Ser	Gly	Gly
Ser	Trp 210	Val	Asp	Ile	Val	Leu 215	Glu	His	Gly	Ser	Cys 220	Val	Thr	Thr	Met
Ala 225	Lys	Asn	Lys	Pro	Thr 230	Leu	Asp	Phe	Glu	Leu 235	Ile	Гла	Thr	Glu	Ala 240
Lys	Gln	Pro	Ala	Thr 245	Leu	Arg	Lys	Tyr	Cys 250	Ile	Glu	Ala	Lys	Leu 255	Thr
Asn	Thr	Thr	Thr 260	Glu	Ser	Arg	Cys	Pro 265	Thr	Gln	Gly	Glu	Pro 270	Ser	Leu
Asn	Glu	Glu 275	Gln	Asp	Lys	Arg	Phe 280	Val	Cys	Lys	His	Ser 285	Met	Val	Asp
Arg	Gly 290	Trp	Gly	Asn	Gly	Суз 295	Gly	Leu	Phe	Gly	Lys 300	Gly	Gly	Ile	Val
Thr 305	Cys	Ala	Met	Phe	Arg 310	Суз	ГЛа	Lys	Asn	Met 315	Glu	Gly	Lys	Val	Val 320
Gln	Pro	Glu	Asn	Leu 325	Glu	Tyr	Thr	Ile	Val 330	Ile	Thr	Pro	His	Ser 335	Gly
Glu	Glu	His	Ala 340	Val	Gly	Asn	Asp	Thr 345	Gly	Lys	His	Gly	Lys 350	Glu	Ile
Lys	Ile	Thr 355	Pro	Gln	Ser	Ser	Ile 360	Thr	Glu	Ala	Glu	Leu 365	Thr	Gly	Tyr
Gly	Thr 370	Val	Thr	Met	Glu	Сув 375	Ser	Pro	Arg	Thr	Gly 380	Leu	Asp	Phe	Asn
Glu 385	Met	Val	Leu	Leu	Gln 390	Met	Glu	Asn	Lys	Ala 395	Trp	Leu	Val	His	Arg 400
Gln	Trp	Phe	Leu	Asp 405	Leu	Pro	Leu	Pro	Trp 410	Leu	Pro	Gly	Ala	Asp 415	Thr
Gln	Gly	Ser	Asn 420	Trp	Ile	Gln	Lys	Glu 425	Thr	Leu	Val	Thr	Phe 430	Lys	Asn
Pro	His	Ala 435	Lys	Lys	Gln	Asp	Val 440	Val	Val	Leu	Gly	Ser 445	Gln	Glu	Gly
Ala	Met 450	His	Thr	Ala	Leu	Thr 455	Gly	Ala	Thr	Glu	Ile 460	Gln	Met	Ser	Ser
Gly 465	Asn	Leu	Leu	Phe	Thr 470	Gly	His	Leu	Lys	Cys 475	Arg	Leu	Arg	Met	Asp 480
Lys	Leu	Gln	Leu	Lys 485	Gly	Met	Ser	Tyr	Ser 490	Met	Сүз	Thr	Gly	Lys 495	Phe
Lys	Val	Val	Lys 500	Glu	Ile	Ala	Glu	Thr 505	Gln	His	Gly	Thr	Ile 510	Val	Ile
Arg	Val	Gln 515	Tyr	Glu	Gly	Asp	Gly 520	Ser	Pro	Суз	ГЛа	Ile 525	Pro	Phe	Glu
Ile	Met 530	Asp	Leu	Glu	ГЛа	Arg 535	His	Val	Leu	Gly	Arg 540	Leu	Ile	Thr	Val
Asn 545	Pro	Ile	Val	Thr	Glu 550	Lys	Asp	Ser	Pro	Val 555	Asn	Ile	Glu	Ala	Glu 560
Pro	Pro	Phe	Gly	Asp 565	Ser	Tyr	Ile	Ile	Ile 570	Gly	Val	Glu	Pro	Gly 575	Gln
Leu	Lys	Leu	Asn 580	Trp	Phe	Lys	Lys	Gly 585	Ser	Ser	Ile	Gly	Gln 590	Met	Phe
Glu	Thr	Thr 595	Met	Arg	Gly	Ala	Lys 600	Arg	Met	Ala	Ile	Leu 605	Gly	Asp	Thr
Ala	Trp 610	Asp	Phe	Gly	Ser	Leu 615	Gly	Gly	Val	Phe	Thr 620	Ser	Ile	Gly	Lys

Ala Leu His Gln Val Phe Gly Ala Ile Tyr Gly Ala Ala Phe Ser Gly 625 630 635 640 Val Ser Trp Thr Met Lys Ile Leu Ile Gly Val Ile Ile Thr Trp Ile 645 650 655 Gly Met Asn Ser Arg Ser Thr Ser Leu Ser Val Thr Leu Val Leu Val 660 665 670 Gly Ile Val Thr Leu Tyr Leu Gly Val Met Val Gln Ala 675 680 685 <210> SEQ ID NO 44 <211> LENGTH: 5293 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = svnthetic construct <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (910) .. (2964) <400> SEOUENCE: 44 gacggategg gagateteec gateceetat ggtgeactet cagtacaate tgetetgatg 60 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180 ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240 gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420 attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt 480 atcatatgec aagtacgece ectattgacg teaatgacgg taaatggeee geetggeatt 540 atgeccagta catgacetta tgggaettte etaettggea gtacatetae gtattagtea 600 tegetattac catggtgatg eggttttgge agtacateaa tgggegtgga tageggtttg 660 actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720 aaaatcaacq qqactttcca aaatqtcqta acaactccqc cccattqacq caaatqqqcq 780 gtaggegtgt acggtgggag gtetatataa geagagetet etggetaaet agagaaecea 840 900 ctgettactg gettategaa attaataega eteactatag ggagaeeeaa gettggtaee gccgccgcc atg ggc aag agg tcc gcc ggc tca atc atg tgg ctc gcg agc Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser 951 5 10 1 ttg gca gtt gtc ata gct tgt gca ggc gcc ttc cat tta acc aca cgt 999 Leu Ala Val Val Ile Ala Cys Ala Gly Ala Phe His Leu Thr Thr Arg 15 20 25 30 aac gga gaa cca cac atg atc gtc agc aga caa gag aaa ggg aaa agt 1047 Asn Gly Glu Pro His Met Ile Val Ser Arg Gln Glu Lys Gly Lys Ser 35 40 45 ctt ctg ttt aaa aca gag gat ggc gtg aac atg tgt acc ctc atg gcc 1095 Leu Leu Phe Lys Thr Glu Asp Gly Val Asn Met Cys Thr Leu Met Ala 50 55 60 atg gac ctt ggt gaa ttg tgt gaa gac aca atc acg tac aag tgt ccc 1143 Met Asp Leu Gly Glu Leu Cys Glu Asp Thr Ile Thr Tyr Lys Cys Pro 65 70 75 ctt ctc agg cag aat gag cca gaa gac ata gac tgt tgg tgc aac tct 1191 Leu Leu Arg Gln Asn Glu Pro Glu Asp Ile Asp Cys Trp Cys Asn Ser 80 85 90

acg Thr 95	tcc Ser	acg Thr	tgg Trp	gta Val	act Thr 100	tat Tyr	glà aaa	acg Thr	tgt Cys	acc Thr 105	acc Thr	atg Met	gga Gly	gaa Glu	cat His 110	1239	
aga Arg	aga Arg	gaa Glu	aaa Lys	aga Arg 115	tca Ser	gtg Val	gca Ala	ctc Leu	gtt Val 120	cca Pro	cat His	gtg Val	gga Gly	atg Met 125	gga Gly	1287	
ctg Leu	gag Glu	aca Thr	cga Arg 130	act Thr	gaa Glu	aca Thr	tgg Trp	atg Met 135	tca Ser	tca Ser	gaa Glu	ggg gly	gcc Ala 140	tgg Trp	aaa Lys	1335	
cat His	gtc Val	cag Gln 145	aga Arg	att Ile	gaa Glu	act Thr	tgg Trp 150	atc Ile	ttg Leu	aga Arg	cat His	cca Pro 155	ggc Gly	ttc Phe	acc Thr	1383	
atg Met	atg Met 160	gca Ala	gca Ala	atc Ile	ctg Leu	gca Ala 165	tac Tyr	acc Thr	ata Ile	gga Gly	acg Thr 170	aca Thr	cat His	ttc Phe	caa Gln	1431	
aga Arg 175	gcc Ala	ctg Leu	att Ile	ttc Phe	atc Ile 180	tta Leu	ctg Leu	aca Thr	gct Ala	gtc Val 185	act Thr	cct Pro	tca Ser	atg Met	aca Thr 190	1479	
atg Met	cgt Arg	tgc Cys	ata Ile	gga Gly 195	atg Met	tca Ser	aat Asn	aga Arg	gac Asp 200	ttt Phe	gtg Val	gaa Glu	glà aaa	gtt Val 205	tca Ser	1527	
gga Gly	gga Gly	agc Ser	tgg Trp 210	gtt Val	gac Asp	ata Ile	gtc Val	tta Leu 215	gaa Glu	cat His	gga Gly	agc Ser	tgt Cys 220	gtg Val	acg Thr	1575	
acg Thr	atg Met	gca Ala 225	aaa Lys	aac Asn	aaa Lys	cca Pro	aca Thr 230	ttg Leu	gat Asp	ttt Phe	gaa Glu	ctg Leu 235	ata Ile	aaa Lys	aca Thr	1623	
gaa Glu	gcc Ala 240	aaa Lys	cag Gln	cct Pro	gcc Ala	acc Thr 245	cta Leu	agg Arg	aag Lys	tac Tyr	tgt Cys 250	ata Ile	gag Glu	gca Ala	aag Lys	1671	
cta Leu 255	acc Thr	aac Asn	aca Thr	aca Thr	aca Thr 260	gaa Glu	tct Ser	cgc Arg	tgc Cys	cca Pro 265	aca Thr	caa Gln	gjà djà	gaa Glu	ccc Pro 270	1719	
agc Ser	cta Leu	aat Asn	gaa Glu	gag Glu 275	cag Gln	gac Asp	aaa Lys	agg Arg	ttc Phe 280	gtc Val	tgc Cys	aaa Lys	cac His	tcc Ser 285	atg Met	1767	
gta Val	gac Asp	aga Arg	gga Gly 290	tgg Trp	gga Gly	aat Asn	gga Gly	tgt Cys 295	gga Gly	cta Leu	ttt Phe	gga Gly	aag Lys 300	gga Gly	ggc Gly	1815	
att Ile	gtg Val	acc Thr 305	tgt Cys	gct Ala	atg Met	ttc Phe	aga Arg 310	tgc Cys	aaa Lys	aag Lys	aac Asn	atg Met 315	gaa Glu	gga Gly	aaa Lys	1863	
gtt Val	gtg Val 320	caa Gln	cca Pro	gaa Glu	aac Asn	ttg Leu 325	gaa Glu	tac Tyr	acc Thr	att Ile	gtg Val 330	ata Ile	aca Thr	cct Pro	cac His	1911	
tca Ser 335	glà aaa	gaa Glu	gag Glu	cat His	gca Ala 340	gtc Val	gga Gly	aat Asn	gac Asp	aca Thr 345	gga Gly	aaa Lys	cat His	ggc Gly	aag Lys 350	1959	
gaa Glu	atc Ile	aaa Lys	ata Ile	aca Thr 355	cca Pro	cag Gln	agt Ser	tcc Ser	atc Ile 360	aca Thr	gaa Glu	gca Ala	gaa Glu	ttg Leu 365	aca Thr	2007	
ggt Gly	tat Tyr	ggc Gly	act Thr 370	gtc Val	aca Thr	atg Met	gag Glu	tgc Cys 375	tct Ser	cca Pro	aga Arg	acg Thr	ggc Gly 380	ctc Leu	gac Asp	2055	
ttc Phe	aat Asn	gag Glu 385	atg Met	gtg Val	ttg Leu	ttg Leu	cag Gln 390	atg Met	gaa Glu	aat Asn	aaa Lys	gct Ala 395	tgg Trp	ctg Leu	gtg Val	2103	
cac His	agg Arg 400	caa Gln	tgg Trp	ttc Phe	cta Leu	gac Asp 405	ctg Leu	ccg Pro	tta Leu	cca Pro	tgg Trp 410	ttg Leu	ccc Pro	gga Gly	gcg Ala	2151	

gac Asp 415	aca Thr	caa Gln	ggg ggg	tca Ser	aat Asn 420	tgg Trp	ata Ile	cag Gln	aaa Lys	gag Glu 425	aca Thr	ttg Leu	gtc Val	act Thr	ttc Phe 430	2199
aaa Lys	aat Asn	ccc Pro	cat His	gcg Ala 435	aag Lys	aaa Lys	cag Gln	gat Asp	gtt Val 440	gtt Val	gtt Val	tta Leu	gga Gly	tcc Ser 445	caa Gln	2247
gaa Glu	д1À ааа	gcc Ala	atg Met 450	cac His	aca Thr	gca Ala	ctt Leu	aca Thr 455	glà aaa	gcc Ala	aca Thr	gaa Glu	atc Ile 460	caa Gln	atg Met	2295
tca Ser	tca Ser	gga Gly 465	aac Asn	tta Leu	ctc Leu	ttc Phe	aca Thr 470	gga Gly	cat His	ctc Leu	aag Lys	tgc Cys 475	agg Arg	ctg Leu	aga Arg	2343
atg Met	gac Asp 480	aag Lys	cta Leu	cag Gln	ctc Leu	aaa Lys 485	gga Gly	atg Met	tca Ser	tac Tyr	tct Ser 490	atg Met	tgc Cys	aca Thr	gga Gly	2391
aag Lys 495	ttt Phe	aaa Lys	gtt Val	gtg Val	aag Lys 500	gaa Glu	ata Ile	gca Ala	gaa Glu	aca Thr 505	caa Gln	cat His	gga Gly	aca Thr	ata Ile 510	2439
gtt Val	atc Ile	aga Arg	gtg Val	caa Gln 515	tat Tyr	gaa Glu	glà aaa	gac Asp	ggc Gly 520	tct Ser	cca Pro	tgc Cys	aag Lys	atc Ile 525	cct Pro	2487
ttt Phe	gag Glu	ata Ile	atg Met 530	gat Asp	ttg Leu	gaa Glu	aaa Lys	aga Arg 535	cat His	gtc Val	tta Leu	ggt Gly	cgc Arg 540	ctg Leu	att Ile	2535
aca Thr	gtc Val	aac Asn 545	cca Pro	att Ile	gtg Val	aca Thr	gaa Glu 550	aaa Lys	gat Asp	agc Ser	cca Pro	gtc Val 555	aac Asn	ata Ile	gaa Glu	2583
gca Ala	gaa Glu 560	cct Pro	cca Pro	ttc Phe	gga Gly	gac Asp 565	agc Ser	cac His	atc Ile	atc Ile	ata Ile 570	gga Gly	gta Val	gag Glu	ccg Pro	2631
gga Gly 575	caa Gln	ctg Leu	aag Lys	ctc Leu	aac Asn 580	tgg Trp	ttt Phe	aag Lys	aaa Lys	gga Gly 585	agt Ser	tct Ser	atc Ile	ggc Gly	caa Gln 590	2679
atg Met	ttt Phe	gag Glu	aca Thr	aca Thr 595	atg Met	agg Arg	ggg Gly	gcg Ala	aag Lys 600	aga Arg	atg Met	gcc Ala	att Ile	tta Leu 605	ggt Gly	2727
gac Asp	aca Thr	gcc Ala	tgg Trp 610	gat Asp	ttt Phe	gga Gly	tcc Ser	ttg Leu 615	gga Gly	gga Gly	gtg Val	ttt Phe	aca Thr 620	tct Ser	ata Ile	2775
gga Gly	aag Lys	gct Ala 625	ctc Leu	cac His	caa Gln	gtg Val	ttt Phe 630	ggt Gly	ggt Gly	gcc Ala	ttc Phe	aga Arg 635	aca Thr	ctc Leu	ttt Phe	2823
glÀ aaa	gga Gly 640	atg Met	tct Ser	tgg Trp	atc Ile	aca Thr 645	caa Gln	gga gga	cta Leu	atg Met	ggt Gly 650	gcc Ala	cta Leu	ctg Leu	ctc Leu	2871
tgg Trp 655	atg Met	ggc Gly	gtc Val	aac Asn	gca Ala 660	cga Arg	gac Asp	cga Arg	tca Ser	att Ile 665	gct Ala	ttg Leu	gcc Ala	ttc Phe	tta Leu 670	2919
gcc Ala	aca Thr	glà aaa	ggt Gly	gtg Val 675	ctc Leu	gtg Val	ttc Phe	tta Leu	gcg Ala 680	acc Thr	aat Asn	gtg Val	cat His	gct Ala 685		2964
taat	tagt	tt g	lddco	gaca	gc to	gago	atgo	atc	taga	ıggg	ccct	atto	cta t	agto	Jtcacc	3024
taaa	atgct	ag a	ageto	gete	ga to	cageo	tcga	u ctg	Itgco	ttc	tagt	tgco	ag o	cato	tgttg	3084
tttç	jecec	etc c	cccç	gtgco	et to	ctto	jacco	tgg	Jaago	ytgc	cact	ccca	act g	gtcct	ttcct	3144
aata	aaat	ga g	gaaa	attgo	ca to	cgcat	tgto	tga	igtag	gtg	tcat	tcta	att d	tggg	laaata	3204
gggt	9999	jca g	gaca	agcaa	ag gg	ggag	gatt	ggg	Jaaga	acaa	tago	aggo	at g	getge	ggatg	3264
cggt	gggo	tc t	atg	gette	t ga	iggee	gaaa	u gaa	iccaç	gctg	catt	aato	jaa t	cggc	caacg	3324

-continued

cgcgggggaga ggcggtttgc gtattggggcg ctcttccgct tcctcgctca ctgactcgct 3384 gcgctcggtc gttcggctgc ggcgagcggt atcagctcac tcaaaggcgg taatacggtt 3444 atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaaggcc agcaaaaggc 3504 caggaaccgt aaaaaggccg cgttgctggc gtttttccat aggctccgcc cccctgacga 3564 gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac tataaagata 3624 ccaggegttt ccccctggaa geteectegt gegeteteet gtteegaeee tgeegettae 3684 cggatacctg tccgcctttc tcccttcggg aagcgtggcg ctttctcata gctcacgctg 3744 taggtatete agtteggtgt aggtegtteg etceaagetg ggetgtgtge acgaaceeee 3804 cqttcaqccc qaccqctqcq ccttatccqq taactatcqt cttqaqtcca acccqqtaaq 3864 acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag cgaggtatgt 3924 aggeggtget acagagttet tgaagtggtg geetaactae ggetacaeta gaagaacagt 3984 atttggtate tgegetetge tgaageeagt taeettegga aaaagagttg gtagetettg 4044 atccggcaaa caaaccaccg ctggtagcgg tggttttttt gtttgcaagc agcagattac 4104 gegeagaaaa aaaggatete aagaagatee tttgatettt tetaeggggt etgaegetea 4164 gtggaacgaa aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac 4224 ctagatcctt ttaaattaaa aatgaagttt taaatcaatc taaagtatat atgagtaaac 4284 ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga tctgtctatt 4344 tcgttcatcc atagttgcct gactccccgt cgtgtagata actacgatac gggagggctt 4404 accatctggc cccagtgctg caatgatacc gcgagaccca cgctcaccgg ctccagattt 4464 atcagcaata aaccagccag ccggaagggc cgagcgcaga agtggtcctg caactttatc 4524 cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtagtt cgccagttaa 4584 tagtttgcgc aacgttgttg ccattgctac aggcatcgtg gtgtcacgct cgtcgtttgg 4644 4704 tatggettea tteageteeg gtteecaacg ateaaggega gttacatgat eccecatgtt gtgcaaaaaa gcggttagct ccttcggtcc tccgatcgtt gtcagaagta agttggccgc 4764 agtgttatca ctcatggtta tggcagcact gcataattct cttactgtca tgccatccgt 4824 aagatgettt tetgtgaetg gtgagtaete aaceaagtea ttetgagaat agtgtatgeg 4884 gcgaccgagt tgctcttgcc cggcgtcaat acgggataat accgcgccac atagcagaac 4944 5004 tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga aaactctcaa ggatcttacc getgttgaga tecagttega tgtaaceeae tegtgeacee aactgatett cageatettt 5064 tactttcacc agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg 5124 aataagggeg acaeggaaat gttgaataet cataetette ettttteaat attattgaag 5184 catttatcag ggttattgtc tcatgagcgg atacatattt gaatgtattt agaaaaataa 5244 5293 acaaataggg gttccgcgca catttccccg aaaagtgcca cctgacgtc

<210> SEQ ID NO 45 <211> LENGTH: 685 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct <400> SEQUENCE: 45

Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 1 5 10 15

Val	Val	Ile	Ala 20	Суз	Ala	Gly	Ala	Phe 25	His	Leu	Thr	Thr	Arg 30	Asn	Gly
Glu	Pro	His 35	Met	Ile	Val	Ser	Arg 40	Gln	Glu	Lys	Gly	Lys 45	Ser	Leu	Leu
Phe	Lys 50	Thr	Glu	Asp	Gly	Val 55	Asn	Met	Сүз	Thr	Leu 60	Met	Ala	Met	Asp
Leu 65	Gly	Glu	Leu	Суз	Glu 70	Asp	Thr	Ile	Thr	Tyr 75	Lys	Суз	Pro	Leu	Leu 80
Arg	Gln	Asn	Glu	Pro 85	Glu	Asp	Ile	Asp	Суз 90	Trp	Суз	Asn	Ser	Thr 95	Ser
Thr	Trp	Val	Thr 100	Tyr	Gly	Thr	Суз	Thr 105	Thr	Met	Gly	Glu	His 110	Arg	Arg
Glu	Гла	Arg 115	Ser	Val	Ala	Leu	Val 120	Pro	His	Val	Gly	Met 125	Gly	Leu	Glu
Thr	Arg 130	Thr	Glu	Thr	Trp	Met 135	Ser	Ser	Glu	Gly	Ala 140	Trp	Lys	His	Val
Gln 145	Arg	Ile	Glu	Thr	Trp 150	Ile	Leu	Arg	His	Pro 155	Gly	Phe	Thr	Met	Met 160
Ala	Ala	Ile	Leu	Ala 165	Tyr	Thr	Ile	Gly	Thr 170	Thr	His	Phe	Gln	Arg 175	Ala
Leu	Ile	Phe	Ile	Leu	Leu	Thr	Ala	Val 195	Thr	Pro	Ser	Met	Thr	Met	Arg
СЛа	Ile	Gly	Met	Ser	Asn	Arg	Asp	Phe	Val	Glu	Gly	Val	Ser	Gly	Gly
Ser	Trp	Val	Asp	Ile	Val	Leu	200 Glu	His	Gly	Ser	Сув	∠05 Val	Thr	Thr	Met
Ala	210 Lys	Asn	Lys	Pro	Thr	215 Leu	Asp	Phe	Glu	Leu	220 Ile	Lys	Thr	Glu	Ala
225 Lys	Gln	Pro	Ala	Thr	230 Leu	Arg	Lys	Tyr	Суз	235 Ile	Glu	Ala	Lys	Leu	240 Thr
Asn	Thr	Thr	Thr	245 Glu	Ser	Arg	Cys	Pro	250 Thr	Gln	Gly	Glu	Pro	255 Ser	Leu
Asn	Glu	Glu	260 Gln	Asp	Lvs	Ara	Phe	265 Val	Cvs	Lvs	f	Ser	270 Met	Val	Asp
220	Cl.	275	C1	Acr	-15 C1		280	Lou	Dho	-y 5	Larc	285	C1	T10	vol
т.у т	290	71°	чтү ман	DPC	лт	295 0	GT Å	Leu	1110	от Мот	300 300	ory.	GTÀ	110 V-1	vai Vai
305	- cys	AIA	met	rne	Arg 310	- Сув	гуа	гда	Asn	меt 315	GIU	- сту	гуа	vai	va1 320
Gln	Pro	Glu	Asn	Leu 325	Glu	Tyr	Thr	Ile	Val 330	Ile	Thr	Pro	His	Ser 335	Gly
Glu	Glu	His	Ala 340	Val	Gly	Asn	Asp	Thr 345	Gly	Lys	His	Gly	Lys 350	Glu	Ile
ГЛа	Ile	Thr 355	Pro	Gln	Ser	Ser	Ile 360	Thr	Glu	Ala	Glu	Leu 365	Thr	Gly	Tyr
Gly	Thr 370	Val	Thr	Met	Glu	Cys 375	Ser	Pro	Arg	Thr	Gly 380	Leu	Asp	Phe	Asn
Glu 385	Met	Val	Leu	Leu	Gln 390	Met	Glu	Asn	Lys	Ala 395	Trp	Leu	Val	His	Arg 400
Gln	Trp	Phe	Leu	Asp 405	Leu	Pro	Leu	Pro	Trp 410	Leu	Pro	Gly	Ala	Asp 415	Thr
Gln	Gly	Ser	Asn 420	Trp	Ile	Gln	Lys	Glu 425	Thr	Leu	Val	Thr	Phe 430	Lys	Asn
Pro	His	Ala 435	Lys	Lys	Gln	Asp	Val 440	Val	Val	Leu	Gly	Ser 445	Gln	Glu	Gly

_

Ala	Met 450	His	Thr	Ala	Leu	Thr 455	Gly	Ala	Thr	Glu	Ile 460	Gln	Met	Ser	Ser		
Gly 465	Asn	Leu	Leu	Phe	Thr 470	Gly	His	Leu	Lys	Cys 475	Arg	Leu	Arg	Met	Asp 480		
Lys	Leu	Gln	Leu	Lys 485	Gly	Met	Ser	Tyr	Ser 490	Met	Суз	Thr	Gly	Lys 495	Phe		
Lys	Val	Val	Lys 500	Glu	Ile	Ala	Glu	Thr 505	Gln	His	Gly	Thr	Ile 510	Val	Ile		
Arg	Val	Gln 515	Tyr	Glu	Gly	Asp	Gly 520	Ser	Pro	Суз	Lys	Ile 525	Pro	Phe	Glu		
Ile	Met 530	Asp	Leu	Glu	Lys	Arg 535	His	Val	Leu	Gly	Arg 540	Leu	Ile	Thr	Val		
Asn 545	Pro	Ile	Val	Thr	Glu 550	Lys	Aab	Ser	Pro	Val 555	Asn	Ile	Glu	Ala	Glu 560		
Pro	Pro	Phe	Gly	Asp 565	Ser	His	Ile	Ile	Ile 570	Gly	Val	Glu	Pro	Gly 575	Gln		
Leu	Lys	Leu	Asn 580	Trp	Phe	Lys	Lys	Gly 585	Ser	Ser	Ile	Gly	Gln 590	Met	Phe		
Glu	Thr	Thr 595	Met	Arg	Gly	Ala	Lys 600	Arg	Met	Ala	Ile	Leu 605	Gly	Asp	Thr		
Ala	Trp 610	Asp	Phe	Gly	Ser	Leu 615	Gly	Gly	Val	Phe	Thr 620	Ser	Ile	Gly	Lys		
Ala 625	Leu	His	Gln	Val	Phe 630	Gly	Gly	Ala	Phe	Arg 635	Thr	Leu	Phe	Gly	Gly 640		
Met	Ser	Trp	Ile	Thr 645	Gln	Gly	Leu	Met	Gly 650	Ala	Leu	Leu	Leu	Trp 655	Met		
Gly	Val	Asn	Ala 660	Arg	Asp	Arg	Ser	Ile 665	Ala	Leu	Ala	Phe	Leu 670	Ala	Thr		
Gly	Gly	Val 675	Leu	Val	Phe	Leu	Ala 680	Thr	Asn	Val	His	Ala 685					
<210 <211 <211 <221 <221 <221 <221 <221	D> SI 2> TY 3> OF 3> OF 3> OT 3> OT 2> FF 2> LC 2> LC 0> SF	EQ II ENGTH (PE : RGAN) EATUH THER /nthe EATUH AME /I OCAT	D NO H: 52 DNA ISM: RE: INFC ≥tic RE: RE: CEY: ION:	46 293 Art: DRMA CDS (910 46	ific: FION struc	ial : : De: :t (2964	Seque scriț 1)	ence	n of	art:	Lfic:	ial :	seque	ence	; note	=	
gac	ggato	add d	gagat	cete	cc ga	atcco	cctat	c ggt	ccgad	tct	cagt	cacaa	atc 1	get	ctgatg		60
ccg	cataç	gtt a	aagco	cagta	at ci	gct	ccct	g ctt	gtgt	gtt	gga	ggtc	gct (gagta	agtgcg		120
cga	gcaaa	aat t	taa	gcta	ca ad	caago	gcaaç	g get	tgad	ccga	caat	tgea	atg a	aagaa	atctgc		180
ttag	gggtt	ag g	gcgti	ttg	cg ct	gcti	cgcg	g ato	gtaco	gggc	caga	atata	acg (cgtt	gacatt		240
gati	atto	gac t	agti	tatta	aa ta	agtaa	atcaa	a tta	acggó	ggtc	atta	agtto	cat a	ageed	catata		300
tgga	agtto	ccg d	gtta	acata	aa ct	tace	ggtaa	a atç	ggcco	egee	tgg	ctga	ccg (cccaa	acgacc		360
ccc	geeea	att ç	gacgi	ccaat	ca at	gaco	gtato	g tto	eccat	agt	aaco	gecaa	ata 🤉	gggao	etttee		420
atte	gacgt	ca a	atgg	gtgga	ac ta	attta	acggt	c aaa	actgo	ccca	ctt	ggca	gta 🤇	catca	aagtgt		480
atca	atatç	gee a	aagta	acgco	cc co	ctati	gaco	g tca	aatga	acgg	taaa	atggo	ccc (gcct	ggcatt		540
atq	cccad	qta d	atga	accti	ta to	ggad	cttt	c cta	actto	qca	qta	catci	tac d	gtati	tagtca		600

163

continued

										-	con	tın	ued				
tcgcta	ttac (catg	gtga	tg co	ggtti	tggo	c agt	cacat	tcaa	tgg	gegt	gga 1	cage	ggtttg	660		
actcac	aaaa 4	attt	ccaa	gt ct	ccca	cccca	a ttç	gacgt	tcaa	tgg	gagti	tg 1	ttt	ggcacc	720		
aaaatca	aacg 🤉	ggaci	ttc	ca aa	aatgi	cgta	a aca	aacto	ccgc	ccca	attga	acg (caaat	gggcg	780		
gtaggc	gtgt a	acggi	ggg	ag gt	cctat	tataa	a gca	agago	ctct	ctg	gcta	act a	agaga	aaccca	840		
ctgctta	actg 🤉	gctta	atcga	aa at	taat	cacga	a cto	cacta	atag	gga	gacco	caa 🤉	gctt	ggtacc	900		
geegee	gcc at Me 1	tg ge et Gi	gc aa ly Ly	ag ag ys Ai	gg to rg Se 5	ec go er Al	cc go La Gi	gc to Ly Se	ca at er I:	tc at le Me 19	tg tg et T: D	gg ct rp Le	eu Al	cg agc La Ser	951		
ttg gca Leu Ala 15	a gtt a Val	gtc Val	ata Ile	gct Ala 20	tgt Cys	gca Ala	ggc Gly	gcc Ala	ttc Phe 25	cat His	tta Leu	acc Thr	aca Thr	cgt Arg 30	999		
aac gga Asn Gly	a gaa y Glu	cca Pro	cac His 35	atg Met	atc Ile	gtc Val	agc Ser	aga Arg 40	caa Gln	gag Glu	aaa Lys	д17 дад	aaa Lys 45	agt Ser	1047		
ctt cto Leu Lei	g ttt u Phe	aaa Lys 50	aca Thr	gag Glu	gat Asp	ggc Gly	gtg Val 55	aac Asn	atg Met	tgt Cys	acc Thr	ctc Leu 60	atg Met	gcc Ala	1095		
atg gao Met Asj	c ctt p Leu 65	ggt Gly	gaa Glu	ttg Leu	tgt Cys	gaa Glu 70	gac Asp	aca Thr	atc Ile	acg Thr	tac Tyr 75	aag Lys	tgt Cys	ccc Pro	1143		
ctt cto Leu Leu 80	c agg u Arg	cag Gln	aat Asn	gag Glu	cca Pro 85	gaa Glu	gac Asp	ata Ile	gac Asp	tgt Cys 90	tgg Trp	tgc Cys	aac Asn	tct Ser	1191		
acg tco Thr Se: 95	c acg r Thr	tgg Trp	gta Val	act Thr 100	tat Tyr	glÀ aaa	acg Thr	tgt Cys	acc Thr 105	acc Thr	atg Met	gga Gly	gaa Glu	cat His 110	1239		
aga aga Arg Arg	a gaa g Glu	aaa Lys	aga Arg 115	tca Ser	gtg Val	gca Ala	ctc Leu	gtt Val 120	cca Pro	cat His	gtg Val	gga Gly	atg Met 125	gga Gly	1287		
ctg gag Leu Glu	g aca u Thr	cga Arg 130	act Thr	gaa Glu	aca Thr	tgg Trp	atg Met 135	tca Ser	tca Ser	gaa Glu	ддд ддд	gcc Ala 140	tgg Trp	aaa Lys	1335		
cat gto His Val	c cag l Gln 145	aga Arg	att Ile	gaa Glu	act Thr	tgg Trp 150	atc Ile	ttg Leu	aga Arg	cat His	cca Pro 155	ggc Gly	ttc Phe	acc Thr	1383		
atg atg Met Mei 160	g gca t Ala 0	gca Ala	atc Ile	ctg Leu	gca Ala 165	tac Tyr	acc Thr	ata Ile	gga Gly	acg Thr 170	aca Thr	cat His	ttc Phe	caa Gln	1431		
aga gco Arg Ala 175	c ctg a Leu	att Ile	ttc Phe	atc Ile 180	tta Leu	ctg Leu	aca Thr	gct Ala	gtc Val 185	act Thr	cct Pro	tca Ser	atg Met	aca Thr 190	1479		
atg cg Met Arg	t tgc g Cys	ata Ile	gga Gly 195	atg Met	tca Ser	aat Asn	aga Arg	gac Asp 200	ttt Phe	gtg Val	gaa Glu	ggg Gly	gtt Val 205	tca Ser	1527		
gga gga Gly Gly	a agc y Ser	tgg Trp 210	gtt Val	gac Asp	ata Ile	gtc Val	tta Leu 215	gaa Glu	cat His	999 91y	agc Ser	tgt Cys 220	gtg Val	acg Thr	1575		
acg ato Thr Me	g gca t Ala 225	aaa Lys	aac Asn	aaa Lys	cca Pro	aca Thr 230	ttg Leu	gat Asp	ttt Phe	gaa Glu	ctg Leu 235	ata Ile	aaa Lys	aca Thr	1623		
gaa gco Glu Ala 240	c aaa a Lys 0	cag Gln	cct Pro	gcc Ala	acc Thr 245	cta Leu	agg Arg	aag Lys	tac Tyr	tgt Cys 250	ata Ile	gag Glu	gca Ala	aag Lys	1671		
cta aco Leu Th: 255	c aac r Asn	aca Thr	aca Thr	aca Thr 260	gaa Glu	tct Ser	cgc Arg	tgc Cys	cca Pro 265	aca Thr	caa Gln	999 Gly	gaa Glu	ccc Pro 270	1719		

age eta aat gaa gag eag gae aaa agg tte gte tge aaa eae tee atg 1767 Ser Leu Asn Glu Glu Gln Asp Lys Arg Phe Val Cys Lys His Ser Met

165

	275	280	285
gta gac aga gga Val Asp Arg Gly 290	tgg gga aat gga tgt Trp Gly Asn Gly Cys 295	gga cta ttt gga aag Gly Leu Phe Gly Lys 300	gga ggc 1815 Gly Gly
att gtg acc tgt Ile Val Thr Cys 305	gct atg ttc aga tgc Ala Met Phe Arg Cys 310	aaa aag aac atg gaa Lys Lys Asn Met Glu 315	gga aaa 1863 Gly Lys
gtt gtg caa cca Val Val Gln Prc 320	gaa aac ttg gaa tac Glu Asn Leu Glu Tyr 325	acc att gtg ata aca Thr Ile Val Ile Thr 330	cct cac 1911 Pro His
tca ggg gaa gag Ser Gly Glu Glu 335	cat gca gtc gga aat His Ala Val Gly Asn 340	gac aca gga aaa cat Asp Thr Gly Lys His 345	ggc aag 1959 Gly Lys 350
gaa atc aaa ata Glu Ile Lys Ile	aca cca cag agt tcc Thr Pro Gln Ser Ser 355	atc aca gaa gca gaa Ile Thr Glu Ala Glu 360	ttg aca 2007 Leu Thr 365
ggt tat ggc act Gly Tyr Gly Thr 370	gtc aca atg gag tgc Val Thr Met Glu Cys 375	tct cca aga acg ggc Ser Pro Arg Thr Gly 380	ctc gac 2055 Leu Asp
ttc aat gag atg Phe Asn Glu Met 385	gtg ttg ttg cag atg Val Leu Leu Gln Met 390	gaa aat aaa gct tgg Glu Asn Lys Ala Trp 395	ctg gtg 2103 Leu Val
cac agg caa tgg His Arg Gln Trp 400	ttc cta gac ctg ccg Phe Leu Asp Leu Pro 405	tta cca tgg ttg ccc Leu Pro Trp Leu Pro 410	gga gcg 2151 Gly Ala
gac aca caa ggg Asp Thr Gln Gly 415	tca aat tgg ata cag Ser Asn Trp Ile Gln 420	aaa gag aca ttg gtc Lys Glu Thr Leu Val 425	act ttc 2199 Thr Phe 430
aaa aat ccc cat Lys Asn Pro His	gcg aag aaa cag gat Ala Lys Lys Gln Asp 435	gtt gtt gtt tta gga Val Val Val Leu Gly 440	tcc caa 2247 Ser Gln 445
gaa ggg gcc atg Glu Gly Ala Met 450	cac aca gca ctt aca His Thr Ala Leu Thr 455	ggg gcc aca gaa atc Gly Ala Thr Glu Ile 460	caa atg 2295 Gln Met
tca tca gga aac Ser Ser Gly Asn 465	tta ctc ttc aca gga Leu Leu Phe Thr Gly 470	cat ctc aag tgc agg His Leu Lys Cys Arg 475	ctg aga 2343 Leu Arg
atg gac aag cta Met Asp Lys Leu 480	. cag ctc aaa gga atg . Gln Leu Lys Gly Met 485	tca tac tct atg tgc Ser Tyr Ser Met Cys 490	aca gga 2391 Thr Gly
aag ttt aaa gtt Lys Phe Lys Val 495	gtg aag gaa ata gca Val Lys Glu Ile Ala 500	gaa aca caa cat gga Glu Thr Gln His Gly 505	aca ata 2439 Thr Ile 510
gtt atc aga gtg Val Ile Arg Val	caa tat gaa ggg gac Gln Tyr Glu Gly Asp 515	ggc tct cca tgc aag Gly Ser Pro Cys Lys 520	atc cct 2487 Ile Pro 525
ttt gag ata atg Phe Glu Ile Met 530	gat ttg gaa aaa aga Asp Leu Glu Lys Arg 535	cat gtc tta ggt cgc His Val Leu Gly Arg 540	ctg att 2535 Leu Ile
aca gtc aac cca Thr Val Asn Prc 545	att gtg aca gaa aaa Ile Val Thr Glu Lys 550	gat agc cca gtc aac Asp Ser Pro Val Asn 555	ata gaa 2583 Ile Glu
gca gaa cct cca Ala Glu Pro Pro 560	ttc gga gac agc tac Phe Gly Asp Ser Tyr 565	atc atc ata gga gta Ile Ile Ile Gly Val 570	gag ccg 2631 Glu Pro
gga caa ctg aag Gly Gln Leu Lys 575	ctc aac tgg ttt aag Leu Asn Trp Phe Lys 580	aaa gga agc acg ctg Lys Gly Ser Thr Leu 585	ggc aag 2679 Gly Lys 590
gcc ttt tca aca Ala Phe Ser Thr	act ttg aag gga gct Thr Leu Lys Gly Ala	caa aga ctg gca gcg Gln Arg Leu Ala Ala	ttg ggc 2727 Leu Gly

167

-concinued	
595 600 605	
gac aca gcc tgg gac ttt ggc tct att gga ggg gtc ttc aac tcc ata Asp Thr Ala Trp Asp Phe Gly Ser Ile Gly Gly Val Phe Asn Ser Ile 610 615 620	2775
gga aaa gcc gtt cac caa gtg ttt ggt ggt gcc ttc aga aca ctc ttt Gly Lys Ala Val His Gln Val Phe Gly Gly Ala Phe Arg Thr Leu Phe 625 630 635	2823
ggg gga atg tct tgg atc aca caa ggg cta atg ggt gcc cta ctg ctc Gly Gly Met Ser Trp Ile Thr Gln Gly Leu Met Gly Ala Leu Leu Leu 640 645 650	2871
tgg atg ggc gtc aac gca cga gac cga tca att gct ttg gcc ttc tta Trp Met Gly Val Asn Ala Arg Asp Arg Ser Ile Ala Leu Ala Phe Leu 655 660 665 670	2919
gcc aca ggg ggt gtg ctc gtg ttc tta gcg acc aat gtg cat gct Ala Thr Gly Gly Val Leu Val Phe Leu Ala Thr Asn Val His Ala 675 680 685	2964
taattagttt gagcggccgc tcgagcatgc atctagaggg ccctattcta tagtgtcacc	3024
taaatgctag agetegetga teageetega etgtgeette tagttgeeag eeatetgttg	3084
tttgcccctc ccccgtgcct tccttgaccc tggaaggtgc cactcccact gtcctttcct	3144
aataaaatga ggaaattgca tcgcattgtc tgagtaggtg tcattctatt ctggggggtg	3204
gggtggggca ggacagcaag ggggaggatt gggaagacaa tagcaggcat gctggggatg	3264
cggtgggctc tatggcttct gaggcggaaa gaaccagctg cattaatgaa tcggccaacg	3324
cgcggggaga ggcggtttgc gtattgggcg ctcttccgct tcctcgctca ctgactcgct	3384
gcgctcggtc gttcggctgc ggcgagcggt atcagctcac tcaaaggcgg taatacggtt	3444
atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaaggcc agcaaaaggc	3504
caggaaccgt aaaaaggccg cgttgctggc gtttttccat aggctccgcc cccctgacga	3564
gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac tataaagata	3624
ccaggegttt ccccctggaa getecetegt gegeteteet gtteegaeee tgeegettae	3684
cggatacetg teegeettte teeetteggg aagegtggeg ettteteaat geteaegetg	3744
taggtatete agtteggtgt aggtegtteg etceaagetg ggetgtgtge acgaaceeee	3804
cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca acccggtaag	3864
acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag cgaggtatgt	3924
aggeggtget acagagttet tgaagtggtg geetaactae ggetaeata gaaggaeagt	3984
atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg gtagctcttg	4044
atccggcaaa caaaccaccg ctggtagcgg tggtttttt gtttgcaagc agcagattac	4104
gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggt ctgacgctca	4164
gtggaacgaa aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac	4224
ctagatcctt ttaaattaaa aatgaagttt taaatcaatc taaagtatat atgagtaaac	4284
ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga tctgtctatt	4344
togttcatec atagttgeet gaeteeegt egtgtagata aetaegatae gggagggett	4404
accatctggc cccagtgctg caatgatacc gcgagaccca cgctcaccgg ctccagattt	4464
atcagcaata aaccagccag ccggaagggc cgagcgcaga agtggtcctg caactttatc	4524
cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtagtt cgccagttaa	4584
tagtttgcgc aacgttgttg ccattgctac aggcatcgtg gtgtcacgct cgtcgtttgg	4644
tatggettea tteageteeg gtteecaaeg ateaaggega gttaeatgat eeecatgtt	4704

168

1	69
---	----

ntinued

-continu	led
gtgcaaaaaa gcggttagct ccttcggtcc tccgatcgtt gtcagaagta a	gttggeege 4764
agtgttatca ctcatggtta tggcagcact gcataattct cttactgtca t	gccatccgt 4824
aagatgettt tetgtgaetg gtgagtaete aaceaagtea ttetgagaat a	gtgtatgcg 4884
gcgaccgagt tgctcttgcc cggcgtcaat acgggataat accgcgccac a	tagcagaac 4944
tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga aaactctcaa g	gatcttacc 5004
getgttgaga tecagttega tgtaaceeae tegtgeacee aaetgatett e	agcatcttt 5064
tactttcacc agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg c	aaaaaaggg 5124
aataagggcg acacggaaat gttgaatact catactette ettttteaat a	ttattgaag 5184
catttatcag ggttattgtc tcatgagcgg atacatattt gaatgtattt a	gaaaaataa 5244
acaaataggg gtteegegea cattteeeeg aaaagtgeea eetgaegte	5293
<210> SEQ ID NO 47 <211> LENGTH: 685 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic Construct	
<400> SEQUENCE: 47	
Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser 1 5 10	Leu Ala 15
Val Val Ile Ala Cys Ala Gly Ala Phe His Leu Thr Thr Arg 20 25 30	Asn Gly
Glu Pro His Met Ile Val Ser Arg Gln Glu Lys Gly Lys Ser 35 40 45	Leu Leu
Phe Lys Thr Glu Asp Gly Val Asn Met Cys Thr Leu Met Ala 50 55 60	Met Asp
Leu Gly Glu Leu Cys Glu Asp Thr Ile Thr Tyr Lys Cys Pro 65 70 75	Leu Leu 80
Arg Gln Asn Glu Pro Glu Asp Ile Asp Cys Trp Cys Asn Ser 85 90	Thr Ser 95
Thr Trp Val Thr Tyr Gly Thr Cys Thr Thr Met Gly Glu His 100 105 110	Arg Arg
Glu Lys Arg Ser Val Ala Leu Val Pro His Val Gly Met Gly 115 120 125	Leu Glu
Thr Arg Thr Glu Thr Trp Met Ser Ser Glu Gly Ala Trp Lys 130 135 140	His Val
Gln Arg Ile Glu Thr Trp Ile Leu Arg His Pro Gly Phe Thr 145 150 155	Met Met 160
Ala Ala Ile Leu Ala Tyr Thr Ile Gly Thr Thr His Phe Gln . 165 170	Arg Ala 175
Leu Ile Phe Ile Leu Leu Thr Ala Val Thr Pro Ser Met Thr 180 185 190	Met Arg
Cys Ile Gly Met Ser Asn Arg Asp Phe Val Glu Gly Val Ser 195 200 205	Gly Gly
Ser Trp Val Asp Ile Val Leu Glu His Gly Ser Cys Val Thr 210 215 220	Thr Met
Ala Lys Asn Lys Pro Thr Leu Asp Phe Glu Leu Ile Lys Thr 225 230 235	Glu Ala 240
Lys Gln Pro Ala Thr Leu Arg Lys Tyr Cys Ile Glu Ala Lys 245 250	Leu Thr 255

Asn Thr Thr Glu Ser Arg Cys Pro Thr Gln Gly Glu Pro Ser Leu 260 265 270

Asn	Glu	Glu 275	Gln	Asp	Lys	Arg	Phe 280	Val	Cys	Lys	His	Ser 285	Met	Val	Asp
Arg	Gly 290	Trp	Gly	Asn	Gly	Cys 295	Gly	Leu	Phe	Gly	Lys 300	Gly	Gly	Ile	Val
Thr 305	Cys	Ala	Met	Phe	Arg 310	Сүз	Lys	Lys	Asn	Met 315	Glu	Gly	Lys	Val	Val 320
Gln	Pro	Glu	Asn	Leu 325	Glu	Tyr	Thr	Ile	Val 330	Ile	Thr	Pro	His	Ser 335	Gly
Glu	Glu	His	Ala 340	Val	Gly	Asn	Asp	Thr 345	Gly	Lys	His	Gly	Lys 350	Glu	Ile
Lys	Ile	Thr 355	Pro	Gln	Ser	Ser	Ile 360	Thr	Glu	Ala	Glu	Leu 365	Thr	Gly	Tyr
Gly	Thr 370	Val	Thr	Met	Glu	Cys 375	Ser	Pro	Arg	Thr	Gly 380	Leu	Asp	Phe	Asn
Glu 385	Met	Val	Leu	Leu	Gln 390	Met	Glu	Asn	Lys	Ala 395	Trp	Leu	Val	His	Arg 400
Gln	Trp	Phe	Leu	Asp 405	Leu	Pro	Leu	Pro	Trp 410	Leu	Pro	Gly	Ala	Asp 415	Thr
Gln	Gly	Ser	Asn 420	Trp	Ile	Gln	Lys	Glu 425	Thr	Leu	Val	Thr	Phe 430	Lys	Asn
Pro	His	Ala 435	Lys	Lys	Gln	Asp	Val 440	Val	Val	Leu	Gly	Ser 445	Gln	Glu	Gly
Ala	Met 450	His	Thr	Ala	Leu	Thr 455	Gly	Ala	Thr	Glu	Ile 460	Gln	Met	Ser	Ser
Gly 465	Asn	Leu	Leu	Phe	Thr 470	Gly	His	Leu	Lys	Cys 475	Arg	Leu	Arg	Met	Asp 480
Lys	Leu	Gln	Leu	Lys 485	Gly	Met	Ser	Tyr	Ser 490	Met	Сүз	Thr	Gly	Lys 495	Phe
Lys	Val	Val	Lys 500	Glu	Ile	Ala	Glu	Thr 505	Gln	His	Gly	Thr	Ile 510	Val	Ile
Arg	Val	Gln 515	Tyr	Glu	Gly	Asp	Gly 520	Ser	Pro	Суз	Гла	Ile 525	Pro	Phe	Glu
Ile	Met 530	Asp	Leu	Glu	Lys	Arg 535	His	Val	Leu	Gly	Arg 540	Leu	Ile	Thr	Val
Asn 545	Pro	Ile	Val	Thr	Glu 550	Lys	Asp	Ser	Pro	Val 555	Asn	Ile	Glu	Ala	Glu 560
Pro	Pro	Phe	Gly	Asp 565	Ser	Tyr	Ile	Ile	Ile 570	Gly	Val	Glu	Pro	Gly 575	Gln
Leu	Lys	Leu	Asn 580	Trp	Phe	Lys	Lys	Gly 585	Ser	Thr	Leu	Gly	Lys 590	Ala	Phe
Ser	Thr	Thr 595	Leu	Lys	Gly	Ala	Gln 600	Arg	Leu	Ala	Ala	Leu 605	Gly	Asp	Thr
Ala	Trp 610	Aab	Phe	Gly	Ser	Ile 615	Gly	Gly	Val	Phe	Asn 620	Ser	Ile	Gly	ГЛа
Ala 625	Val	His	Gln	Val	Phe 630	Gly	Gly	Ala	Phe	Arg 635	Thr	Leu	Phe	Gly	Gly 640
Met	Ser	Trp	Ile	Thr 645	Gln	Gly	Leu	Met	Gly 650	Ala	Leu	Leu	Leu	Trp 655	Met
Gly	Val	Asn	Ala 660	Arg	Asp	Arg	Ser	Ile 665	Ala	Leu	Ala	Phe	Leu 670	Ala	Thr
Gly	Gly	Val 675	Leu	Val	Phe	Leu	Ala 680	Thr	Asn	Val	His	Ala 685			

<210> SEQ ID NO 48 <211> LENGTH: 34 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 48 tgtgcaggcg cettecattt aaccacacgt aacg 34 <210> SEQ ID NO 49 <211> LENGTH: 40 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEOUENCE: 49 tcgagcggcc gctcaactaa ttaggcctgc accatgactc 40 <210> SEQ ID NO 50 <211> LENGTH: 30 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 50 cttatcgaaa ttaatacgac tcactatagg 30 <210> SEQ ID NO 51 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 51 25 atagattgct ccaaacactt ggtgg <210> SEQ ID NO 52 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 52 24 actccatagg aaaagccgtt cacc <210> SEQ ID NO 53 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEOUENCE: 53 gcgageteta gcatttaggt gacactatag 30 <210> SEQ ID NO 54

<211> LENGTH: 33

-continued <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 54 ctccaccaag tgtttggtgg tgccttcaga aca 33 <210> SEQ ID NO 55 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 55 Leu His Gln Val Phe Gly Gly Ala Phe Arg Thr 1 5 10 <210> SEQ ID NO 56 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 56 cttatcgaaa ttaatacgac tcactatagg 30 <210> SEQ ID NO 57 <211> LENGTH: 39 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 57 gaattegtet caetteettt ettaaaceag ttgagette 39 <210> SEQ ID NO 58 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 58 ggaattcgtc tcggaagcac gctgggcaag g 31 <210> SEQ ID NO 59 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct <400> SEQUENCE: 59 gcgagctcta gcatttaggt gacactatag 3.0 <210> SEQ ID NO 60 <211> LENGTH: 33

<211> LENGTH: 33 <212> TYPE: DNA

-continued
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct
<400> SEQUENCE: 60
aactggttta agaaaggaag cacgctgggc gcc 33
<210> SEQ ID NO 61 <211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence; note = synthetic construct
<400> SEQUENCE: 61
Asn Trp Lys Lys Gly Ser Thr Leu Gly Lys Ala 1 5 10
<210> SEQ ID NO 62 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide
<400> SEQUENCE: 62
Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 1 5 10 15
Val Val Ile Ala Cys Ala Gly Ala Met Lys Leu Ser Asn Phe Gln Gly 20 25 30
ГЛа
<210> SEQ ID NO 63 <211> LENGTH: 39 <212> TYPE: PRT <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide
<400> SEQUENCE: 63
Met Gly Arg Lys Gln Asn Lys Arg Gly Gly Asn Glu Gly Ser Ile Met 1 5 10 15
Trp Leu Ala Ser Leu Ala Val Val Ile Ala Gly Thr Ser Ala Met Lys 20 25 30
Leu Ser Asn Phe Gln Gly Lys 35
<210> SEQ ID NO 64 <211> LENGTH: 33 <212> TYPE: PRT <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide
<400> SEQUENCE: 64
Met Gly Lys Arg Ser Ala Gly Ser Ile Met Trp Leu Ala Ser Leu Ala 1 5 10 15
Val Val Ile Ala Gly Trp Ser Ala Met Lys Leu Ser Asn Phe Gln Gly 20 25 30
Lys

45

The invention claimed is:

1. An immunogenic polypeptide expressed from a nucleic acid comprising a transcriptional unit encoding a Japanese encephalitis virus (JEV) prM signal sequence fused to the N-terminus of an immunogenic flavivirus antigen, wherein the antigen comprises flavivirus M and E proteins, and the antigen is of a second flavivirus or the antigen is a chimeric antigen comprising an amino acid sequence from JEV and a second flavivirus, and wherein the transcriptional unit directs the synthesis of the antigen.

2. The immunogenic polypeptide of claim 1, wherein the immunogenic flavivirus antigen is of a second flavivirus selected from the group consisting of yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, St. Louis encepha- 15 litis virus, Powassan virus and West Nile virus.

3. The immunogenic polypeptide of claim **1**, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus and an M protein and an E protein of West Nile virus.

4. The immunogenic polypeptide of claim **1**, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus and an M protein and an E protein of yellow fever virus.

5. The immunogenic polypeptide of claim **1**, wherein the 25 transcriptional unit encodes prM a signal sequence of Japanese encephalitis virus and an M protein and an E protein of St. Louis encephalitis virus.

6. The immunogenic polypeptide of claim 1, wherein the transcriptional unit encodes a prM signal sequence of Japa- 30 nese encephalitis virus and an M protein and an E protein of Powassan virus.

7. The immunogenic polypeptide of claim 1, comprising a polypeptide sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 22 and SEQ 35 ID NO: 24.

8. The immunogenic polypeptide of claim **1**, wherein the transcriptional unit comprises a control sequence disposed appropriately such that it operably controls the synthesis of the antigen.

9. The immunogenic polypeptide of claim 8, wherein the control sequence is the cytomegalovirus immediate early promoter.

10. An isolated cell expressing the immunogenic polypeptide of claim **1**.

11. A composition comprising the immunogenic polypeptide of claim 1 and a pharmaceutically acceptable carrier.

12. A method of eliciting an immune response in a subject against infection by a flavivirus, comprising administering to the subject an effective amount of the composition of claim 50 **11**.

13. The method of claim 12, wherein the second flavivirus is selected from the group consisting of yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, St. Louis encepha-55 litis virus, Powassan virus and West Nile virus.

14. The method of claim 12, wherein the flavivirus antigen is both the M protein and the E protein, and wherein a cell within the body of the subject, after incorporating the nucleic acid within it, secretes subviral particles comprising the M $_{60}$ protein and the E protein.

15. The method of claim **12**, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus, and an M protein and an E protein of West Nile virus.

16. The method of claim 12, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus, and an M protein and an E protein of vellow fever virus.

17. The method of claim 12, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus, and an M protein and an E protein of St. Louis encephalitis virus.

18. The method of claim **12**, wherein the transcriptional unit encodes a prM signal sequence of Japanese encephalitis virus, and an M protein and an E protein of Powassan virus.

19. The method of claim **12**, comprising administering the composition to the subject in a single dose.

20. The method of claim **12**, wherein the composition is administered via a parenteral route.

21. A method of detecting a flavivirus antibody in a sample, 20 comprising:

- contacting the sample with the immunogenic polypeptide of claim 1 under conditions whereby an antigen/antibody complex can form; and
- detecting antigen/antibody complex formation, thereby detecting a flavivirus antibody in the sample.

22. The immunogenic polypeptide of claim **1**, wherein the prM signal sequence comprises the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 27.

23. The immunogenic polypeptide of claim 1, wherein the immunogenic flavivirus antigen is a chimeric antigen comprising amino acid sequence from JEV and a second flavivirus, wherein the second flavivirus is selected from yellow fever virus, dengue serotype 1 virus, dengue serotype 2 virus, dengue serotype 3 virus, dengue serotype 4 virus, St. Louis encephalitis virus, Powassan virus and West Nile virus.

24. The immunogenic polypeptide of claim 23, wherein the immunogenic flavivirus antigen comprises a chimeric E protein.

25. The immunogenic polypeptide of claim **23**, wherein the immunogenic flavivirus antigen comprises an M protein from the second flavivirus and a chimeric E protein comprising amino acid sequence from Japanese encephalitis virus and the second flavivirus.

26. The immunogenic polypeptide of claim 25, wherein the chimeric E protein comprises a carboxy terminal portion from Japanese encephalitis virus, wherein the carboxy terminal portion is 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50% or 75% of the chimeric E protein.

27. The immunogenic polypeptide of claim 26, wherein the carboxy terminal portion is at least 10% of the chimeric E protein.

28. The immunogenic polypeptide of claim **27**, wherein the carboxy terminal portion is at least 20% of the chimeric E protein.

29. The immunogenic polypeptide of claim **25**, wherein the second flavivirus is a dengue virus.

30. The immunogenic polypeptide of claim **25**, wherein the second flavivirus is a St. Louis encephalitis virus.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

: 8,221,768 B2
: 12/580080
: July 17, 2012
: Gwong-Jen J. Chang

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Section (56) Other Publications:

- Title Page 2, column 2, under Heinz et al., "von Regenrnortel" should read --von Regenmortel-Title Page 2, column 2, under Kitchener et al., "in health Australian" should read
 --in healthy Australian-Title Page 2, column 2, under Konishi et al., "vaccines: use a" should read --vaccines: use as-Title Page 3, column 1, under Laemmli, "Head of Bateriophage T4" should read
 --Head of Bacteriophage T4-Title Page 3, column 1, under Lai et al., "Cold Springs Harbor" should read
 --Cold Spring Harbor--
- Title Page 3, column 2, under Schimaljohn et al., "Schimaljohn et al." should read --Schmaljohn--
- Title Page 3, column 2, under Seeger et al., "5849-4852" should read --5849-5852--
- Title Page 3, column 2, under Sela, "edited by Amon)" should read --edited by Arnon)--

In the Specification:

Column 9, line 39, "JE RAF" should read --JE HIAF--

Column 9, line 56, "pCB8D2-2H-2-9-1" should read --pCB8D2-2J-2-9-1--

Column 11, line 16, "formed by from" should read --formed by--

Column 14, line 34, "cleaved to but" should read --cleaved to--

Column 15, lines 11-12, "Preparation of the Tu of the Invention is Readily Accomplished by Methods Well known" should read --Preparation of the TU of the invention is readily accomplished by methods well known--

> Signed and Sealed this Twenty-first Day of May, 2013

lea Stand the

Teresa Stanek Rea Acting Director of the United States Patent and Trademark Office

Page 1 of 2

CERTIFICATE OF CORRECTION (continued) U.S. Pat. No. 8,221,768 B2

- Column 16, line 51, "to an subject" should read --to a subject--
- Column 16, line 59, "see Amon" should read --see Arnon--
- Column 17, line 58, "according the clinical" should read --according to clinical--
- Column 19, line 34, "pharmaceutical acceptable" should read --pharmaceutically acceptable--
- Column 19, line 47, "is a an improved" should read --is an improved--
- Column 24, line 11, "pcDNA3" should read --pCDNA3--
- Column 24, line 25, "pcDNA3" should read --pCDNA3--
- Column 24, line 36, "pCDA3" should read --pCDNA3--
- Column 24, line 42, "pcDNA3" should read --pCDNA3--
- Column 26, line 8, "JE-SA" should read --JE-5A--
- Column 26, line 9, "200 µg/nL" should read --200 µg/mL--
- Column 26, line 11, "by WFA using" should read --by IFA using--
- Column 27, line 7, "JM10" should read --JM01--
- Column 28, line 4, "pcDNA3" should read --pCDNA3--
- Column 28, line 26, "pcDNA3" should read --pCDNA3--
- Column 29, line 15, "pcDNA3" should read--pCDNA3--
- Column 29, line 33, "pcDNA-3" should read --pCDNA3--
- Column 29, line 67, "an strain" should read --a strain--
- Column 30, line 20, "DNA was" should read --DNA and was--
- Column 30, line 29, "and Kas I enzymes" should read -- and KasI enzymes--
- Column 30, line 30, "was inserted in to" should read --was inserted into--
- Column 31, line 56, "1999 outbreak In" should read -- 1999 outbreak. In--
- Column 48, line 23, "(SEQ ID NO: 46), in which" should read --(SEQ ID NO: 46) were generated, in which--
- Column 50, line 9, "vaccine has been used" should read --vaccine have been used--
- Column 52, line 64, "No Survivors/total" should read -- No. of Survivors/total--
- Column 53, Table 7, "MG<u>**RK**</u>QN<u>**KR**</u>GGN<u>**E**</u>GSIMWLASLAVVTACAGA", should read

____MG<u>**RK**</u>QN<u>KR</u>GGN<u>E</u>GSIMWLASLAVVIACAGA ___

Column 53, Table 7, "MNVLRGFRKEIGRMLNILNRRRRTAGMIIMLIPTVMA,"

should read -- MNVL<u>R</u>GF<u>RKE</u>IG<u>R</u>MLNILN<u>RRRR</u>TAGMIIMLIPTVMA